Paramagnetic Probes for Magnetic Resonance by Harvey, Peter
Durham E-Theses
Paramagnetic Probes for Magnetic Resonance
HARVEY, PETER
How to cite:
HARVEY, PETER (2013) Paramagnetic Probes for Magnetic Resonance , Durham theses, Durham
University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/7011/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-profit purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Office, Durham University, University Office, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
  
 
 
 
 
 
Paramagnetic Probes for  
Magnetic Resonance 
 
Peter Harvey 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
December 2012 
  
Department of Chemistry 
i 
 
Abstract 
Novel paramagnetic lanthanide complexes have been synthesised for use as probes for 
magnetic resonance imaging and spectroscopy.  Initially, complexes containing a 
trifluoromethyl group were examined for 19F MRI/S, due to the large chemical shift 
range, favourable NMR properties, and the absence of a background signal in vivo.  The 
use of paramagnetic lanthanide ions increases relaxation rates, allowing faster 
acquisition times and increased signal intensity per unit time.  In addition, chemical 
shift non-equivalence is enhanced, which is important for the development of 
responsive probes.  Examples are presented that report selectively on changes to 
citrate concentration levels in the presence of other anions or signal enzyme 
hydrolysis. 
 
To improve signal intensity for in vivo applications, conjugate systems have been 
developed containing a number of fluorinated lanthanide complexes covalently bound 
to high molecular weight adducts (glycol chitosan, PAMAM dendrimer).  These systems 
resulted in one major species being observed in solution, despite the broad molecular 
weight ranges exhibited by these polymeric entities.  Preliminary in vivo MRI studies in 
animal models were undertaken with the glycol chitosan conjugate. 
 
In order to enhance the signal further, a set of fluorinated complexes was synthesised 
containing a pyridyl moiety designed to increase the rigidity of the overall system, 
thereby reducing dynamic exchange broadening. Additionally, the 19F NMR spectra of 
these complexes displayed much larger lanthanide induced shifts than observed for 
the previous systems.  By substituting the CF3 group for a tert-butyl moiety, the 
corresponding 1H NMR signal was shifted well beyond the standard diamagnetic range, 
leading to the development of a new series of complexes for use as 1H MRI and MRS 
probes.  These complexes have been applied to preliminary in vivo MRI studies.  A 
further system has been developed that displays pH-dependent behaviour, observed 
by both 1H NMR spectroscopy and in phantom imaging studies. 
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Abbreviations 
5-FU  5-fluorouracil 
Ar  aromatic 
BOC  tert-butoxycarbonyl 
br  broad 
CSI  chemical shift imaging 
cyclen  1,4,7,10-tetraazacyclododecane 
d  doublet 
DCM  dichloromethane 
DIPEA  N,N-Diisopropylethylamine 
DMF  N,N-dimethylformamide 
DMSO  dimethyl sulphoxide 
DO2A  1,7-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
DO3A  1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
DOTA  1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTP  1,4,7,10- tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphinate) 
DTPA  diethylenetriaminepentaacetic acid 
EDC  N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
EPR  enhanced permeability and retention 
ESI/MS+  electrospray ionisation with positive ion detection 
ESI/MS-  electrospray ionisation with negative ion detection 
FBAL  α-fluoro-β-alanine 
FDG  2-fluorodeoxyglucose 
FSB  (E,E)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene 
GPC  gel permeation chromatography 
HATU  1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate  
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
HOBt  hydroxybenzotriazole 
HPLC  high pressure liquid chromatography 
HRMS  high resolution mass spectrometry 
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LIS  lanthanide induced shift 
Ln  lanthanide 
m  multiplet 
MR  magnetic resonance 
MRI  magnetic resonance imaging 
MRS  magnetic resonance spectroscopy 
MW  molecular weight 
MWCO  molecular weight cut-off 
NBS  N-bromosuccinimide 
NMM  4-methylmorpholine 
NMR  nuclear magnetic resonance 
PAMAM  polyamidoamine 
PBS  phosphate buffered saline 
PCS  pseudocontact shift 
PET  positron emission tomography 
PFC  perfluorocarbon 
ppm  parts per million 
q  quartet 
RF  radiofrequency 
RP  reverse phase 
s  singlet 
SAP  square-antiprismatic 
SNR  signal-to-noise ratio 
t  triplet 
TBTU  O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
tri-Boc  1,4,7-tris-tert-butoxycarbonyl-1,4,7,10-tetraazacyclododecane 
TSAP  twisted square-antiprismatic 
UV  ultra-violet 
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1. Introduction 
1.1 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a widely employed imaging method and is 
acknowledged as one of the essential tools of clinical diagnostics, with over 46 MRI 
exams being carried out per 1000 population every year, according to the OECD 
(Organisation for Economic Co-operation and Development) Health Data 2011.1,2  It is a 
powerful, non-invasive technique that utilises the strong 1H NMR signal of water 
molecules in vivo to generate highly detailed, anatomical three-dimensional images 
with impressive (sub mm) spatial resolution, without the need for harmful ionising 
radiation.3,4  This has been applied to countless human and animal studies, with some 
examples shown in Figure 1.1.  The global importance of this imaging technique was 
highlighted by the award of the 2003 Nobel Prize in Medicine to Paul Lauterbur and Sir 
Peter Mansfield for their efforts into the development of MRI, which can be placed 
with 12 other Nobel Prizes directly and indirectly linked to the advance of MRI.5 
 
Figure 1.1   1H MRI images displaying the anatomical details and powerful 
resolution possible. A) Vertical section through a human; B) horizontal 
section through the head of a mini pig; C) horizontal section through the 
head of a human; D) horizontal image through an entire alligator.6,7 
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Proton MRI can be used to determine the distribution of water in vivo by taking 
advantage of the differing longitudinal (T1) and transverse (T2) relaxation times of the 
water proton signal.  It is possible to utilise the variation in these relaxation times to 
help distinguish between different tissue types.  For example, malignant breast tissue 
has a significantly longer T1 value (1.080 s) than healthy tissue (0.367 s), giving rise to 
differential image contrast in a T1-weighted scan.
8  As well as being an important tool 
in medical diagnosis, MRI is also starting to find applications in reporting certain 
chemical reactions.9  This has been utilised by numerous groups to image a variety of 
processes, such as flow systems,10 corrosion effects,11 and tracking temperature 
changes during reactions.12 
 
Figure 1.2  Ex vivo T2-weighted coronal MR images of a) control and b) APP-
transgenic mouse brains after injection of iron-oxide nanoparticles 
(MION) with 15% mannitol to transiently open the blood-brain barrier. 
Arrowheads indicate dark spots caused by accumulation of MION, 
corresponding to location  of amyloid-β plaques, demonstrating the 
‘negative contrast’ image13 
 
MRI signal intensity increases with increasing longitudinal relaxation rate, R1 (R1 = T1
-1), 
and decreases with increasing transverse relaxation rate, R2 (R2 = T2
-1) .  This allows two 
common methods of enhancing the contrast of an image to be devised.  The first 
method, and the one that will be focussed on more in this work, utilises paramagnetic 
gadolinium(III)14 or manganese(II)15 contrast agents, which significantly increase both 
the R1 and R2 of nearby water protons.  However, the relative change of R1 is much 
larger than that of R2 and, therefore, they are best visualised using T1 weighted images, 
which utilise pulse sequences that accentuate changes in R1.
14  The second class of 
contrast agent are mainly based on polysaccharide iron oxide particles that work by 
increasing the transverse relaxation rate, producing a ‘negative contrast’ image (Figure 
1.2).  Each of these systems results in an increased contrast between healthy and 
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malignant tissue.  Both are in clinical practice, although the majority of those used are 
those containing gadolinium, and they will be discussed in further detail.  Another, 
more recent class of MRI contrast agents are based on the use of paramagnetic 
lanthanide complexes that utilise the chemical exchange saturation transfer (CEST) 
mechanism.  These so called PARACEST agents increase the frequency difference 
between two pools under chemical exchange and have been shown to be capable of 
reporting on changes in temperature and pH.  The theory behind this mechanism is too 
complex to be discussed in detail here, but can be found elsewhere.16,17   
 
The first paramagnetic compounds used to increase relaxation rates of water protons 
were simple salts of manganese(II),18 but research quickly progressed into the use of 
gadolinium(III).  The choice of Gd(III) could be predicted, due to the fact that it is the 
only stable ion with seven unpaired electrons.  There is more than this to its success, 
however, as two other lanthanide ions, dysprosium(III) and holmium(III), actually have 
larger magnetic moments than Gd(III) due to orbital contributions to electron angular 
momentum.  The asymmetry of the electronic states of Dy(III) and Ho(III) causes very 
rapid electron spin relaxation, whereas the near symmetrical Gd(III) allows for slower 
electronic relaxation rates more closely in tune with the proton frequency of water, 
leading to much greater increases in relaxation rates.14 
 
The free Gd(III) ion, however, is toxic (LD50 ≈ 0.2 mmol/kg in mice) and so multidentate 
ligands must be employed in order to form stable chelates to ensure that the 
paramagnetic metal complex is well tolerated in vivo (LD50 ≈ 10 mmol/kg).
19  Countless 
examples of these coordinating ligands have been published in the literature.  
Gd(DTPA)(H2O), commercially marketed as Magnevist®, was introduced in 1988 and 
became the first contrast agent to be used in clinical MRI.2  By the turn of the century, 
it was estimated over 30 metric tons of gadolinium had been administered to patients 
worldwide.  There are now eight gadolinium-based contrast agents that have been 
FDA approved for clinical use, and these are employed in around 30 % of current MRI 
scans.2,14  
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The ability of a compound to enhance the relaxation of nearby nuclei per unit 
concentration is termed the relaxivity (r1), which is often given in units of mM
-1 s-1.  It is 
used when determining the ability of a contrast agent to increase the relaxation rate of 
bulk water, defined as the increase in 1/T1 and 1/T2, and is proportional to the 
concentration of the paramagnetic species, [Gd] (Equation 1.1).  Three different terms 
must be taken into account when analysing the relaxivity of water protons in the 
presence of a contrast agent, depending on how the water molecules interact with the 
paramagnetic species.  The first is the inner-sphere contribution, ri
IS (where i=1 for 
longitudinal and i=2 for transverse relaxation), and results from water molecules 
directly bound to the Gd(III) ion.14  The second term is the outer-sphere contribution, 
ri
OS.  This arises from the fact that bulk solvent molecules diffusing around the 
paramagnetic complex also experience an increase in relaxivity.  Finally, when 
hydrogen bonding or other similar interactions occur, a loose layer of water molecules 
between the inner- and outer-sphere can arise.  This is the second-sphere 
contribution, ri
SS.  The total relaxivity of the system is a sum of these three terms 
(Equation 1.2).  An illustration of these contributions is shown in Figure 1.3. 
 
     
 
 
   
   [  ]          (1.1)       
     
     
       (1.2) 
 
 
Figure 1.3 Illustration of inner-, outer-, and second-sphere water molecules 
around a gadolinium(III) complex. 
 
a b 
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The practicality of the current system is also its major drawback, i.e. the intense 
background of the water signal.  Due to this severe background signal, differentiation 
between tissue types can be extremely challenging.  The ability to distinguish easily 
between healthy and tumourous tissues is crucial in the early detection of cancer and 
related illnesses.  The detection of metabolites other than water can also be of vital 
importance in the detection of disease, for example low levels of citrate in prostate 
and seminal fluid can be indicative of prostate cancer.20,21  However, in vivo such 
metabolites generally suffer from unmanageable spectral overlap, or are not present 
in sufficient concentrations to allow direct observation by standard 1H MRI against the 
strong background signal, although more complicated in vivo NMR spectroscopic 
techniques (e.g. two-dimensional methods) can be attempted.22  
 
In an effort to overcome this issue, and increase the applicability of MRI, a variety of 
Gd(III) contrast agents have been described that respond to changes in pH,23 
selectively signal the presence of certain metal ions in a competitive media,24,25 and 
report on various chemical processes, such as enzyme cleavage26 (for further details, 
see Section 1.5).  The major drawback with these systems is that the behaviour being 
investigated is signalled by a change in relaxivity.  However, relaxivity is also 
dependent on concentration.  Therefore, in order for these systems to be applicable 
towards in vivo studies, it is necessary to be able to determine the local concentration 
of the contrast agent.  Whilst some methods have been designed to overcome this 
problem, such as combining MRI with alternative techniques (optical emission, PET, CT, 
etc.),24 in most cases calculation of the local concentration is highly problematic, if at 
all possible. 
 
1.2 19F MRI/MRS 
1.2.1 Advantages of Heteronuclear MRI/MRS 
A potential solution to some of the issues discussed in the previous section is to move 
away from using 1H as the imaging nucleus.  Therefore, the use of heteronuclear 
magnetic resonance has been investigated as a tool in order to overcome the difficulty 
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caused by the intense water signal present in the body.27–30  Of particular interest are 
heteronuclei that are not biologically prevalent, the most promising of these being 19F 
(see Table 1.1).31  The attractive properties of 19F are its 100 % natural abundance, its 
nuclear spin (I = ½), and its high NMR sensitivity (0.83 relative to 1H).  The large 
gyromagnetic ratio is only 6 % lower than that of 1H, which should allow spectral 
acquisition on existing instrumentation, with relatively straightforward tuning of the RF 
coil.   
 
Table 1.1 Selection of nuclear isotopes and their properties31,32  
Isotope Spin state Natural 
abundance / % 
Magnetogyric ratio 
γ / 106 rad s-1 T-1 
Atomic abundance 
in humans (a) / % 
1H 1/2 ~ 100 267.522
 63 
2H 3/2 0.015 41.066 0.0095 
11B 3/2 80.1 85.847 3 x 10
-6 
12C 0 98.9 N/A  12 
13C 1/2 1.1 67.283 0.13 
15N 1/2 0.37 -27.126 0.58 
16O 0 ~ 100 N/A 24 
17O 5/2 0.04 -36.281 0.0096 
19F 1/2 ~ 100 251.815 0.0012 
23Na 3/2 ~ 100 70.808 0.037 
29Si 1/2 4.7 -53.190 0.0058 
31P 1/2 ~ 100 108.394 0.14 
129Xe 1/2 24.4 -74.521 N/A 
(a) As percentage of total atoms
33,34
 
 
Other than its excellent properties for NMR spectroscopy, the main advantage of 19F 
from an imaging perspective is its scarcity in biological systems.  Whilst fluorine is 
present in low quantities in the body, the physiological concentrations of detectable 
fluorine are below the detection limit (<10-3 µmol/g wet tissue weight).35 Fluorine does 
exist at higher concentrations in the bone matrix and teeth, but displays a very short 
transverse relaxation time due to the immobilised form, making them invisible by 
standard NMR methods.36  This results in an almost complete lack of endogenous 
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background signal and so, in theory, it should be possible to utilise 19F MRI to observe 
directly an exogenous fluorine-containing compound administered to a patient.  The 
large chemical shift range of 19F NMR, with respect to 1H, also allows the development 
of chemical shift reporters.  This would alleviate the problem of calculating local probe 
concentration in responsive systems, as variation in environment could be reported by 
changes in the chemical shift, which is a parameter that is independent of 
concentration.  However, in order for this to be a practicable method, it is imperative 
that any chemical shift non-equivalence is amplified as much as possible. 
 
1.2.2 The Advent of 19F MRI and the development of perfluorocarbons 
 
Figure 1.4  First example of the detection of tumours using 19F MRI; a) 1H coronal 
image of a mouse with implanted tumour indicated by the arrow, 
b) corresponding 19F image with identical orientation after intravenous 
injection of 10g/kg of PFOB emulsion. 19F signal is observed in the liver 
(L), spleen (S), and in the centre of the tumour (T).  Chemical structure of 
PFOB is shown above.37 
 
The use of 19F as an imaging nucleus was suggested in the late 1970s,38 only a few 
years after 1H MRI was developed by Lauterbur in 1973.39  The first detection of 
tumours utilising 19F MRI was achieved around a decade later, utilising perfluorooctyl 
bromide (PFOB) as the imaging probe (Figure 1.4).37  A PFOB emulsion is known to 
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localise in the reticuloendothelial system and it is a successful agent in the imaging of 
tumours.  When it is intravenously injected, it leaks through the gaps in the tumour 
vascular endothelium and collects in the extracellular space.  The concentration of 
PFOB builds up in this region and the fluorine signal can be detected.  It should be 
noted that the 19F NMR spectrum of PFOB contains numerous peaks, due to the 
chemical inequivalence of the fluorine groups in the molecule.  Only selective imaging 
of one set of peaks is possible in an imaging experiment, otherwise chemical shift 
artefacts would be observed if all peaks were attempted to be imaged simultaneously.  
More recent examples have focussed on perfluoropolyethers, for example containing 
12-, 15-, or 18-crown ethers, as they display a single sharp resonance, thereby 
eliminating this problem.35  
 
 
Figure 1.5  Above; schematic illustration of the use of PFCs for monitoring 
inflammatory processes. Emulsified PFC is taken up by the monocyte-
macrophage system and transported to areas of inflammation. Below; 
corresponding 1H and 19F images and overlay (19F in red) from the mouse 
thorax recorded 4 days after ligation of the left anterior descending 
coronary artery showing an accumulation of 19F signal near the infarcted 
region (I) and at location of surgery, where the thorax was opened (T). 40 
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Since then, many examples of the use of perfluorocarbons (PFCs) in imaging have been 
published, due to the strong 19F NMR signal present and their interesting biological 
properties.  For example, the high oxygen affinity of PFCs was first recognised in the 
1960s, when mice and cats were shown to survive complete immersion in oxygenated 
PFCs, followed by long-term survival post-treatment without ill-effects.41  This has led 
to the development of PFCs as blood substitutes and aerosols, including applications in 
drug delivery during liquid ventilation.42  One issue regarding the use of PFCs for 
biological applications is their poor water solubility, although this can be overcome by 
preparing them as water emulsions.43  This inherent poor water solubility can result in 
the benefit of slow diffusion, causing a long retention time at the target site of the 
compound.35  PFCs have also shown good uptake by the monocyte/macrophage 
system, resulting in transportation to areas of inflammation.  This has been used to 
visualise macrophage infiltration in the infarcted myocardium (heart muscle after 
cardiac arrest) by the in vivo 19F MRI of perfluoro-15-crown-ether (Figure 1.5).40 
 
1.2.3 Fluorinated gases 
Fluorinated gases have also been suggested as potential imaging agents, in particular 
for imaging lung function, due to the possibility of direct imaging and their unique 
properties.  For example, various fluorinated gases (SF6, C2F6, CF4, C3F8) can be mixed 
with 20 % oxygen and allow continuous breathing with simultaneous imaging of the 
lungs.35  They were first reported for use in MRI in the early 1980s,44 and have since 
been employed in both experimental and clinical applications, with SF6 being one of 
the more widely used fluorinated molecules.35  However, unfavourable relaxation rates 
and the poor diffusivity of this gas has led to the use of fluoroethane (C2F6) and 
fluoropropane (C3F8) gases, which are more suitable and promising for measurements 
of diffusion in human lungs by 19F MRI.45,46  Fluoropropane is in fact currently used 
clinically for ultrasound imaging of internal organs in humans, under the trade name 
Optison®.  Hyperpolarised noble gases have been suggested as a viable alternative to 
fluorinated gases due to their much improved SNR.  However, this benefit is somewhat 
offset by the increase in cost, associated with the hyperpolarisation apparatus 
required.  A direct comparison of imaging capabilities of both fluoroethane and 
hyperpolarised helium is displayed in Figure 1.6.  
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Figure 1.6  Comparison of C2F6 (top row) and hyperpolarised 
3He (bottom row) 
gradient-echo spin density images (left) and apparent diffusion 
coefficient maps (right) of a formalin-fixed emphysematous lung.45 
 
1.2.4 Fluorinated drugs and biomarkers 
Fluorine is also a very attractive element from a biological perspective, as substitution 
of hydrogen for fluorine often has little effect on the biological activity of a molecule.  
Traditional medicinal chemistry was based almost entirely on the use of natural 
compounds or closely related derivatives, and so did not contain fluorinated 
compounds.  Hence, fluorinated drugs were extremely rare before the 1970s.  This has 
changed quite dramatically in the last 20 years and fluorine is becoming an increasingly 
important element in drug design.47  There are now many examples where fluorine has 
effectively replaced hydrogen or oxygen (the size and electronegativity of fluorine is 
much closer to oxygen than hydrogen) in a molecule whilst retaining or increasing the 
compound’s biological activity, albeit often with different properties.48  According to 
the World Drug Index, as of 2004 there were 128 fluorinated compounds with US trade 
names and of the 31 molecules approved in 2002, nine contained fluorine.47  19F MRS is 
therefore becoming an increasingly attractive method for the investigation of 
fluorinated drugs and their metabolic by-products, generally focussing on their 
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chemical structure, anabolism, catabolism, distribution, and pharmacokinetics in 
vivo.35  It is also relatively simple to create new tracers by the fluorination of 
biologically active compounds49 and this can also be combined with 18F positron 
emission tomography to lend further diagnostic detail.50,51   
 
Figure 1.7  Coronal MR images of a rat with transplanted Morris hepatoma; (a) 1H 
MRI, (b-d) 19F MR images superimposed onto 1H MRI (green = 5-FU, red = 
FBAL). T = tumour and its position is the same in each image. Early 5-FU 
image (b)  5-37 min after injection shows transport of the drug into body 
tissue, the FBAL image (c) 40-72 min after injection indicates catabolic 
conversion of 5-FU to FBAL in the liver, and the late 5-FU image (d) 75-
107 min after injection displays the retention of the active drug in areas 
that showed a strong uptake in the transport phase, including the 
tumour. Vials on right-hand side of images indicate complete 
suppression of the 19F MR signal of either 5-FU (upper vial) or FBAL 
(lower vial) when imaging one selectively. Chemical structures of 5-FU 
and FBAL are shown above.52 
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One of the most exploited uses of 19F MRS in the pharmaceutical field has been the 
investigation of the pharmacokinetic behaviour of the fluorinated anticancer drug 
5-FU, with the first MRS studies carried out in the late 1970s and early 1980s.53,54  The 
mode of action of this drug involves inhibition of RNA function and interference with 
DNA synthesis via anabolites of 5-FU; 5-fluorouridine-5’-triphosphate and 5-fluoro-2’-
deoxyuridine-5’-monophosphate.  However, in the competing catabolic pathway, 5-FU 
is converted within the liver to the amino acid analogue α-fluoro-β-alanine (FBAL), 
which displays low toxicity and minimal activity, reducing the overall bioavailability of 
the drug.55  It is possible to independently monitor the biodistribution of the two 
compounds in vivo, as shown in Figure 1.7.52  Investigations such as this have 
developed the understanding of the metabolic pathway of 5-FU and aided in the 
design of pro-drugs that display higher activity and improved selectivity. 
O
HO
HO
OH
F
OH
FDG     
2-Fluorodeoxyglucose (FDG) is one of the most commonly employed compounds for 
18F positron emission tomography (PET).  As FDG is an analogue of glucose, it exploits 
glucose transporters to enter highly metabolically active cells (tumours, brain, heart, 
etc.).  Once inside these cells, it is converted to FDG-6-phosphate and is no longer 
recognised as a substrate, so does not undergo further metabolism, causing it to 
accumulate inside the cells.  Regional uptake can then be monitored with great 
sensitivity by PET.  However, it cannot differentiate between FDG and its metabolites, 
severely limiting the information that can be gathered from in vivo studies.  19F MRS 
has therefore been applied in order to investigate the metabolic pathway of FDG in 
more detail.  This has led to the identification of further, previously unidentified 
metabolites of FDG, highlighting the need to consider multiple imaging approaches 
when investigating the behaviour of drugs and other biologically relevant 
compounds.56 
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The concept of adding a fluorine atom to a compound that is known to target 
biological sites has recently been utilised for potential early diagnosis of Alzheimer’s 
disease by in vivo 19F NMR. 19F-containing (E,E)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-
hydroxy)styrylbenzene (FSB) has been shown to cross the blood-brain barrier and 
display high selectivity for β-amyloid plaques, which are one of the earliest indicators 
for the onset of Alzheimer’s disease.57  Intravenous injection of FSB, followed by 
19F MRI analysis, showed specific and definitive identification of β-amyloid plaques, 
when overlaid with the non-specific 1H MRI image (Figure 1.8).  This was confirmed by 
fluorescence studies on frozen brain sections.58   
OH
HO
O
HO
OH
O
F
FSB  
 
Figure 1.8  Coronal MR images after injection of FSB into bilateral basal ganglia of 
6-month-old wild-type mice; (a) 19F MRI, (b) T1-weighted gradient echo 
1H MRI, (c) overlay of 19F and 1H MR images, (d) fluorescence image of 
corresponding frozen brain section. Chemical structure of FSB shown 
above.58 
 
1.2.5 Limitations of 19F MRI 
The signal in 1H MRI derives from nearly two thirds of all nuclei present in the body.  In 
order for 19F MRI to produce an image of similar quality, it is essential to significantly 
improve the sensitivity of the resulting signal.  That is why, for the majority of 
published examples, perfluorinated probes have proved so attractive.35  One of the 
reasons these agents require such a high density of 19F nuclei on the molecule, in 
addition to a very high tissue concentration in vivo, is due to the intrinsically slow 
relaxation rates of the 19F nucleus.  The longitudinal relaxation rate for a 19F nucleus in 
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a diamagnetic solution is generally of the order of 1 Hz, resulting in a relaxation time of 
around 1 s.  For a MRS experiment, it is necessary to wait at least four times the 
magnitude of the relaxation time per scan in order to allow for sufficient relaxation of 
the NMR active nuclei of interest.  This results in extremely long acquisition times, 
making most MRS experiments clinically unsuitable without the use of perfluorinated 
compounds, which still suffer from slow acquisition times, as well as added drawbacks 
and limited applications. 
 
This presents a method of increasing the sensitivity in MR studies by increasing the 
longitudinal relaxation rate of the 19F nucleus, which can be achieved by introducing a 
lanthanide ion, or other paramagnetic centre, in close proximity to the fluorine nucleus 
of interest.  This is the technique that will be concentrated on for the remainder of this 
work.  By increasing the relaxation rates, acquisition times are significantly reduced 
and hence a much greater number of scans may be carried out in a given length of 
time.  There is an added benefit in that chemical shift non-equivalence may also be 
increased, improving the possibility of resulting probes to act as chemical shift 
reporters.  Before discussing applications further, the theory behind these phenomena 
should first be considered.  
 
1.3 Lanthanide Relaxation Theory 
The most stable oxidation state of the lanthanides is +3, resulting in an electronic 
configuration of [Xe]4fn, where n varies from 0 to 14 (Table 1.2).  There are exceptions 
to this, such as when the ion can achieve an empty (f0), half-filled (f7), or filled (f14) f 
orbital, for example Eu(II).  When a Ln(III) ion interacts with a Lewis base, the unpaired 
4f electrons of the lanthanide influence any NMR active nuclei that are within close 
proximity.  This leads to perturbations of NMR parameters, such as increased 
relaxation, linewidth broadening, and change in chemical shift.  Gadolinium(III) is 
unique amongst the lanthanides, in that it has an isotropic spatial distribution of 
unpaired f electrons.  The remaining Ln(III) ions have an anisotropic spatial distribution 
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of unpaired f electrons and so are able to instigate a dipolar lanthanide induced shift 
(LIS) in solution. 
 
The first major use for paramagnetic compounds in NMR spectroscopy was as shift and 
relaxation agents.  The ability of lanthanide containing compounds to act as shift 
agents derives from the LIS,59 the origins of which are described in further detail below.  
Due to the effects of this LIS, the chemical shift range for a 1H NMR spectrum can be 
increased from the standard diamagnetic 0 to 12 ppm range up to -500 to 500 ppm, 
depending on the Ln(III) ion chosen. This phenomenon was employed to investigate 
complicated, overlapping NMR spectra of protein samples, for example.60  This 
technique has become less popular in recent times, due to the introduction of high 
field superconducting magnets and the increasing availability of high resolution NMR 
spectrometers.61 
 
As discussed above, another potentially advantageous property of paramagnetic NMR 
spectroscopy is the significant increase in relaxation rates of paramagnetic over 
diamagnetic compounds.  In the past, this behaviour has been exploited as a mapping 
device.  The closer a nucleus is to the paramagnetic centre, the quicker its T2 relaxation 
time will be, and so, the broader its resonance will be. This allows estimations of the 
distance between the lanthanide ion and  certain nuclei within the compound, 
resulting in structural information and mapping of the molecule.62  However, the 
advent of 2D NMR spectroscopy (COSY, NOESY, etc.) has lessened the demand for such 
paramagnetic techniques.  Again, further details on the basis of this relaxation 
enhancement effect are given below. 
 
1.3.1 Chemical Shift 
The LIS for a nucleus within a ligand that is coordinated to a Ln(III) ion can be 
expressed as the sum of three terms; the diamagnetic (Δd), the contact (Δc), and the 
pseudocontact shift (Δp) (Equation 1.3). 
                (1.3) 
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The diamagnetic shift mainly derives from effects such as conformational changes, and 
is generally negligible, unless the nucleus is directly coordinated to the Ln(III) ion.63  
The contact shift stems from through-bond transmission of unpaired electron spin 
density to the nucleus from the 4f orbital.  This is expressed in Equation 1.4.  The 
magnitude of this contact shift decreases significantly as the number of bonds 
between the Ln(III) ion and the nucleus under investigation increases.  This allows the 
identification of the nuclei directly bound to the metal:64 
             
  
     
              (1.4) 
where <SZ> is the expectation value of the time-average electron spin polarisation for a 
given paramagnetic ion (Table 1.2), B0 is the magnetic field strength, γ1 the 
gyromagnetic ratio, and A/ħ the hyperfine coupling constant of the nucleus under 
investigation.  
 
The pseudocontact shift (PCS) is the rotationally invariant component of the dipolar 
interaction between the nuclei and the Curie magnetisation induced on the unpaired 
electrons by the applied magnetic field.65  The electron magnetisation supplements the 
applied magnetic field, which leads to additional chemical shielding of the nuclei.  PCS 
has been derived elsewhere,66 but it can be expressed in a simplified form if the 
principal magnetic axes system is used. The resulting expression displays strong 
directional dependence (Equation 1.5):65,67 
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 ] (1.5) 
where CJ is the Bleaney constant characteristic of the particular Ln(III) ion (Table 1.2), 
µB is the Bohr magneton, Θ is the angle between the nucleus under consideration and 
the principal axis of the lanthanide ion, and   
  and   
  are second order crystal field 
terms determined by local symmetry and donor polarisability. 
 
For a given probe nucleus, PCS may be viewed as a 3D scalar field.  Figure 1.9 displays a 
typical distribution of PCS, along with an example of the effect it induces on the 1H 
NMR spectrum of a given Eu(III) complex, in this case [Eu(DOTA)H2O]
-.  If the nucleus 
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under investigation resides in an area of strong positive PCS (red), the NMR shift 
relating to this nucleus will be shifted in the opposite direction to a nucleus located in 
an area of strong negative PCS (blue).  In the case of [Eu(DOTA)H2O]
-, any nuclei that 
experience positive PCS are shifted to a value of positive ppm, whereas those 
experiencing negative PCS are shifted to a value of negative ppm.  
 
Figure 1.9  Schematic stereodrawing of the pseudocontact shift field around a 
typical lanthanide complex, [Eu(DOTA)H2O]
-, with an axial magnetic 
susceptibility tensor and the effect this has on the shifts in the 1H NMR 
spectrum.  
 
For a given series of isostructural complexes, it is generally assumed that the ligand 
field coefficients are invariant amongst the lanthanides, although it has been shown 
that there is a general contraction across the series.68  However, the different Ln(III) 
ions possess Bleaney coefficients (Table 1.2) of varying magnitude and sign, and it is 
largely this contribution that can lead to dramatically different pseudocontact shifts for 
common resonances in a given complex.  The strong dependence of the PCS on the 
nuclear coordinates can be exploited in order to enhance chemical shift non-
equivalence.  For example, this is important in the development of chemical shift 
reporters that respond to changes in environmental parameters, such as pH. 
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Table 1.2. Selected magnetic and relaxation properties of lanthanide(III) ions 
Ln(III) Electronic 
configuration 
Ground 
state 
term 
µeff/µB (a)  Electronic 
relaxation time (b)  
(aqua ion, 2.1 T) / 
10-13 s  
<SZ> 
(c) CJ 
(d) 
Ce [Xe] 4f1 2F5/2 2.56 0.90 -0.97 -6.5 
Pr [Xe] 4f2 3H4 3.62 0.57 -2.96 -11.4 
Nd [Xe] 4f3 4I9/2 3.68 1.15 -4.45 -4.5 
Pm [Xe] 4f4 5I4 2.68 unknown -3.94 2.4 
Sm [Xe] 4f5 6H5/2 1.55-1.65 0.45 0.22 -0.5 
Eu [Xe] 4f6 7F0 3.40-3.51 0.09 7.57 4.0 
Gd [Xe] 4f7 8S7/2 7.94 10
4-105 31.5 0 
Tb [Xe] 4f8 7F6 9.7 2.03 31.9 -87 
Dy [Xe] 4f9 6H15/2 10.6 2.99 28.6 -100 
Ho [Xe] 4f10 5I8 10.6 1.94 22.6 -39 
Er [Xe] 4f11 4I15/2 9.6 2.38 15.4 32 
Tm [Xe] 4f12 3H6 7.6 3.69 8.21 53 
Yb [Xe] 4f13 2F7/2 4.5 1.37 2.59 22 
(a) Ref.
69
 (b) Refs.
70–72
 (c) Ref.
73
 (d) Ref.
65
 
 
1.3.2 Relaxation Theory 
In a standard NMR experiment, the nucleus of interest is excited by a radiofrequency 
pulse that tips the magnetisation vector from the z-axis to the transverse plane. The 
magnetisation processes around the direction of the magnetic field and recovers to the 
state of equilibrium.  This process is recorded as a free-induction decay (FID), which is 
then converted by Fourier transform to obtain the final NMR spectrum.  The speed of 
this process is defined by the relaxation rates.74 
 
The longitudinal relaxation time, T1, is so-called as it is related to the time it takes for 
the magnetisation to relax back to the thermal equilibrium, along the direction of the 
magnetic field, i.e. along the z-axis.  Likewise, the transverse relaxation time (T2) 
describes the relaxation of the x and y components.  The corresponding longitudinal 
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and transverse relaxation rates (R1 and R2 respectively) are simply the reciprocal of 
these relaxation times, as shown in Equation 1.6. 
   
 
  
                          
 
  
  (1.6) 
Relaxation processes are driven by fluctuations in the local field experienced by the 
nucleus of interest.31  In paramagnetic NMR spectroscopy, the unpaired electron(s) 
present provide additional pathways for relaxation back to the ground-state, thereby 
increasing relaxation rates significantly.  Further details into this relaxation 
enhancement are discussed below, with a particular emphasis on Ln(III) paramagnetic 
relaxation rate enhancement on 19F NMR spectroscopy. 
 
1.3.2.1 Fluorine relaxation in lanthanide-based systems 
As discussed, the coordination of a ligand to a paramagnetic lanthanide ion enhances 
both the longitudinal and transverse relaxation rates.  For 19F nuclei in non-viscous 
solutions of paramagnetic ions, there are five important spin relaxation processes that 
contribute to this increase in relaxation rates.  The first two of these processes, 
chemical shift anisotropy (CSA) and inter-nuclear dipole-dipole (DD) relaxation, can 
largely be ignored.  This is due to the fact that they are diamagnetic relaxation 
processes and so are negligible in comparison to the much larger paramagnetic terms.  
For example, experimentally observed 19F T1 values are generally of the order of 1 s.  
This means that CSA and inter-nuclear DD interactions cannot contribute more than 
1 Hz to the paramagnetic relaxation rates, which may be of the order of 100 Hz.  The 
third process, the contact mechanism, can also be ruled out due to its strong distance 
dependence.  DFT calculations have shown that a 19F nucleus positioned over 5 Å away 
from an f-type unpaired electron gives a zero value for this term.75–77 
 
The remaining two processes (electron-nucleus DD and the Curie relaxation) do 
contribute significantly to paramagnetic relaxation rates and so have to be taken into 
consideration.  Combination of their independent contributions to the relaxation rates 
result in Equations 1.7 and 1.8, with the first term in each equation relating to 
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modulation of the electron-nucleus dipolar interactions and the second term arising 
from the Curie relaxation:75 
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where µ0 is the vacuum permeability, γN is the magnetogyric ratio of the nucleus (i.e. 
19F), r is the electron-nuclear distance, τR is the rotational correlation time, ωN is the 
nuclear Larmor frequency, T is the absolute temperature, k is the Boltzmann constant, 
and the remaining symbols are defined as below: 
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in which gJ is the effective electron g-factor, µB is Bohr magneton, J(J + 1) is the 
effective electron angular momentum, and T1e is the longitudinal relaxation time of the 
electron spin.   
 
The behaviour of the relaxation rates can be plotted as a function of the effective 
magnetic moment, µeff, and the electron-nuclear separation, r.  This is represented in 
Figure 1.10.  The dependence on the electron-nuclear separation is to the reciprocal 
sixth power in both the dipolar and Curie mechanism, while the effective magnetic 
moment is quadratic.  It is important to note that the relaxation rates are strongly 
temperature dependent, with the effective magnetic moment, electron relaxation 
rate, rotational correlation time, and the Curie term all affected by changes in 
temperature.  It is therefore imperative to keep the temperature at a constant value 
during experimental measurements.  As the longitudinal relaxation rate can be 
measured with very high precision, it is possible to extract the electron-nucleus 
distances, rotational correlation times, and effective magnetic moments by fitting to 
these equations.75  
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Figure 1.10  Longitudinal 19F spin relaxation rate as a function of Ln-F distance (r) and 
the effective magnetic moments of the electron (µeff) at two different 
magnetic fields (3.0 and 9.4 T). T1e = 0.2 ps, τr = 250 ps, and T = 298 K.
67 
 
While an increase in the longitudinal relaxation rate will allow faster acquisition times 
and increase sensitivity in imaging experiments, an increase in the transverse 
relaxation rate will lead to increased line broadening and so decrease sensitivity.  
Therefore, a balance needs to be struck between increasing R1 while keeping R2 as 
relatively low as possible when designing a suitable probe.  Volumetric plots (Figure 
1.11) have been generated that display the dependence of both R1 and R2 on the 
magnetic field (B0), the internuclear distance (r), and the rotational correlation time 
(τr).
75  Analysis of these plots allows a good estimation of the ideal Ln-F distance to be 
extracted.  To achieve two-orders of magnitude increases in both relaxation rates (ca. 
100 Hz) at 3.0 T, a Ln-F distance of between 5.5 and 7 Å would be expected for a 
general macrocyclic lanthanide (Ln = Tb, Dy, Ho, Er, Tm) complex, with rotational 
correlation times for such complexes being in the region of 102-103 ps.  It is also 
important to note that chemical exchange processes may also contribute to an 
increase in R2, so it is also essential to keep exchange processes at a minimum.
67 
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Figure 1.11  Volumetric plots showing the variations in the longitudinal (left) and 
transverse (right) relaxation rates with applied field (B0), mean distance 
from paramagnetic centre (r), and effective rotational correlation time 
(τr). Analysis is based upon Equations 1.7 and 1.8 with the assumptions 
µeff = 10 BM and τe = 0.2 ps.
75 
 
1.4 Responsive Systems for MRI applications 
MRI contrast provides excellent sensitivity for detecting subtle changes in anatomy 
and function, but poor specificity when assigning image contrast to pathologies.23  A 
good example is in the diagnosis of breast cancer lesions, where MRI is in fact better 
than X-ray mammography in its ability to detect such tumour tissues.  However, many 
non-cancerous lesions are also detected by MRI, leading to false-positive diagnosis and 
so MRI is only recommended for women with a high cancer risk in this case.78  Also, the 
changes in anatomy and function that are detected by standard MRI techniques are 
often caused by mid- to late- stage developments of a disease, which may be too late 
for early-stage intervention.23  In order to overcome this limitation, a large amount of 
research has been undertaken into the development of responsive MRI contrast 
agents whose relaxivity can signal a specific parameter of the microenvironment in 
which they localise.  However, a large amount of the work published has so far 
concentrated on in vitro examples, with very few applications of systems that work in 
vivo.79  It is also important to note that relaxivity is concentration dependent.  
Therefore, in order for such a system to be applicable there must be some method of 
examining the concentration of the probe in vivo, which is extremely challenging.  A 
selection of examples will now be discussed, covering a number of diagnostically 
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relevant physiochemical variables that have been successfully reported by changes in 
the relaxivity of Gd(III) complexes. 
 
1.4.1 pH-responsive systems 
Changes in pH often accompany the development of various pathologies, such as 
stroke, infection, and renal failure.  Therefore, mapping pH in vivo is an important task 
in medical imaging and can also be vital for developing therapies that remain effective 
in regions of altered pH.80  Assessment of in vivo pH levels can be particularly 
important when diagnosing cancer, as poor perfusion, reduced bicarbonate levels, and 
increased lactic acid secretion within cancerous tissue often leads to acidic 
conditions.81  The high spatial resolution of MRI is particularly well suited for 
evaluation of pH variations over small tissue volumes.23  The pKa of any pH-dependent 
modulation should ideally be in the physiologically relevant pH range of 6.5 to 7.5. 
 
One method of reporting changes in pH is to develop pH-dependent ligands that alter 
water accessibility to the Gd(III) ion.  Gillies, Sherry, and co-workers have developed a 
dual injection technique for measuring the extracellular pH (pHe) in kidney and tumour 
models, involving the use of two different Gd(III) contrast agents; pH-insensitive 
[Gd(DOTP)]5- and pH-sensitive [Gd(DOTA-4AmP)]5- (Figure 1.12).82,83 The pH-dependent 
behaviour of [Gd(DOTA-4AmP)]5- is believed to arise from the hydrogen-bonding 
network created by the protonated phosphonates aiding exchange of the bound water 
protons with the protons of the bulk water, resulting in a two-fold increase in T1 
relaxation time from pH 6.0 to 8.5.  The idea behind this dual contrast agent strategy is 
that the distribution of the pH-insensitive agent can be used to infer the local 
concentration of the pH-sensitive agent, removing the issue of monitoring the 
concentration directly.  Despite being structurally dissimilar, the two complexes were 
found to have similar renal pharmokinetics due to similarities in their structure and 
charge and so were assumed to have identical local concentrations.  This may not be 
entirely accurate, as minor structural differences can have large effects on 
biodistribution kinetics.  The system did generate the expected pH profile images with 
mice kidney studies. With more difficult tumour models (C6 glioma, Figure 1.12), the 
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pharmokinetics of the two contrast agents were well correlated over the whole 
tumour model, but this correlation was substantially reduced when the tumours were 
examined on a pixel-by-pixel basis.  It is also important to note that the two contrast 
agents cannot be applied simultaneously in this example.  An in vivo experiment would 
require a long delay between administrations of the two contrast agents, in order to 
allow for full body clearance of the first probe before addition of the second. During 
this time, physiopathological changes may occur, further endangering the assumption 
of identical biodistribution.79 
 
Figure 1.12 Top; chemical structures of [Gd(DOTP)]5- and [Gd(DOTA-4AmP)]5- with 
dependence of [Gd(DOTA-4AmP)]5- relaxivity on pH (37°C, 4.7 T). Bottom; 
representative time-to-maximal intensity (TMI) images and calculated 
pHe map of a C6 glioma in the brain of a live rat. (A) T1-weighted 
1H MRI 
of the brain prior to administration of either contrast agent, (B) TMI 
image after administration of pH-insensitive [Gd(DOTP)]5-, (C) TMI image 
after administration of pH-sensitive [Gd(DOTA-4AmP)]5-, (D) resulting 
calculated pHe image.
83 
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A further example utilising the pH-dependent nature of [Gd(DOTA-4AmP)]5- has been 
published that negates the need to measure an absolute value of the tissue pH by only 
aiming to image areas of abnormally low pH, therefore not requiring knowledge of the 
probe concentration.  For example, when the complex was administered to control 
hearts, there were no regions with observable differences in their contrast 
enhancement, whereas ischemic hearts display distinctly brighter areas that are 
attributable to areas with low pH values.  This complex has also been applied to rat 
pancreatic islets embedded in alginate beads, which showed considerable contrast 
enhancement only upon exposure to high levels of glucose.  This is due to glucose-
mediated insulin secretion being accompanied by the release of protons and the 
resulting increase in local proton concentration is detected by increase in relaxivity of 
[Gd(DOTA-4AmP)]5-.84  Another recent in vitro example from Caravan and co-workers 
has involved the use of a derivative of [Gd(DOTA-4AmP)]5- with an incorporated 18F 
atom to form a bimodal MR/PET agent.85  This allows the concentration of the complex 
to be calculated from the total PET signal, which is independent of pH, but does 
require the use of ionising radiation and the associated increase in cost.  
 
Early work in Durham and Italy led to the development of a sulphonamide-based 
system that displays pH-dependent modulation of relaxivity due to a change in 
hydration state (q) associated with the on/off ligation of a sulphonamide nitrogen 
donor (Figure 1.13).86  Control over the pKa of the protonation can be exerted by 
variation of the electron density of the nitrogen, which can be tuned by altering the 
identity of the para-substituent, R.  Variation of this substituent led to the 
determination of protonation constants of 5.7, 6.4, and 6.7 for the -CF3, -Me, and 
-OMe moieties respectively.  
 
It was expected that intermolecular binding of endogenous anions (lactate, 
bicarbonate, etc.) or protein might displace bound water, thereby suppressing the 
change in relaxivity.  In order to combat this, a related series of ligands were designed 
with carboxyalkyl substituents on the carboxylate pendant arms.  However, from the 
related europium(III) emission studies it was found that competitive intramolecular 
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carboxylate coordination was occurring. This could be minimised by either enhancing 
electron density at the sulphonamide nitrogen or by enlargement of the chelate ring 
from 7 to 8.  Therefore, the most successful system was found to be that with the 
para-CF3 substituent and a longer carboxyalkyl arm (3-CF3, Figure 1.13), which 
displayed a 48 % change in relaxivity over the pH range 7.4-6.8 (298 K, 65.6 MHz, 50 % 
human serum solution).  This system also displays significant amplification of relaxivity 
changes upon protein binding. This amplification derives from the non-covalent 
interaction of the gadolinium complex undergoing relatively fast water exchange with 
a more slowly tumbling macromolecule.86  In order to allow the concentration of this 
system to be mapped in vivo, a proof of concept dual MRI/SPECT agent has recently 
been developed that utilises a gadolinium(III) sulphonamide compound (1-OMe, 
Figure 1.13) in combination with the equivalent holmium(III) complex as a 
concentration reporting SPECT tracer.87  Another recent example has taken the same 
idea of alteration of hydration state with varying pH, but with an aminoethyl 
substituent in place of the sulphonamide.88  However, unlike the sulphonamide 
compounds, the pKa for this system is not in the ideal physiological range, although 
there is scope to improve this by variation of the amino-substituents. 
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Figure 1.13  Chemical structure of sulphonamide-based pH responsive systems 
(R = CF3, Me, OMe) and the variation in coordination environment of the 
lanthanide ion as a function of pH. 
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An alternative approach is to design contrast agents that experience a change in 
rotational tumbling time as a function of pH.  For example, in the phospholipid mimetic 
structure [Gd((C18)2-DTPAGlu)], high pH causes deprotonation resulting in higher 
lipophilicity, driving the formation of colloidal aggregates and causing an increase in 
relaxivity (Figure 1.14).89  This has also been reported with an analogous DO3A-
derivative,90 as well as gadofullerene derivatives that behave in the opposite manner, 
i.e. increased relaxivity at low pH.91  A related PAMAM dendritic contrast agent has 
been shown to display an increase in rigidity as pH decreases from 11 to 6, resulting in 
a relaxivity increase of 60 %.92 
 
Figure 1.14  Chemical structure of [Gd((C18)2-DTPAGlu)] pH responsive system and 
illustration of the different structural forms the ligand takes at varying 
pH.89 
 
1.4.2 Molecular imaging of cations, anions, and other metabolites 
MRI contrast agents are relatively insensitive, requiring a minimum threshold of 
around 0.01-10 mM for adequate in vivo detection (for comparison PET, SPECT, and 
fluorescence imaging typically have pM detection sensitivity thresholds).  This means 
that endogenous metabolites present at higher concentrations than this detection 
threshold are suitable targets for responsive MRI.23  It is vital that the specificity of any 
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non-covalent metabolite binding targets only the particular molecule of interest in a 
competitive medium, otherwise interpretation of any relaxivity changes is almost 
impossible.  Ideally, any responsive behaviour should also be reversible. 
 
Metal ions are associated with numerous biological signalling pathways and 
pathologies and the rapid flux of metal ions on a sub-second timescale can require 
rapid measurements, posing difficulty for accurate quantitative investigation by MRI.23  
For example, intracellular calcium plays an important role in muscular contraction, 
neuronal transduction, and hormonal secretion, leading to a number of gadolinium(III) 
compounds being proposed to signal variation in Ca(II) concentration by changes in 
relaxivity.93  One example of a system developed in Durham, involves the use of an 
eight-coordinate pyro-EGTA-based moiety that is attached to the Gd(III)-containing 
macrocycle via an amide bond (Scheme 1.1, A).25  In the absence of Ca(II), the amide 
carbonyl oxygen binds to the Gd(III) ion resulting in a 7-ring chelate.  However, when 
Ca(II) is added the amide carbonyl preferentially coordinates to the added metal, 
resulting in a vacant site at the Gd(III) that can be occupied with water.  This is 
accompanied by an increase in relaxivity.  Ca(II) levels in cerebrospinal fluid may drop 
by up to 90 % in a traumatic event and this should be reflected by a 22 % variation in 
r1p with this system at 1.4 T, provided that the timescale for MRI data acquisition is 
faster than the time it takes for the Ca(II) levels to return to equilibrium and that the 
local concentration of contrast agent does not change over this time.   
 
Minor alteration to the structure of this compound (6-coordinate pyro-EGTA instead of 
8-coordinate) allows selective binding of Zn(II) (Scheme 1.1, B).  A similar example 
based on the same principle but with a di-2-picolylamine chelator containing a 
naphthylamine-derivative moiety has recently been proposed as a bimodal probe for 
detection of copper(II), with the addition of Cu(II) signalled by both an increase in 
relaxivity and quenching of the naphthylamine fluorescence signal (Scheme 1.1, C).94  
Examples of systems that exhibit an increase in relaxation rates due to an increase in 
rotational correlation times in the presence of iron(II) and iron(III) have also been 
reported.95–97  
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Scheme 1.1  Mode of action of cation-responsive Gd(III) complexes discussed.25,94 
 
As mentioned previously, variation in levels of endogenous anions can be indicative of 
serious health issues.  However, unlike the numerous examples of metal-responsive 
MRI systems, contrast agents that report on anionic analytes are much rarer, mainly 
due to the intrinsic difficulty in binding anions selectively in aqueous media.98  There 
have been some studies into the behaviour of Gd(III) complexes with biologically 
significant anions (acetate, lactate, citrate, etc.)99,100 and systems have been developed 
that show changes in luminescence for selective anions,21,101,102 but there are very few 
examples of systems that selectively report on the presence of anions by modulation 
of relaxivity.  Recently, Vilar and co-workers did report a pyrophosphate-responsive 
system that utilises two phosphate-binding zinc(II)-dipicolylamine moieties attached to 
a Gd(III)-DTPA-bis-amide complex (Figure 1.15).98  Addition of pyrophosphate initially 
causes a decrease in relaxivity until one equivalent of pyrophosphate (PPi) had been 
added, which is suggested to be due to the formation of a more spherical overall 
species, reducing the rotational correlation time, as the hydration state of the complex 
remains unchanged.  Upon addition of further equivalents of PPi, the binding mode 
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changes, resulting in an increase in τR
 and a corresponding increase in r1p.  While this 
system does show good specificity for PPi over mono-phosphates and other similar 
anions, addition of other polyphosphates (e.g. ATP) is likely to be competitive.  Also, 
the dual-mechanism of relaxivity modulation that results in an initial decrease in r1p 
followed by a significant increase is likely to prove too complicated to be directly 
applicable in an in vivo situation. 
 
Figure 1.15  (a) Relaxivity plot displaying suggested binding modes with initial 
formation of the 1:1 complex accompanied by a decrease in relaxivity, 
followed by conversion to the 1:2 complex that displays a marked 
increase in r1p; (b) Phantom images of increasing equivalents of PPi with 
respect to concentration of Gd(III) complex.98 
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1.5 Potential Molecular Adducts for Contrast Enhanced MRI 
Conjugation of multiple paramagnetic MRI contrast agents to a macromolecular 
adduct can have a number of advantages.  By dramatically increasing the molecular 
weight and steric bulk of the system, the rate of clearance from the body is markedly 
reduced with in vivo experiments, increasing the retention time and reducing the 
concentration of contrast agent that needs to be administered.  Macromolecular 
adducts can also be employed to target specific areas of the body.  Of particular 
interest is the potential to target tumour cells by the enhanced permeability retention 
effect,103 which is detailed further below.  There are a wide range of adducts that have 
so far been investigated, with a far from exhaustive selection chosen to be discussed 
here. 
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Figure 1.16  Chemical structure of polycarboxylated EDTA-type cyclodextrin (CD) 
ligand reported by Yannakopoulou and co-workers (n = 0, AEDTA; n = 1, 
BEDTA; n = 2, GEDTA).104 
 
A potential Gd(III) contrast agent had been developed by Yannakopoulou and co-
workers based on a polycarboxylated EDTA-type cyclodextrin (CD) ligand, which 
contained an α-, β-, or γ-CD core (AEDTA, BEDTA, and GEDTA respectively) with 
bis(carboxymethyl)amino groups on all the primary hydroxyl CD sites (Figure 1.16).104  
Mass spectrometry and luminescence emission analysis showed the formation of 
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multimetallic complexes upon addition of a lanthanide(III) ion (2-3 for AEDTA, mainly 3 
for BEDTA, and 4 for GEDTA), with DFT calculations predicting each Ln(III) ion binding 
via four carboxylate oxygen atoms, two nitrogen atoms, and a glucopyranose oxygen.  
They show some potential for use as contrast agents as they display relaxivity values 
up to 12 times larger than commercial probes (Magnevist® and Dotarem®) in human 
blood plasma at 100 MHz and show no sign of toxicity in preliminary cytotoxicity 
studies in human skin fibroblasts.  However, the kinetic stability of these systems with 
respect to loss of gadolinium has not been evaluated in detail and it is likely that 
significant loss of the Ln(III) ion from the adduct would occur in vivo. 
 
Figure 1.17  Schematic representation of the polymeric micelle MRI probe developed 
by Yokoyama and co-workers displaying the concept of the enhanced 
permeability retention effect (EPR).105 
 
Yokoyama and co-workers have developed a polymeric micelle MRI probe based on 
anionic block co-polymers.  As the polymeric micelle is an associate of many block 
copolymer chains, when dissociated the individual chains can be easily excreted 
through the kidneys, lowering chronic toxicity and keeping the signal intensity in 
vascular space low.  However, the pharmacokinetics of this system is suitable for the 
targeting of tumours, where the micelle can enter into the tumour vasculature.  The 
micelle is then dissociated to its individual block co-polymers and they are retained for 
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a relatively long time due to the poor lymphatic drainage at the tumours site (EPR 
effect, Figure 1.17).105  This system works particularly well for MRI purposes as the 
dissociated block co-polymers display a much greater relaxivity than the polymeric 
micelle, due to the Gd(III) being situated in the inner core of the micelle, hindering 
access to the bulk water.  The block copolymers only accumulate in tumour tissue, as 
they are rapidly excreted from the rest of the body, and hence the only major increase 
in signal intensity should be within the tumour.  This principle was proved in vivo with 
colon 26-bearing CDF1 female mice.  A two-fold increase in signal intensity was 
observed following selective accumulation of the polymeric micelle 24 hours after 
injection (Figure 1.18).106   
 
Figure 1.18  Chemical structure of anionic block copolymer reported by Yokoyama 
and co-workers and T1-weighted MR images of axial slices (a) before and 
(b) 24 h after injection at dose of 0.05 mmol Gd/kg. Arrow indicates the 
tumour and circles are stock solutions of (left to right) 1.0 mM, 0.5 mM, 
0.1 mM, and 0 mM Gd(III) ion in agarose gel.106 
 
Dendrimers are becoming an increasingly important class of high molecular weight 
adducts and have found multiple applications in drug delivery, transfection, and tissue 
engineering.  This is due to the highly branched nature of these systems with a defined 
number of end-groups and the possibility of tuning the structural elements to affect 
both the surface and core properties of the macromolecule.107,108 Numerous ideas 
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have been suggested for developing dendrimer-based MRI contrast agents.  For 
example, Sherry and co-workers have designed a system based on an ethylenediamine 
core Generation 5-PAMAM dendrimer (128 terminal amines) coupled to a pH-
responsive Gd(III) probe, with around a 75 % coverage of complexes on the 
macromolecule, i.e. 96 of the 128 sites per dendrimer.109  This succeeded in both 
increasing the relaxivity, r1p, and enhancing the difference in relaxivity, Δr1p, between 
the low and high pH states by more than a factor of 2, as shown in Figure 1.19.  This 
clearly shows great potential, but further work needs to be done to see if such a 
system could be applied in vivo, and whether such a large macromolecule would be 
well tolerated by the body.  There also needs to be a method for analysing the local 
concentration of the probe as discussed in Section 1.4. 
 
Figure 1.19  Left) Representation of G5-PAMAM dendrimer coupled to pH-responsive 
Gd(III) complexes; Right) Variation of relaxivity with pH (upper line is 
generated from dendrimer-based Gd(III) complexes while lower lines are 
from analogous monomer units of the Gd(III) complex).109  
 
 
1.6 Paramagnetic Enhanced Heteronuclear MRI/MRS 
As discussed in Section 1.3, relaxation rates of NMR active nuclei can be dramatically 
increased by the introduction of a proximate paramagnetic ion, resulting in an increase 
in signal intensity for a given time.  It can also have the added benefit of increased 
chemical shift non-equivalence, depending on the paramagnetic ion chosen.  While a 
large amount of research has been carried out in the area of paramagnetic MRI 
contrast agents that enhance the relaxation rates of water molecules, comparatively 
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little work has been published in the area of paramagnetic enhanced heteronuclear 
MRI/MRS, despite the enormous potential of imaging nuclei such as 19F.  Interest has 
started to increase in the last few years and a brief overview of some of the more 
recent studies carried out in paramagnetic enhanced 19F MRI/MRS and related areas 
will now be detailed, followed by the work conducted previously within our research 
group that laid the foundations for the research reported in this thesis.  Alternative 
methods not discussed here have also been suggested for enhancing 19F MRI signal 
intensity, such as the use of hyperpolarisation.110 
 
1.6.1 Enhancing signal intensity  
One of the earliest examples of 19F MRI paramagnetic relaxation enhancement was 
reported in the mid-1990s, utilising Gd(DTPA) to enhance the in vivo signal observed 
from previously administered trifluoromethylsulphonate to image a rabbit brain 
abscess.  An approximate signal enhancement factor of around 4 was calculated upon 
addition of the paramagnetic Gd(III) complex, with imaging times generally less than 
5 mins.111  Studies have also looked at the paramagnetic relaxation enhancement in 
fluorinated derivatives of biological substrates, such as fluoroacetate and 
trifluorolactate.112,113  An illustrative example of the increase in signal intensity 
achieved by utilising the paramagnetic enhancement effect is shown in Figure 1.20,  
where the 19F NMR signal for trifluoro-L-lactate is shown both with (B) and without (A) 
the addition of Gd(DO3A).113 
 
Figure 1.20  19F NMR T1-weighted spin echo spectra of a 10 mM solution of trifluoro-
L-lactate with (B, 0.9 mM) and without (A) Gd(DO3A).113  
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However, with systems that rely on an intermolecular interaction between the 
fluorinated probe and the paramagnetic ion, the encounter probability is inherently 
low, resulting in modest relaxation enhancements.67  This can be increased if both 
moieties are contained within the same molecule.  An early example from Sherry and 
co-workers focussed on a series of [Ln(F-DOTPME)]- complexes (Figure 1.21), which 
were observed to exist as a mixture of diastereoisomers in solution.114  Due to the 
sensitivity of 19F NMR spectroscopy to minor structural changes, it was possible to 
assign several of the shifted fluorine resonances to specific isomers.  Addition of ionic 
detergents was then monitored by variations in shift and/or population of individual 
stereoisomers.  While this is an interesting example of using the intrinsic sensitivity of 
19F NMR spectroscopy to probe the structural forms of a Ln(III) complex, for imaging 
applications it is important to promote the formation of one species in solution to 
maximise the signal intensity obtained. 
 
A more recent example involved the use of a perfluoro-tert-butyl group coupled to a 
DO3A-based ligand via a short helical oxyethylene chain to aid with water solubility 
([Ln(FC)], Figure 1.21).115  As could be expected, introduction of a variety of di- and tri-
valent paramagnetic metal ions caused increases in relaxation rates and resulted in 
distinct 19F NMR shifts for each metal complex.  This has led to the system being 
described as a multi-chromic 19F tracer, whereby different therapeutic agents could be 
labelled with individual metal complexes of FC allowing them to be tracked 
independently in vivo by the different 19F NMR frequencies.  However, it is debatable 
whether the chemical shift non-equivalence between the different species is large 
enough for this application, with only 7-8 ppm variation across the entire series tested.  
This may be improved by positioning the fluorine containing moiety in closer proximity 
to the metal ion, which would likewise improve upon the fairly modest increases in 
relaxation rates reported (e.g. for [Tb(FC)] R1 ≈ 14 Hz).  Further work also needs to be 
done into investigating why this system does not follow the patterns set out by the 
Bleaney coefficients.  For example, the 19F signal for the Er(III) complex should be 
shifted in an opposite direction to the corresponding Dy(III), Ho(III), and Tb(III) 
complexes compared to the diamagnetic analogue, yet this is not the case.  Similarly, 
the Gd(III) complex shows the largest relaxation rate enhancement as would be 
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expected, but it also displays a significant shift in the 19F NMR signal in comparison to 
the diamagnetic Y(III) complex, which should not occur due to the isotropic nature of 
the Gd(III) ion (see Section 1.3.1 for further details of chemical shift behaviour in 
paramagnetic lanthanide systems). 
 
Figure 1.21 Top) Chemical structures of [Ln(F-DOTPME)]- 114 and [Ln(FC)]; 
Bottom) Example of chemical shift differences noted when FC ligand is 
complexed with a variety of metals.115 
 
While not technically heteronuclear imaging, an interesting example of a 1H chemical 
shift magnetic resonance probe has been reported by Caravan and co-workers.116  This 
utilises the four magnetically equivalent cyclen ring protons on a simple ytterbium(III) 
complex, [Yb(DOTA)]-.  Due to the presence of the paramagnetic Yb(III) ion, the 
resonance for this set of protons is shifted to 19.9 ppm, out of the typical biological 
range of 1H NMR spectroscopy. This was imaged simultaneously with sodium 
3-(trimethylsilyl)-1-propanesulphonate (DSS) and 3-(2-hydroxyethyl)thiazolium 
bromide (HETB), which display shifts on the limits of the standard ‘biological window’ 
at 0 ppm and 9.8 ppm respectively.  To investigate the possibility for multiplex 
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detection of these probes, they were imaged separately and as a mixture at the three 
different resonances, which indicated that simultaneous detection of all the 
investigated compounds was possible (Figure 1.22).  An experiment was also run that 
successfully incorporated DSS within a liposome to improve the in vivo applicability, 
with a commercial Gd(III) compound added to increase the relaxation rates.  These are 
promising preliminary results and it would be interesting to see the effect that 
changing the lanthanide ion in the DOTA complex would have on the shift observed, in 
addition to whether this concept could be applied to in vitro and/or in vivo studies. 
 
Figure 1.22  1H Chemical shift imaging agents (protons with relevant chemical shifts 
highlighted in blue) and colour overlays showing the chemical shift 
images at (A) 0 ppm (DSS resonance), (B) 9.8 ppm (HETB resonance), and 
(C) 19.9 ppm ([Yb(DOTA)]- resonance). Five phantoms contain equimolar 
proton concentrations of (i) DSS, (ii) HETB, (iii) DSS, HETB, [Yb(DOTA)]-, 
(iv) blank, (v) [Yb(DOTA)]-; YbCl3 was added to samples not containing 
[Yb(DOTA)]- to compensate for the bulk magnetic susceptibility effect of 
Yb(III).116      
 
1.6.2 Responsive systems 
A gadolinium-based probe has recently been developed for the in vitro imaging of 
protease activity, utilising variable transverse relaxation rates of 19F nuclei to signal 
enzyme cleavage.  The probe consists of three sections; a Gd(III) complex, a 19F-
containing label, and a peptide to link the two together (Figure 1.23).117  This peptide is 
designed as a substrate for caspase-3, which is of interest as it is an effective marker 
for cell apoptosis.  In its intact state, the 19F signal of the probe experiences large 
enhancement of the transverse relaxation rate, resulting in significant line broadening 
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and a weak signal.  However, addition of caspase-3 causes cleavage of the peptide 
bond, releasing the fluorine containing moiety.  As the fluorine is no longer in close 
proximity to the Gd(III) ion, the paramagnetic transverse relaxation enhancement is 
reduced and the 19F NMR signal intensity increases in a time-dependent manner.  
However, there are some severe limitations to this design, in that the process is 
irreversible and the longitudinal relaxation rate of the 19F signal after cleavage is slow, 
presenting the usual problem of long acquisition times in diamagnetic systems.  A 
related example has recently been reported whereby a 19F-containing aglycone 
derivative is cleaved in the presence of β-galactosidase, inducing a large 19F NMR 
chemical shift response.118  The released diamagnetic aglycone spontaneously traps 
ferric ions, rendering the 19F NMR signal invisible due to line broadening and 
generating intense proton MRI T2 contrast, allowing a dual modality approach to 
imaging.  This system has been applied to preliminary in vivo experiments. 
 
Figure 1.23  Design principle of probe to detect protease activity (top) and structure 
of probe used (bottom).  Time-dependent 19F NMR spectral change of 
probe after addition of caspase-3 at 37°C (top right).117 
 
An interesting system has been suggested by Aime and co-workers that utilises a 
fluorine- containing probe to allow local concentration of a pH-responsive Gd(III) 
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complex to be monitored, resulting in the possibility of ratiometric pH mapping.119  The 
probe consists of a poly-β-cyclodextrin (poly-β-CD) carrier comprising of 8-10 β-CD 
units, to which the separate Gd(III) and fluorine-containing molecules are non-
covalently bound via adamantane moieties (Figure 1.24).  The Gd(III) compound 
displays pH-sensitive modulation of relaxivity in the range of 6 to 9, with the variation 
in relaxivity increased by conjugation to the higher molecular adduct due to an 
increase in rotational correlation time.  The 19F signal, however, is not affected by 
changes in pH and so will be proportional to the fluorine density, allowing the local 
probe concentration to be calculated.  To avoid line broadening and resulting loss of 
signal, the system has been designed so that the fluorine-containing molecules are 
sufficiently far enough away from the Gd(III) ion that they do not experience significant 
transverse relaxation rate enhancement.  While this system has been successfully 
applied in vitro, major modifications would be necessary for in vivo application due to 
the competition effect that proteins, oxy-anions, and endogenous molecules would 
exhibit on both the adamantane to β-CD binding (e.g. KA = 1300 M
-1 for Gd complex to 
β-CD and 13000 M-1 for Gd complex to HSA) and on the availability of water molecules 
to the gadolinium probe. 
 
Figure 1.24  Schematic representation of potential ratiometric pH mapping probe 
containing a pH-responsive Gd(III) complex, a concentration reporting 
fluorinated molecule, and a poly-β-CD adduct.119  
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1.6.3 Previous work in the group 
 
 
 
Figure 1.25  (A) pH Dependence of the 19F chemical shift for the holmium 
sulphonamide complex in water, urine, and plasma; (B) the variation of 
chemical shift for the two isomers of the holmium ortho-cyano amide 
complex.75,120,121  
 
Research in Durham over the last five years has led to the development of a number of 
novel fluorinated paramagnetic lanthanide(III) complexes with interesting 19F magnetic 
resonance behaviour.  From the theory outlined in Section 1.3, these have been based 
on tetraazacyclododecane (cyclen) derivatives, in which a homotopic CF3 group has 
been incorporated in the region of 4.5 – 7.5 Å from the paramagnetic centre, in order 
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to increase the 19F relaxation rate by around two orders of magnitude.  The first 
examples were designed as 19F NMR chemical shift pH probes, with two different 
designs of complex investigated whereby variation in pseudocontact shifts result in 
dramatic amplification of shift non-equivalence between the acid and base forms in 
each case.  The first was based on a fluorinated sulphonamide system and displayed 
reversible slow exchange between the low and high pH forms, resulting in a 19F signal 
for each form whose relative ratio varied with pH.120,121  The associated pKa of this 
process was 5.71 in 0.1 M NaCl solution, however this rose to 6.92 in serum or urine 
due to competitive hydrogen carbonate binding shifting the process in favour of the 
acid form (Figure 1.25.A).  The 19F chemical shift difference between the two forms 
was 40 ppm, with the basic species observed as two diastereoisomers. 
 
The second pH responsive system was based on fluorine-containing mono-amide 
derivatives, with protonation/deprotonation of the amide nitrogen occurring with 
varying pH.  A range of substituents was investigated, with the most promising results 
being displayed by the ortho-cyano system (pKa = 7.1, Figure 1.25.B).
121,75  Unlike the 
sulphonamide example, the exchange between the acid and base forms is fast on the 
NMR timescale, resulting in the observation of an averaged signal that varies in shift as 
the pH is altered.  This system exists as two major isomers due to restricted rotation 
about the aryl carbon-nitrogen bond.  Each isomer exhibited a large chemical shift 
non-equivalence in addition to differing pH-dependent shifts, allowing the shift 
separation between the two isomers (ΔδF = 14 ppm) to be used to calculate the pH.  In 
both cases, this alleviates the requirement for calibration of chemical shift, as in this 
case pH can be measured as a chemical shift separation and in the previous 
sulphonamide example it relies upon measuring the ratio of two signals. 
 
The limitations to the examples discussed above were numerous isomeric species in 
solution and linewidths greater than anticipated, due to prototropic exchange or 
dynamic intramolecular conformational exchange processes.  For in vivo applications, 
it is necessary to maximise any signal observed, therefore promotion of one major 
isomer and reduction of any chemical exchange line broadening in solution is vital.  
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Therefore a number of systems were investigated in an attempt to improve the signal 
intensity obtained.122  The most promising system studied involved mono-amide 
triphosphinate complexes, as they possessed increased longitudinal relaxation rates 
over their carboxylate analogues (CF3 around 0.3 Å closer to Ln(III) in phosphinates 
compared to carboxylates) yet displayed narrower linewidths due to the bulkier 
phosphinate groups suppressing dynamic motion of the complex.  They also give rise 
to one major isomer (>85%) in solution, as shown in Figure 1.26.  In order to maximise 
signal intensity with this system, phantom experiments were run with the series of 
Ln(III) ions of this complex (Figure 1.26.c).123  From this it was determined that 
dysprosium(III) complex gave the highest signal intensity at 7 T, with an overall lower 
limit for detection by imaging of 20 µM.  Ultrafast imaging sequences can also be 
employed to increase signal intensity further.124  However, despite all the advances in 
these systems, an in vivo 19F magnetic resonance signal has so far proved elusive, 
necessitating the need for further improvements in signal intensity. 
 
Figure 1.26 19F NMR spectra of the monoamide carboxylate (a) and phosphinate 
analogue (b) indicating greatly reduced isomerisation in the phosphinate 
complex. (c) Phantom imaging data acquired for the phosphinate 
complex with different Ln(III) ions at 7.0 T with image intensities scaled 
to the same value; Inset Y image scaled in intensity by a factor of 
10.122,123 
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1.7 Project Aims 
The aim of this work is to continue the advancement of fluorinated paramagnetic 
lanthanide complexes as probes for 19F magnetic resonance imaging and spectroscopy 
by the synthesis and evaluation of novel systems, with the main goal to develop a 
system that is applicable for in vivo studies.  Therefore, it is imperative to improve on 
the signal intensity that has been observed in previous examples.  There are two main 
methods that will be investigated in order to do this.  The first is to incorporate 
numerous complexes into high molecular weight adducts, examples of which were 
discussed in Section 1.5.  This should have two significant benefits for in vivo use; the 
overall fluorine signal density per unit concentration should be dramatically increased 
by having a number of complexes bound to one conjugate, and the clearance rate from 
the body should be greatly reduced.  Other forms of complex will also be examined 
with a view to improving the signal intensity by further reducing dynamic motion and 
increasing the rigidity of the compound.  It is also important that any new systems 
developed are present as one major isomer in solution and any fluorine signals present 
display one main resonance in their 19F NMR spectra.                                                                                                                                                                                                                                                                                          
 
Further investigations will also be carried out into the development of responsive 
probes, the importance of which was detailed in Section 1.4.  A particular emphasis will 
be placed on designing systems that are sensitive to variation in pH and/or signal the 
presence of biologically significant anions, with any changes ideally reported by 
significant modulations in the 19F chemical shift.  Any sensitivity discovered will also be 
analysed by a second method (variations in relaxivity, emission, etc.) to validate the 
results. 
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2. Development of Responsive Probes  
2.1 Introduction 
As introduced in Chapter 1, 19F NMR spectroscopy studies with fluorinated probes 
offer substantial opportunity, due to the favourable properties (high receptivity and 
Larmor frequency) of the nucleus.  In addition, the large chemical shift range is 
generally an order of magnitude greater than for 1H NMR spectroscopy.  As has been 
previously demonstrated, the long acquisition times of 19F MRS studies can be 
alleviated somewhat by the introduction of a paramagnetic lanthanide centre in close 
proximity to the observed fluorine nucleus.1,2  The introduction of a Ln(III) ion can also 
have the added benefit of amplifying chemical shift non-equivalence, via the pseudo-
contact shift mechanism (see Section 1.3.1), allowing a general means of tracking 
changes in probe geometry by using NMR spectroscopy or chemical shift imaging.  This 
concept has been applied previously in Durham, by positioning a CF3 group within 6 to 
6.5 Å of a lanthanide ion linked by an amide bond.1,3,4  As the pH passes through the 
amide bond pKa, this is signalled by the CF3 group as a shift in δF.  The presence of the 
Ln(III) ion accentuates the difference in chemical shift between the acid and base 
forms of the complex.  This value is up to 36 ppm over the physiological pH range, 
offering a vast improvement over systems currently in use (ΔδH ≈ 1 ppm).
5,6  
 
This principle will be employed here in the development of new responsive probes.  
Two different strategies for probe design can be envisioned, depending on whether 
the process under investigation leads to either a reversible change in structure or an 
irreversible alteration of the probe.  In each case, in order for the relaxation rates of 
the CF3 group to remain unaltered, it is preferable that the distance between the Ln(III) 
ion and the fluorinated label should stay fixed.  These concepts have led to the 
development of two different probe designs reported here.  The first involves the 
reversible interaction of anions with the probe at the metal centre by displacement of 
weakly coordinated water molecules.  This is accompanied by a change in the local 
ligand field, and is reported as variation in δF.  The second example exploits an 
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irreversible amide hydrolysis that is enzyme activated.  Careful positioning of the CF3 
label allows the perturbation in local electron density to be signalled by a shift of δF. 
 
2.2 An Anion Responsive System 
There is a range of illnesses associated with abnormal levels of anions in the body.  
Therefore, it is of great importance to develop probes that can report on relative levels 
of specific analytes.  In order to be applicable, the key properties for a probe that 
responds to a certain analyte are as follows; 
 The probe must be sensitive to a specific analyte in competitive media 
 There must be an easy and direct method for monitoring analyte levels 
 Any changes should be accompanied by large variations in the parameter being 
monitored, i.e. large shift changes in the 19F NMR spectrum 
 The probe should be water soluble and fully functional in aqueous solution 
 Binding should be fully reversible  
N N
NN
H
O
O H
N
O
O
O
CF3
RLnH2O
N N
NN
H
O
O H
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O
O
O
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RLnHO
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O
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Scheme 2.1 Variation in lanthanide ion speciation following reversible anion binding 
(citrate in this example).  
 
For the detection of anions, most reported lanthanide probes have been based on the 
displacement of water at the metal centre in a coordinatively unsaturated 
heptadentate complex.  The majority of cases use modulation of lanthanide 
luminescence as the signalling method.7–9  This concept has been incorporated in the 
design of the cationic monoamide complexes investigated here, [Ln.L1]+ and [Ln.L2]+, in 
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which the coordinated water is displaced by an anion, while the CF3 label remains in a 
constant relative position (Scheme 2.1).  [Ln.L2]+ contains a cyano-group (Scheme 2.2), 
which should significantly reduce the pKa of the amide nitrogen, and it will be of 
interest to investigate how this affects the behaviour of the complex. The ability of the 
two complexes to report on the concentration of biologically significant anions by 
variations in δF is discussed below, along with full synthetic details and spectroscopic 
properties.   
 
2.2.1 Synthetic details 
The syntheses of [Ln.L1]+ and [Ln.L2]+ are fairly straightforward, requiring only a few 
steps and resulting in relatively high overall yields (Scheme 2.2).  Firstly, the 
α-chloroamides (1 and 9) were made from the relevant amines by stirring with sodium 
hydride to deprotonate the amine, followed by the addition of chloroacetyl chloride.  
These were then purified over silica gel.  Controlled alkylation of the tertiary butyl 
ester of 1,7-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DO2A, synthesised by 
published methods10,11) by mild heating with the α-chloroamides and sodium 
carbonate resulted in the formation of the corresponding mono-amides, 5 and 10, 
which were purified by column chromatography.  The tert-butyl ester protecting 
groups were removed by stirring overnight with trifluoroacetic acid in 
dichloromethane, to generate the di-acid ligands as the triflate salts.  Metal 
complexation was achieved using an aqueous solution of the appropriate metal 
chloride at pH 5.5 and 60°C overnight, before the pH was raised to 10 in order to 
precipitate any excess Ln(III) ions as the metal hydroxide.  The free metal was removed 
by centrifugation before the pH was lowered back to 5.5 and the water removed by 
lyophilisation.  The resulting solid was extracted into a mixture of methanol and 
dichloromethane and insoluble material again removed by centrifugation.  Pre-treated 
anion exchange resin was used to prepare the chloride salts of [Ln.L1]+ and [Ln.L2]+. 
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Scheme 2.2 General procedure for the synthesis of [Ln.L1]+ and [Ln.L2]+ (yields stated 
for R=CN; yields for R=H are comparable). 
 
2.2.2 Characterisation of complexes 
Low resolution electrospray and high resolution accurate mass spectrometry was 
carried out to confirm the constitution of each complex.  A characteristic isotope 
pattern was observed in each case, showing good correlation with the calculated 
spectrum.  An example is shown in Figure 2.1.  19F NMR spectroscopic data were also 
collected for each complex.  In all cases, one major isomer appeared to form in 
solution (>85 %) with the appearance of a number of small, minor isomers.  For the 
following discussion, the chemical shift values quoted refer to the dominant isomer. 
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Figure 2.1 Theoretical (top) and experimental (bottom) high resolution electrospray 
mass spectrum of [Eu.L2]+ showing characteristic isotope pattern. 
 
Crystals of [Tm.L2]+ were grown from aqueous solution, from which the X-ray structure 
was determined (Figure 2.2).  These were the first molecular structures generated for 
such fluorinated lanthanide complexes, and revealed the geometry of the charge 
neutral conjugate base, which is formed following deprotonation of the amide NH 
proton.  Analysis of this molecular structure divulges several interesting features.  
There is a single coordinated water molecule, which is located 0.55 Å out of the plane 
defined by the other three coordinated oxygen molecules.  The twist angle between 
the N4 and O4 planes (38.4o) is typical of related square anti-prismatic eight 
coordinate complexes.12,13  The individual fluorine atoms have Tm-F distances of 5.34, 
6.78, and 7.33 Å, with an average distance of 6.48 Å.  This average distance is likely to 
be more relevant when comparing behaviour in the solution state as fast rotation 
about the C-CF3 bond occurs in solution.  The amide carbon-nitrogen bond is relatively 
short (1.30 Å), consistent with its double bond character resulting from deprotonation 
of the amide group and charge delocalisation into the o-cyano moiety. 
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Figure 2.2 Views of the molecular structure of [Tm.L2]+ from the X-ray analysis 
viewed from the side (top) and down the z-axis (bottom) showing the 
bound water molecule that can be displaced upon addition of anions. 
Atoms shown are C (grey), N (blue), O (red), F (light green), and Tm (dark 
green). H atoms are omitted for clarity. Further data for the molecular 
structure above are included in Section 6.1.6. 
  
2.2.3 Anion responsive behaviour of the R=H system, [Ln.L1]+ 
Changes in the 19F NMR parameters for the Ho(III) and Tm(III) complexes of L1 were 
investigated, upon addition of up to a ten-fold excess of the sodium salts of 
bicarbonate, citrate, lactate, and hydrogen phosphate at pD 7.4 in HEPES buffer (Table 
2.1).  Addition of the anions resulted in a characteristic 19F chemical shift for each 
adduct formed.  The large shift non-equivalence between the different ternary adducts 
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and the aqua species were promising, with around a 20 ppm range in resonance values 
exhibited by both complexes.   
 
Table 2.1 19F NMR spectroscopy data for [Ln.L1]+ and their anion adducts (D2O, 
188 MHz, 295 K, pD 7.4, 2 mM complex, 50 mM HEPES, 20 mM anion). 
Complex Anion δF / ppm R1 / Hz Linewidth, ωf / Hz 
[Ho.L1]+ aqua species -76.8 45 67 
 bicarbonate -66  broad(a) 
 lactate -64.6  214 
 phosphate -53.6  230 
 citrate -66.5 48 208 
[Tm.L1]+ aqua species -67.6 23 120 
 bicarbonate -63.2  189 
 lactate -70.2  99 
 phosphate -83.0  198 
 citrate -72.3(b) 25 175 
(a) Linewidth > 1500 Hz; (b) Significant decomplexation of the Ln ion from the ligand was observed over 
a period of 24 h. 
 
Linewidth broadening was not too severe in the resulting ternary adducts, in 
comparison with the aqua species, with the exception of the bicarbonate adduct of 
[Ho.L1]+.  Chemical exchange broadening was apparent with some of the other 
adducts, but to manageable levels.  Unfortunately, with an equimolar mixture of the 
anions, no significant preference for binding to a given anion was observed for either 
complex.  Instead, single resonances corresponding to all the individual adduct species 
were observed, with increased linewidth broadening attributed to chemical exchange 
between the free and bound anion adducts that is fast on the NMR timescale. 
 
Another major limiting feature of this system is the modest stability of the compounds 
to decomplexation of the Ln(III) ion by the added anions.  This was most apparent with 
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[Tm.L1]+, in particular upon the addition of citrate.  Figure 2.3 shows the 19F NMR 
spectra for the aqua species, the ternary adducts for each anion, and the ligand, L1.  As 
well as the major signals corresponding to the anion bound complexes, there is a 
significant signal observed that corresponds to the decomplexed ligand at -61.7 ppm.  
This is most noticeable for the citrate bound species, which undergoes substantial 
decomplexation almost immediately following addition of 20 equivalents of citrate.  
Smaller additions of citrate do allow the citrate bound ternary adduct to be observed 
independently without significant decomplexation occurring.  However, leaving the 
complexes in solution with any of the anions for a longer period of time (>1 week for 
citrate, >1 month for the other species) led to almost complete decomplexation 
occurring.  This made this system impractical for applications and so it was not studied 
further. 
 
Figure 2.3 19F NMR spectra for [Tm.L1]+ before and after the addition of anions; 
(a) aqua species, (b) 20 equivalents lactate, (c) 20 equivalents 
phosphate, (d) 20 equivalents citrate, (e) 20 equivalents bicarbonate, 
(f) L1 before the addition of any Ln(III) ion, with dotted line indicating 
position of signal relating to the ligand at -61.7 ppm (9.4 T, 2 mM 
complex, 50 mM HEPES, D2O, 295 K, pD 7.4). 
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2.2.4 Anion responsive behaviour of the R=CN system, [Ln.L2]+ 
2.2.4.1 pH dependent behaviour 
For the previous compound, where R=H, the pKa associated with the amide nitrogen is 
> 8.5 and, hence, lies outside the biological pH range that is of interest with these 
studies.  However, the introduction of a cyano-group at the ortho-position of the 
aromatic ring has been shown to significantly increase the acidity of the amide 
moiety.1  Therefore, before any investigation into potential anion binding behaviour, it 
was imperative to understand how the 19F NMR chemical shift varied with pH.  
 
Figure 2.4 Partial UV absorption spectrum (left) and pH profile (right) generated by 
monitoring the change in intensity of the absorbance at 300 nm for 
[Tm.L2]+. 
 
The protonation/deprotonation of the amide group can be followed by changes in the 
UV absorption spectral profile, due to charge delocalisation from the amide carbonyl 
bond into the o-cyano moiety of the aromatic ring upon formation of the conjugate 
base.  In particular, a significant decrease in the absorbance band at 300 nm was 
observed as the pH was lowered (Figure 2.4).  By plotting the intensity of this band as a 
function of pH and fitting the resulting curves, the pKa of the amide was measured.  
The values obtained for the different complexes are shown in Table 2.2. 
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Table 2.2 pKa values for [Ln.L
2]+ calculated by measuring changes in intensity of the 
UV absorbance band at 300 nm as a function of pH. 
Complex pKa
 
[Ho.L2]+ 7.01 (± 0.03) 
[Tm.L2]+ 6.57 (± 0.06) 
[Eu.L2]+ 6.10 (± 0.04) 
 
For [Ho.L2]+, the deprotonation of the amide nitrogen was also followed by 19F NMR 
spectroscopy by monitoring changes of δF as a function of pH (Figure 2.5).  A 7 ppm 
difference in the shifts was found for the protonated and deprotonated forms.  For 
intermediate pH values only one signal is observed, corresponding to the weighted 
average of the chemical shifts of the individual forms.  This behaviour is consistent 
with an acid-base equilibrium that is fast on the NMR timescale and is accompanied by 
an increase in chemical exchange line-broadening, as was observed for related 
systems.1,4  The resulting pH profile generated is in good agreement with the curve 
obtained from the UV absorbance study (Figure 2.6).  For [Tm.L2], the exchange 
broadening was so severe that a fluorine NMR signal could only be observed under 
acidic conditions (at pD 4, 9.4 T, and 295 K; δF = -61.4 ppm, R1 = 67 Hz).  As the pH 
increased, exchange between the acid and base forms caused linewidth broadening 
and the peak was barely discernible (linewidth > 1500 Hz).  Therefore, a similar plot of 
pH versus δF for the thulium compound was not generated. 
 
Figure 2.5 19F NMR spectra of [Ho.L2]+ at selected pH values. 
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Figure 2.6 pH profile for [Ho.L2]+ generated by monitoring changes in intensity of 
the UV absorbance band at 300 nm (blue) and the change in the 
chemical shift of the 19F NMR signal (red). 
 
2.2.4.2 Anion responsive behaviour 
After carrying out promising preliminary 19F NMR spectroscopy studies, it was decided 
to first investigate the anion affinities of the emissive europium complex, [Eu.L2]+, as 
the emission spectra of Eu(III) complexes are amenable to examination and have been 
frequently studied in the literature.7  Ideally, the complex would contain a sensitising 
chromophore to absorb light energy and transfer this to the europium 5D1
 or 5D0 
excited states.  However, due to the lack of such ‘antennae’, the Eu(III) ion had to be 
directly excited at 397 nm, which led to weak but interpretable spectra being recorded 
(Figure 2.7).  Incremental addition of anions could be observed by monitoring the 
changes in the form and intensity of the europium emission bands, in particular 
variations in the ΔJ = 1 and ΔJ = 2 bands.  The addition of lactate, citrate, and 
bicarbonate led to significant increases in the intensity of the ΔJ = 2 band.  However, 
with added phosphate, the ΔJ = 2 band remained relatively unchanged.  Instead, a 
change in the form of the ΔJ = 1 band is observed.  This suggests a difference in binding 
modes between the carboxy anions and phosphate. 
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Table 2.3 Apparent binding constants for [Eu.L2]+ with selected anions, calculated 
from changes in the ratio of the ΔJ = 2 to ΔJ = 1 emission bands (H2O, pH 
7.4, 50 mM HEPES, 2 mM complex, 0 to 100 mM anion, 295 K, 
λexc = 397 nm). 
Anion log K (±0.05) 
citrate 2.71 
lactate 1.98 
phosphate 1.93 
bicarbonate 0.81 
citrate in anion mixture(a) 1.95 
(a) Citrate competition experiment involved incremental addition of sodium citrate to a solution 
containing complex (2 mM), HEPES (50 mM), sodium bicarbonate (20 mM), sodium 
dihydrogenphosphate (1 mM), and sodium lactate (2 mM). 
 
In each case, by plotting the change in the intensity ratio of the Eu(III) ΔJ = 2 to ΔJ = 1 
emission band areas as a function of added anion concentration, relative binding 
affinities were calculated using reported methods (Table 2.3).7,14–16  At pH 7.4, these 
calculated binding affinities suggest selectivity for citrate over the other anions tested.  
A ‘competition’ experiment was run, incrementally adding citrate to the complex in a 
fixed background of the other anions at biologically relevant concentrations.  It was 
observed that citrate bound selectively, but with a reduced apparent affinity, 
associated with a Kd value of the order of 10 mM. 
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Figure 2.7 Eu(III) emission spectra and accompanying fits of the ΔJ = 2/ΔJ = 1 
intensity ratio against anion concentration for [Eu.L2]+ with incremental 
addition of; (a) citrate, (b) bicarbonate, (c) lactate, (d) phosphate, and 
(e) citrate in a fixed background of 20 mM bicarbonate, 2 mM lactate, 
and 1 mM phosphate (H2O, pH 7.4, 2 mM complex, 50 mM HEPES, 295 K, 
λexc = 397 nm). 
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These results, in particular the selectivity displayed for citrate over the other analytes 
tested, were extremely promising.  Accordingly, the 19F NMR spectra of [Ho.L2]+ and 
[Tm.L2]+ were measured before and after the addition of a ten-fold excess of the 
sodium salts of bicarbonate, citrate, lactate, and hydrogen phosphate at pD 7.4 in 
HEPES buffer.  In the case of the holmium species, addition of the anions again 
resulted in shifted resonances with a characteristic 19F chemical shift for each adduct 
formed (Table 2.4), as was observed with [Ln.L1]+.  Chemical shift values for the citrate 
and lactate bound species were most similar, suggesting a common coordination mode 
to the Ln(III) ion, involving chelation of the α-hydroxy and carboxylate groups.  This is 
consistent with the similar europium emission profiles of the two complexes, in 
addition to reported crystallographic analyses of related compounds.17  For the 
thulium complex, however, exchange broadening remained so extreme that no signal 
was observed for any species, except the citrate bound adduct.   
 
While the chemical shift non-equivalence for the different ternary adducts of [Ln.L2]+ 
was not as high as for [Ln.L1]+, they did not display any evidence of decomplexation 
upon addition of anions, even over relatively long periods of time, which was the 
major drawback in the earlier experiments with [Ln.L1]+.  For a given field, the R1 values 
for the complexes of L2 were also significantly faster than for the corresponding L1 
compounds.  For example, at 4.7 T the R1 values for [Ho.L
1]+ and [Ho.L2]+ were 45 and 
83 Hz respectively.  Utilising knowledge gained from the X-ray analysis of [Tm.L2]+, and 
given the r-6 dependence of R1 (see Section 1.3), it can be estimated that the CF3 group 
is around 0.6 Å closer to the lanthanide ion in complexes of L2 compared to those of L1.  
In each case, R1 values were not significantly altered upon binding of anions, 
suggesting that the Ln-F distance does not change upon anion binding, as surmised in 
the design of the probe. 
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Table 2.4 19F NMR spectroscopic data for [Ln.L2]+ and their anion adducts (D2O, 
188 MHz, 295 K, pD 7.4, 2 mM complex, 50 mM HEPES, 20 mM anion). 
Complex Anion δF / ppm R1 / Hz Linewidth, ωf / Hz 
[Ho.L2] aqua species -66.3 83 420 
 bicarbonate -64.6  400 
 lactate -68.6  1200 
 phosphate -64.8  700 
 citrate -68.0 91 260 
 mixture(a) -68.1 92 250 
[Tm.L2](b) aqua species No signal observed  
 bicarbonate No signal observed 
 lactate No signal observed 
 phosphate No signal observed 
 citrate -61.1 54 134 
(a) Mixture consists of 10 equivalents each of phosphate, bicarbonate, lactate, and citrate; (b) only 
addition of citrate gave rise to an observable signal at pD 7.4. 
 
As before, introduction of the anions led to a general exchange broadening of the 
observed signals of the corresponding ternary adducts, dramatically so in the case 
[Tm.L2].  With [Ho.L2], an exception occurred for addition of citrate, when a significant 
reduction in linewidth was observed from 420 Hz for the aqua species to 260 Hz for the 
citrate adduct.  This behaviour suggested a slower rate of exchange between anion 
and aqua species than for the other anions, consistent with a higher affinity constant.  
Earlier, the binding constants generated by analysis of europium emission spectra had 
also indicated selectivity for citrate over the other anions tested.  For a mixture of the 
holmium complex and ten equivalents each of citrate, lactate, phosphate, and 
bicarbonate, the only signal observed in the resulting 19F NMR spectrum correlates to 
the signal observed for the citrate adduct, confirming the selectivity of this system. 
 
Now that the selectivity of the system for citrate had been determined, it was decided 
to investigate the binding of this anion in more detail.  Citrate (0 to 30 mM) was 
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incrementally added to a fixed concentration of the complex (2 mM) and HEPES 
(50 mM), with the 19F NMR spectrum obtained after each addition.  This allowed free 
and bound species to be observed simultaneously (Figure 2.8), consistent with 
chemical exchange between the aqua species and the citrate adduct that is slow on 
the NMR timescale.  Following addition of half an equivalent of citrate, each species 
was observed in around a 50:50 ratio.  By measuring the ratio of the areas of each 
peak as a function of [citrate], a rough binding curve could be generated.  However, 
due to the broad and overlapping nature of the peaks, the data obtained was not 
accurate enough to determine an affinity constant. 
 
Figure 2.8 19F NMR spectra of [Ho.L2] (4.7 T, 4 min spectral acquisition time, 2 mM 
complex, 50 mM HEPES, D2O, 295 K, pD 7.4) following addition of 
increasing amounts of citrate. Bottom spectrum shows signal for 
complex before addition of citrate. Top spectrum after addition of 
twenty equivalents of citrate; only the signal corresponding to the citrate 
adduct was observed. 
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For [Tm.L2], the case was complicated somewhat by the extreme exchange broadening 
apparent in the system.  However, the fact that the signal was observed only for the 
citrate species, and that it was present as a relatively sharp resonance, suggests that 
the thulium compound is also selective for citrate.  Addition of a mixture of the other 
anions to this citrate adduct did not result in any change in the 19F NMR spectrum, 
confirming this hypothesis.  As there was no other signal to which to compare the 
intensity of the signal, and in order to analyse the binding behaviour, it was necessary 
to employ an internal, fixed reference.  Using trifluoroethanol as the reference 
compound, this procedure allowed incremental addition of citrate at pD 7.4 to be 
monitored by 19F NMR spectroscopy (Figure 2.9.a).  The ratio of the two signals was 
compared as a function of [citrate].  In this case, the two signals are sufficiently far 
apart (ΔδF ≈ 16 ppm) and narrow that an affinity constant could be measured from the 
resulting binding curve (Figure 2.9.b).  This generated a value (log K = 2.79 (± 0.03)), 
corresponding well to that defined by monitoring the emission spectral changes for 
[Eu.L2] (log K = 2.71 (± 0.05)). 
 
Figure 2.9 (a) 19F NMR spectra of [Tm.L2] (4.7 T, 4 min spectral acquisition time, 
3 mM complex, 50 mM HEPES, 0.2 mM CF3CH2OH, D2O, 298 K, pD 7.4) 
following addition of increasing amounts of citrate. Bottom spectrum 
shows the signal for the complex before addition of citrate. Top 
spectrum was obtained after addition of excess citrate; only the signal 
corresponding to the citrate adduct is observed. (b) Resulting binding 
curve, showing the fit (line) to the experimental data, following the 
increase in relative intensity of the [Tm.L2(citrate)] signal at -61.1 ppm 
as the ratio of total signal area with respect to added trifluoroethanol at 
-77.3 ppm. Integrals normalised so that maximum ratio = 1. 
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2.3 A Probe for Signalling Ester Hydrolysis 
Fluorinated lanthanide probes have previously been utilised for the signalling of 
enzyme-activated cleavage, but have been mainly based on an ‘on/off’ mode of action 
with dramatic changes in relaxation rates upon cleavage.18,19  However, it is more 
desirable for the fluorine containing moiety to remain a fixed distance from the Ln(III) 
ion, so that R1 and R2 are minimally perturbed, allowing standard pulse sequences to 
be employed throughout the monitoring process.  Accordingly, such a probe was 
developed by De Luca that contained an integral CF3 group in an amide bound subunit 
(Scheme 2.3).20,21  
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Scheme 2.3 Envisaged stepwise cleavage induced by pig-liver esterase. Second step 
is not observed experimentally without the use of elevated pH.20,21  
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 The distal ester group was designed to undergo irreversible cleavage in the presence 
of pig-liver esterase, followed by relayed self-immolative hydrolysis of the para-
substituted aryl ester group.  This process was expected to lead to a change in the 
chemical shift of the reporting CF3 group, amplified by the presence of the 
paramagnetic lanthanide ion.  However, it was found that whilst the initial ester 
hydrolysis did occur, following the addition of pig-liver esterase, very little change was 
observed by 19F NMR spectroscopy.  Reaction progress had to be followed by mass 
spectrometry.  At physiological pH, complete hydrolysis via the self-immolative 
pathway was not observed, and could only be triggered by raising the pH to 10.  The 
19F NMR spectra for this system were also rather complex, owing to the presence of 
several isomers in solution. 
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Figure 2.10 Chemical structure of [Ln.L4] 
 
With this previous work in mind, we set out to improve the behaviour of this system.  
In order to reduce the number of isomers present in solution, the carboxylate pendant 
arms were replaced by phosphinate groups, increasing the rigidity of the complex and 
reducing the number of observed isomers, as shown previously.22  In an attempt to 
coerce the self-immolative behaviour, the distal ester group was replaced by an amide, 
creating a substrate for α-chymotrypsin.  The resulting target molecule, [Ln.L4], is 
shown in Figure 2.10.  The ability of this complex to signal ester hydrolysis by 
variations in δF is discussed below.  
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2.3.1 Synthetic details 
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Scheme 2.4 General procedure for the synthesis of the intermediate complex, [Ln.L3]. 
 
For the synthesis of [Ln.L4], the ester bond was formed from the corresponding 
p-carboxylic acid complex, [Ln.L3], in the final step (Scheme 2.4).  The synthesis of the 
intermediate triphosphinate complex, [Ln.L3], began with oxidation and esterification 
of the nitrile compound, followed by alkylation to generate the previously reported 
α-chloroamide, 16.1  Monoalkylation of cyclen in acetonitrile gave 17, using an excess 
of the macrocycle to prevent over-alkylation and to act as the base in the reaction.  
Soxhlet equipment was used in a one-pot synthesis involving a co-condensation of the 
mono-alkylated macrocycle with paraformaldehyde and diethyl methylphosphonite.  
An Arbusov rearrangement yielded the desired triethylphosphinate ester, 18, which 
was formed as a mixture of stereoisomers differing in configuration at each 
stereogenic phosphorus centre.  Alumina gel column chromatography was initially 
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used to purify this compound.  However, improved separation was achieved utilising a 
3:1 mixture of alumina and silica respectively.   
 
Ideally, acid hydrolysis would have been performed to remove the ester protecting 
groups, due to the simple work-up required and faster reaction times.  However, such 
conditions can also lead to cleavage of the amide bond, and so base hydrolysis was 
employed instead, using 0.1 M KOD solution at 40°C, with the reaction being 
monitored by 1H, 19F, and 31P NMR spectroscopy.  Under these conditions, no cleavage 
of the amide bond was observed, and hydrolysis of all of the ester groups generally 
took 2-3 days to complete.  After this time, the pH was lowered and the solvent 
removed before the ligand, L3, was extracted with ethanol.  Metal complexation was 
achieved using an aqueous solution of the appropriate metal chloride at pH 5.5 and 
60°C, before the pH was raised to 10 in order to precipitate any excess Ln(III) ions as 
the metal hydroxide.  The free metal was removed by centrifugation before the pH 
was lowered back to 5.5 and the intermediate complex, [Ln.L3], was purified by 
preparative reverse phase HPLC.   
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Scheme 2.5 Alternative pathways for the synthesis of [Ln.L4] 
 
The ester, [Ln.L4], was then prepared via two different methods (Scheme 2.5).  The first 
method involved O-alkylation with N-(4-(chloromethyl)phenyl)acetamide and 
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potassium carbonate as the base.  The second proceeded by a coupling reaction with 
N-(4-(hydroxymethyl)phenyl)acetamide, mediated by HATU.  Crude products from 
both reactions were purified by reverse phase HPLC and each resulted in a 35 % yield. 
 
2.3.2 Characterisation of complexes 
Low resolution electrospray and high resolution accurate mass spectra were obtained 
to confirm the constitution of the complexes.  Characteristic isotope patterns were 
observed in each case that showed a good correlation with the calculated spectra.  
19 F NMR spectroscopic data was collected for each complex, revealing the presence of 
one observable signal in solution, consistent with the formation of one major isomeric 
species in solution. 
 
2.3.3 Signalling a remote functional group transformation 
In order to test the ability of these probes to report enzyme hydrolysis, 
α-chymotrypsin was added to solutions of [Dy.L4] and [Tm.L4], and the resulting 
mixtures stirred at 25°C in water at pH 7.4.   The 19F NMR spectra were acquired 
periodically to follow the reaction as a function of time.  In each case, a negative 
control was applied by simultaneously monitoring a sample containing the complex 
without the presence of the enzyme. 
 
For [Dy.L4], the paramagnetic enhanced 19F chemical shift non-equivalence was 
4.9 ppm between [Dy.L4] (- 69.4 ppm) and the product carboxylate complex, [Dy.L3] 
(- 64.5 ppm).  This allowed straightforward monitoring of the cleavage reaction.  
However, the 19F NMR signal for [Dy.L4] suffers from increased exchange broadening at 
pH 7.4, due to the associated lower pKa of the internal amide group with a para-ester 
substituent, in comparison to the acid functionality found in [Dy.L3].  This behaviour 
had been previously observed with related systems.1,4  Therefore, in order to reduce 
this exchange broadening, the pH was temporarily lowered to 6.5 during spectral data 
acquisition, before being increased back to pH 7.4 for the reaction to proceed.  The 
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series of 19F NMR spectra for [Dy.L4] over time after the addition of α-chymotrypsin 
are shown in Figure 2.11. 
 
Figure 2.11 Change in the 19F NMR spectrum of [Dy.L4] as a function of time, 
following cleavage of the remote amide bond induced by α-chymotrypsin 
(H2O, pH 7.4, 9.4 T, 295 K); spectra above measured at pH 6.5 with a D2O 
coaxial insert to lock the NMR instrument; substrate spectrum is at the 
top, product at the bottom. 
 
As can be seen from the 19F NMR spectra, upon enzymatic cleavage the reaction 
proceeds directly to the product acid complex, [Dy.L3], with no signal observed for the 
intermediate amino compound.  The above spectra show the ease of interpretation of 
this system, as the relative intensities of the two clearly defined peaks can be readily 
measured as a function of time after addition of the enzyme.  However, the major 
drawback was the very slow rate of reaction, taking around 10 days to reach 
completion.  After this time, an HPLC chromatogram was acquired of the reaction 
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mixture, showing >95 % conversion of the substrate, [Dy.L4], into the product, [Dy.L3] 
(Figure 2.12). 
 
 
Figure 2.12 HPLC chromatograms of: (a) [Dy.L4], (b) [Dy.L4] + α-chymotrypsin after 
10 days, and (c) [Dy.L3]. 
 
For [Tm.L4], the behaviour was more complex.  The 19F chemical shift non-equivalence 
was even larger for this system, at 12.1 ppm between the ester [Tm.L4] 
(δF = -102.4 ppm) and the product carboxylate complex, [Tm.L
3] (δF = -90.3 ppm).  
However, when α-chymotrypsin was added to [Tm.L4], only a weak signal was 
apparent in the region expected for [Tm.L3].  Indeed, this was barely discernible above 
the baseline noise and did not get stronger over time.  A new, exchange broadened 
shift appeared at -77 ppm (Figure 2.13).  This may be due to the formation of an 
adduct between the enzyme and the cleaved product, [Tm.L3], which is in chemical 
exchange and leads to linewidth broadening.  In order to confirm this, α-chymotrypsin 
was added to a separate sample of [Tm.L3] and the 19F NMR spectrum recorded.  The 
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same signal at -77 ppm was observed, albeit to a much lesser extent.  This behaviour 
suggests there is some interaction occurring between this complex and the enzyme 
that was not apparent with the dysprosium analogue.  More analyses would have to be 
carried out in order to fully understand the behaviour of this system with α-
chymotrypsin, although separate mass spectral analysis revealed the presence of 
[Tm.L4], [Tm.L3], and the intermediate amine, suggesting that the reaction process was 
proceeding.  
 
Figure 2.13 19F NMR spectra for; (a) [Tm.L3], (b) [Tm.L4], and (c) [Tm.L4] + 
α-chymotrypsin after 1 week showing the emergence of a new, broad 
peak at -77 ppm (H2O, pH 7.4, 9.4 T, 295 K; D2O coaxial insert to lock the 
NMR instrument). 
 
 
 
(a) 
(b) 
(c) 
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2.4 Conclusions 
These examples demonstrate how amplified chemical shift non-equivalence can be 
combined with decreased spectral acquisition times in the development of novel 
paramagnetic MR probes that allow the signalling of both reversible and irreversible 
reactions by 19F NMR spectroscopy.  In the first case, reversible anion binding at a 
lanthanide centre in aqueous solution resulted in a dipolar shift of the ligand probe 
resonance, induced by changing the local coordination environment.  Characteristic 
chemical shifts were observed in the 19F NMR spectra for the adducts formed with 
each anion.  For the first complex, [Ln.L1]+, no anion selectivity was observed, with a 
combination of exchange broadened peaks observed upon the addition of an 
equimolar mixture of the anions.  This system also suffered from poor complex 
stability in the presence of anions, with considerable leaching of the lanthanide ion 
observed.  However, the second complex tested, [Ln.L2]+, showed considerable 
improvement, both in terms of selectivity and stability.  Citrate selectivity was 
demonstrated by NMR spectroscopy for Ho(III) and Tm(III) complexes.  With the 
related Eu(III) complex, emission spectral changes allowed a quantification of anion 
binding constants.  The inherently large linewidths observed are the major drawback 
of these systems, and need to be minimised in order to make the probes more 
applicable.  However, a proof-of-principle has been demonstrated, correlating well 
with previous emission-based studies using related lanthanide complexes.  
 
In the second example, it was demonstrated that ester cleavage can be signalled by a 
19F NMR shift change of a remote CF3 reporter, with chemical shift non-equivalence up 
to 12 ppm depending on the lanthanide chosen.  This is an order of magnitude greater 
than differences typically found with diamagnetic systems.23  There are, however, a 
number of issues that would need to be overcome to proceed with such a system.  The 
major drawback is the slow reaction time, taking over 10 days to reach completion.  It 
is necessary to find a better substrate for the hydrolytic enzyme, in order to reduce the 
reaction time significantly.  However, this work does establish the feasibility of such 
systems and sets the groundwork in place for further investigations. 
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3. Strategies to Enhance Signal Intensity; 
Increasing Fluorine Density 
3.1 Introduction 
As discussed in Chapter 1, one of the major drawbacks of 19F MRI is the low sensitivity 
of the technique.  The incorporation of a paramagnetic lanthanide ion alleviates this 
somewhat by increasing relaxation rates and dramatically reducing acquisition times.  
Unfortunately, this approach has yet to be demonstrated for in vivo studies, showing 
the need for further improvements to be developed that increase the sensitivity of any 
imaging experiment.  One method to do this is to increase the fluorine density per unit 
concentration, something that has been commonly applied in diamagnetic systems 
through the use of perfluorocarbon compounds.  However, there are limitations with 
the strategy of perfluorination, especially with cyclen-based lanthanide complexes.  It 
is imperative that all of the fluorine atoms are magnetically equivalent, and so give rise 
to one major signal in solution, otherwise any potential signal intensity gains would be 
lost.  It is also essential that biocompatibility is maintained, i.e. good water solubility 
and low toxicity. 
 
Figure 3.1 Schematic of conjugate principle: red centre represents high molecular 
weight vector, Ln-19F represents fluorinated lanthanide complex, and 
blue line represents covalent bond linker. 
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A potential solution to increase the fluorine density per unit concentration, without 
the need for perfluorinated compounds, is to covalently link a number of fluorine 
containing lanthanide complexes to a central, higher molecular weight adduct (Figure 
3.1).  This would retain the benefits of the individual complexes, which should all be 
equivalent in the resulting conjugate, resulting in one signal in the 19F NMR spectrum.  
In addition to increasing the signal per unit concentration, medium to high molecular 
weight conjugates should possess relatively slow rates of clearance in the body.1–3  This 
increase in retention time should result in an accompanied rise in the local signal 
density in vivo.  In order to assess the behaviour and potential benefits of such 
compounds, two different adducts were investigated: chitosan, a naturally derived 
linear polysaccharide; and PAMAM, a polyamidoamine-based dendrimer. 
  
3.2 Glycol chitosan based system 
3.2.1 Previous work 
Previous, unpublished work has demonstrated the feasibility of forming medium to 
high molecular weight conjugates using glycol chitosan as the vector.4,5  These studies 
used both commercially available glycol chitosan (≈ 195,000 D) and a modified form 
that results from acidic digestion of the commercial sample with 4 M HCl at 50°C over 
24 h.  This procedure results in a significantly reduced molecular weight (≈ 6,500 D), in 
addition to complete de-acetylation being observed (Scheme 3.1).  The latter, lower 
average molecular weight compound displayed greatly improved solubility, and was 
studied in further detail.  A conjugate was formed using this chitosan compound with a 
carboxylate lanthanide complex, [Ln.31] (Scheme 3.1).   
 
Firstly, the gadolinium compound, [Gd.31-chitosan], was investigated to determine 
biodistribution and tumour uptake.  Nude mice bearing HT29 colorectal tumour 
xenografts were injected with the conjugate complex at a dose of 0.017 mmol kg-1 and 
analysed by dynamic contrast enhanced 1H MRI.  Almost immediately, contrast 
enhancement (< 1 min) was observed after tail vein injection in both the tumour area 
and the bladder.  The conjugate was well tolerated by the animals and the presence of 
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the compound in the bladder is desirable, as it is indicative of renal excretion 
eliminating it from the system.  The longer retention time in the tumour offered an 
improvement on analogous low molecular weight complexes that had previously been 
investigated. 
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Scheme 3.1 Synthesis of previously investigated chitosan conjugate, 
[Ln.31-chitosan].4 
 
Unfortunately, when a similar 19F MRI dynamic experiment was undertaken using the 
holmium complex, [Ho.31-chitosan], no fluorine signal was detected over one hour 
following administration, even with an increase in dose (0.034 mmol kg-1).  This lack of 
observable signal was most likely due to the rather broad linewidth of the fluorine 
resonance, leading to inadequate signal intensity for observation.  Therefore, in an 
effort to overcome this issue, the analogous phosphinate complex is investigated here.  
It possesses a narrower linewidth and exists as predominantly one isomeric species in 
solution.  Each of these factors have been attributed to the presence of the more bulky 
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phosphinate groups, that favour one main species and inhibit intramolecular chemical 
exchange.6 
 
3.2.2 Synthesis and characterisation of the complex 
The synthesis of the complex, [Ln.L3], is detailed in Chapter 2.  For potential in vivo 
applications, as discussed here, the only change necessary in the synthetic procedure 
was for the deprotection of the ethyl protecting groups to form the ligand, L3.  
Previously, aqueous potassium hydroxide had been used to hydrolyse the ethyl groups.  
However, in this case it was more ideal to employ NaOD as the agent for base 
hydrolysis, due to the lower relative toxicity of sodium in comparison to potassium 
salts; hydrolysis took around twice as long to reach completion.  In all other aspects, 
the synthetic route followed that described previously.   
 
The complex was purified by preparative scale reverse-phase HPLC.  As previously 
described, low resolution electrospray and high resolution accurate mass spectrometry 
were carried out to confirm the presence of the complex, with characteristic isotope 
patterns observed showing good correlation with calculated spectra.  A 19 F NMR 
spectrum showed the presence of one signal in solution, indicating the formation of 
one major isomer (>90 %) in solution. 
 
3.2.3 Conjugate synthesis 
The synthesis of the conjugate, [Dy.L3-chitosan] is outlined in Scheme 3.2.  The 
carboxylic acid group of [Dy.L3] was first converted to an active ester, by reacting with 
o-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and 
4-methylmorpholine (NMM) in DMF.  After stirring for 1 h, to allow formation of the 
active ester, a concentrated aqueous solution of glycol chitosan was added and the 
mixture stirred for a further 36 h.  Purification of [Dy.L3-chitosan] was achieved by 
extensive dialysis, using dialysis tubing and Float-A-Lyzer G2 filters with 5000 
molecular weight cut-offs (MWCO) to remove unreacted coupling reagents and excess 
complex. 
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Scheme 3.2 Synthesis of the chitosan conjugate complex, [Dy.L3-chitosan]. 
 
3.2.4 Characterisation of the conjugate 
Table 3.1 Gel permeation chromatography (GPC) data for the starting glycol 
chitosan compound and the corresponding conjugate, [Dy.L3-chitosan]. 
Sample Mw 
(a) Mn 
(b) PDI (c) 
Glycol chitosan 6700 3150 2.1 
[Dy.L3-chitosan] 10900 5590 1.9 
For corresponding unreacted complex, [Dy.L
3
], Mw = 852. (a) Calibrated using Pullulan polysaccharides 
and calculated molecular weight averages are expressed as the polysaccharide equivalent molecular 
weights. (b) Number average molecular weights. (c) Polydispersity (Mw/Mn). 
 
To determine the average size and mean number of complexes conjugated to chitosan, 
the complex was analysed by aqueous gel permeation chromatography (GPC).  The 
results indicated an increase in the molecular weights of the conjugates (Table 3.1), 
with respect to the unreacted glycol chitosan, confirming the formation of covalently 
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bound complex conjugates.  By comparing the molecular weights of the unreacted 
complex and glycol chitosan with that of [Dy.L3-chitosan], it can be calculated that 
there are around 5 complexes bound to each molecule of glycol chitosan.  As glycol 
chitosan is a polydisperse system, such values are averages for the whole system.  Poor 
solubility in water had been observed for some previous chitosan-based systems 
studied, but no issues were seen with the conjugate reported here, at the 
concentrations employed (2-5 mM). 
 
Figure 3.2 19F NMR spectra of [Dy.L3-chitosan] (D2O, 9.4 T, pD 7.4, 0.1 M NaCl, 
298 K). 
 
The 19F NMR spectrum of [Dy.L3-chitosan] displayed one principal resonance (> 90 %), 
indicating equivalence of each complex in the conjugated adduct (Figure 3.2).  
Promotion of one major signal is necessary for any potential in vivo applications, to 
ensure that signal intensity is maximised.  The next area to consider is the relaxation 
rates, which are shown in Table 3.2, along with the data for the unreacted complex, 
[Dy.L3], and a previous chitosan-based system, [Ho.31-chitosan].  
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Table 3.2 19F NMR longitudinal and transverse relaxation rates at two magnetic 
fields (4.7 and 9.4 T) for [Dy.L3], its glycol chitosan adduct, 
[Dy.L3-chitosan], and comparison with the previously analysed 
[Ho.31-chitosan]. 
Complex δF / ppm 4.7 T 9.4 T 
 R1 / Hz R2 / Hz 
(a) R1 / Hz R2 / Hz 
(a) 
[Dy.L3]  -64.5 110 217 186 440 
[Dy.L3-chitosan]  -65.7 108 176 183 367 
[Ho.31-chitosan] (b) -56.8 56 741 100 807 
(a) R2 values were estimated as (πω1/2) for a Lorentzian line fit. (b) Values taken from unpublished work.
4
  
 
There is a substantial improvement in relaxation rates for the phosphinate conjugate, 
[Dy.L3-chitosan], over the previously studied carboxylate based system, 
[Ho.31-chitosan].  The longitudinal relaxation rate, R1, is almost twice as large for the 
dysprosium system, coupled with a sizeable reduction in the transverse relaxation rate, 
R2, calculated from the linewidths.  Both of these factors will serve to improve signal 
intensity and the combination of the improvement in both relaxation rates suggested 
considerable scope for acquisition of a 19F MR image with [Dy.L3-chitosan], in 
comparison with the work previously done with [Ho.31-chitosan].  The only potential 
drawback with the dysprosium system is that the conjugate formed possessed fewer 
complexes per molecule of chitosan than was found for the previous system 
([Dy.L3-chitosan] ≈ 5 complexes/chitosan, [Ho.31-chitosan] ≈ 11 complexes/chitosan). 
 
3.2.5 Preliminary MRI studies 
Preliminary imaging studies of [Dy.L3-chitosan] were carried out at 7 T by Prof. Andrew 
Blamire at the Newcastle Magnetic Resonance Centre using a 3D gradient echo 
sequence (Figure 3.3) with a 4 turn solenoid coil (20 mm diameter, 20 mm coil length).  
The R1 and R2 values were estimated to be 145 and 270 Hz, respectively, leading to a 
calculated Ernst angle of 60.7o for a repetition rate, TR, of 25 ms.  With a total scan 
duration of 131 s, good quality images were acquired at a resolution of 1x1x1 mm3, 
which was a significant improvement over the 1x1x25 mm3 resolution obtained with 
previous systems.  Shorter echo times, TE (2.07 ms), were applied in order to minimise 
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R2 loss.  The resulting mean signal-to-noise ratio (SNR) from 1x1x1 mm
3 was calculated 
to be 9.1, which was a significant improvement on previously studied compounds 
when scaled for comparison.  These results were highly promising for further 
investigation, leading to an in vivo experiment being undertaken. 
 
 
Figure 3.3 19F MR phantom images of [Dy.L3-chitosan] contained in an Eppendorf 
tube (2 mM complex, H2O, 0.1 M NaCl, 7 T, 295 K, 3D gradient echo 
sequence, 1x1x1 mm3 resolution, TR = 4.91 ms, TE = 2.07 ms, flip 
angle = 60.7o, 26 averages, scan duration = 131 s, mean SNR from 
1x1x1 mm3 = 9.1). 
 
Preliminary in vivo studies were carried out by Prof. Andrew Blamire and Dr. Ian 
Wilson, at the Newcastle Magnetic Resonance Centre, on SCID male mice (25 g) with 
HT29 tumours (human colorectal carcinoma).  Measurements were taken 10-14 days 
after inoculation when tumours were around 10 mm in diameter, with the mouse 
anaesthetised with a mixture of ketamine (0.75 mg/kg) and medetomidine 
(0.5-1.0 mg/kg).  A solution (5 mM) of [Dy.L3-chitosan] was administered by 
intravenous injection in the tail.  The mouse received 200 µL of the solution, 
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corresponding to a dose of 0.04 mmol kg-1.  The results were obtained with a 19F tuned 
square surface coil (30 mm coil length), onto which the animal was laid, and are shown 
in Figure 3.4.    
 
Figure 3.4 MR images obtained of a HT29 tumour-bearing SCID male mouse 
showing: (a) 1H MR image (tumour indicated by arrow, blue line 
indicates approximate location of slice with maximal 19F signal 
observed); (b) in vivo 19F NMR resonances and (c) 19F MR images 
observed at indicated times after administration. 
 
A fluorine resonance was observed in the tissue in an unlocalised data collection 
during infusion.  The image could then be refined and 19F 3D gradient echo scans were 
obtained, which were overlaid onto the basic anatomical 1H MR image and indicated a 
build-up of the compound in one of the major arteries of the mouse.  Unfortunately, 
the mouse expired at some stage in the experiment.  Due to the set up required for 
this imaging method, the life signs of the mouse could not be monitored during the 
experiment and so it is not known when, or why, the mouse expired.  It is likely that 
the mouse was alive when intravenously injected, and expired shortly afterwards, 
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which would explain why the compound was present in an artery and why very little 
change in distribution was observed over the time scale of the experiment (≈ 1 h).   
 
While the death of the animal was disappointing and limited the data that could be 
obtained from the experiment, the fact that a signal has been observed is promising 
and is the first in vivo 19F MR signal obtained for such compounds.  These results 
indicate that the system works in principle, although the experiment needs to be 
repeated in order to fully understand the behaviour of the compound.  Further in vivo 
investigations are on-going, utilising both the gadolinium and dysprosium analogues of 
[Ln.L3-chitosan], in order to establish biodistribution, toxicity, and imaging behaviour 
of the compound. 
 
3.3 Dendrimer based system 
3.3.1 Design of probe 
While the chitosan based system showed considerable potential, a drawback of this 
system is the polydisperse nature of the compounds.  This polydispersity has 
limitations for clinical practice, both in terms of reproducibility and the variability in 
the rate of clearance.  Therefore, it was decided to attempt to form a well-defined 
system, with a known number of complexes and molecular weight.  A class of medium-
to-high molecular weight adducts that stand out as suitable for such a purpose are 
dendrimers, as they possess branched three-dimensional structures with elements 
that can control both the surface and internal properties of the macromolecules.7 
Dendrimers have been previously investigated for use with Gd(III)-based contrast 
agents,8–10 in addition to applications as drug transporters, tissue engineering, and as 
drugs themsleves.11–13  There are a number of commercially available dendrimers that 
could be used, but the system chosen here was PAMAM generation 2.0, with an 
ethylenediamine core (Figure 3.5).  This dendrimer was chosen for a number of 
reasons: the favourable size and molecular weight (1430 g mol-1); the well-defined, 
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functionable end groups (eight primary amine surface groups); and its relatively low 
cost.   
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Figure 3.5 Structure of PAMAM dendrimer, ethylenediamine core, generation 2.0, 
and abbreviated form to be used for the rest of this work. 
 
3.3.2 Trial studies 
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Scheme 3.3 Procedure for the synthesis of the active ester compound. 
 
In order to determine the feasibility of functionalising all eight terminal amine groups 
of the dendrimer, a preliminary study was first undertaken on a model CF3 containing 
compound.  The active ester of 4-amino-3-(trifluoromethyl)benzoic acid was formed 
and isolated by the synthetic procedure shown in Scheme 3.3.  Base hydrolysis of the 
ethyl ester, 15, using potassium hydroxide resulted in formation of the acid, 25.  This 
was stirred with NMM and TBTU in DMF, followed by purification with alumina gel 
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column chromatography to obtain the active ester, 26.  Twelve equivalents of this 
stable, isolated active ester were stirred with PAMAM generation 1.0 dendrimer in 
DMF, with NMM added as a base (Scheme 3.4).  After removal of DMF, the resulting 
residue was washed with DCM followed by water.  Methanol and its deuterated 
analogue were used as solvents in the analysis of the resulting product, PAMAM-(F8).   
PAMAM
H
N
8
O
CF3
NH2
PAMAM-G1,
NMM, DMF
O
O
NH2
CF3
N
N
N
26 PAMAM-(F8)  
Scheme 3.4 Reaction between the active ester compound and PAMAM generation 
1.0, ethylenediamine core. 
 
Analysis of PAMAM-(F8) by MALDI
+ indicated formation of the desired conjugate, with 
a signal corresponding to the functionalisation of each of the eight amine groups 
(Figure 3.6).  This suggested complete reaction and indicated the potential of this 
system to behave in the required manner.  The 19F NMR spectrum of the product 
indicated one main species, shifted around 1 ppm away from the resonance associated 
with the fluorinated starting material (Figure 3.6).  The 1H NMR spectrum was more 
complex, but the relative integrals between the aromatic and alkyl regions were 
consistent with complete conversion to the desired compound. 
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Figure 3.6 MALDI+ (left) and 19F NMR (right) spectra of PAMAM-(F8) indicating 
complete conversion to desired octa-substituted product. 
 
3.3.3 Conjugate synthesis and characterisation 
Due to success of the trial system, the analogous reaction with [Dy.L3] was then 
attempted (Scheme 3.5).  The reaction followed a similar sequence to that described 
for the chitosan conjugate above, with the complex first stirred in DMF with TBTU and 
NMM for 30 min to form the active ester, before a solution of PAMAM dissolved in 
DMF was added and stirred for a further 4 h.  After removal of the solvent, the residue 
was dissolved in water and purified by extensive dialysis (MWCO = 5000 D). 
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Scheme 3.5 Synthesis of [(Dy.L3)n-PAMAM]. 
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Unfortunately, unlike with the trial system this reaction did not proceed to completion, 
even with an excess of 20 equivalents of the complex.  This behaviour was likely to be 
due to the introduction of the more sterically and electronically demanding lanthanide 
complexes in comparison to the smaller aromatic molecules used in the model system.  
A representative MALDI+ spectrum is shown in Figure 3.7, which indicates the 
formation of a mixture of one to five molecules of [Dy.L3] coupled to the dendrimer.  
Further complex was added to this mixture, but resulted in no further reaction being 
observed.  Heating of the reaction was attempted, but appeared to cause degradation 
of the system and resulted in no high molecular weight species being observed.  Seven 
was the highest number of conjugated complexes observed in any of the reactions, 
and by dialysing with a high MWCO (8000 D) the di- and tri-substituted PAMAM 
species could be removed, although this still left a mixture of higher order substituted 
compounds.  It should be noted that, even for these mixtures, a single resonance was 
observed in the 19F NMR spectrum, with similar characteristics to the signal observed 
in the previous chitosan complex (Figure 3.7).  The products formed were also fully 
water soluble. 
 
Figure 3.7 (a) MALDI+ and (b) 19F NMR spectrum (D2O, 9.4 T, 298 K; δF = -65.7 ppm, 
R1 = 177 Hz, R2 = 333 Hz) observed for [(Dy.L
3)n-PAMAM]. Numbers 
above MALDI spectrum refer to peaks corresponding to molecular 
weights of PAMAM + (n x complex). 
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3.3.4 Alternative approaches 
Due to the difficulties apparent in functionalising all eight sites of the dendrimer with 
this complex, it was decided to investigate alternative compounds.  The first idea was 
to insert a linker group between the complex and the dendrimer, in order to space the 
complexes from each other and the compact centre of the dendrimer.  The linker 
chosen was β-alanine, which required a new synthetic pathway to form the complex 
(Scheme 3.6).  The ethyl ester protected linker group was incorporated in the first step 
by stirring the acid, 25, with 1-hydroxybenzotriazole (HOBt) hydrate and NMM in DMF, 
followed by addition of β-alanine ethyl ester hydrochloride to form the extended ethyl 
ester compound, 29.  The rest of the synthesis then followed the general scheme 
outlined for [Dy.L3] (Section 2.3.1).  The resulting complex, [Dy.L3-βala], was reacted 
with PAMAM as described above, which again resulted in a mixture of species being 
formed.  No evidence for complete conversion at all eight sites was found. 
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Scheme 3.6 Synthetic route for the formation of [Dy.L3-βala]. 
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A second approach was investigated to attempt the conjugation at the ligand stage, 
rather than with the metal complexes, in an effort to overcome the problem of having 
a number of polar lanthanide ions in close proximity to each other whilst attempting 
the coupling reaction.  This approach required a new synthetic route, in order to 
introduce a protecting group at the terminal carboxylate group that could be 
selectively cleaved (Scheme 3.7).  The protecting group chosen was tert-butyl, as this 
can be cleaved under relatively mild conditions that will leave the phosphinate ethyl 
ester and the amide bond intact.  The introduction of this group was achieved by 
stirring 25 in tert-butyl acetate with a few drops of perchloric acid, to form 35, in a 
procedure adapted from Wright and co-workers.14  The formation of the protected 
ligand then followed the usual pathway.  The tert-butyl group was cleaved by stirring 
with trifluoroacetic acid in dichloromethane to give the acid, 39.    
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Scheme 3.7 Synthetic route for the formation of tri-phosphinate ethyl ester 
protected L3. 
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The phosphinate ethyl ester protected analogue of L3 was then reacted with PAMAM 
in the usual manner.  Again, no evidence was observed for the desired full completion 
of the reaction.  Unfortunately, as the resulting polydisperse nature of these PAMAM 
conjugates investigated gave no benefit over the chitosan systems, they were not 
studied further. 
 
3.4 Conclusions 
In order to increase the fluorine density per unit concentration, while promoting one 
major signal in the 19F NMR spectrum, high molecular weight adducts were 
investigated as potential platforms for the conjugation of multiple CF3-containing 
lanthanide complexes.  The first adduct investigated was glycol chitosan, a naturally 
derived polymer, in a modified form with a reduced molecular weight (6,500 D) and 
almost complete deacetylation.  When a coupling reaction was performed with this 
chitosan compound and [Dy.L3], a conjugate between the two was successfully 
formed, with an average of 5 complexes per molecule of chitosan determined by 
aqueous GPC.   
 
The 19F NMR spectrum of this system displayed one major resonance (>90 %), with 
favourable relaxation properties.  Phantom imaging experiments were then 
undertaken, which resulted in good quality, high resolution images being acquired.  
These systems gave rise to the highest comparative signal-to-noise ratio yet obtained 
for such fluorine-based probes within our group.  These promising results led to the 
investigation of the conjugate in vivo.  Unfortunately, the animal expired during the 
singular experiment that was performed, although the image obtained is still 
extremely promising as it is the first in vivo fluorine image to date from this work.  
Further studies need to be carried out on these conjugates, to determine whether they 
are tolerated by the animals and the biodistribution of the probes after administration.  
Studies are currently on-going to address these issues. 
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The other high molecular weight adduct that was investigated was a PAMAM 
conjugate, based on a dendrimer with eight primary amino surface groups.  A trial 
reaction, with a small, fluorine-containing, organic compound successfully resulted in 
the functionalisation of all eight amine moieties and gave rise to signal in the 19F NMR 
spectrum.  However, when the reaction was repeated with fluorine-containing 
lanthanide complexes, complete reaction at each surface group could not be achieved.  
Instead, a mixture of products was obtained, with between one and seven complexes 
per molecule of PAMAM.  Modifications of the complex structure were attempted, but 
gave no improvement and so this system was not investigated further.  Nevertheless, if 
a system could be formed allowing full functionalisation of every primary amine group, 
this would have benefits over the chitosan system due to the defined nature of the 
probe.  A possible solution could be to alter the nature of the active ester functional 
group, e.g. the acid group of the complex that forms an amide linker could be replaced 
with an arylisothiocyanate. 
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4. Strategies to Enhance Signal Intensity; 
Reducing Dynamic Motion 
4.1 Introduction 
It is well known that the ratio of R2/R1 is always greater than unity for systems in which 
paramagnetic relaxation is dominant, resulting in broadened lines and a reduction in 
signal strength.  Chemical exchange processes can contribute further to increases in 
linewidth, accentuating this problem.  Previous work has shown that linewidth 
broadening caused by dynamic motion effects could be reduced by increasing the 
overall rigidity of the complex being investigated.  This was achieved by the 
introduction of phosphinate groups in place of the carboxylate pendant arms, resulting 
in significantly reduced linewidths.  In addition, one major species in solution was 
observed (see Section 1.6.3).1  However, the fluorine containing moieties in these 
compounds are connected to the macrocyclic ring via an amide bond, about which 
restricted rotation can occur in solution.  This rotation is likely to lead to an increase in 
exchange broadening depending on temperature and local steric demand.  Therefore, 
it was decided to investigate whether the incorporation of further rigidity into the 
system, in particular to the fluorine containing element, would result in an additional 
decrease in linewidth.  Pyridyl nitrogens have previously been shown to be excellent 
donors for Ln(III) ions.2  Therefore, if the CF3 group is incorporated onto a coordinating 
pyridyl motif, as shown in Scheme 4.1, then this should lock the arm in place more 
effectively and prevent dynamic motion involving the fluorinated moiety. 
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Scheme 4.1 Comparison of mono-amide (left) and pyridine (right) analogues 
displaying rotation about amide bond and the locked coordinating 
pyridyl arm.  
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Various systems were chosen to be investigated, as shown in Scheme 4.2.  The first 
compounds consisted of the direct pyridyl equivalent of the monoamide phosphinate 
complex, [Ln.L5], and a chlorinated analogue, [Ln.L6].  The corresponding carboxylate 
complex, [Ln.L7] was also developed in order to investigate whether the influence of 
the pendant arms was comparable to the mono-amide system.  A final complex was 
designed with the fluorine substituent at the para-position of the pyridine ring, 
[Ln.L8]-, varying the Ln to CF3 distance, r.  From previous knowledge (Section 1.3.2.1), it 
can be calculated that the ideal value for r is in the region of 5.5 to 6.5 Å in order to 
generate around a two-orders of magnitude increase in both longitudinal and 
transverse relaxation rates.  For these complexes, it was predicted that r would lie in 
the region of 6-6.5 Å for the meta-substituted systems and 7-7.5 Å for the para-
substituted system. 
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Scheme 4.2 Complexes synthesised for the work described in this chapter. 
 
4.2 Synthetic Details 
4.2.1 The meta-substituted pyridyl systems; [Ln.L5], [Ln.L6], and [Ln.L7] 
The synthesis of L5 began with the introduction of a carbon atom at the 2-position of 
the pyridine ring, utilising 2-bromo-5-trifluoromethyl pyridine as the starting material 
(Scheme 4.3).  Numerous methods were attempted for this step, such as substitution 
of the bromo-group with a cyano moiety.  However, the reaction that provided the 
highest yield involved lithiation using n-butyl lithium, followed by carboxylation with 
solid carbon dioxide, as developed by Schlosser and co-workers.3  After work up, the 
desired acid product (40) was recrystallised from hexane.  Esterification in methanol 
and sulphuric acid, followed by reduction with sodium borohydride, led to the desired 
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alcohol, 42.  Bromination of this alcohol was successfully achieved by stirring in 
phosphorus tribromide (to form 43), although formation of the mesylate (44) by 
reaction with mesyl chloride was preferred due to the higher yield, faster reaction 
time, and ease of purity  of the latter reaction, averting purification by column 
chromatography.  The mesylate was reacted immediately after being formed to ensure 
degradation did not occur. 
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Scheme 4.3 Synthetic procedure for the preparation of the pyridine arm precursors. 
 
While this pyridyl arm could be successfully synthesised in a moderate yield, a related 
commercially available precursor, 2-chloromethyl-3-chloro-5-trifluoromethyl pyridine, 
was obtained.  This chloromethyl group can be directly reacted with the cyclen ring, 
reducing the number of synthetic steps required.  The additional meta-chloro-
substituent should not have any significant effect on the behaviour of the final 
complex, although both arms were used in tandem in order to confirm this.  This 
substituent may also have an added advantage in that it could allow further 
functionalisation at a later stage. 
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Scheme 4.4 General procedure for the synthesis of [Ln.L5] and [Ln.L6] (yields stated 
for R=Cl, yields for R=H are comparable). 
 
The analogous complexes, [Ln.L5] and [Ln.L6], were synthesised as shown in Scheme 
4.4.  The first step involved mono-addition of the relevant pyridine arm onto the cyclen 
ring.  This was attempted by a direct addition with an excess of cyclen, as was 
successfully achieved in the synthesis detailed in an earlier chapter (Section 2.3.1).  
However, in this case the pyridine compounds were too reactive and could not be 
controlled, resulting in a mixture of mono-, di-, and tri-substituted products that were 
difficult to separate by column chromatography.  Therefore, it was decided to use the 
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triprotected carbamate 1,4,7-tris-tert-butoxycarbonyl-1,4,7,10-tetraazacyclododecane 
(tri-Boc), which was synthesised according to published methods.4,5  Mono-addition of 
the pyridine arm was achieved by refluxing in acetonitrile with an excess of base 
(potassium carbonate), followed by purification with silica gel column chromatography 
to generate the desired intermediates, 46 and 52.  The protecting groups were 
removed by stirring with trifluoroacetic acid in dichloromethane to form the mono-
substituted cyclen derivatives, 47 and 53. 
 
Figure 4.1 19F NMR spectra of 54, highlighting the reduction of signals upon 
shaking the sample with a few drops of deuterium oxide (9.4 T, 295 K). 
 
Soxhlet equipment was then used to synthesise 48 and 54 in a one-pot synthesis via a 
co-condensation of the mono-alkylated macrocycle with paraformaldehyde and diethyl 
methylphosphonite.  An Arbusov rearrangement yielded the desired 
triethylphosphinate esters, 48 and 54, which were formed as a mixture of 
stereoisomers differing in configuration at each phosphorus centre.  Separation was 
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achieved using a 3:1 mixture of alumina and silica.  The resulting NMR spectra of these 
compounds in deuterated chloroform were complicated due to the formation of the 
[H2L]
2+ complex and similar adducts, in well-defined conformations.  The spectra were 
simplified significantly by agitating with a few drops of deuterium oxide (see Figure 
4.1).  Under these conditions, the ring is diprotonated and one major solution species 
was formed. 
 
Base or acid hydrolysis of the ester groups is feasible, due to the stability of the 
pyridine moiety to both conditions.  However, acid hydrolysis allowed a simpler work 
up (i.e. excess acid can be removed under reduced pressure) and generally required 
shorter reaction times.  Therefore, the compounds were heated under reflux in 6 M 
hydrochloric acid to form the protonated phosphinic acid ligands.  Metal complexation 
was achieved using an aqueous solution of the appropriate metal chloride at pH 5.5 
and 60°C, before the pH was raised to 10 in order to precipitate any excess Ln(III) ions 
as the metal hydroxide.  The free metal was removed by centrifugation before the pH 
was lowered to 5.5 once more and the complexes were purified by preparative scale 
HPLC.   
 
An analogous carboxylate complex was also synthesised, [Ln.L7] (Scheme 4.5).  It was 
decided to only investigate the chloro-substituent in this case due to the availability of 
the starting material. The first step involved alkylation of 1,4,7-tris-(tert-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane (DO3A), which was 
synthesised according to literature methods,6 with 2-chloromethyl-3-chloro-5-
trifluoromethyl pyridine in a similar method to the reaction with the tricarbamate 
(tri-Boc). After purification by silica gel column chromatography the desired 
compound, 66, was isolated.  Deprotection of the tert-butyl ester groups was carried 
out using 6 M HCl to generate the tri-acid, followed by complexation with the 
lanthanide ion. 
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Scheme 4.5 General procedure for the synthesis of [Ln.L7]. 
 
4.2.2 The para-substituted pyridyl system; [Ln.L8]- 
P
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OEt
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70  
Scheme 4.6 Synthesis of a 50/50 mixture of ethyl methylphosphinate and ethanol. 
 
The synthesis of [Ln.L8]- required the introduction of a new pyridine arm (Scheme 4.7).  
The first step consisted of halogenation of 6-methyl-4-trifluoromethyl-2(1H)-pyridone 
with a large excess of phosphorus oxychloride.  Unreacted POCl3 was carefully 
removed under reduced pressure, before work-up gave the desired chlorinated 
pyridine, 71.  Direct substitution of this chloro-group with diethyl methylphosphinite 
was attempted.  However, no reaction was observed.  Therefore, the phosphinite was 
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first stirred with one equivalent of deoxygenated water at room temperature to form a 
mixture of ethyl methylphosphinate (70) with one equivalent of ethanol (Scheme 4.6), 
which was confirmed by 1H and 31P NMR spectroscopy.  This mixture was used directly 
in a palladium coupling reaction with 71.  Dry toluene was degassed three times via 
freeze-thaw cycles and was used to dissolve a mixture of the pyridine (71), the 
phosphinate, (70), and triethylamine.  Tetrakis(triphenylphosphine)palladium(0) was 
added to the mixture and the solution degassed a further three times to ensure the 
removal of oxygen and prevent oxidation of the palladium catalyst.  After being heated 
at 100°C overnight, the starting materials had been consumed and the pyridinyl 
phosphinate product (72) was obtained following silica gel column chromatography. 
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Scheme 4.7 General procedure for the synthesis of [Ln.L8]-. 
 
The 6-methyl group can be directly brominated, using N-bromosuccinimide as 
described elsewhere for related systems.7  However, this is a rather capricious reaction 
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and so it was decided to proceed via the longer but cleaner pathway to form the 
mesylate.  This sequence involved formation of the pyridyl N-oxide (73) using meta-
chloroperoxybenzoic acid, followed by a thermal rearrangement to a trifluoroactetate 
ester intermediate, which can be hydrolysed in situ by a mixture of water and ethanol 
to generate the alcohol, 74.  The alcohol was purified by silica gel column 
chromatography before reaction with mesyl chloride and triethylamine gave the 
reactive mesylate compound (75).  Again, this compound was used immediately after 
being formed.  It is interesting to note that a “D2O shake” experiment was also 
successful in significantly simplifying the 1H and 19F NMR spectra.  This time it was 
evident for the alcohol compound, 74, allowing the detailed multiplets to be observed.  
This is likely due to intermolecular associations via hydrogen bonding to form dimers 
or higher order aggregates.  Shaking with a few drops of D2O inhibits these processes, 
giving rise to the expected simple splitting pattern (Figure 4.2).  
 
Figure 4.2 1H NMR spectra (400 MHz, 295 K, CDCl3) of 74 indicating simplification 
of signals after a “D2O shake”. 
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Unlike with the previous pyridyl compounds described, mono-addition using an excess 
of cyclen was successfully achieved in high yield under mild conditions.  There was no 
evidence for the formation of unwanted over-alkylated side-products, possibly due to 
the slightly greater steric demand of this electrophile, associated with the phosphinate 
group.  The rest of the synthesis followed the same pathway as described for [Ln.L5] 
and [Ln.L6]: formation of the tri-ethyl phosphinate ester (77), followed by deprotection 
to the tetra-acid species (H3L
8) by heating in 6 M HCl, and finally formation of the 
desired complex, [Ln.L8]-. 
 
4.3 Characterisation of Complexes 
As detailed in Chapter 2, low resolution electrospray ionisation and high resolution 
accurate mass spectrometry measurements were carried out to confirm the presence 
of the complexes.  Characteristic isotope patterns were observed for each complex, 
showing an excellent correlation with the calculated spectra.  19F NMR spectroscopic 
data were collected for each complex, which was analysed and discussed in detail 
below.  In most cases, there were two main observable signals in solution, even after 
purification by HLPC, indicating the formation of two major stereoisomers in solution. 
 
The metal hydration state of the complex (q value) was assessed for the terbium 
complex of L6 by measuring the radiative lifetime of the lanthanide excited state, k, in 
H2O and D2O.  The q value was calculated using Equation 4.1:
8 
                            (4.1) 
where      and      are the reciprocals of the luminescence lifetimes of the complex 
in each solvent,      and      respectively, and n is the number of carbonyl-bound 
amide NH oscillators.  Values of 0.30 and 0.26 ms-1 were recorded experimentally for 
     and      respectively, resulting in a calculated q value of 0.1.  This indicates that 
there are no bound water molecules on the Ln(III) ion for complexes of L6, consistent 
with related phosphinate complexes.1  It is highly likely that the other phosphinate 
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complexes, [Ln.L5] and [Ln.L8] will also possess a zero q value, while the less bulky 
carboxylate complex is expected to have one directly bound water molecule. 
 
4.4 19F NMR Spectroscopic Studies 
4.4.1 NMR Shift Behaviour 
For each ligand, it was decided to investigate the 19F NMR properties with two 
different lanthanide ions; one with a large positive Bleaney coefficient (CJ) and one 
with a large negative value.  For [Ln.L5], [Ln.L6], and [Ln.L7], thulium (CJ = +53) and 
dysprosium (CJ = -100) were chosen, and for [Ln.L
8]- erbium (CJ = +32) was used instead 
of thulium.   The 19F NMR spectroscopic data for these complexes are reported in 
Table 4.1, along with chemical shifts for the free ligands in each case, for comparison.  
In every case, no pH- or time-dependent variations were observed. 
 
Table 4.1 19F NMR chemical shift data (ppm) for Ln(III) complexes (D2O, 295 K). 
Complex Ligand(a) Dy Tm Er 
[Ln.L5](b) -63.3 -154.7 10.7 --- 
  (-160.8) (13.1) --- 
[Ln.L6](b) -63.0 -162.4 17.1 --- 
  (-168.9) (20.3) --- 
[Ln.L7](b) -63.1 -115.1 -42.0 --- 
  (-42.0) (-5.0) --- 
[Ln.L8]- (c) -65.3 -67.0 --- -61.3 
  --- --- --- 
(a) Chemical shift of the free ligands without the presence of Ln(III) ions. (b) Values in parenthesis refer 
to the minor isomer, with ratios of major to minor isomers around 4:1 for the three complexes.  
(c) Present as one major signal with a shoulder suggesting two isomers with shifts in close proximity. 
 
The 19F NMR spectra for complexes of the meta-substituted ligands (L5, L6, and L7) 
displayed two signals, in a 4:1 ratio for each complex.  With [Dy.L8]- and [Er.L8]-, 
however, the situation was less clear and they appeared to consist of one main species 
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in solution, although there is evidence of a shoulder to the main peak.  It may well be 
the case that there are two isomers for the complexes of L8 also, but due to the 
relatively small shift from the ligand signal, the two signals may overlap.  Higher fields 
(up to 16.4 T) were utilised in an attempt to separate out the peaks.  However, they 
could still not be resolved.   
 
Figure 4.3 Schematic representation of the common coordination geometries 
adopted by [LnDOTA]- and related compounds.9 
 
Isomeric species with Ln(III) complexes of cyclen-based systems with carboxylate arms 
can be related to the presence of differing elements of chirality associated with the 
NCCN and NCCO metal-chelate rings.  Each NCCN chelate ring is characterised by a 
torsion angle of +60o or -60o, assigned as a δ or λ configuration.  Common 
configurations are favoured, i.e. δδδδ or λλλλ, with other possibilities being higher in 
energy and have often not been observed crystallographically.  The behaviour of the 
NCCO chelate rings can be considered similarly, with a common torsion angle of +30o 
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or -30o typically observed for each chelate, which gives rise to a common ‘twist’ of the 
four pendant arms.9  This is illustrated in Figure 4.3. 
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Table 4.2 NMR data for [Dy.L6], [Dy.L7], [Tb.41], and [Tb.42] indicating the isomeric 
species observed by 19F NMR spectroscopy (D2O, 295 K). 
Complex Major species (%)(a) No. of species present in 
solution(b) 
[Dy.L6] 80 2 
[Dy.L7] 81 2 
[Tb.41](c) 87 6 
[Tb.42](c) 50 7 
(a) Amount of major signal as percentage of total signal intensity. (b) Total number of observable 
species. (c) Taken from the literature.
1
 
 
For phosphinate complexes, this is complicated further by the possibility of differing 
configurations at each phosphorus centre.  However, it has been previously shown 
that Ln(III) complexes of cyclen with 3 phosphinate arms give rise to favourable low-
energy systems in  which the configuration is constant at each phosphorus chiral 
centre, i.e. RRR or SSS configurations.10,11  For the previously investigated mono-amide 
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systems, [Ln.41] and [Ln.42], further isomers had been observed.1  These related to 
restricted rotation about the amide bond, which can be considered in terms of placing 
the CF3 group ‘cis’ or ‘trans’ with respect to the coordinated amide oxygen.  For the 
pyridyl systems reported here, these extra ‘rotational isomers’ are no longer possible 
due to the pyridine nitrogen binding to the Ln(III) ion, thereby ‘locking’ the CF3 into 
one position, reducing the number of thermodynamically stable configurations 
available for the complex.  This rigidification effect results in the simplified NMR 
spectra observed, with only two species being observed for both the phosphinate and 
carboxylate pyridine complexes ([Ln.L6] and [Ln.L7]) compared to 6 and 7 for the 
mono-amide analogues, [Ln.41] and [Ln.42] (Table 4.2). 
 
Unfortunately, the major isomer constitutes around 80 % of the observed signal 
intensity for the pyridyl complexes, which is not quite as high as for [Ln.41] (87 %), 
albeit significantly better than for [Ln.42] (50 %).  However, the ratio of isomers is 
considerably better than related unsubstituted pyridyl-containing cyclen complexes in 
which two diastereoisomeric species in ratio 2:1 were observed, corresponding to the 
regular square-antiprismatic (SAP) and twisted square-antiprismatic (TSAP) complexes 
for the major and minor isomers respectively.2  It is likely that a similar situation occurs 
for the compounds reported here, i.e. a SAP coordination is adopted for the major 
species and a TSAP geometry for the minor species.  It is interesting that the 19F NMR 
spectrum of the carboxylate pyridyl complex, [Ln.L7], displays the same form as the 
analogous phosphinate complex ([Ln.L6]), i.e. two species are observed in a 4:1 ratio.  
This indicates that the pyridyl moiety is effective at increasing the rigidity of the 
complex and can ‘lock’ the system into place with either the bulky phosphinate arms 
or the less sterically hindered carboxylate.  In the carboxylate series of complexes, 
dynamic exchange processes between isomers with different configurations have been 
observed.   
 
The 19F NMR spectra for the dysprosium complexes of the discussed ligands are shown 
in Figure 4.4.  As expected, the shifts for [Ln.L8]- were the smallest, with less than a 
5 ppm difference between the complexes and the free ligand.  This is due to the 
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reciprocal cubic dependence of the pseudocontact shift on the lanthanide-to-fluorine 
distance.  In addition, a change in angle (Θ) is likely between the fluorine atoms and 
the principal axis of the complex (see Section 1.3.1 for further details).12,13  It is 
estimated that the CF3 label is at least 0.5 Å further away from the Ln(III) centre in 
[Ln.L8]- than for the other complexes investigated, and so should experience a 
significantly smaller pseudocontact shift.  Correlation of the shifts to the Ln-F distance 
are not directly quantifiable, however, as the substantial differences in the 
coordination spheres of these molecules will lead to deviations in the ligand field 
parameters and, as mentioned already, Θ is likely to be inconsistent between the two 
sets of compound.  Further information, and determination of distances, can be gained 
from an analysis of the field dependence of relaxation (see Section 4.4.2). 
 
 
Figure 4.4 19F NMR spectra (376 MHz, D2O, 295 K) of the Dy(III) complexes of L
5, L6, 
L7, and L8 with the signal relating to the ligand L7 for comparison. 
 
For the meta-substituted pyridyl systems, the dipolar shifts for the phosphinate 
complexes were considerably larger than for the analogous carboxylate compound.  
Comparisons with the related mono-amide compounds1 suggest that the carboxylate 
complex possesses one bound water (q=1), while the phosphinate complexes possess 
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no bound water molecules (q=0).  This change in hydration state results in significant 
variations in the coordination geometry about the Ln(III) ion, with the carboxylates 
being 9-coordinate overall, while the phosphinates adopt a more compact 8-
coordinate geometry.  This change will be associated with a variation in the ligand field 
coefficients, e.g.   
  and   
 , giving a significant change in the observed shifts for the 
two sets of complex. 
 
While the coordination mode about the lanthanide ion in [Ln.L5] and [Ln.L6] should be 
similar, the presence of the chloride substituent on the pyridyl ring of the latter 
complex may slightly alter the position the CF3 group adopts, changing the angle 
between the fluorine atoms and the principal axis of the complex.  This should have a 
marked effect on the pseudocontact shift of the system and may explain why, for 
example, [Dy.L6] has around a 10 ppm larger shift than [Dy.L5] with respect to the 
signal of the free ligands, which are nearly identical to each other. 
 
The shift observed with [Dy.L6] is almost 100 ppm to lower frequency of the ligand 
signal.  To the best of our knowledge, this is the largest reported lanthanide induced 
fluorine shift for such compounds.  This was an unexpected result, being much larger 
than the previous highest shift (<40 ppm) observed for related systems examined in 
Durham.14  Therefore, it was decided to investigate the chemical shift and other NMR 
spectroscopic properties of this complex further, the results of which are discussed in 
Section 4.5. 
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4.4.2 19F NMR Relaxation Behaviour 
The 19F NMR relaxation data were obtained for each complex at 4.7, 9.4, 11.7, 14.1, 
and 16.5 T (188, 376, 470, 564, and 658 MHz respectively); data are summarised in 
Table 4.3. 
 
Table 4.3 19F NMR longitudinal relaxation rate (R1) data for [Ln.L
5], [Ln.L6], [Ln.L7], 
and [Ln.L8]- at different field strengths (D2O, 295 K). Values given in Hz. 
Complex 4.7 T 9.4 T 11.7 T 14.1 T 16.5 T 
[Dy.L5](a) 56 ±2.5 110 ±1.2 137 ±2.4 165 ±0.3 190 ±0.7 
 (41 ±0.3) (116 ±2.8) (139 ±3.6) (166 ±1.2) (187 ±1.5) 
[Tm.L5](a) 54 ±2.2 99 ±3.6 128 ±0.4 147 ±0.5 165 ±0.6 
 (64 ±1.6) (107 ±3.3) (132 ±1.2) (166 ±1.2) (187 ±1.5) 
[Dy.L6](a) 64 ±1.7 114 ±0.5 142 ±1.1 166 ±0.4 192 ±0.5 
 (67 ±0.6) (114 ±8.4) (146 ±5.5) (165 ±1.1) (186 ±2.6) 
[Tm.L6](a) 59 ±0.5 107 ±0.4 132 ±1.6 152 ±0.6 173 ±1.2 
 (67 ±0.6) (111 ±4.4) (140 ±0.3) (153 ±2.7) (168 ±6.5) 
[Dy.L7](a) 70 ±0.7 132 ±0.8 158 ±2.4 197 ±0.9 233 ±1.7 
 (68 ±1.6) (119 ±3.3) (139 ±3.6) (172 ±2.4) (219 ±5.1) 
[Tm.L7](a) 27 ±0.4 54 ±2.2 71 ±1.2 90 ±2.1 113 ±3.1 
 (32 ±2.5) (80 ±8.3) (117 ±11.8) (210 ±17.3) (316 ±14.6) 
[Dy.L8]- (b) 34 ±0.2 66 ±0.7 87 ±1.8 100 ±0.9 112 ±2.2 
      
[Er.L8]- (b) 20 ±0.6 49 ±0.3 58 ±1.0 69 ±0.6 78 ±0.5 
      
(a) Values in parenthesis refer to minor isomer, with ratios of major to minor isomers around 4:1 for the 
three complexes. (b) Present as one major signal with shoulder suggesting two isomers with shifts in 
close proximity.  
 
Comparison of the R1 data between the complexes of the meta-substituted ligands (L
5, 
L6, and L7) and the para-substituted system (L8) highlights the substantially slower 
longitudinal rates measured for the latter compound.  This can be ascribed to a 
lengthening of the mean distance, r, between the Ln(III) ion and the CF3 group.  The 
relationship between the longitudinal relaxation rate and the separation, r, follows an 
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r-6 dependence, resulting in significant variation in R1 with relatively small changes in 
distance.  The separation  (r), in addition to the rotational correlation time (τR) and the 
electronic relaxation time (T1e) can be calculated, assuming values for paramagnetic 
susceptibility (µeff), by fitting sets of relaxation rate data at different magnetic field 
strengths to the classical equations describing relaxation, seeking a global minimum 
computationally (Figure 4.5 and Table 4.4).15   
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Figure 4.5 Variation of 19F NMR longitudinal relaxation rates with magnetic field 
for [Dy.L5], [Dy.L6], [Dy.L7], and [Dy.L8]- (295 K, D2O) showing the 
experimentally obtained values (circles) and fit (line) to the data, using 
global minimisation methods. 
 
From this, it can be seen that, for the dysprosium complexes, the Ln(III) to CF3 distance 
for [Dy.L8]- is over 0.5 Å larger than in the related meta-substituted pyridyl 
phosphinate complexes ([Dy.L5] and [Dy.L6]), as expected.  This also fits well with the 
data gathered from analysis of the shift behaviour of these compounds, where the 
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lanthanide induced shift values (r-3 dependence) for the complexes of L8 were much 
smaller than for the other compounds.   
 
Table 4.4  Ln-CF3 distance (r), rotational correlation time (τR), and electronic relaxation 
time (T1e) for dysprosium complexes of L
5, L6, L7 and L8. 
Complex r / Å (a) τR / ps 
(a) T1e / ps 
(a) 
[Dy.L5](b) 6.59 235 0.35 
[Dy.L6](b) 6.60 238 0.46 
[Dy.L7](b) 6.36 190 0.42 
[Dy.L8]- 7.16 293 0.28 
(a) Calculated by Levenberg-Marquadt minimisation of the non-linear squares error function of Equation 
1.7 (see Section 1.3.2).  (b) Data given is for major isomer (minor isomer is comparable in each case). 
 
It can also be observed that the R1 value for the dysprosium carboxylate complex, 
[Dy.L7], is substantially larger than for the analogous phosphinate systems.  At first 
glance, this appears to be due to the CF3 group being positioned closer to the Ln(III) 
ion, which correlates with the r value calculated from the fitting calculations.  
However, this behaviour is reversed for the thulium(III) complexes (i.e. R1 for [Tm.L
7] < 
[Tm.L5], [Tm.L6]) suggesting that the system may be more complicated than this.  
There may be a structural change between the series of phosphinate and carboxylate 
complexes, which is backed up by the large differences in chemical shift between the 
two sets of compound.   There may even be some form of structural change between 
the different complexes of L7, due to the smaller nature of the Tm(III) ion compared to 
Dy(III).  This would explain the differences in relaxation behaviour observed here, as 
well as the relatively small shift displayed by [Tm.L7] in comparison to the other 
systems.  Global fitting for [Ln.L7] with a series of Ln(III) ions would likely yield more 
accurate values of r than the singular value generated for the Dy(III) complex. 
 
The values calculated for the rotational correlation time can be justified by comparing 
the increase in size from the carboxylate system to the phosphinate complex, which is 
roughly the equivalent of three extra methyl groups.  At 298 K, τR scales as r
3, in a 
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simple Stokes-Einstein model, where r in this case is the radius of the ‘sphere’ 
occupied by the entire molecule.  The molecular diameter of the phosphinate 
complexes is increased by the extra bulkiness of these arms, it is reasonable to expect 
an increase in τR of around 40-50 ps.  This could also partially explain the increase in 
relaxation rates observed for [Dy.L7] in comparison to the phosphinate complexes.  
 
The electron relaxation time, T1e, is related to the paramagnetic relaxation 
enhancement of the Ln(III) ion and is determined by the nature of the metal ion and by 
the local ligand field.  The values calculated above are roughly of the same order, and 
are in good agreement with literature values.16,17 
 
The transverse relaxation rates, R2, can be estimated from the individual peak 
linewidths (at half-height), using a π x ω1/2 relationship in a Lorentzian fit (Table 4.5).  
For a given field, there is a reduction in R2 for [Dy.L
5] and [Dy.L6] in comparison with 
the mono-amide equivalents, [Dy.41] and [Dy.42].  However, this is offset by an 
accompanying decrease in longitudinal relaxation rates.  Therefore, a more informative 
value is the R1/R2 ratio, bearing in mind that the R2 will always be larger than R1 and 
that for imaging purposes it is imperative to keep this ratio as close to one as possible.  
As chemical exchange processes also add to line broadening, it is important to keep 
these to a minimum also.  
 
For the meta-substituted pyridine complexes, it can be seen that the phosphinate 
complexes, [Dy.L5] and [Dy.L6], display a larger R1/R2 ratio, compared to the analogous 
carboxylate complex, [Dy.L7].  This can be attributed to the enhanced rigidity created 
by the bulky phosphinate groups, reducing the intramolecular exchange processes 
between potential isomers, via arm rotation as discussed above.  A surprising 
observation is the unexpectedly large transverse relaxation rate value for [Dy.L8].  It 
had been anticipated that the R2 value for this complex should be the lowest, due to 
the increase in the lanthanide to fluorine distance, r, in addition to the presence of an 
extra phosphinate moiety to further decrease dynamic motion of the system.  
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However, this value may be slightly misleading and is likely to be inflated due to the 
presence of a suspected overlapping isomer peak.  This would explain the anomalous 
R1/R2 ratio observed for this compound. 
 
Table 4.5 Longitudinal (R1) and transverse (R2) relaxation rates and the ratio of the 
two for the Dy(III) complexes of L5, L6, L7, and L8, with comparisons to 
literature compounds (D2O, 298 K, 4.7 T). 
Complex R1 / Hz R2 / Hz 
(a) R1/R2 
[Dy.LC1] (b) 75 116 0.65 
[Dy.LP1] (b) 104 135 0.77 
[Dy.L5] (c) 56 94 0.60 
[Dy.L6] (c) 64 107 0.60 
[Dy.L7] (c) 70 151 0.45 
[Dy.L8]- 34 141 0.24 
(a) R2 values were estimated as (πω1/2) for a Lorentzian line fit. (b) Values taken from the literature.
1
 
(c) Data given is for major isomer (minor isomer is comparable in each case). 
 
Unfortunately, when these pyridine complexes are compared to the analogous amide 
complexes, it can be seen that the R1/R2 ratio has not been improved by the 
incorporation of the CF3 reporter group onto the pyridine moiety, as was envisioned in 
the design of the compounds.  In fact, the values obtained are comparable with the 
carboxylate amide complex, [Dy.42], and are significantly lower than the phosphinate 
complex, [Dy.41].  This, combined with the significant minor isomer observed with all 
of the pyridine complexes, suggests that these systems may show no improvement in 
imaging experiments compared to previous studies.  However, a positive aspect to 
come out of these investigations is the unprecedented range of chemical shift values 
for the different Ln(III) complexes of the meta-substituted systems.  In particular, 
[Ln.L6] shows up to a 100 ppm dipolar shift.  An improved understanding of the 
physical basis of such large shifts would help in the design of future probes, particularly 
in the development of responsive systems that display large chemical shift non-
equivalence between different forms.  Therefore, a more in depth investigation of the 
19F NMR chemical shift behaviour of [Ln.L6] was undertaken. 
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4.5  Investigation into the Increased Chemical Shift Range of [Ln.L6] 
Due to the large variations in shift seen with the thulium and dysprosium complexes of 
L6 (around 180 ppm difference between the major isomers of each complex), it was 
decided to investigate the behaviour of this system further.  This involved the synthesis 
of a series of lanthanide(III) complexes (from Eu(III) to Yb(III) plus Y(III) as a 
diamagnetic analogue), followed by full analysis of their 19F NMR shift and relaxation 
properties (Table 4.6). 
 
Table 4.6 19F NMR shift and longitudinal relaxation rate (R1) data for [Ln.L
6] at 
different field strengths (D2O, 295 K). 
Ln Shift / 
ppm 
  R1 / Hz 
(b)   
  4.7 T 9.4 T 11.7 T 14.1 T 16.5 T 
Y(a) -63.1 1.1 ±0.02 1.2 ±0.01 --- --- --- 
 (-63.1) (1.1 ±0.02) (1.2 ±0.02) --- --- --- 
Eu(a) -58.6 1.7 ±0.03 3.5 ±.0.01 4.3 ± 0.19 4.9 ± 0.03 5.7 ±0.03 
 (-57.9) (1.7 ±0.01) (3.5 ±0.01) (3.9 ±0.70) (4.9 ±0.03) (5.6 ±0.08) 
Tb(a) -158.4 56 ±1.4 89 ±0.3 117 ±3.2 133 ±1.0 150 ±3.8 
 (-158.9) (56 ±0.5) (93 ±3.1) (104 ±9.4) (129 ±2.9) (143 ±7.7) 
Dy(a) -162.4 64 ±1.7 114 ±0.5 142 ±1.1 166 ±0.4 192 ±0.5 
 (-168.9) (67 ±0.6) (114 ±8.4) (146 ±5.5) (165 ±1.1) (186 ±2.6) 
Ho(a) -107.8 67 ±0.8 129 ±0.6 154 ±1.9 189 ±0.7 218 ±0.2 
 (-111.4) (67 ±0.7) (122 ±5.4) (131 ±9.9) (186 ±2.3) (212 ±2.2) 
Er(a) -16.9 94 ±1.2 136 ±0.7 175 ±1.4 188 ±1.1 219 ±3.1 
 (-13.6) (104 ±5.5) (142 ±7.2) (176 ±13.1) (192 ±3.9) (236 ±8.1) 
Tm(a) 17.1 59 ±0.5 107 ±0.4 132 ±1.6 152 ±0.6 173 ±1.2 
 (20.3) (67 ±0.6) (111 ±4.4) (140 ±0.3) (153 ±2.7) (168 ±6.5) 
Yb(a) -41.5 14 ±0.5 15 ±0.1 17 ±1.1 18 ±0.1 19 ±0.3 
 (-38.9) (11 ±0.02) (16 ±0.21) (17 ±0.8) (17 ±0.6) (20 ±0.6) 
(a) Values in parenthesis refer to minor isomer, with ratios of major to minor isomers around 4:1 for 
each complexes.  
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Again, fitting of the longitudinal relaxation rates at five different magnetic field 
strengths was undertaken (Figure 4.6), in order to estimate the mean distance, r, 
between the lanthanide ion and the CF3 group, and the rotational correlation time, τR.  
Global fitting of the combined data for all the Ln(III) complexes allows a more accurate 
estimation of these values.  This was carried out using Levenburg-Marquadt 
minimisation of the non-linear squares error function of Equation 1.7 (see Section 
1.3.2).  This resulted in values of 6.12 ±0.06 Å (r) and 238 ±12 ps (τR).  These values fall 
in the expected range, but it is important to note that these are average values for all 
the complexes investigated and there will be around a 0.08 Å variation in r due to the 
“lanthanide contraction” from Dy to Yb. 
 
Figure 4.6 Variation of 19F NMR longitudinal relaxation rates with magnetic field 
for [Ln.L6] (295 K, D2O) showing the experimentally obtained values 
(symbols) and fit (line) to the data, using a global minimisation strategy. 
 
To understand the 19F NMR chemical shift values observed, it is necessary to recall the 
origins of the pseudocontact shift (Δp) in paramagnetic lanthanide complexes, as 
discussed in Section 1.3.1.  For an axially symmetric complex with spherical coordinates 
r, Θ, and φ with respect to the Ln(III) ion on the principal axis, the pseudocontact shift 
is given by: 
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where CJ is the Bleaney constant characteristic of the particular Ln(III) ion, µB is the 
Bohr magneton, Θ is the angle between the nucleus under consideration and the 
principal axis of the lanthanide ion, and   
  and   
  are second order crystal field terms 
determined by local symmetry and donor polarisability.12,13 
 
It is generally assumed that for a given series of isostructural complexes, the ligand 
field coefficients are invariant amongst the lanthanides.  Therefore, if the temperature 
is kept constant for all measurements, it is predicted that the comparative resonance 
for a given probe nucleus should be determined almost entirely by the Bleaney 
constants, as the spherical coordinates should remain relatively unaltered.  Therefore, 
the 19F NMR spectra for all of the Ln(III) complexes of L6 were superimposed, with the 
CJ values listed (Figure 4.7). 
 
From this, it can be seen that the resonances are observed at chemical shifts that are 
in good overall agreement with the Bleaney constants and follow the predicted 
pattern; from high positive CJ values shifted to higher frequency (Tm, CJ = +53, 
δF = + 17.1 ppm), through to large negative CJ values shifted to lower frequency (Dy, 
CJ = -100, δF = - 162.4 ppm).  Yttrium is the diamagnetic analogue, and has a Bleaney 
constant of zero.  This can therefore be seen as the relative ‘centre’ for the shifts 
observed.  While the shifts do proceed in the correct order as predicted by the CJ 
values, when plotted they do not fit precisely to a linear trend (Figure 4.8).  It has been 
noted before that the Bleaney theory has limited applicability for quantitative 
studies.18,19  Therefore, it was decided to investigate the parameters of the above 
equation in more detail. 
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Figure 4.8 Relationship between 19F NMR chemical shift values obtained for [Ln.L6] 
and the Bleaney constant for each lanthanide. 
 
The simplest parameter to confirm is the temperature, as this was verified separately 
using an ethylene glycol standard reference solution before each spectrum was 
measured.  The distance, r, is likely to decrease across the series due to the 
“lanthanide contraction”. However, this cannot contribute more than a 0.08 Å 
variation between the different lanthanide complexes.  When this is incorporated into 
the shift values obtained with an inverse cubed dependence, there is little difference in 
the form of the plot from that shown in Figure 4.8.  It is harder to assess the impact of 
changes to the other spherical polar coordinate parameters (Θ, φ) without crystal 
structure information.   
 
This leaves the crystal field terms and their relative importance.  They are generally 
assumed to be constant.  However, it has been shown that there can be variations 
across the series by Gruber and co-workers.  They found an increase in   
  and an 
accompanying decrease in   
  from Tb(III) to Yb(III) for lanthanide ions in the C3i sites of 
Y2O3.
20  It is possible to estimate   
 
 alone by measuring the splitting between the A 
and E energy levels present in the Eu 5D0←
7F1 transition (ΔJ = 1 band).  Therefore, an 
emission spectrum was obtained for [Eu.L6] (Figure 4.9). 
0
20
40
60
80
100
120
0 50 100 150
δ
F 
/ 
p
p
m
 
CJ 
Chapter 4: Strategies to Enhance Signal Intensity; Reducing Dynamic Motion 
 
125 
 
Figure 4.9 Eu(III) emission spectrum for [Eu.L6] (H2O, 298 K, λexc = 276 nm). 
 
The splitting of the bands is roughly 0.3   
 ,21 resulting in a value of -550 cm-1 for the 
second order ligand field splitting.  This is large compared to other values obtained for 
related lanthanide complexes (typically of the order of around 200 cm-1), which may 
explain the poor fitting of the data presented above.  Bleaney had assumed that the 
crystal field splitting terms would be comparable to kT (≈ 205 cm-1 at 298 K) when 
making his predictions about chemical shift behaviour.  However, with larger crystal 
field terms, such as the one observed in this case, this may not be accurate and further 
terms may need to be introduced in order to fully understand and predict chemical 
shift behaviour in lanthanide complexes.  Previous studies have focussed on fairly 
dynamic systems, and it may be the case that the more rigid complexes discussed here 
are in fact improved ‘models’ to investigate in the future.   
 
While the temperature was kept constant for the measurements carried out above, it 
was of interest to investigate the dependence of the observed chemical shifts on 
temperature, due to the inverse square relationship.  Determination of temperature in 
vivo can provide information on physiological conditions of both healthy and diseased 
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tissue.  For example, elevated temperatures have been observed in the imaging of 
cancerous tissue, which is linked to an increase in the rate of metabolism of 
glucose.22,23  It is also critically important for monitoring thermal therapy techniques.24  
Currently, temperatures within a biological system can be monitored by the 
application of invasive external probes, which pose the risk of infection or acute 
damage, or by using non-invasive thermometry methods, such as T1/T2 relaxation 
measurements.  However, these latter methods suffer from low accuracy readings.  
Thermal mapping of water is possible, but is associated with a very low sensitivity 
change of 0.01 ppm K-1.  This has led to the development of lanthanide based contrast 
agents as temperature probes as they can display increased chemical shift non-
equivalence, leading to higher temperature sensitivity.25–28  These have led to the 
development of probes that display sensitivity values up to 1.76 ppm K-1.29  Examples 
have also been published that allow simultaneous imaging of brain temperature and 
pH.30,31  The majority of these examples utilise highly shifted 1H resonances, but there 
has been an example that uses the temperature-dependent 19F chemical shift of a CF3 
functionality.32 
 
Figure 4.10 19F NMR spectra of [Ho.L6] at a range of temperatures and 
accompanying plots of δF as a function of 1/T
2. 
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It is of interest to see how the systems reported here would compare to these 
previously reported temperature probes, and so for the Dy, Ho, and Tm complexes of 
L6, the 19F NMR spectrum was recorded at seven different temperatures over a range 
of 25 K (from 298 to 323 K).  Examples of the spectra obtained for [Ho.L6] are shown in 
Figure 4.10.  An additional feature of these spectra that can be observed is the 
increase in linewidth with increasing temperature, due to an increase in chemical 
exchange processes at elevated temperatures.  As can be seen, there is a considerable 
shift in both resonances over the temperature range tested, over 12 ppm in the case of 
the Dy(III) complex.  By plotting δF as a function of 1/T
2, a linear fit can be plotted 
(Figure 4.10).  This allows a method of calculating the temperature from the 19F NMR 
chemical shift.  However, in order to do this it is necessary to calibrate the system 
when recording the NMR spectrum, which can be time consuming and difficult, 
especially with in vivo studies.  The presence of two species in solution in this case is 
advantageous, as the second signal can be used as an internal reference.  If the relative 
resonances are taken as a function of temperature, then it is possible to calculate the 
temperature from the difference between the two peaks, negating the need for 
calibration (Table 4.7).   
 
Table 4.7 Change in chemical shift per unit temperature for [Ln.L6] (Ln = Dy, Ho, Tm) 
for major and minor isomers, with difference between the change in shifts 
also given.  
Complex ΔδF / T (ppm K
-1) 
 Major isomer Minor isomer Major - minor 
[Dy.L6] 0.48 0.51 0.03 
[Ho.L6] 0.23 0.25 0.02 
[Tm.L6] 0.42 0.42 0.004 
 
The values for the different lanthanide complexes above correlate well with the overall 
shifts of the compounds, i.e. the larger the shift of the complex the larger the change 
in the shift as a function of temperature (Dy > Tm > Ho), with an increase in 
temperature causing the resonances to become less shifted with respect to the 
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diamagnetic analogue.  Unfortunately, whilst the internal calibration using both the 
major and minor isomer of a given complex does work in theory here, this method 
reduces the change in shift over a set temperature from up to 0.48 ppm K-1 down to 
0.03 ppm K-1 (Table 4.7).  In practice, this limits the application of such compounds and 
reduces the reliability of temperature values obtained.  However, a suitable alternative 
would be to use two of the complexes in tandem.  In particular, as the resonances for 
the Dy(III) and Tm(III) complexes are both highly shifted and move towards each other 
with an increase in temperature, using both together increases the change in shift to 
almost 1 ppm K-1 (Figure 4.11).  This brings it up to the same magnitude as the 
currently employed compounds, although these suffer from increased complexity and 
low signal intensity,30,31 or have much more severe line-broadening.32  The simplicity 
and potential for fast acquisition of the complexes presented here are promising and 
warrant further investigation in the future, in particular into the applicability of these 
probes in vivo. 
 
Figure 4.11 Variation in the distance between the resonances for the major isomers 
of [Tm.L6] and [Dy.L6] as a function of 1/T2 (D2O, 14.1 T, 0.93 ppm K
-1). 
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4.6 Conclusions 
When designing these fluorine-labelled lanthanide complexes, the initial aims were to 
improve the R1/R2 ratio by incorporating the CF3 reporter group onto a pyridine 
moiety, in order to increase the conformational rigidity in comparison to previously 
studied mono-amide complexes.  This should have reduced dynamic motion, thereby 
reducing exchange broadening.  Unfortunately, there was no real improvement upon 
the R1/R2 ratio found with previous compounds and, while there was a decrease in the 
number of stable isomeric species, the pyridine based complexes exist as a two main 
species in solution, in around a 4:1 ratio.  However, an unexpected result that arose 
from this study was the unprecedented range of chemical shifts observed, in particular 
for [Ln.L6].  These were significantly larger than those previously observed for related 
compounds.  
 
This led to a further investigation into the chemical shift behaviour of [Ln.L6] to 
investigate the origin of these remarkable shifts and examine potential applications.  It 
was found from the europium emission spectrum that the system possesses a 
relatively large second order crystal field splitting term that plays an important role in 
determining the magnitude of the pseudocontact shift experienced by the fluorine 
atoms, as a result of being close to the paramagnetic lanthanide ion.  When plotted as 
a function of the Bleaney constant, the shifts do not correlate linearly as would be 
expected, although they do follow the correct general trend.  It may be the case that 
for complexes with such large crystal field terms, the assumptions made by Bleaney in 
his calculations need to be rethought.  Due to the large dipolar shift, it was suggested 
that these complexes may be able to act as NMR thermometers.  Initial experiments 
were undertaken that demonstrate the feasibility of such an application, with almost a 
1 ppm K-1 variation, using a combination of two different Ln(III) complexes.  
 
The extent of the chemical shift range also opens another possible use for related 
systems.  If the CF3 group is replaced by a proton containing group, e.g. 
tBu, it should 
be possible to generate high intensity shifted resonances in 1H NMR spectroscopy.  If 
relatively large shifts can be produced, then it may be possible to generate probes for 
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1H MRS, with strong signals that are shifted well away from the water resonance and 
other background signals.  In this way, it would incorporate the advantages of 
heteronuclei with those of imaging protons, i.e. no background signal combined with 
the high sensitivity and widespread use of 1H magnetic resonance.  This concept forms 
the basis of the work presented in the next chapter. 
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5. Strategies to Enhance Signal Intensity;  
A New Approach 
5.1 Introduction 
The strong 1H NMR background signal in vivo has significant limitations for magnetic 
resonance imaging and spectroscopy, particularly when attempting to distinguish 
between tissue types or developing responsive probes.  This drawback has led to the 
development of heteronuclear imaging, with 19F possessing the most promising 
attributes, due to its 100 % isotopic abundance and relatively high NMR sensitivity.  
The most important characteristic of fluorine, and the main reason it has been of 
interest, is the combination of these factors with the almost zero background signal in 
vivo.  However, as has been shown here and in previous studies, fluorine imaging using 
conventional MR set-ups (with 19F imaging coils) is far from trivial, leading to limited 
success in the work reported here. 
 
The large, lanthanide induced chemical shifts observed for the fluorinated pyridine 
complexes of up to 100 ppm in the previous chapter has led to thoughts of developing 
an alternative method of circumventing the background signal, without the need for 
heteronuclear based probes and the added drawbacks involved.  General 1H NMR 
chemical shifts for compounds in biological systems fall within the 0-10 ppm range, 
with the majority of the signal arising from internal water and fat.  If the corresponding 
1H NMR signal of a probe compound can be shifted away from these background 
signals, i.e. through the use of a paramagnetic lanthanide ion, then it should be 
possible to selectively image this resonance while excluding the endogenous signals.  
This selective imaging method would retain the advantages of using protons as the 
imaging nucleus.  Namely, the current widespread use and understanding of 1H MRI 
should allow far simpler analysis of such a probe, alleviating some of the difficulties 
witnessed through attempting to image fluorinated compounds.  In addition, there are 
far more 1H imaging coils available for use than the corresponding fluorine systems, 
increasing the range of experiments and applications that can be carried out.  
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In theory, any resonance greater than 10 ppm or lower than 0 ppm should be 
applicable to such studies, which is the range that individual proton frequencies are 
commonly shifted in paramagnetic lanthanide complexes, with chemical shift ranges 
up to -500 to +500 ppm often observed.  However, the signal required must still 
possess compatible relaxation properties; i.e. increased longitudinal relaxation rates 
on the order of 100 Hz, without severe linewidths caused by greatly increased 
transverse relaxation rates and/or chemical exchange broadening.  Ideally, a number 
of magnetically equivalent nuclei would contribute to the particular resonance, in 
order to maximise the signal intensity that could be obtained. 
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Scheme 5.1 Previous examples of 1H NMR shift probes, with proton nuclei of interest 
highlighted in red. 
 
There is some precedence in the literature for such shifted proton resonance probes as 
described above, with the first examples appearing 15 to 20 years ago.  These 
examples were focussed primarily on the Yb(III), Tm(III), and Pr(III) complexes of 
DOTMA, DOTP, and MOEDO3A (Scheme 5.1).  [Yb-DOTMA] possesses four equivalent 
methyl groups, giving rise to twelve magnetically equivalent proton nuclei, with a 
corresponding resonance located at -14.2 ppm.  Aime and co-workers imaged this 
methyl signal selectively in a phantom imaging experiment in the presence of water, 
although to observe a 3 mM aqueous solution of the complex at 4.7 T and 300 K, with 
the parameters required, took 6 h and 23 min (R1 = 15 Hz, R2 ≈ 30 Hz under these 
conditions).  Obviously the acquisition time required for this complex is far too long for 
clinical applications, but as a prototypical probe gave encouragement for further work, 
leading the researchers themselves to comment that the concept “may prove to be a 
valuable alternative in applications that currently require fluorine-containing probes.”1 
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While the methyl signal of [Yb-DOTMA] does display a temperature dependent 
chemical shift (0.41 ppm K-1), further responsive behaviour was sought, leading the 
same group to investigate the 1H NMR resonances of [Yb-DOTP].2  The six proton 
resonances highlighted in Scheme 5.1 (two equatorial ring-, two axial ring-, and two 
phosphonate arm-protons) are magnetically inequivalent, leading to six separate 
signals in the 1H NMR spectrum that lie outside the standard diamagnetic range.  
Selecting a pair of these resonances and following the chemical separation between 
the two as a function of pH allowed linear dependences to be plotted over the pH 
range 5.0-7.5, with a change of 7 ppm per pH unit observed.  By using pairs of 
resonances, the need for calibration is negated, and the large chemical shift range of 
the resonances should avoid interference with background signals.   
 
Around the same time as these studies, Frenzel and co-workers developed a similar 
concept utilising the methoxy resonance of [Pr-MOEDO3A], which resonates 
at -24.1 ppm at room temperature.3,4  The work carried out mainly focussed on 
applications towards development of an NMR thermometer (0.13 ppm K-1), and 
although the signal present was relatively broad, the complex was successfully used to 
monitor an in vivo temperature increase within the liver of a rat. 
 
Despite these early successes, there followed a slight hiatus in the interest of these 
compounds, although further research has been published in this area in the last six or 
so years.  Bansal and co-workers utilised the earlier promising results obtained with 
the DOTMA system, utilising Tm(III) in place of Yb(III).5  The methyl shift of 
[Tm-DOTMA] resonates at -102 ppm, a large increase on the previously reported 
complexes.  The magnitude of this shift allowed large improvements to be made in the 
imaging methods, resulting in strong phantom signals that could now be selectively 
acquired for 0.5 mM solutions in a matter of minutes, instead of hours (4 min 10 s 
acquisition time, 9.4 T, R2 ≈ 250 Hz).  The complex was then applied to mapping 
temperature changes in vivo, with doses of 0.5-0.6 mmol kg-1.  While the results were 
promising, it would be difficult to incorporate further responsive behaviour (e.g. pH 
reporting) into the complex without interfering with the magnetic equivalence of the 
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methyl groups, thereby immediately reducing the signal intensity by a factor of 4.  
More recent work has involved encapsulation of a related Yb(III) complex inside 
liposomal nano-carriers, in order to increase the sensitivity and biocompatibility.6 
 
Further work has also been undertaken with the thulium complex of DOTP.  Using the 
same set of proton resonances, Hyder and co-workers have successfully generated 
temperature and pH distribution maps for rat brains in vivo, with a continuous infusion 
of the complex.7  Although care was taken to ensure the rate of infusion of the 
compound was within the autoregulatory range of cerebral perfusion, the safe infusion 
doses quoted, of 1 mmol kg-1, are ten times higher than the approved dose for related 
gadolinium contrast agents.  The rats were also nephrectomised before the 
experiment, to prevent clearance of the complex via the kidneys, clearly limiting the 
feasibility of such studies.  Another recent example describes the development of a 
new, but related complex that displays 2-3 times the level of temperature dependence 
compared with [Tm-DOTMA], with values up to 1.76 ppm K-1 obtained.8  However, the 
signals used for these measurements correspond to proton resonances that are 
significantly broadened, with R1 and R2 relaxation rates over 3,000 Hz (14.1 T, 308 K).           
  
These examples demonstrate the potential for the development of a 1H MR chemical 
shift reporter.  Clearly, the main attributes required are a strong signal (ideally more 
than one equivalent proton) that is significantly shifted away from the standard 
diamagnetic range.  Specific relaxation properties are also required, in order to achieve 
high signal intensity and be able to perform fast acquisition.  The fluorinated pyridine 
complexes presented in the previous chapter seemingly meet these criteria; they 
display outstandingly large pseudocontact shifts, multiple equivalent nuclei that give 
rise to mainly one signal (≈ 80 %) in solution, and possess reasonable relaxation rates.  
Therefore, if the CF3 group in the complex is replaced by a similar proton containing 
moiety, the resulting 1H MR reporter should potentially retain these key properties. 
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Scheme 5.2 Comparison between the CF3- and 
tBu-based probes, highlighting the 
major advantages of the latter system (imaging nuclei indicated in red 
(19F) and green (1H)).  
 
This reasoning led to the design of the model complex, [Ln.L9] (Scheme 5.2).  The 
proton group chosen was a tert-butyl moiety, as it introduced the maximum possible 
number of equivalent proton nuclei, and should be relatively straightforward to 
synthesise.  Providing that the properties of the complex were as expected, there are a 
number of advantages to using the tBu moiety over the original CF3 group.  There are a 
higher number of imaging nuclei, 1H NMR spectroscopy is intrinsically more sensitive 
than fluorine, and there is the added benefit of proton MRI being the clinically 
employed system.  This latter point should increase the ease of imaging for the 
resulting complexes, alleviating some of the difficulties experienced with the previous 
fluorine experiments.  
 
The carboxylate, rather than the phosphinate, structure was chosen for the model 
compound due to the ease of synthesis of the former.  From the results of initial 
studies with [Ln.L9], improvements could easily be made to the structure, based on 
what has been learnt from the fluorine work.  Similarly, providing the compound works 
as a proof-of-principle, efforts will be made to develop further complexes that display 
responsive behaviour.  The Dy(III) and Tm(III) complexes will be examined, due to the 
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fact that these lanthanide ions should display the largest shifts, as predicted by 
Bleaney, and as observed in the previous chapter. 
 
5.2 A Model System 
5.2.1 Synthetic procedure 
The tert-butyl moiety required for the imaging probe was introduced in the first step of 
the reaction by performing a Grignard reaction on 5-bromo-2-methylpyridine using 
tert-butyl magnesium chloride in anhydrous THF with copper(I) cyanide as a catalyst 
(Scheme 5.3), following a procedure adapted from Bell and co-workers.9  However, 
applying large excesses of the catalyst, as suggested in the literature, gave rise to 
complicated work ups, with emulsions forming after quenching of the Grignard 
reagent with ammonium hydroxide and during subsequent aqueous washings.  These 
mixtures were problematic to separate, resulting in poor yields and large amounts of 
cyanide waste being generated.  In order to overcome these difficulties, a catalytic 
amount (≈ 10 mg) of CuCN was used, which yielded greatly improved yields and a more 
practicable purification procedure.  Other simple Cu(I) salts were trialled with the 
reaction, but only the cyanide salt successfully resulted in formation of the desired 
product, 81, which was isolated as a partially volatile liquid.  In order to avoid potential 
loss of this volatile compound, extractions were performed with diethyl ether as the 
organic solvent, due to its relatively low boiling point, and further purification was not 
performed at this stage. 
 
The remaining steps to synthesise the pyridine arm were similar to those described 
previously for [Ln.L8]- (Section 4.2.2).  Firstly, meta-chloroperoxybenzoic acid was used 
to generate the pyridyl N-oxide, 82, which was purified by silica gel column 
chromatography.  A rearrangement followed, firstly to the trifluoroactetate ester 
intermediate, which was then hydrolysed in situ to form the alcohol, 83.  The alcohol 
was reacted with mesyl chloride, with triethylamine as a base, to give the reactive 
mesylate compound, 84. 
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Scheme 5.3 General procedure for the synthesis of [Ln.L9].  
 
The mesylate, 84, was used immediately in an alkylation reaction with 1,4,7-tris-(tert-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane (DO3A), boiled under reflux in 
acetonitrile with potassium carbonate used as the base, to form the desired alkylated 
product, 85, after purification with silica gel column chromatography.  The tert-butyl 
ester groups were deprotected by stirring with trifluoroacetic acid in dichloromethane, 
to generate the acid compound.  Metal complexation was achieved by stirring an 
aqueous mixture of the ligand, L9, with the hydrated chloride salt of the chosen 
lanthanide ion at pH 5.5 and 60°C.  Excess metal was removed by raising the pH to 10, 
causing Ln(III) hydroxide to precipitate out of solution.  After removal of this 
precipitate, the pH was lowered back to 5.5 before the compound was lyophilised.  The 
resulting solid was extracted with ethanol to eliminate further insoluble inorganic salts, 
before the solvent was removed to yield the desired complex, [Ln.L9].   
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5.2.2 Characterisation of the complexes 
As detailed in Chapter 2, low resolution electrospray and high resolution accurate mass 
spectrometry were carried out to confirm the identity of each complex, with 
characteristic isotope patterns observed that correlated well with the calculated 
spectra.  1H NMR spectroscopic data were collected for each complex and are 
discussed below. 
 
5.2.3 1H NMR studies 
5.2.3.1 Shift behaviour 
After forming the complexes, an initial investigation was carried out into the chemical 
shift behaviour of the resonance associated with the tert-butyl group, which is easily 
identifiable due to the strong signal generated by the nine equivalent protons.  The 
1H NMR spectra of the Tm(III) and Dy(III) complexes of L9 are shown in Figure 5.1.  As 
can be seen, the tert-butyl groups give rise to strong, sharp resonances that are shifted 
well away from both the common resonance for a tBu group (δH ≈ 1 ppm) and from the 
HOD signal present in the sample.   As expected, the signals for the two complexes are 
shifted in opposite directions, with shifts of +10.8 and -20.5 ppm for the Tm(III) and 
Dy(III) complexes respectively.  This is the sense predicted by the Bleaney constants,10 
and correlates well with the pattern observed for the fluorine analogues (Section 4.5)  
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Figure 5.1 Superimposed 1H NMR spectra (D2O, 9.4 T, 298 K) of [Tm.L
9] (red) and 
[Dy.L9] (blue).  
 
The 1H NMR spectra indicate that the compounds exist as a mixture of isomers in 
solution, as expected for pyridine based lanthanide complexes.  These isomeric species 
are shown in more detail for the Tm(III) complex in Figure 5.2.  The ratio of the isomers 
in [Tm.L9] was roughly 5.5:1, with the signals for the major isomer being contained 
within those of the minor isomer; i.e. the shift range for the major isomer was -207.1 
to +83.5 ppm, whereas the corresponding range for the minor isomer was -398.5 to 
+326.9 ppm.  The tBu signal for the minor isomer resonated at +52.0 ppm, which by 
integral analysis seemingly overlapped with a signal arising from the major isomer.  
The fact that the resonances associated with the major isomer were less shifted than 
the minor suggests that the preferred structure for the Tm(III) compound is q=0 
twisted square anti-prismatic (TSAP), with the minor species adopting a square anti-
prismatic (SAP) structure, with q=1. 
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Figure 5.2 1H NMR spectrum of [Tm.L9] indicating isomeric solution species (D2O, 
11.7 T, 298 K). 
 
For the Dy(III) compound, the NMR spectrum was more complicated to assign, due to 
the increase in line broadening associated with complexes of this lanthanide.  
However, there seemed to be a slight improvement in the ratio of the isomers (>6:1), 
with a possible switch in the nature of the major species, i.e. SAP for the major species 
and TSAP for the minor.  Such a switching of the preferred conformer across the series 
of Ln(III) ions has been observed previously, and is usually associated with a change in 
hydration state. 11 
 
The tert-butyl resonances for the major species of each complex are shifted out of the 
‘biological window’ of 1H NMR spectroscopy, with the Dy(III) compound being of 
particular interest.  As the shift observed occurs at a negative ppm value, it is over 
20 ppm away from any other resonance that would be present in vivo, and should 
allow selective imaging of the signal.  However, the R1 and R2 relaxation rates must 
first be considered to examine the suitability of such complexes as imaging probes.   
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5.3.2.2 Relaxation behaviour in solution 
The longitudinal relaxation rates, R1, for both the Tm(III) and Dy(III) complexes are 
shown in Table 5.1.  As can be seen for Dy(III), the longitudinal relaxation rates were of 
the order required, i.e. around 100 Hz at 7 T and comparable to the relaxation rates 
obtained for the analogous CF3-containing complexes presented in the previous 
chapter.  As expected, R1 values for the dysprosium complex were considerably higher 
than those for the thulium complex at a respective field, due to the increased effective 
magnetic moment, µeff, and electronic relaxation time, T1e.  In addition to the 
electronic relaxation times shown in Table 5.1, average values for the rotational 
correlation time (τR, 240 ±6 ps), and the Ln-
tBu distance (r, 6.45 ±0.03 Å) could be 
estimated by global fitting of the relaxation rate data at variable magnetic fields, using 
the equation below (Figure 5.3).  Again, these values were consistent with the values 
obtained for the related fluorinated compounds presented in the previous chapter.  
 
Table 5.1 1H NMR longitudinal relaxation rate (R1) data for the tert-butyl 
resonance of [Ln.L9] at different field strengths (D2O, 295 K). Values 
given in Hz. 
Complex  
4.7 T 
 
9.4 T 
R1 / Hz 
11.7 T 
 
14.1 T 
 
16.5 T 
µeff / µB 
(a) T1e / ps 
(b) 
[Dy.L9] 73 ±0.3 124 ±0.4 149 ±1.1 170 ±0.9 210 ±1.5 10.6 0.54 ±0.03 
[Tm.L9] 31 ±0.1 54 ±0.5 68 ±2.5 71 ±0.5 83 ±1.2 7.6 0.25 ±0.05 
(a) Values taken from the literature.
12
 (b) Calculated by fitting of the longitudinal relaxation rate 
data (see Figure 5.3).   
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Figure 5.3 Variation of 1H NMR longitudinal relaxation rate with magnetic field for 
the tert-butyl resonance of [Ln.L9] (295 K, D2O) showing the 
experimentally obtained values (symbols) and fit (line) to the data, using 
a global minimisation method applied to the above equation. 
 
As before, another important consideration when considering probes for imaging 
purposes was the relationship between the longitudinal (R1) and transverse (R2) 
relaxation rates, as the latter is associated with line broadening.  An increase in R2 
leads to an increase in linewidth, which will also be affected by chemical exchange 
processes.  Therefore, in order to maximise signal intensity, it is imperative to maintain 
line broadening to a minimum and to make the R1/R2 ratio as close to one as possible.  
As can be seen in Table 5.2, at 9.4 T this ratio was almost 0.6, which is an improvement 
upon the carboxylated fluorine analogue, [Ln.L7] (Section 4.4.2), though not as high as 
for some other related CF3-containing complexes.
13  However, as a starting point for a 
model complex, this value was considered reasonable and sufficiently high to consider 
attempting imaging studies. 
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Table 5.2 Longitudinal (R1) and transverse (R2) relaxation rates and the ratio of the 
two for the tert-butyl resonances of [Dy.L9] and [Tm.L9] (D2O, 298 K). 
Complex  
R1 / Hz 
4.7 T 
R2 / Hz 
(a) 
 
R1/R2 
 
R1 / Hz 
9.4 T 
R2 / Hz 
(a) 
 
R1/R2 
[Dy.L9] 73 107 0.68 124 223 0.56 
[Tm.L9] 31 66 0.47 54 94 0.57 
(a) R2 values were estimated as (πω1/2), for a Lorentzian line fit.  
 
5.2.4 Removing the water signal 
While the results obtained from the preliminary 1H NMR studies were promising, 
before any imaging experiments could be attempted, it was necessary to determine 
whether the resonance of interest could be visualised selectively in the presence of a 
strong water signal, i.e. can the solvent signal be removed from the spectrum in order 
to observe only the resonance of the tert-butyl group of the complex?  A potential 
solution involves saturation of the water signal, though this technique may affect other 
nearby signals, depending on the frequency separation between the solvent signal and 
the resonance of interest.  A simple option would be to remove the data 
corresponding to the water peak from the FID trace selectively, after obtaining the 
spectrum.  However, while this post-acquisition ‘solvent suppression’ technique is 
relatively straightforward in a standard NMR spectroscopy experiment and proved to 
be highly successful, it is difficult to apply to a more complicated in vivo MRI 
experiment.  Therefore, an alternative pre-acquisition water suppression technique 
was applied (Figure 5.4). 
 
Figure 5.4 Pulse sequence used for water suppression experiment. 
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The pulse sequence used employed a pulse field gradient to remove all transverse 
magnetisation.  A 90o pulse, followed by a second pulse field gradient removed 
magnetisation perpendicular to the first gradient.  This process was repeated again to 
remove any final artefacts, essentially removing all magnetic polarisation from the 
system.  A 20 ms delay was applied following these gradients, so that only resonances 
displaying fast relaxation rates could relax significantly, i.e. signals corresponding to 
the complex and not the solvent water signal.  A 10-15o pulse then uniformly excited a 
wide spectral range.  The following acquisition should then show signals corresponding 
predominantly to the complex and not the solvent.  The results are shown in Figure 
5.5. 
 
Figure 5.5 1H NMR spectra of [Dy.L9] before (a) and after (b) application of the 
water suppression pulse sequence shown above. 
 
The above spectra showed that the water suppression method was partially successful.  
The water signal has been significantly attenuated after application of the pulse 
sequence.  However, the solvent resonance has not been removed entirely, as a 
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proportion of the water resonance can still relax in the short delay time applied.  It is 
also important to remember that, as the complex has a bound water molecule in 
exchange with the bulk solvent, there is additional relaxation of the water resonance 
by the paramagnetic Dy(III) ion, increasing the signal intensity.  In pure water, the 
solvent signal would be even more pronounced, and so an alternative method was 
required. 
 
As the signal of interest is shifted so far away from the water resonance, a seemingly 
simple solution to remove the solvent peak involves the use of digital filtering, i.e. set 
the spectral window around the peak of interest to ‘cut off’ unwanted signals.  
Advancements in modern NMR spectrometers have made this a feasible prospect, as 
previously, ‘folding’ of the water signal into the spectrum would have been observed.  
In order to test if this concept would work, [Dy.L9] was dissolved in H2O with a capillary 
insert containing deuterium oxide used to lock the NMR instrument and a standard 
1H NMR experiment was run with an increased sweepwidth (Figure 5.6).  
 
The resulting spectrum (Figure 5.6.a) was dominated by the water signal, so much so 
that the tert-butyl resonance was only observed when the spectrum was blown up 
considerably.  The spectral window was then moved, centred on the peak of interest, 
and reduced in size.  Working at 14.1 T, sweepwidths of 9 kHz (15 ppm) and 2.4 kHz 
(4 ppm) were examined, and each resulted in successful filtering out of the solvent 
signal, so that the only resonances observed corresponded to signals arising from the 
complex (Figure 5.6.b).  For the smaller sweepwidth, the acquisition time had to be 
increased slightly in order obtain sufficient data points for processing.  However, due 
to the high intensity and fast relaxation exhibited by the tBu signal, the total 
acquisition time for the resulting spectrum was still only 10 s, using a 2 mM sample at 
298 K. 
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Figure 5.6 1H NMR spectra of [DyL9] (2mM complex, H2O, 298 K, 14.1 T). 
(a) Standard paramagnetic 1H NMR experiment with large sweepwidth. 
(b) Resulting spectrum acquired after setting the spectral window 
around the peak of interest as indicated by the red lines in each 
spectrum (sweepwidth = 2.4 kHz, total acquisition time = 10 s). 
 
Digital filtering, therefore, seems to be a highly successful method of removing the 
solvent resonances, to allow selective observation of the signal of interest.  It is a fast 
technique, fairly simple to implement, and should remove other ‘background’ 1H NMR 
signals from the spectrum.  However, it relies on the resonance of interest being 
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shifted far enough away from other signals to allow a reasonable sweepwidth to be 
used, and so would not be possible without the use of paramagnetic complexes, such 
as these introduced here.  Digital filters on MRI instruments are very similar to those 
found on modern NMR spectrometers, and consequently this technique should be 
directly applicable in imaging experiments. 
 
5.2.5 Imaging studies 
Preliminary imaging studies were carried out at 7 T by Prof. Andrew Blamire at 
Newcastle Magnetic Resonance Centre.  To begin with, the Dy(III) complex was 
examined, as the combination of higher relaxation rates and the largest shift from the 
water signal suggested it would have the best characteristics for potential imaging.  
However, current 1H imaging coils were not designed for resonances outside of the 
standard 1H NMR spectral shift range (ca. 0-10 ppm), resulting in broad background 
humps and water signal artefacts appearing outside of this range.  This interference 
prevented any signal being observed for [Dy.L9]. 
 
Therefore, the Tm(III) complex was investigated instead.  In order to overcome the 
background signal from the coil, a volume selection method was applied, which is a 
standard technique used for in vivo MRS for removing contamination of the signal 
from outside of the target region.  The sequence used was a “STEAM” (stimulated echo 
acquisition mode) sequence, that consisted of a single 90o water suppression pulse, 
followed by two further 90o pulses before acquisitions, with pauses between the 
pulses related to TE/2 (half the echo time) and TM (the “mixing time”).  The three 90o 
pulses are selective on orthogonal spatial axes, and the result is a stimulated echo 
arising only from spins at the intersection of the three slices, i.e. a selected volume. 
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Figure 5.7 (a) Sample (2 mM [Tm.L9], H2O) contained in an Eppendorf tube 
displaying location of the 5x5x5 mm3 selected volume (green box). 
(b) STEAM volume selected 1H MRS with single pulse water suppression 
(7 T, 10 cm diameter volume imaging coil, TR = 82 ms, TE = 2.34 ms, 
TM = 4.52 ms, sweepwidth = 20.2 kHz, total acquisition time = 5 m 34 s). 
Resulting tBu signal (red box) displays a linewidth of 30 Hz, with a 
calculated signal to noise ratio of around 10. 
 
Applying this “STEAM” method, a 5x5x5 mm cube was selected at the top of the 
sample tube (Figure 5.7.a).  The section was shimmed, before various combinations of 
sweepwidth and sample points were trialled, with optimisation of the water 
suppression carried out each time, and resulted in a reasonable spectrum being 
obtained from a 5 ½ min acquisition time (Figure 5.7.b).  The signal obtained was an 
encouraging start, but there were some limitations with the method used: 
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(i) The “STEAM” sequence removed the background noise from the coil 
and allowed a good local shim to be obtained, but the stimulated echo 
contains only half of the total signal available, i.e. half of the potential 
signal intensity is lost immediately. 
(ii) “STEAM” has an echo time (TE) during which signal is lost by T2 decay, in 
addition to signal being lost by T1 processes during TM. 
(iii) The linewidths and shift of this system require water suppression to be 
applied, rather than setting a small sweepwidth to filter out the water 
signal. 
 
The results obtained left a lot of room for potential improvements to be made to the 
system.  The data were also collected with a large volume imaging coil (10 cm diameter 
quadrature birdcage coil), in comparison to the 10 mm solenoid coil used for the 
previous fluorine imaging work (Section 3.2.5).  The larger the coil, the lower the 
sensitivity, and so to acquire a reasonable spectrum from such a large coil was 
encouraging.  Based on the data acquired, it was estimated that a 0.25 mM 
concentration of this compound could be observed in a 125 µL volume of tissue 
anywhere in a large animal in around 10 min of scanning, if the signal lost by the 
“STEAM” sequence (50 %) could be reclaimed. 
 
While these results were promising, the unfamiliar imaging techniques required would 
be far easier to implement if a higher signal intensity could be generated from the 
complex.  Despite the problems that arose when trying to observe the signal for the 
Dy(III) complex at -20.5 ppm, imaging of such a resonance should theoretically be 
possible and have pronounced improvements upon the signal observed thus far.  A 
resonance so far away from the water signal should allow different imaging methods 
to be employed and larger sweepwidths to be used, as long as the signal can be 
observed over the background noise from the coil.  Therefore, it was decided to 
redesign the probe in order to increase potential signal intensity, to improve the 
possibility of the resonance being observed and to allow imaging techniques and 
parameters to be refined. 
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5.3 Increasing the Sensitivity 
5.3.1 Probe design 
During phantom imaging experiments with the monopyridine-based complex, [Ln.L9], 
it became apparent that, in order to optimise conditions and methods used, an 
increase in signal intensity would be required.  Any increase in signal intensity would 
obviously also be advantageous when applying the system to in vivo studies.  
Conjugating the complex onto a high molecular weight adduct was considered, in a 
similar manner to that described for the fluorine systems (Chapter 3).  However, a 
more straightforward option was to add a second, equivalent tert-butyl group to the 
complex, hence doubling the signal that can be observed. 
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Scheme 5.4 Comparison between the chemical structure of [Ln.L9], and [Ln.L10]+. 
 
This concept led to the development of the dipyridine-based complex, [Ln.L10]+.  
Providing the two tert-butyl groups are equivalent in the complex and that the 
relaxation and shift parameters remain reasonably similar to the previous complex, the 
resulting 1H NMR signal should be twice as intense.  The resulting complex is also 
monocationic, which may lead to unusual behaviour in vivo, compared with related 
lanthanide complexes previously investigated. 
 
5.3.2 Synthesis and characterisation 
The synthesis of [Ln.L10]+ is shown in Scheme 5.5, with the mesylated pyridine 
compound, 84, being prepared as detailed above.  The mesylate was used to dialkylate 
the secondary amine sites of 1,7-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
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(DO2A), forming the fully alkylated intermediate, 89.  Fairly mild conditions were used 
in this alkylation step, as the mono-alkylated intermediate was also desired for later 
work (Section 5.4), resulting in a deceptively low apparent yield for the reaction.  The 
two products were separated by silica gel column chromatography, before the 
tert-butyl ester groups of 89 were cleaved by heating in hydrochloric acid (6 M), to 
generate the deprotected ligand, L10.  It should be noted that, in this case, it was 
decided to implement HCl for acid hydrolysis over trifluoroacetic acid, as it was hoped 
that the resulting complexes would be employed for in vivo experiments, and the 
resulting chloride salts should be much better tolerated than the comparable 
trifluoroacetate salts.  The complexation reaction was carried out using an analogous 
procedure to that described for [Ln.L9], to generate the desired series of monocationic 
complexes, [Ln.L10]+. 
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Scheme 5.5 General procedure for the synthesis of [Ln.L10]+.  
 
The Dy(III) and Tm(III) complexes were again examined, as they display the greatest 
shifts in each direction and allow direct comparison to the work presented for [Ln.L9].  
The Tb(III) and Gd(III) analogues were also synthesised, as the former should display 
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similar properties in shift to Dy(III) and the latter is useful for MRI tumour uptake 
studies, using it as a conventional water proton contrast agent.  The Tb(III) complex 
also allows the metal hydration state (q value) to be assessed by measuring the 
radiative lifetime of the lanthanide excited state, k, in both H2O and D2O, as described 
in Section 4.3.  Values of 0.55 and 0.35 ms-1 were recorded experimentally for      
and      respectively, resulting in a calculated q value of 0.7.  This suggests that the 
complex possesses one bound water molecule, as to be expected with carboxylate 
based compounds.  Again, complexes were characterised by low resolution 
electrospray and high resolution accurate mass spectrometry. 
 
5.3.3 1H NMR studies 
 
Figure 5.8 1H NMR spectra (D2O, 9.4 T, 298 K) of [Dy.L
9] (top) and [Dy.L10]+ 
(bottom).  
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The 1H NMR spectra obtained for [Ln.L10]+ were comparable to those previously 
observed for [Ln.L9], as can be seen for the dysprosium complexes in Figure 5.8.  For 
both the Dy(III) and Tm(III) complexes of L10, the shifts were not quite as large as found 
for L9.  For [Dy.L10]+, this is less of an issue as the resonance observed for the tert-butyl 
group was -17.8 ppm, which should be far enough away from the water signal for 
imaging purposes.  However, the shift for same group in [Tm.L10]+ was +6.2 ppm, less 
than 2 ppm from the water resonance, and it is difficult to separate from signals arising 
from other biological background compounds.  The shift for the Tb(III) complex was 
observed at -7.2 ppm, which may still be practical for imaging purposes, although at 
under half the shift of the Dy(III) complex it is unlikely to offer many benefits over the 
latter lanthanide.  The spectrum for the Gd(III) complex was not analysed, due to the 
magnetic properties of gadolinium resulting in broad, unshifted resonances.  No 
significant isomers were observed in the 1H NMR spectra of the complexes, with one 
major species (>90%) formed in solution. 
 
The longitudinal relaxation rates were then measured at five fields for the Dy(III), 
Tb(III), and Tm(III) complexes of L10 (Table 5.3).  For [Dy.L10]+, R1 was significantly faster 
than for the analogous mono-pyridine complex, with up to a 60 % increase depending 
on the magnetic field.  For Tm(III), this behaviour was reversed, with a similar decrease 
in R1 observed when comparing [Tm.L
9] to [Tm.L10]+.  Combined with the low shift 
values obtained, these relatively slow relaxation rates made [Tm.L10]+ unsuitable for 
imaging application, and so this complex was not investigated further.  As for previous 
systems, global fitting of the longitudinal relaxation rate data to the equation shown in 
Figure 5.3 allowed values for the Ln-tBu distance, r, and the rotational correlation time, 
τR, to be calculated as 6.43 ±0.04 Å and 277 ±6 ps respectively.  Values for the 
electronic relaxation rates, T1e, for the individual lanthanide could also be estimated 
from the fitted data, as shown in Table 5.3.   
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Table 5.3 1H NMR longitudinal relaxation rate (R1) data for the tert-butyl 
resonance of [Ln.L10]+ at different field strengths (D2O, 295 K).  
Complex δH / 
ppm 
 
4.7 T 
 
9.4 T 
R1 / Hz 
11.7 T 
 
14.1 T 
 
16.5 T 
T1e / ps 
(a) 
[Dy.L10]+ -17.8 119 ±0.4 178 ±0.7 203 ±0.6 230 ±0.8 256 ±0.5 0.76 ±0.03 
[Tb.L10]+ -7.2 111 ±1.0 152 ±1.0 169 ±1.1 188 ±0.6 207 ±1.9 0.94 ±0.05 
[Tm.L10]+ +6.2 21 ±0.3 40 ±0.3 51 ±0.4 59 ±0.3 68 ±0.6 0.20 ±0.06 
 (a) Calculated by fitting of the longitudinal relaxation rate data (see Figure 5.X).   
 
The longitudinal relaxation rates for the Dy(III) and Tb(III) complexes were similar, and 
so the relationship between the longitudinal and transverse relaxation rates was 
investigated (Table 5.4).  The R1/R2 ratios obtained were a significant improvement 
upon the values calculated for the previous mono-pyridine (L9) complexes (ca. 0.56 at 
9.4 T) and were comparable with the values obtained with the best fluorine imaging 
probes investigated.  These ratios were improved further still at lower fields, with 
values of 0.86 and 0.87 obtained at 4.7 T, for the Dy(III) and Tb(III) complexes 
respectively.   
 
Table 5.4 Longitudinal (R1) and transverse (R2) relaxation rates and the ratio of the 
two for the tert-butyl resonances of [Dy.L10]+ and [Tm.L10]+ (D2O, 298 K). 
Complex  
R1 / Hz 
4.7 T 
R2 / Hz 
(a) 
 
R1/R2 
 
R1 / Hz 
9.4 T 
R2 / Hz 
(a) 
 
R1/R2 
[Dy.L10]+ 119 138 0.86 178 223 0.72 
[Tb.L10]+ 111 128 0.87 152 192 0.79 
 (a) R2 values were estimated as (πω1/2), for a Lorentzian line fit.  
 
Such high values were very promising for applications in imaging, as high longitudinal 
relaxation rates coupled with relatively low transverse relaxation rates serve to 
increase potential signal intensity, vital for fast acquisition times.  While the Tb(III) 
complex displayed reasonable shift and relaxation rate characteristics, when compared 
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to the Dy(III) complex there was no advantage in using the terbium system.  Therefore, 
imaging studies focussed upon the use of [Dy.L10]+ only. 
 
5.3.4 Cell studies 
Before undertaking imaging studies, it was decided to investigate whether the 
complex, [Dy.L10]+, could be utilised for cell labelling.  A 100 µM solution of the 
complex was dissolved in the cell growth medium before being added to a sample of 
NIH 3T3 cells (4,000,000 cells per experiment, average cell volume 4000 µm3).  The 
cells were loaded with the complex for 4 h, before the cell growth medium was 
removed and the remaining cells were washed with pH 7.4 phosphate buffer saline 
solution (PBS) three times.  After removal of this buffer solution, the cells were scraped 
off the well plate, diluted to a 1 mL final volume with PBS, and sonicated to break up 
the cell membrane.  After sonification for 30 min, the sample was lyophilised, before 
being dissolved in the minimum volume of D2O (200 µL) and the 
1H NMR acquired 
(Figure 5.9). 
 
Figure 5.9 1H NMR spectrum of [Dy.L10]+ loaded onto NIH 3T3 cells (D2O, 14.1 T, 
298 K, total acquisition time =  34 min, SNR = 2.5:1). 
 
A weak signal can be observed, with a total acquisition time of 34 min and signal-to-
noise ratio (SNR) of 2.5:1.  As a control, the 1H NMR spectrum of the initially removed 
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PBS solution was acquired, which resulted in a strong, observable signal after a short 
acquisition time, with SNR = 22:1 after 26 s.  The low intensity signal found for the cell 
loaded complex suggests that only a small proportion of the compound is 
permeabilised by the cell, with the rest remaining extracellular and being removed in 
the PBS washing step.  However, for further studies the complex could be 
functionalised with a group known to efficiently permeabilise cell membranes.  
Alternatively, systems exist that have been shown to aid delivery of an agent into a 
cell.  This lack of cell permeabilisation is not a limiting factor for further imaging 
studies, as the vast amount of contrast agents employed are extracellular probes, 
which are more likely to be cleared easily by the body. 
 
5.3.5 Imaging studies 
5.3.5.1 Phantom imaging 
Preliminary imaging studies were carried out at 7 T by Prof. Andrew Blamire at the 
Newcastle Magnetic Resonance Centre using a 2 mM sample of [Dy.L10]+, contained 
within a cut-down 5mm NMR tube placed vertically (i.e. 90o to B0) in the bore of a 
30 mm volume birdcage coil.  This is the coil generally used for standard mouse MRI 
experiments.  The increase in signal intensity, compared to the previous mono-pyridine 
complexes, allowed a resonance to be easily observed over the background noise, 
allowing images to be obtained and not just spectra as was the case in the previous 
experiment.   
 
By applying a 2D thick slice imaging method, the water signal was observed separately 
from that of the compound resonance, which was shifted in the image due to the 
interaction between the imaging gradients and the chemical shift offset.  Such splitting 
of images is commonly seen in clinical MRI as a water to fat shift, as spatial encoding 
assigns absolute frequency to a point in space.  Frequency offset due to the gradient 
field adds to that ascribed to differences in chemical shift, causing an additional shift.  
Therefore, despite being in the same point in space, the two signals effectively split 
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into two separate images.  This is useful when investigating techniques to eliminate 
the water signal, as relative signal intensities can be easily compared by eye. 
 
Figure 5.10 Single slice gradient echo 2D scan (sagittal orientation, 2 mM complex, 
H2O, SW = 25 kHz, TR = 30 ms, TE = 2.56 ms) displaying images for: 
(a) the water signal, (b) the tert-butyl resonance of [Dy.L10]+.  Left-hand 
image acquired with no water suppression, right-hand image acquired 
with water suppression applied. 
 
As in the 1H NMR studies, water suppression was attempted to remove the water 
signal, and was partially successful (Figure 5.10).  However, there was an artefact 
clearly visible, attributed to coherences building from residual transverse 
magnetisation being acted upon by subsequent RF pulses in the imaging experiment.  
This process causes the signal to refocus and reappear, resulting in the appearance of 
the artefact signal.  It may be possible to remove such ‘left-over’ resonances by 
refining the parameters, but it was decided instead to focus on investigating the effect 
that changing the sweepwidth (SW) had on the image, as shown in Figure 5.11. 
 
 
Figure 5.11 Single slice gradient echo 2D scan (axial orientation, 2 mM complex, 
H2O) displaying images for the water signal (top) and the tert-butyl 
resonance of [Dy.L10]+ (bottom). (a-e) Sweepwidth is reduced from left to 
right as indicated by the SW values given for each scan.   
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By centring the spectral window on the peak of interest, i.e. at -17.9 ppm, and 
reducing the sweepwidth, the water signal can be eliminated from the imaging field of 
view, although only when the SW was reduced to 10 kHz.  This is to be expected, as at 
7 T the two resonances are roughly 6.7 kHz apart.  Therefore, to entirely eliminate the 
water signal, the scan must be centred at -17.9 ppm with a SW of less than double this 
separation.  Lower SW values lead to longer acquisition times, and the results may be 
more complicated when transferred from a model system (small tube) to an extended 
object (animal).  If a system could be developed that displayed an increased shift, this 
would allow a larger SW to be employed and potentially increase signal intensity.  
However, this method did allow good quality 3D images to be acquired with optimised 
parameters (Figure 5.12).   
 
 
Figure 5.12 Gradient echo 3D image of the tert-butyl resonance of [Dy.L10]+ (2 mM 
complex, H2O, TR = 10 ms, TE = 2.88 ms, SW = 20 kHz, total scan 
time = 6 min 19 s). 
 
From these images, the signal-to-noise ratio (SNR) could be calculated.  For a 
1x1x1 mm3 volume, SNR was calculated to be 14, which compares favourably to the 
value of 9 achieved with the fluorinated glycol chitosan compound, [Dy.L3-chitosan] 
(Section 3.2.5), and is almost 4 times larger than relative values obtained with similar 
fluorinated compounds that were previously tested.14  The coil used in these proton 
imaging studies was also a standard mouse imaging coil, unlike the surface coil used 
for the fluorine work, which should make the methods refined above more amenable 
to in vivo studies.  
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5.3.5.2 In  vivo imaging 
Preliminary in vivo studies were carried out by Prof. Andrew Blamire and Dr. Ian 
Wilson, at the Newcastle Magnetic Resonance Centre, on SCID male mice (25 g) with 
HT29 tumours (human colorectal carcinoma).  Measurements were taken 10-14 days 
after inoculation when tumours were around 10 mm in diameter, with the mouse 
anaesthetised with oxygen/1-2 % isofluorane.  Solutions of [Gd.L10]+ and [Dy.L10]+ were 
administered to separate mice by intravenous injection in the tail, with each mouse 
receiving an overall dose of 0.06 mmol kg-1 of the respective complex per experiment.  
  
 
Figure 5.13 Relative in vivo T1-weighted 
1H MRI water signal intensity within an 
HT29 tumour on a SCID male mouse as a function of time after 
intravenous administration of [Gd.L10]+. 
 
Firstly, standard 1H MRI experiments were run after administration of [Gd.L10]+ using a 
39mm birdcage volume coil.  A dynamic scan experiment was run using a T1-weighted 
sequence, focussing upon a slice containing the tumour.  The signal intensity within the 
tumour was monitored as a function of time after administration of the complex 
(Figure 5.13).  Within the first 10-15 min, around a 20 % increase in signal intensity was 
observed within the tumour, with little variation for the remainder of the experiment 
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(60 min in total).  This level of increase was comparable with standard, commercial 
contrast agents, and the retention time observed was promising for further studies. 
 
 
Figure 5.14 Top rows; Gradient echo 3D sequence 1H MR images obtained examining 
the tBu resonance of [Dy.L10]+ 90 min after intravenous administration to 
a HT29 bearing SCID male mouse (0.06 mmol kg-1 complex, 7 T, 
TR = 10 ms, TE = 4.39 ms, SW = 5 kHz, total scan time = 5 min 28 s, 
maximum SNR = 20). Bottom rows; Overlay of above data onto the 
standard structural 1H MR image. 
 
After obtaining promising results with the Gd(III) complex, the analogous experiment 
was run with [Dy.L10]+, using the same 39 mm birdcage volume coil.  Due to the 
baseline roll generated by water and fat in vivo, a signal could not be observed to 
begin with.  However, after refinement of the excitation pulse bandwidth, a strong 
signal could be observed.  However, by the time the signal was observed, 90 min had 
passed since injection of the compound.  Due to the length of time after 
administration of the complex, the signal could only be observed localised within the 
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bladder, confirmed by overlaying the sequence of images obtained for the tert-butyl 
resonance onto the standard structural scan (Figure 5.14).  The excitation pulse was 
centred upon the resonance of interest (-17.9 ppm) with a 5 kHz sweepwidth, to avoid 
excitation of the water protons interfering with the image.  
 
While it was unfortunate that the signal was only observed after 90 min, and hence 
only in the bladder, the acquisition of an image within a live animal was extremely 
encouraging.  The signal was obtained within a relatively short amount of time 
(5 min 28 s) and the complex was well tolerated by the animal.  Further studies are on-
going to determine the biodistribution and clearance profile of the complex in the 
earlier stages of the experiment, before it reaches the bladder. If necessary, the 
concentration of the complex administered can be easily increased, as the approved 
dose for standard, related contrast agents is 0.1 to 0.2 mmol kg-1.   
 
5.4 A Responsive Proton CSI System 
5.4.1 Probe design 
As mentioned throughout this report, the development of responsive magnetic 
resonance probes is key for increasing the applicability of MRI for diagnosis, therapy, 
and drug design.  Of particular significance are contrast agents that can report on local 
pH in vivo, as changes in pH are associated with various pathologies (e.g. stroke, 
infection, renal failure).  Being able to monitor pH may be particularly important for 
the diagnosis of cancer, as cancerous tissue is often acidic due to poor perfusion, 
reduced bicarbonate levels, and increased lactic acid secretion.15  Mapping of pH is 
also vital for developing therapies that are effective in regions of altered pH.16 
 
The relevance of pH mapping in vivo has led to a variety of gadolinium-based contrast 
agents that respond to changes in pH, some of which are discussed in Section 1.4.1.  
However, for traditional Gd(III) probes, in order to calculate the pH it is necessary to 
determine the local concentration of the contrast agent, a very difficult task often 
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requiring the use of a secondary imaging method (e.g. PET, CT).17  The use of 
heteronuclear MRI is far more relevant, as changes in pH can be signalled by a change 
in relative chemical shift, or a change in intensity between two resonances, both of 
which should be far easier to monitor in an imaging experiment. 
 
These thoughts have led to the development of two forms of lanthanide-based probes 
within the group that report on variations in pH through changes in the 19F NMR 
spectrum; one method utilises the protonation equilibrium of an amide bond to adjust 
the relative angle of the fluorine nuclei with respect to the principal axis of the 
lanthanide ion,18,19 the other system is based on the ‘on-off’ ligation of a sulphonamide 
moiety.19,20  This latter method should be possible to incorporate with the pyridine-
based systems reported here, by placing a sulphonamide arm at the trans position to 
the pyridyl moiety, leading to the design of the potential pH-responsive chemical shift 
imaging (CSI) complex, [Ln.L11].     
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Scheme 5.7 Design of the pH-responsive probe, [Ln.L11]. 
 
As shown in Scheme 5.7, the concept of the probe works by variable coordination of 
the sulphonamide arm.  At higher pH, the sulphonamide moiety is deprotonated and 
bound to the metal ion.  As the pH lowers, protonation occurs and the coordination 
about the lanthanide changes, with the sulphonamide uncoordinated and the inclusion 
of a water molecule is to be expected to complete the coordination sphere.  This 
change in coordination will affect the ligand field experienced by the Ln(III) ion, which 
in turn should affect the 1H NMR shift of the tert-butyl resonance.  By changing the 
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lanthanide ion complexed, other methods should also be available for monitoring pH, 
e.g. Gd(III) allows relaxivity measurements, Tb(III) for emission profiles. 
 
5.4.2 Synthesis and characterisation 
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Scheme 5.8 General procedure for the synthesis of [Ln.L11].  
 
The synthesis of [Ln.L11] is shown in Scheme 5.8.  The mono-pyridine compound, 95, 
was formed in the same reaction as the di-pyridine compound, 89, described for the 
synthesis of [Ln.L10]+.  The desired compound was isolated by silica gel column 
chromatography, before alkylation with N-methanesulfonylaziridine (generated in situ) 
was performed by heating in acetonitrile with potassium carbonate added as a base.  
The fully substituted product, 96, was purified by silica gel column chromatography.  
Deprotection of the tert-butyl ester groups was carried out using trifluoroacetic acid, 
to form the ligand, L11.  The lanthanide complexes were obtained in the usual manner, 
by reaction with LnCl3.6H2O at pH 5.5.   
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Complexes were characterised by low resolution electrospray and high resolution 
accurate mass spectrometry.  The metal hydration state (q value) was assessed at high 
and low pH by measuring the radiative lifetime of the lanthanide excited state, k, of 
the Tb(III) complex in both H2O and D2O, as described in Section 4.3.  At pH 8, values of 
0.47 and 0.42 ms-1 were recorded experimentally for      and      respectively, 
resulting in a calculated q value of 0.05.  At pH 4, however,      and      were found 
to be 0.69 and 0.43 ms-1, respectively, giving a q value of 1.0.  This suggests that there 
are no waters bound to the Ln(III) ion at higher pH values, when the sulphonamide arm 
is deprotonated and coordinated to the metal.  As the pH lowers, the sulphonamide 
nitrogen is protonated and is no longer coordinated.  This leads to a space in the 
coordination sphere of the Ln(III) ion, allowing a water molecule to bind to the 
complex.    
 
5.4.3 1H NMR studies 
The chemical shifts attributed to the tert-butyl resonance of the complexes were far 
greater than anticipated, as shown in Figure 5.15.  Significant increases were observed 
for each lanthanide, with around a 40 ppm gain in shift non-equivalence, when 
compared to the previous complexes investigated.  The chemical shifts were observed 
at +44.3 ppm for the tBu group in [Tm.L11] and at -58.9 ppm in [Dy.L11].  These 
unprecedentedly large shifts were promising for further studies, as an increased shift 
from the water signal allows a larger bandwidth to be used in imaging experiments, 
increasing the signal intensity that can be obtained per unit time.  The major isomer 
for the Tm(III) complex seemed to account for around 80 % of the overall signal, with 
the tert-butyl signal for the minor species resonating at +28.1 ppm.  The methyl 
substituent of the sulphonamide arm appeared to resonate as one major signal at 
+52.7 ppm, assigned by relative integral values.  Previous studies have shown that such 
species arise from coordination isomers via each oxygen at the stereogenic S centre of 
the sulphonamide arm.19  
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Figure 5.15 1H NMR spectra (D2O, 9.4 T, 298 K, pD 8.5) for [Tm.L
11] (left) and 
[Dy.L11] (right). 
 
Longitudinal relaxation rate, R1, data were obtained for each complex at various 
magnetic field strengths (Table 5.5).  The R1 values calculated were more comparable 
with those obtained for [Ln.L9] than for [Ln.L10]+, suggesting the two compounds may 
adopt a similar structure.  The rates below for the dysprosium complex are significantly 
slower than for the relevant bis(pyridine) complex, which may result in a comparative 
loss of signal intensity in imaging experiments.  Fitting of the longitudinal relaxation 
rate data was again undertaken, as described in Section 5.2.3, leading to the values of 
the electronic relaxation rate, T1e, given in Table 5.5.  Global fitting of all the data for 
the three complexes of L11 allowed average values of the rotational correlation time, 
τR, and the Ln(III)-
tBu distance, r, to be estimated, as 214 ±8 ps and 6.57 ±0.04 Å 
respectively.  
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Table 5.5 1H NMR longitudinal relaxation rate (R1) data for the tert-butyl 
resonance of [Ln.L11] at different field strengths (D2O, 295 K, pD 8.5).  
Complex δH / 
ppm 
 
4.7 T 
 
9.4 T 
R1 / Hz 
11.7 T 
 
14.1 T 
 
16.5 T 
T1e / ps 
(a) 
[Dy.L11] -58.9 74 ±0.3 113 ±1.1 137 ±1.6 160 ±1.5 185 ±1.6 0.67 ±0.04 
[Tb.L11] -55.8 63 ±0.7 89 ±1.1 108 ±0.7 123 ±1.2 139 ±1.0 0.74 ±0.04 
[Tm.L11] +44.3 40 ±3.4 60 ±1.7 77 ±0.4 89 ±0.2 101 ±0.3 0.34 ±0.03 
(a) Calculated by fitting of the longitudinal relaxation rate data (see Figure 5.3).   
 
The ratio of the longitudinal (R1) and transverse (R2) relaxation rates for the complexes 
of L11 were measured and compared (Table 5.6).  For imaging purposes, a value as 
close to one as possible is ideal, as this allows fast acquisition whilst keeping line 
broadening to a minimum.  However, for [Ln.L11] the values obtained are low, 
especially in comparison to the values obtained for the complexes of L9 (≥ 0.56) and L10 
(≥ 0.72).  The smaller values of R1/R2 for this system may offset any potential signal 
gain arising from the increased shift of the sulphonamide complexes. 
 
Table 5.6 Longitudinal (R1) and transverse (R2) relaxation rates and the ratio of the 
two for the tert-butyl resonances of [Dy.L11], [Tb.L11], and [Tm.L11] (D2O, 
298 K, 9.4 T). 
Complex  
R1 / Hz 
4.7 T 
R2 / Hz 
(a) 
 
R1/R2 
 
R1 / Hz 
9.4 T 
R2 / Hz 
(a) 
 
R1/R2 
[Dy.L11] 74 260 0.28 113 380 0.30 
[Tb.L11] 63 182 0.35 89 518 0.17 
[Tm.L11] 40 225 0.18 60 305 0.20 
(a) R2 values were estimated as (πω1/2), for a Lorentzian line fit.  
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5.4.4 pH Dependent behaviour 
The data for [Ln.L11] presented above were collected above pH 8, as the 1H NMR signal 
was strongest at these values.  As the pH lowered, the resonance observed decreases 
in intensity until no signal can be observed around pH 4 (Figure 5.16).  Over this pH 
range, there was no observable shift in the signal, nor was there an obvious 
appearance of a new, shifted resonance associated with the protonated form of the 
complex.   
 
Figure 5.16 1H NMR spectra for [Dy.L11] at high and low pH values indicating ‘loss of 
signal’ at low pH (2 mM complex, D2O, 9.4 T, 298 K, total acquisition 
time = 2 min 13 sec). 
 
It is hypothesised that the major signal observed (e.g. -58.9 ppm for [Dy.L11]) 
corresponds to the deprotonated form of the complex, which is fairly rigid in structure 
with little exchange occurring due to the fully coordinated nature of the complex.  As 
the pH lowers, the sulphonamide arm becomes protonated and no longer coordinates 
to the lanthanide ion, resulting in a new signal associated with the tBu group.  
However, as the protonated form of the sulphonamide is no longer bound to the 
metal, a significant increase in the rate of chemical exchange is experienced by the 
complex, both in terms of the “on-off” mechanism of the arm and with increased 
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interaction with solvent molecules.  The increase in chemical exchange experienced 
leads to severe linewidth broadening, resulting in no signal being observed at low pH 
values.  Such severe chemical exchange broadening is similar to the behaviour 
observed earlier with [Tm.L2] (Chapter 2).21 
 
Figure 5.17 Eu(III) emission spectra for [Eu.L6] at pH 8.6 and 3.8 (H2O, 298 K, 
λexc = 270 nm). 
 
In order to better understand the shift behaviour of [Ln.L11], the europium emission 
spectra were obtained at pH 4 and 8 (Figure 5.17).  As introduced in the previous 
chapter, the splitting in the ΔJ = 1 band is proportional to the second order ligand field 
term (ΔJ = 1 splitting ≈ 0.3   
 ), which, in turn, is associated with the magnitude of the 
pseudocontact shift as described by Bleaney.10  Therefore, the splitting of the ΔJ = 1 
band was measured at high and low pH, from which   
  values were calculated to 
be -550 and +850 cm-1 respectively.  The value obtained at pH 8.6 (-550 cm-1) was 
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comparable to the value obtained for [Eu.L6], which also displayed a similarly large 
NMR chemical shift.  The value obtained at pH 3.8 (+850 cm-1) suggests that the 
broadened signal is even more shifted than for the high pH form, and may be shifted in 
the opposite direction, due to the change in sign.  However, other ligand field terms, 
e.g.   
 , may also alter with pH, and the NMR spectra may not be directly proportional 
to the   
  values calculated.  The geometric terms associated with the pseudocontact 
shift, i.e. the angle and the distance, should remain relatively constant due to the 
pyridine moiety remaining unchanged upon protonation/deprotonation.  
 
The ‘loss of signal’ observed as the pH was lowered made quantification of the pH 
response more challenging, as it was not possible to measure pH by monitoring a 
change in shift or as a function of the intensity of corresponding “acid-” and “base-
form” resonances of the complex directly, as has been applied in previous 
examples.18,19  In Chapter 2, an external reference (trifluoroethanol) was used to 
quantify a similar system, whereby the 19F NMR signal for one of the forms of the 
complex, [Tm.L2], was exchange broadened and unobservable.  The use of an external 
reference is also technically possible for use with the pH study of [Ln.L11] by 1H NMR 
spectroscopy.  However, due to the nature of the shifted resonance being investigated, 
and the desire to carry out spectroscopic and imaging studies without interference 
from background signals, standard reference compounds are not suitable as they 
resonate too closely to solvent and other background peaks.   
 
In order to circumvent this problem, it was recognised that the mono-pyridine DO3A 
complex, [Ln.L9], would make a useful external reference for this system, as it exists as 
predominantly one signal, with similar relaxation parameters to [Ln.L11], and by design 
is shifted out of the way of any background signals.  It is also almost 40 ppm away from 
the signal of interest, and so will not interfere with analysis of the pH responsive 
behaviour.  Most importantly, the resonance for [Ln.L9] does not change with pH, 
allowing a fixed standard against which the intensity of the pH responsive resonance of 
[Ln.L11] can be compared. 
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The dysprosium complexes were considered to be the most suitable for this 
investigation, due to the relatively large shifts present in each complex.  Therefore, the 
relevant Dy(III) complexes of L9 (1 mM) and L11 (2 mM) were dissolved in the same 
NMR tube, and 1H NMR spectra were obtained at a variety of pH values (Figure 5.18).  
Above pH 6.5, there was no change in the relative signal intensities observed.  As the 
pH was lowered, the relative intensity of the [Dy.L11] resonance (-58.9 ppm) decreased 
in comparison to the intensity of the [Dy.L9] resonance (-20.5 ppm), which remained at 
a constant level throughout the experiment.  Below pH 4, only the latter resonance 
could be observed.  The ratio of intensities of the two signals was plotted as a function 
of pH, allowing a pKa of 5.27 ±0.04 to be calculated.  The behaviour observed was fully 
reversible. 
 
Figure 5.18 1H NMR spectra at a range of pH values (1 mM [Dy.L9], 2 mM [Dy.L11], 
D2O, 0.1 M NaCl, 9.4 T, 298 K). Inset shows plot of the ratio of signal 
intensities as a function of pH, with a calculated pKa of 5.27 ±0.04. 
 
Further studies were required in order to verify the above observations.  By 
substituting the lanthanide ion in the complex, other forms of analyses become 
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available with the same complex.  Firstly, by using terbium, the intensity and form of 
the emission spectrum can be analysed as a function of pH (Figure 5.19).  When the 
terbium emission spectrum of [Tb.L11] was monitored with varying pH, a decrease in 
intensity was observed, accompanied by a slight change in spectral form.  As the 
protonation equilibrium is associated with a change in hydration state (q), a significant 
decrease was expected with lowering of pH due to the increase in quenching processes 
that occurs with an increase in q.  By plotting the intensity of the ΔJ = 1 band as a 
function of pH, a response curve could be generated with an associated pKa value of 
5.09 ±0.07, in good agreement with the data obtained from the 1H NMR spectroscopic 
studies.  Again, the observed behaviour was fully reversible. 
 
Figure 5.19 Tb(III) emission spectra at varying pH and accompanying fit of the ΔJ = 1 
band as a function of pH for [Tb.L11], with a calculated pKa of 5.09 ±0.07 
(H2O, 0.1 M NaCl, 298 K, λexc = 270 nm). 
 
Similarly, by using gadolinium as the lanthanide ion in the same complex, the relaxivity 
of the system can be measured as a function of pH.  As the hydration state changes 
from 0 to 1 as the pH is lowered, there was expected to be a corresponding increase in 
relaxivity due to a rise in the contribution of the inner sphere term.  Such a change was 
observed when measuring the relaxivity of an aqueous solution of [Gd.L11] over the 
relevant pH range (Figure 5.20).  By plotting the relaxivity value as a function of pH, a 
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value of 4.86 ±0.12 could be calculated for the pKa.  This was again in fairly good 
agreement with the previous studies. 
 
Figure 5.20 Variation of water proton relaxivity with pH for an aqueous solution of 
[Gd.L11], with a calculated pKa of 4.86 ±0.12 (1mM complex, H2O, 0.1 M 
NaCl, 1.4 T, 310 K). 
 
5.4.5 Temperature dependent behaviour 
The majority of related 1H NMR probes have focussed on applications as temperature 
sensors.  Therefore, it was decided to investigate the temperature dependence of the 
tert-butyl resonance of [Dy.L11].  The dysprosium complex was chosen as it displays the 
largest shift of the complexes investigated, and so should display the largest variation 
in chemical shift with increasing temperature for the complexes presented here.  
Therefore, the 1H NMR chemical shift of the tert-butyl resonance was recorded at 
different temperature values over a range of 25 K.   
 
Figure 5.21 Variation in the tert-butyl resonance of [Dy.L11] as a function of 1/T2 
(D2O, 14.1 T, 0.27 ppm K
-1). 
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Over the temperature range investigated, there was around a 7 ppm variation in the 
chemical shift observed.  A linear fit can be generated by plotting δH as a function of 
the inverse square of the temperature (Figure 5.21), allowing the temperature to be 
calculated from the chemical shift value.  The lack of an internal reference within the 
complex would make calibration difficult, particularly with regards to in vivo studies.  
The rate of change, 0.27 ppm K-1, is also lower than the fluorinated probes presented 
in the previous chapter and other previously reported compounds,8 although should 
still be significant enough for potential applications.  The prospect of simultaneous 
temperature and pH reporting with one compound is particularly intriguing.  This 
concept has been presented previously,7 but no other pH responsive probe possesses 
such a high intensity 1H NMR signal.  Most examples examine the shifts of four 
equivalent proton nuclei, rather than nine protons as reported here.  However, further 
studies would be required to overcome the issues of internal calibration, for both the 
pH and temperature responsive behaviour, before the system could be applied to in 
vivo experiments. 
 
5.4.6 Imaging studies 
Imaging studies were carried out with the dysprosium complex, [Dy.L11], due to the 
increased chemical shift and enhanced relaxation rates in comparison to the other 
Ln(III) ions.  As discovered through the 1H NMR analyses of the compounds, the shift 
for the tert-butyl resonance of [Dy.L11] was considerably larger than the corresponding 
resonance of [Dy.L10]+, with values of -58.9 and -17.8 ppm respectively.  This should 
allow a larger sweepwidth (SW) to be used in the imaging experiment, potentially 
increasing the signal intensity available.  However, the longitudinal relaxation rate (R1) 
of [Dy.L10]+ is significantly faster than that for [Dy.L11], whereas the opposite is true for 
the transverse relaxation rate (R2).  This may serve to offset any gain attained by using 
a larger SW, as signal intensity increases with increasing R1 and decreases with 
increasing R2.  Simulations suggest that the sensitivity ratio of the two complexes 
should be 1.42, in favour of [Dy.L10]+. 
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Therefore, a comparative imaging study was carried out at 7 T by Prof. Andrew Blamire 
at the Newcastle Magnetic Resonance Centre using separate 2 mM samples of 
[Dy.L10]+ and [Dy.L11] contained within cut-down 5mm NMR tubes placed vertically in 
the bore of a 30 mm volume birdcage coil.  The compounds were initially run 
individually, to optimise the different parameters (TR, TE, flip angles, etc.), based on 
the relaxation rates of each complex, in addition to achieving efficient separation from 
the water signal.  The two samples were then run at the same time, using alterations in 
these parameters and excitation frequencies to selectively image the resonances, in 
turn, for the water signal, [Dy.L10]+, and [Dy.L11] (Figure 5.22). 
 
Figure 5.22 Gradient echo 3D sequences (7 T, 298 K, H2O, 2 mM [Dy.L
10]+, left; 2 mM 
[Dy.L11], right) of two samples loaded into a 30 mm Birdcage imaging 
coil. (a) Water signal (tof = - 351 Hz, TR = 30 ms, TE = 2.21 ms, 8o flip, 
1 average), (b) [Dy.L10]+ tBu resonance at -17.8 ppm (tof = -7,077 Hz, 
TR = 8.62 ms, TE = 4.24 ms, 74o flip, SW = 10 kHz, 10 averages, total 
acquisition time = 1 min 28 sec), (c) [Dy.L11]  tBu resonance at -58.9 ppm 
(tof = -19,582 Hz, TR = 5.21 ms, TE = 2.24 ms, 52o flip, SW = 17.8 kHz, 
16 averages, total acquisition time = 1 min 25 sec). 
 
Using this frequency selective excitation pulse method allowed each resonance to be 
observed independently, by only exciting the peak of interest.  For [Dy.L10]+, the 
calculated signal-to-noise ratio (SNR) was a factor of 1.20 higher than for [Dy.L11], 
comparable to the value predicted (1.42), due to the differences in the relaxation rates 
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between the two complexes.  However, in order to completely remove the water 
signal, the imaging spectral bandwidth (i.e. the sweepwidth) must be smaller in 
magnitude than the shift difference between the solvent peak and the resonance of 
interest.  Therefore, for [Dy.L11], the large shift separation allowed the use of a 20 kHz 
SW at 7 T.   
 
However, the closer proximity of [Dy.L10]+ to the water signal necessitated a much 
smaller excitation bandwidth to be employed, as the shift difference was only around 
5.4 kHz.  For the images above the SW for [Dy.L10]+ was set at 10 kHz, which is clearly 
larger than this separation value.  As the object is small, there were no major problems 
with this SW, although some residual water breakthrough was observed.  When 
applied to an extended object (e.g. an animal), interference would have been far more 
significant, which is why a SW of 5 kHz was used for the in vivo experiment with 
[Dy.L10]+ (Section 5.3.5.2).  Such a low value for the SW was not ideal, due to the R2 loss 
caused by the required longer RF pulse.  An ideal probe would combine the properties 
of the two complexes; i.e. the highly shifted nature of [Dy.L11] to facilitate removal of 
the water signal, with the more advantageous relaxation rates experienced by 
[Dy.L10]+. 
 
For the imaging experiments carried out above, the [Dy.L11] sample was maintained at 
pH 8, in order to maximise the signal obtained.  However, it was also of interest to 
investigate the behaviour of this signal at variable pH values.  Therefore, an 
experiment was designed that was similar to the 1H NMR study carried out in Section 
5.4.4, whereby a non-pH sensitive complex, [Dy.L9], would be used as an internal 
reference with which to compare the pH responsive signal of [Dy.L11].  An equimolar 
mixture of [Dy.L9] and [Dy.L11] was dissolved in 0.1 M sodium chloride and the solution 
divided into four cut-down NMR tubes.  The pH of these four solutions was adjusted to 
different values, covering the range over which the signal intensity was observed to 
change (pH 4-7).  These four samples were then imaged, comparing the relative 
intensities of the tert-butyl resonances for each complex.  The results of this study are 
shown in Figure 5.23. 
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Figure 5.23 (a) GE3D images acquired of the signals corresponding to (from left to 
right) water, [Dy.L11], and  [Dy.L9] (sweepwidth = 5 kHz, acquisition time 
= 4 min 6 s); (b) illustration of the experimental array used; (c) variation 
of the ratio of the [Dy.L11]:[Dy.L9] signal intensities as a function of pH 
(2 mM [Dy.L9], 2 mM [Dy.L11], 0.1 M NaCl, 7 T, 298 K, H2O) .   
 
While there are too few data points for an accurate pKa determination, the pH plot 
obtained from this imaging experiment closely resembles the curves generated from 
the previous NMR, luminescence, and relaxivity investigations.  The experiment is a 
good proof-of-principle study, showing the correlation between 1H NMR based work 
and imaging methods.  It would be of interest to take this concept further, with 
enough data points for full analysis. 
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5.5 Conclusions and Future Work 
The use of paramagnetic lanthanide ions to shift proton resonances outside of the 
standard diamagnetic 1H NMR frequency range has been periodically of interest over 
the last twenty years, as shown by the examples highlighted at the beginning of this 
chapter.  However, while some promising initial in vivo studies have been carried out, 
there have been some limitations with signal intensity, leading to long acquisitions or 
high dosages being required.  These limiting factors have seemingly left this field of 
research lagging behind somewhat, in comparison to the more popular area of 
heteronuclear imaging, despite the many advantages of using a highly shifted proton 
resonance over, for example, a comparable fluorine signal. 
 
The results presented here appear to go some way to bridging this gap, with 
encouraging preliminary imaging results.  The complexes formed were, however, 
designed from the knowledge gained from the fluorine imaging work previously 
investigated.  From the CF3 containing systems, a great deal was learnt on the 
development of probes with the required characteristics.  Initially, work focussed on 
the ideal positioning of the reporter group with respect to the lanthanide ion, both in 
terms of the separation distance and the relative angle formed that lead to relaxation 
rates of the desired magnitude and large ligand field splittings.  This latter term was of 
particular importance for the proton work, as the largest ligand field splitting possible 
is required to shift the resonance of interest away from background signals, hence why 
the model proton probe was based on the fluorine systems that displayed the highest 
shifts, i.e. the pyridyl-based complexes.  A great deal has also been learnt through 
previous studies and applied here on methods to minimise chemical exchange 
broadening effects, and hence increase signal intensity, which is a limiting feature of 
some of the previously reported systems. 
 
The strong in vivo image collected upon the injection of [Dy.L10]+ was particularly 
encouraging, despite being observed only in the bladder, as the signal was acquired 
within a clinically acceptable time and dose (5 min 28 s, 0.06 mmol kg-1).  By 
considering the fluorine results once more, a potential system becomes apparent for 
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future studies to improve further in vivo experiments.  In the previous chapter, the 
phosphinate based complex, [Ln.L6], displayed 19F NMR shifts that were almost double 
the magnitude compared to those observed for the comparative carboxylate complex, 
[Ln.L7], due to a change in the coordination sphere about the Ln(III) ion and the effect 
this has on the ligand field splitting parameters.  The CF3 and 
tBu compounds have so 
far behaved in a relatively similar manner and, if the phosphinate analogues of both 
[Ln.L9] and [Ln.L10]+ (Scheme 5.9) follow this same trend, it may be possible to 
significantly increase the shift of the tert-butyl resonances observed, with around -35 
to -40 ppm hypothesised for the Dy(III) complexes.  If this was indeed the case, it 
would allow larger sweepwidths to be employed for imaging protocols, resulting in 
increased signal intensities to be observed, as the relaxation rates should remain 
relatively unchanged. 
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Scheme 5.9 Potential phosphinate analogues of [Ln.L9] and [Ln.L10]+. 
 
The pH-responsive behaviour of [Ln.L11] shows good promise, but a few issues need to 
be addressed in order to make the system more applicable for in vivo studies.  For the 
current system to be of use, it is necessary to have a method of calibrating the local 
signal intensity.  For in vitro experiments, this is not an issue, as a second complex can 
be added at a known concentration and the relative signal intensities of the two 
complexes compared.  However, for in vivo studies the measuring of the signal 
intensity is more problematic.  If another complex was added to the animal system 
simultaneously, for it to work in the same way the two compounds would require 
identical biodistribution profiles, which clearly is unlikely with a significant change in 
structure.  A potential solution could be to link the two complexes together, leading 
back to the work presented in Chapter 3.  If both complexes were altered with a linking 
group attached to the pyridyl moiety, then it would be possible to covalently couple 
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them both to the same adduct, e.g. glycol chitosan.  As long as the comparative 
proportions of each complex were known before injection, which can easily be verified 
by 1H NMR spectroscopy, the signal intensities of the two complexes should allow 
mapping of pH, as the relative local concentrations will be known. 
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Scheme 5.10 Alteration of sulphonamide arm to develop a system with two separate 
pH-dependent tBu signals (highlighted in red).  
 
Another factor that needs to be addressed is the pKa associated with the protonation 
equilibrium of the sulphonamide arm, which needs to be raised to around 7 to make 
the system more relevant to physiological pH values.  It may be the case that this 
fortuitously occurs in biological media, as has been found with related compounds.22  
Therefore, pH studies need to be performed in a mixed background of various analytes 
and proteins, followed by serum to understand the potential behaviour of the system 
in vivo.  Alternatively, the methyl subtituent of the sulphonamide could be altered to a 
different moiety, changing the associated pKa value.  A related compound has recently 
been developed within the group that incorporates a tert-butyl substituted 
sulphonamide arm, allowing pH to be monitored by the variation in chemical shift of 
this tBu moiety.  It would be of interest to combine the two systems, as shown in 
Scheme 5.10, as this would allow two separate signals of equal intensity to be used as 
markers for pH dependence.  The signal for this sulphonamide tBu complex has been 
observed at low pH, and so may also offer more information on the behaviour of the 
pyridine based system under acidic conditions. 
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6. Experimental  
6.1 Experimental Procedures 
6.1.1 General Procedures 
Commercially available reagents were used as received from suppliers.  PAMAM 
dendrimer, ethylenediamine core, generation 1.0, was obtained as a 20 % solution in 
MeOH and the solvent was removed under reduced pressure immediately prior to use.  
2-Methanesulphonate-N-methanesulphonylethylamine was prepared by Dr. Kanthi 
Senanayake following previously reported procedures.1  Solvents were laboratory 
grade and dried using an appropriate drying agent when required.  Water was purified 
by the ‘PuriteSTILLplus’ system, with a conductivity of ≤ 0.04 µS cm
-1.  Reactions 
requiring anhydrous conditions were carried out under an atmosphere of argon using 
Schlenk-line techniques.  Where necessary, solvents were degassed using the freeze-
thaw cycle method. 
 
Thin-layer chromatography was carried out on silica plates (Merck Art 5554) or neutral 
alumina plates (Merck Art 5550) and visualised under UV irradiation (254 nm), or by 
staining with either iodine or Dragendorff’s reagent (solution of bismuth nitrate and 
potassium iodide in AcOH and H2O).  Preparative column chromatography was carried 
out using silica (Merck Silica Gel 60, 230-400 mesh) or neutral alumina (Merck 
Aluminium Oxide 90, activity II-III, 70-230 mesh), with the latter pre-soaked in ethyl 
acetate overnight before use.  Syringe filtration was carried out using PhenexTM PTFE 
membrane syringe filters (0.45 µm, 25 mm, Phenomenex®) and Millex® low protein 
binding hydrophilic LCR PTFE membrane syringe driven filter units (0.45 µm, 4 mm, 
Millipore®). 
 
Anion exchange chromatography was performed using anion exchange resin DOWEX® 
1x8 200-400 mesh Cl (Sigma Aldrich).  Typically, the resin (1 g) was prepared by boiling 
in MeOH (50 mL) for 18 h, followed by washing with H2O (500 mL).  The resin was then 
stirred in HCl(aq) (1 M, 50 mL) for 2h then washed with H2O until the resulting washing 
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were neutral pH.  Suction dried resin was then added to solutions of the complex in 
H2O for 2 h.  Filtration and lyophilisation yielded the desired chloride salts of the 
complex.   
 
Dialysis was performed with Dialysis Tubing Cellulose Membrane MWCO 550 D (Sigma 
Aldrich), Spectra/Por Dialysis Membrane MWCO 1,000 D (Spectrum Laboratories, Inc), 
or Float-A-Lyzer G2 filters MWCO 5,000 D (Spectrum Laboratories, Inc).  All tubing was 
washed thoroughly with H2O, as per manufacturer’s advice.  After addition of the 
complex to the tubing, the ends of the tubing were secured (clamps for the 
membranes, provided screw top for the filters) and the ensemble submerged in 
stirring H2O (ca. 500 mL).  The bulk H2O was exchanged 4 times over a 72 h period, to 
ensure a positive dialysis gradient was maintained.  Filtering of the tubing contents and 
lyophilisation yielded the desired product. 
 
pH measurements were carried out at 295 K using a Jenway 3320 pH meter with a 
Sigma Aldrich micro-pH combination electrode.  Calibration was performed using 
commercially available buffer solutions at pH 4.00 ±0.02, pH 7.00 ±0.02, and pH 10.00 
±0.02 (Merck).  Diluted aqueous solutions of NaOH and HCl (or NaOD and DCl in D2O) 
were used for pH adjustments.  For measurements in D2O, the pD was calculated as pD 
= pH + 0.41, where pH is the meter reading.  
 
6.1.2 Characterisation: NMR Spectroscopy 
1H, 13C, 19F, and 31P NMR spectra were recorded in commercially available deuterated 
solvents on a Varian Mecury-200 (1H at 199.975 MHz, 13C at 50.289 MHz, 19F at 
188.179 MHz, 31P at 80.985 MHz), Varian Mercury-400 (1H at 399.960 MHz, 13C at 
100.572 MHz, 19F at 376.338 MHz, 31P at 161.943 MHz), Bruker Avance-400 (1H at 
400.052 MHz, 13C at 100.603 MHz, 19F at 376.423 MHz, 31P at 161.980 MHz), Varian 
Inova-500 (1H at 499.722 MHz, 13C at 125.671 MHz, 19F at 470.253 MHz, 31P at 202.375 
MHz), Varian VNMRS-600 (1H at 599.944 MHZ, 19F at 564.511, 31P at 242.862 MHz), or 
Varian VNMRS-700 (1H at 699.731 MHz, 13C at 175.948 MHz, 19F at 658.405 MHz, 31P at 
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283.256 MHz) spectrometer.  All chemical shifts are given in ppm and coupling 
constants are in Hz.  Longitudinal relaxation times (T1) were measured in dilute D2O 
solutions at 295 K using the inversion-recovery technique.  For 19F, the relaxation data 
were measured without proton decoupling and the chemical shifts are reported 
relative to fluorotrichloromethane. 
 
The recorded free induction decays were processed using backward linear prediction, 
optimal exponential weighting, zero-filling, Fourier transform, phasing, and baseline 
correction (by polynomial fitting to signal-free spectrum areas).  The signals were 
integrated by Lorentzian line fitting.   
 
Relaxation data was fitted with the help of Alex Funk at Durham University, using a 
modified algorithm originally provided by Dr Ilya Kuprov at Oxford University.  The 
algorithm uses the Solomon-Morgan-Bloembergen equations to fit the measured 
relaxation data using the Matlab internal Levenberg-Marquardt minimisation of the 
non-linear squares error function and the results were analysed iteratively.  Some 
parameters were used globally in the series, and others used for each lanthanide 
individually.  Magnetic moments for each Ln(III) were taken from the literature.2  Each 
relaxation rate measurement was repeated three times to reduce experimental error.  
The number of transients used in the measurements was determined by the signal-to-
noise ratio of the sample.  The signal was fully recovered during the inversion-recovery 
sequence to minimise the experimental error.  Fitting errors were determined by 
calculating the standard deviation of a set of relaxation times. 
 
For non-deuterated solutions, a coaxial insert containing D2O was used to lock the 
NMR instrument.  Operating temperatures of the spectrometers were measured using 
an internal calibration solution of ethylene glycol, with the operating temperature 
measured before recording relaxation data.3,4  Concentrations of the lanthanide 
complexes were calculated using the bulk magnetic susceptibility method, using 1 % 
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tBuOH/H2O solutions of the complexes, with a coaxial insert containing the same 
solution without the complex added. 
 Water proton T1 measurements were recorded on a Bruker Minispec mq60 (60 MHz, 
37°C), and are reported as the mean value of three measurements.  The relaxivities,   , 
of the compounds were calculated as the slope of the function shown in Equation 6.1. 
 
     
 
 
   
            (6.1) 
where T1,obs is the measured T1, T1,d is the diamagnetic contribution of the solvent 
(calculated to be 4000 ms), and [Gd.Ln] is the concentration in mM of the appropriate 
Gd(III) complex. The error for each relaxivity value was less than 0.6 mM-1 s-1. 
 
Variable temperature NMR spectroscopy was carried out using the Varian VNMRS-600 
spectrometer with the assistance of Alex Funk at Durham University, using the 
ethylene glycol method described above to confirm the operating temperature of the 
spectrometer at each temperature measured. 
               
6.1.3 Characterisation: Optical Techniques 
All samples for optical analyses were contained in quartz cuvettes with a path length of 
1 cm and a polished base.  Measurements were recorded at 295 K. 
 
UV/Vis absorbance spectra were measured on a Perkin Elmer Lambda 900 UV/Vis/NIR 
spectrometer, using FL Winlab software.  Samples were measured relative to a 
reference of pure solvent contained in a matched cell. 
 
Emission spectra were measured on a ISA Joblin-Yvon Spec Fluorolog-3 luminescence 
spectrometer, using DataMax v2.20 software. Excitation wavelengths were selected 
according the specific measurement.  An integration time of 1.0 s, increment of 
0.5 nm, and excitation and emission slit widths of 2.5 and 1.0 nm, respectively, were 
used throughout. 
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Lifetime measurements were carried out using a Perkin Elmer LS55B luminescence 
spectrometer.  Lanthanide excited state lifetimes were measured by excitation of the 
sample by a short pulse of light, followed by monitoring the integrated intensity of 
light emitted during a fixed gate time, tg, after a delay time of td.  Excitation and 
emission wavelengths were selected based upon the Ln(III) complex.  Measurements 
were made for at least 30 delay times over a period of three or more lifetimes. A gate 
time of 0.1 ms was used, with the excitation and emission slits set to 10 and 5 nm, 
respectively.  The obtained decay curves were fitted to Equation 6.2, using Origin 6.0 
software. 
        
    (6.2) 
where I is the intensity at time t after the excitation pulse, A0 is the intensity after 
decay is completed, A1 is the pre-exponential factor, and k is the rate constant for 
decay of the excited state.  The excited state lifetime, τ, is the inverse of the rate 
constant, k. 
 
The inner sphere hydration number (q) of Eu(III) and Tb(III) complexes were obtained 
by measuring the excited state lifetime in H2O and D2O. The q value was calculated 
using Equations 6.3 and 6.4, which are derived elsewhere.5 
                                (6.3) 
                                (6.4) 
where qLn is the inner sphere hydration number, k is the inverse of the excited state 
lifetime, τ, and n is the number of proximal amide NH oscillators, for coordinated 
amide carbonyl groups only. 
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6.1.4 Characterisation: Other Techniques 
Both standard and high resolution electrospray mass spectrometry were recorded on a 
Thermo-Finnigan LTQ FT instrument, operating in positive or negative ion mode as 
stated, with MeOH as the carrier solvent.  MALDI mass spectra were recorded on an 
Applied Biosystems Voyager-DE STR instrument with MeOH as the carrier solvent.  LC-
MS analyses were performed on a Waters system comprising a 3100 Mass Detector 
and a 2998 Photodiode array detector. 
 
Gel permeation chromatography (GPC) was undertaken at Smithers Rapra UK, using a 
Viscotek Model 301 TDA instrument with associated pump, autosampler, and 
refractive index detector (with differential pressure and light scattering). Agilent 
PLaquagel-OH Guard plus 2 x PLaquagel-OH Mixed-M, 30 cm, 8 µm columns were used 
with an eluent composed of 0.5 M NaNO3, 0.01 M NaH2PO4 at pH 2 at a flow rate of 1.0 
mL/min at 30°C.  The GPC system was calibrated using Pullulan polysaccharides and 
the data analysed using Malvern/Viscotek ‘OmniSec’ software. 
 
Melting points were recorded using a Gallenkamp (Sanyo) apparatus and are 
uncorrected. 
 
6.1.5 HPLC Analysis 
Reverse phase Analytical HPLC traces were recorded at 298 K using Waters Mass 
Directed Auto Preparation (MDAP) system. XBridge C18 4.6 x 100 mm, i.d. 5 μm 
analytical column and XBridge C18 OBD 19 x 100 mm, i.d. 5 μm semi-preparative 
columns were used to analyse and purify the ligands and complexes. A gradient elution 
with a solvent system composed of H2O + 0.1% HCOOH/MeOH was performed for a 
total run time of 16.5 min. The separation details are reported below (Tables 6.1 and 
6.2). 
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Table 6.1 Analytical procedure: flow rate = 1 ml/min; Solvent A = H2O + 0.1 % 
HCOOH; Solvent B = MeOH + 0.1 % HCOOH. 
Time (min) Solvent A (%) Solvent B (%) Curvature 
0 90 10 0 
10 5 95 6 
13 5 95 6 
13.5 90 10 6 
16.5 90 10 1 
 
Table 6.2 Semi-preparative procedure: flow rate = 17 ml/min; Solvent A = H2O + 
0.1 % HCOOH; Solvent B = MeOH + 0.1 % HCOOH. 
Time (min) Solvent A (%) Solvent B (%) Curvature 
0 90 10 0 
0.2 90 10 6 
0.7 90 10 6 
11 5 95 6 
14 5 95 6 
14.5 90 10 6 
16.5 90 10 1 
 
 
6.1.6 X-ray Studies 
The single crystal X-ray data for [Tm.L2] was collected at 120 K on a Gemini Ultra 
(Agilent Technologies) diffractometer (graphite monochromator, μ(MoKα),  λ= 0.71073 
Å) equipped with Cryostream (Oxford Cryosystems) open-flow nitrogen cryostat.  
Using Olex26 software, the structure was solved with the XS7 structure solution 
program by Patterson methods and refined with the XL7 refinement package with full-
matrix least squares minimisation.  All hydrogen atoms were placed in calculated 
positions and refined in riding mode, disordered atoms were refined isotropically with 
fixed SOF=0.5. CCDC 870354.  
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Crystal data for [Tm.L2]: C22H37F3N6O10Tm, Mr = 771.51, monoclinic, a = 7.55031(18), 
b = 32.7541(7), c = 11.8075(3) Å, β = 101.046(2)°, V = 2865.93(11) Å3, space group 
P21/c, Z = 4, μ(MoKα) = 3.178, 20173 reflections measured, 7618 unique (Rint = 0.0659), 
which were used in all calculations.  The final wR2 was 0.1016 (all data) and R1 was 
0.0604 for 5270 reflections with I>2σ(I), GOF = 1.085. 
 
6.1.7 Enzyme Mediated Transformations 
Enzyme activities were obtained at 25 or 37°C and 188 or 376 MHz using diluted PBS 
solutions of the complex (1 mM) in H2O with a constant pH of 7.4. For each 
experiment, half of the sample without enzyme added was used as a negative control, 
while to the other half 5 mg of the enzyme was added as a lyophilised powder (15 
units/mg, 1 unit hydrolyses 1.0 μmol of ethyl butyrate to butyric acid and ethanol per 
min at pH 8.0 at 25 °C). A coaxial D2O insert was used to lock the NMR instrument.  
 
6.1.8 Determination of Anion Binding Constants 
Apparent binding constants were calculated from the emission/NMR spectroscopy 
data obtained following anion addition titrations using Equation 6.5.  The equation was 
fitted to the data, using a non-linear least squares fitting algorithm in Microsoft Excel 
2010, using the solver add-in.  Highly concentrated anion solutions were added to 
minimise increase in sample volume.  Eu(III) emission spectra were corrected for 
dilution effects. 
    
 
 ⁄           
       
   
   (6.5) 
where [X] is the concentration of the anion in the solution, K is the binding constant, 
[Ln.L] is the total concentration of the complex in solution, and:  
  
    
     
 
where F is the ratio/intensity of the selected signals, F0 is the initial ratio/intensity of 
the selected signals, F1 is the final ratio/intensity of the selected signals. 
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6.1.9 Cell Studies 
The NIH 3T3 (mouse skin fibroblast) cell line was selected for cellular studies, with the 
aid of Dr Robert Pal.  Cells were maintained in exponential growth as monolayers in 
appropriate media, which were supplemented with 10 % foetal bovine serum (FBS) 
and 1 % penicillin and streptomycin.  Cells were incubated at 37°C, 20 % average 
humidity and 5 % (v/v) CO2. 
 
6.1.10 Imaging Studies 
Imaging studies were carried out by Prof. Andrew Blamire, Dr. Ross Maxwell, and Dr. 
Ian Wilson at Newcastle Magnetic Resonance Centre, using a 7 T Varian Unity Inova 
microimaging/Pre-clinical system equipped with broadband capability and actively 
shielded gradients.  For the 19F MRI studies, a purpose built four turn solenoid coil (20 
mm diameter, 20 mm coil length) was used for in vitro experiments and a 19F-tuned 
square surface coil (30 mm, m2m Imaging Corp.) was used for in vivo experiments.  For 
the 1H MRI studies, in vitro experiments were performed with a 30 mm i.d. birdcage 
volume coil (Rapid Biomedical) and in vivo experiments were performed with a 39 mm 
i.d. birdcage volume coil.  All coils were used for both signal excitation and reception. 
 
For phantom studies, dilute aqueous samples (2-5 mM) were placed in Eppendorf 
tubes or cut down (2-3 mm) NMR tubes and positioned on the axis of the coil.  For in 
vivo studies, nude mice bearing a HT29 colorectal tumour xenograft were 
anaesthetised with oxygen/1-2 % isofluorane (for the 1H MRI studies) or with a mixture 
of ketamine (0.75 mg/kg) and medetomidine (0.5-1.0 mg/kg) (for the 19F MRI studies).  
Complexes were administered intravenously as saline solutions via the tail vein, with 
doses typically 0.06 mmol/kg. 
 
 
 
 
Chapter 6: Experimental 
 
193 
6.2 Synthetic Procedures 
 
1. 2-Chloro-N-(2-(trifluoromethyl)phenyl)acetamide8 
H
N
Cl
O
CF3
 
To a stirred solution of 2-aminobenzotrifluoride (1.00 g, 6.2 mmol) and NEt3 (1.03 mL, 
7.4 mmol) in anhydrous DCM (15 mL), chloroacetyl chloride (0.59 mL, 7.4 mmol) was 
added dropwise under argon at 0°C.  After stirring for 2 h, the reaction mixture was 
allowed to warm to rt and stirred for a further 18 h.  The resulting crude mixture was 
washed with HCl(aq) (pH 2-3, 2 x 20 mL), followed by H2O (2 x 20 mL).  The organic layer 
was dried over Na2SO4, filtered, and the solvent removed under reduced pressure, 
before the resulting crude oil was purified by silica gel column chromatography, eluting 
with a gradient starting from 100 % toluene to 20 % DCM/toluene, to yield a white 
solid (0.98 g, 67 %), m.p. 100-102°C.  1H NMR (400 MHz, CDCl3): δ = 8.77 (s, 1H, NH), 
8.24 (d, J = 8 Hz, 1H, H6), 7.67 (d, J = 8 Hz, 1H, H3), 7.61 (t, J = 8 Hz, 1H, H5), 7.31 (t, 
J = 8 Hz, 1H, H4), 4.25 (s, 2H, CH2Cl); 
19F NMR (658 MHz, CDCl3): δ = -60.7; ESI/MS
+/- m/z 
236.2 [M-H]-. 
 
2. 1,4,7,10-Tetraazacyclododecane-1,7-dicarboxylic acid dibenzyl ester9 
N N
NN
H
HO
O
O
O
 
1,4,7,10-Tetraazacyclododecane (5.0 g, 29.0 mmol) was dissolved in a solution of 
aqueous dioxane (70 mL), followed by addition of disodium hydrogen phosphate 
(14.0 g, 98.6 mmol).  The pH of the solution was adjusted to 2.7 by careful addition of 
conc. HCl.  Benzyl chloroformate (11.9 mL, 70.0 mmol) in dioxane (20 mL) was added 
dropwise over a period of 2 h and the solution left to stir for a further 18 h at rt, 
yielding a colourless solution with a white precipitate.  The solvent was evaporated 
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under reduced pressure and the residue dissolved in H2O (100 mL), followed by 
adjustment of the pH to 7 by addition of conc. KOH (aq).  The aqueous phase was 
extracted with Et2O (2 x 100 mL), followed by DCM (2 x 100 mL).  The organic phases 
were combined, dried over MgSO4, filtered, and the solvent removed under reduced 
pressure to give a clear oil.  This oil was repeatedly washed with Et2O to yield a white 
solid (9.73 g, 76 %), m.p. 114-117°C.  1H NMR (400 MHz, CDCl3):  δ = 7.45 – 7.30 (m, 
10H, Ph), 5.18 (s, 4H, CH2Ph), 3.81 – 3.59 (m, 8H, cyclen-CH2), 3.15 – 2.79 (m, 8H, 
cyclen-CH2); ESI/MS
+ m/z 441.2 [M+H]+, 463.3 [M+Na]+. 
 
3. 4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane-1,7-
dicarboxylic acid dibenzyl ester10 
N N
NN
O
O
O
O
O
O
O
O
 
1,4,7,10-Tetraazacyclododecane-1,7-dicarboxylic acid dibenzyl ester (2.0 g, 4.54 mmol) 
and tert-butyl bromoacetate (1.83 g, 9.34 mmol) were dissolved in anhydrous MeCN 
(25 mL) followed by the addition of Cs2CO3 (4.0 g, 12.2 mmol).  The mixture was left to 
heat under reflux for 18 h.  The caesium salts were removed by filtration and the 
solvent removed under reduced pressure.  The resulting dark yellow oil was purified by 
silica gel column chromatography, eluting with a gradient starting from 100 % DCM to 
2 % MeOH/DCM to yield a light yellow oil (2.18 g, 72 %).  1H NMR (400 MHz, CDCl3):  
δ = 7.44 – 7.15 (m, 10H, Ph), 5.11 (s, 4H, CH2Ph), 3.56 – 3.10 (m, 12H, cyclen-CH2 and 
CH2CO2
tBu), 2.87 (br s, 8H, cyclen-CH2), 1.42 (s, 18H, 
tBu); ESI/MS+ m/z 699.4 [M+H]+. 
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4. (7-tert-Butoxycarbonylmethyl-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid 
tert-butyl ester10 
N N
NN
H
H
O
O
O
O  
4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane-1,7-dicarboxylic 
acid dibenzyl ester (2.10 g, 3.15 mmol) was dissolved in absolute EtOH (20 mL) to 
which Pd(OH)2/C (Pd content 10%, 30 mg) was added.  The mixture was hydrogenated 
in a Parr hydrogenation apparatus (40 psi of H2) for 3 days.  The catalyst was filtered 
off using a syringe filter and/or celite  before the solvent was removed under reduced 
pressure to yield a white solid (1.16 g, 55 %). 
The following method was also successfully in achieving the desired compound, but in 
a lower yield; 4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane-1,7-
dicarboxylic acid dibenzyl ester (5.94 g, 8.89 mmol) was dissolved in absolute EtOH 
(50 mL) to which Pd/C (Pd content 20 %, 1.19 g) and ammonium formate (3.92 g, 
62.2 mmol) were added.  This reaction mixture was then boiled under reflux for 3 h, 
with careful supervision to ensure that the condenser did not become blocked.  The 
solution was then filtered before the solvent was removed under reduced pressure to 
give a yellow-white solid.  This crude solid was dissolved in DCM (50 mL) and extracted 
with HCl(aq) (1 M, 2 x 50 mL).  The pH of the aqueous layer was adjusted to 10 with 
careful addition of conc. NaOH (aq) before being extracted with DCM (2 x 50 mL).  The 
organic layers were combined and dried over MgSO4, filtered, and the solvent 
removed under reduced pressure to give a white solid.  To remove any formate 
present in the product, Amberlite® IRA-410 chloride form anion exchange resin was 
used, which was pre-treated using NaOH(aq).  This yielded a white solid (2.15 g, 36 %).  
Both methods resulted in identical products, which were characterised as follows; 
1H NMR (700 MHz, CDCl3): δ = 3.28 (4 H, s, CH2CO2
tBu), 2.77 (8 H, br s, cyclen-CH2), 
2.58 (8 H, br s, cyclen-CH2), 1.43 (18 H, s, 
tBu); 13C NMR (176 MHz, CDCl3): δ = 170.9 
(CO2), 80.9 (C(CH3)3), 57.2 (NHCH2CO2
tBu), 52.0 (cyclen-CH2), 45.7 (cyclen-CH2), 28.2 
(C(CH3)3); ESI/MS
+ m/z 401.4 [M+H]+, 423.4 [M+Na]+. 
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5. Di-tert-butyl 2,2'-(4-(2-oxo-2-(2-(trifluoromethyl)phenylamino)ethyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate 
N N
NN
H
O
H
N
F3C
O
O
O
O
 
A solution of di-tert-butyl 2,2'-(1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate 
(DO2A) (1.1 g, 2.75 mmol) and Na2CO3 (0.29 g, 2.75 mmol) in anhydrous MeCN (50 mL) 
was stirred at rt under an inert atmosphere for 30 min. 2-Chloro-N-(2-
(trifluoromethyl)phenyl)acetamide (0.58 g, 2.45 mmol) was added and the reaction 
mixture heated at 80°C overnight. The completion of reaction was verified by TLC, 
before the solution was filtered and the solvent removed under reduced pressure.  The 
residue was purified by silica gel column chromatography, eluting with a gradient 
starting from 100 % DCM to 10 % MeOH/DCM, to yield a transparent sticky gum 
(0.83 g, 50 %).  Rf (10 % MeOH/DCM) = 0.25.  
1H NMR (400 MHz, CDCl3): δ = 10.19 (br s, 
1 H, NH), 8.69 (br s, 1 H, NH), 7.87 (d, J = 8 Hz, 1H, H3/6), 7.65 (d, J = 8 Hz, 1H, H3/6), 7.59 
(t, J = 8 Hz, 1H, H4/5), 7.32 (t, J = 8 Hz, 1H, H4/5), 3.66 (s, 2H, NCH2CONH), 3.36 (s, 4H, 
NCH2COO), 3.36 (s, 4H, NCH2COO), 3.05 – 3.11 (m, 4H, cyclen-CH2), 2.96 – 3.03 (m, 8H, 
cyclen-CH2), 2.89 - 2.95 (m, 4H, cyclen-CH2), 1.43 (s, 18H, 
tBu); 13C NMR (100 MHz, 
CDCl3): δ = 170.3 (CO), 169.8 (CO), 134.5, 132.8, 128.2 (q, 
3JCF = 5 Hz, C
3), 126.3, 125.7, 
124.3 (q, 1JCF = 272 Hz, CF3), 121.2 (q, 
2JCF = 31 Hz, C
2), 81.8 (C(CH3)3), 58.2, 52.4, 52.0, 
51.7, 49.6, 47.6, 28.1 (C(CH3)3) ; 
19F NMR (376 MHz, CDCl3): δ = -61.2; HRMS Calcd for 
C29H46F3N5O5 602.3529.  Found 602.3519. 
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6. 2,2'-(4-(2-(2-(Trifluoromethyl)phenylamino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetic acid (L1) 
N N
NN
H
O
H
N
F3C
O
OH
HO
O
 
Di-tert-butyl 2,2'-(4-(2-oxo-2-(2-(trifluoromethyl)phenylamino)ethyl)-1,4,7,10-tetraaza- 
cyclododecane-1,7-diyl)diacetate (32 mg, 0.053 mmol) was dissolved in DCM (3 mL) 
with stirring. To this was added TFA (1 mL) and the mixture stirred at rt for 18 h. After 
this time, the solvent was removed under reduced pressure to give a yellow oil, which 
was repeatedly washed with DCM to yield the triflate salt as a pale yellow oil (24 mg, 
92 %). 1H NMR (200 MHz, D2O): δ = 7.66 (d, J = 7 Hz, 1H, H
3/6) 7.54 (m, 1H, H3/6), 7.40 (t, 
J = 7 Hz, 2H, H4/5), 4.31 (s, 2H, CH2CONH), 3.40 (m, 6H, NCH2CO2
tBu, cyclen-CH2), 3.32 
(s, 2H, cyclen-CH2), 3.19 (m, 4H, cyclen-CH2), 2.99 (m, 6H, NCH2CO2
tBu, cyclen-CH2), 
2.79 (s, 2H, cyclen-CH2); 
19F NMR (188 MHz, D2O): δ = - 61.7; ESI/MS
+ m/z 490.3 
[M+H]+. 
 
7. [Ho.L1] 
N N
NN
H
O
O
H
N
O
O
O
CF3
Ho
 
Ho(III)Cl3.6H2O (9.1 mg, 0.024 mmol) was added to a stirred solution of 2,2'-(4-(2-(2-
(trifluoromethyl)phenylamino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl) 
diacetic acid (12 mg, 0.020 mmol) in water (3 mL) and the pH adjusted to 5.5 using 
KOH(aq).  The reaction was left stirring overnight at 50°C.  After cooling to rt, the pH was 
adjusted to 10 the precipitated metal hydroxide was removed by centrifugation.  The 
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solution was adjusted back to pH 5.5 with HCl(aq) and lyophilised to give a pale yellow 
solid that was extracted into 20 % MeOH/DCM.  This organic solution was again 
centrifuged to remove insoluble solid material before the solvent was removed under 
reduced pressure.  The resulting white solid was dissolved in H2O and stirred overnight 
with anion exchange resin (DOWEX 1x2 100-200 mesh Cl, pre-treated with 1M HCl) in 
Purite water to give the chloride salt.  After filtration the water was lyophilised to yield 
a white solid (12 mg, 94 %).  19F NMR (376  MHz, D2O, pD 7.4): δ = -76.8; HRMS Calcd 
for C21H28N5O5F3
165Ho 652.1346. Found 652.1344. 
 
8. [Tm.L1]  
An analogous procedure to that described for the synthesis of [Ho.L1] was followed 
using 2,2'-(4-(2-(2-(trifluoromethyl)phenylamino)-2-oxoethyl)-1,4,7,10-tetraazacyclo-
dodecane-1,7-diyl)diacetic acid (12 mg, 0.020 mmol) and Tm(III)Cl3.6H2O (9.2 mg, 
0.024 mmol) to give a white solid (12 mg, 95 %).  19F NMR (376  MHz, D2O, pD 7.4): 
δ = -67.6; HRMS Calcd for C21H28N5O5F3
169Tm 656.1385. Found 656.1395. 
 
9. 2-Chloro-N-(2-(cyano)-6-trifluoromethylphenyl)-ethanamide8 
O
H
N
F3C
NC
Cl
 
To a stirred solution of 2-amino-3-(trifluoromethyl)benzonitrile (1.00g, 5.37 mmol) in 
dry DMF (35 mL) was added sodium hydride in portions (60% dispersion in mineral oil, 
0.54 g, 13.4 mmol) under argon at 0°C, which resulted in the development of H2.  Once 
no more H2 was evolved, chloroacetyl chloride (1.71 mL, 21.5 mmol) was added 
dropwise.  The reaction mixture was allowed to warm to room temperature and 
stirred for 48 h.  The excess sodium hydride was quenched with H2O (3 mL) and the 
solution concentrated under reduced pressure.  To the crude mixture DCM was added 
and then washed successively with HCl(aq) (pH 2-3, 20 mL), NaOH(aq) (pH 8-9, 20  mL), 
and H2O (20 mL).  The organic layer was dried over K2CO3, filtered, and the solvent 
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removed under reduced pressure to give a black oil.  This was purified over silica gel in 
DCM to yield a light yellow solid (0.91 g, 64 %), m.p. 116-117°C.  1H NMR (700 MHz, 
CDCl3): δ = 8.47 (s, 1H, NH), 7.94 (t, J = 8 Hz, 2H, H
3/H5), 7.58 (t, J = 8 Hz, 1H, H4), 4.31 
(s, 2H CH2Cl); 
13C NMR (176 MHz, CDCl3): δ = 165.0 (NHCO), 136.8 (C
1), 136.4 (C3), 
130.7 (q, 3JCF = 5 Hz, C
5), 128.2 (C4), 128.0 (q, 2JCF = 31 Hz, C
6), 122.4 (q, 1JCF = 274 Hz, 
CF3), 115.2 (C
2), 115.0 (CN), 42.4 (CH2Cl); 
19F NMR (658 MHz, CDCl3): δ = -61.8; 
ESI/MS+/- m/z 261.2 [M-H]-, 285.2 [M+Na]+; HRMS Calcd for C10H6N2OF3ClNa 285.0018. 
Found 285.0026. 
 
10. Di-tert-butyl 2,2'-(4-(2-(2-cyano-6-(trifluoromethyl)phenylamino)-2-oxoethyl)-
1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate 
N N
NN
H
O
H
N
F3C
NC
O
O
O
O
 
2-Chloro-N-(6-(cyano)-2-trifluoromethylphenyl)-ethanamide (0.157 g, 0.60 mmol) and 
(7-tert-Butoxycarbonylmethyl-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid tert-butyl 
ester (0.30 g, 0.75 mmol) were dissolved in anhydrous MeCN (15 mL) under an 
atmosphere of argon.  To this was added Na2CO3 (79.4 mg, 0.75 mmol) and the 
reaction mixture stirred at 50°C for 24 h.  The reaction mixture was then filtered 
before the solvent was removed under reduced pressure to give an off-white solid, 
which was purified by silica gel column chromatography, eluting with a gradient 
starting from 100 % DCM to 5 % MeOH/DCM, to yield a white solid (0.143 g, 38 %).   
1H NMR (500 MHz, CDCl3): δ =
 10.21 (br s, 1H, NH), 9.62 (br s, 1H, NH), 7.97 – 7.85 (m, 
2H, H3/H5), 7.53 (t, J = 8 Hz, 1H, H4), 3.72 (s, 2H, NCH2CONH), 3.39 (s, 4H, NCH2CO2
tBu), 
3.01 (m, 16H, cyclen-CH2), 1.37 (s, 18H, CH3); 
13C NMR (126 MHz, CDCl3): δ = 171.5 
(CONH), 170.7 (CO2
tBu), 138.8 (C1), 136.7 (C3), 131.1 (q, 3JCF = 5 Hz, C
5), 129.3 (q, 
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2JCF = 31 Hz, C
6), 128.1 (C4), 122.8 (q, 1JCF = 274 Hz, CF3), 116.4 (C
2), 116.2 (CN), 82.0 
(C(CH3)3), 58.7 (CH2CO2
tBu), 53.6 (cyclen-CH2), 53.0 (NCH2CONH), 52.4 (cyclen-CH2), 
50.3 (cyclen-CH2), 47.8 (cyclen-CH2), 28.3 (C(CH3)3); 
19F NMR (658 MHz, CDCl3): 
δ = -61.1; ESI/MS+ m/z 627.5 [M+H]+, 649.4 [M+Na]+; HRMS Calcd for C30H46N6O5F3 
627.3482. Found 627.3478. 
 
11. 2,2'-(4-(2-(2-Cyano-6-(trifluoromethyl)phenylamino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetic acid (L2) 
N N
NN
O
H
N
F3C
NC
O
OH
HO
O
H
 
Di-tert-butyl 2,2'-(4-(2-(2-cyano-6-(trifluoromethyl)phenylamino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate (64 mg, 0.10 mmol) was dissolved in DCM 
(3 mL).  To this was added TFA (1 mL) and the mixture was stirred at rt for 3 h.  After 
this time, the solvent was removed under reduced pressure to give a yellow oil, which 
was repeatedly washed with DCM to yield a pale yellow oil (48 mg, 91 %).  1H NMR 
(200 MHz, D2O): δ = 7.79 (d, J = 8 Hz, 2H, H
3/H5), 7.42 (t, J = 8 Hz, 1H, H4), 4.29 (s, 2H, 
NCH2CONH), 3.62 – 2.34 (m, 20H, NCH2CO2
tBu and cyclen-CH2); 
19F NMR (188 MHz, 
D2O): δ = -62.5; ESI/MS
+ m/z 515.3 [M+H]+, 533.3 [M+Na]+. 
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12. [Ho.L2] 
N N
NN
O
H
N
F3C
NCHo
O
O
O
O
+
H
 
Ho(III)Cl3.6H2O (40.5 mg, 0.15 mmol) was added to a stirred solution of 2,2'-(4-(2-(2-
cyano-6-(trifluoromethyl)phenylamino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-
1,7-diyl)diacetic acid (64 mg, 0.12 mmol) in water (3 mL) and the pH adjusted to 5.5 
using KOH(aq).  The reaction was left stirring overnight at 50
°C.  After cooling to rt, the 
pH was adjusted to 10 the precipitated metal hydroxide was removed by 
centrifugation.  The solution was adjusted back to pH 5.5 with HCl(aq) and lyophilised to 
give a pale yellow solid that was extracted into 20 % MeOH/DCM.  This organic 
solution was again centrifuged to remove insoluble solid material before the solvent 
was removed under reduced pressure.  The resulting white solid was dissolved in H2O 
and stirred overnight with anion exchange resin (DOWEX 1x2 100-200 mesh Cl, 
pre-treated with 1M HCl) in Purite water to give the chloride salt.  After filtration the 
water was lyophilised to yield a white solid (81 mg, 97 %).  19F NMR (376  MHz, D2O, pD 
7.4): δ = -63.6; ESI/MS+ m/z 677.3 [M]+; HRMS Calcd for C22H26N6O5F3
165HoNa 
699.1118. Found 699.1115. 
 
13. [Tm.L2] 
An analogous procedure to that described for the synthesis of [Ho.L2] was followed 
using 2,2'-(4-(2-(2-cyano-6-(trifluoromethyl)phenylamino)-2-oxoethyl) 1,4,7,10-tetra- 
azacyclododecane-1,7-diyl)diacetic acid (15 mg, 0.029 mmol) and Tm(III)Cl3.6H2O 
(13 mg, 0.035 mmol) to give a white solid (19 mg, 97 %).  19F NMR (376  MHz, D2O, 
pD 7.4): δ = -61.4; ESI/MS+ m/z 681.4 [M]+; HRMS Calcd for C22H27N6O5F3
169Tm.CH3OH 
713.1599. Found 713.1620. 
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14. [Eu.L2] 
An analogous procedure to that described for the synthesis of [Ho.L2] was followed 
using 2,2'-(4-(2-(2-cyano-6-(trifluoromethyl)phenylamino)-2-oxoethyl)-1,4,7,10-tetra-
azacyclododecane-1,7-diyl)diacetic acid (8 mg, 0.016 mmol) and Eu(III)Cl3.6H2O 
(6.8 mg, 0.019 mmol) to give a white solid (10.4 mg, 98 %).  19F NMR (376  MHz, D2O, 
pD 7.3): δ = -62.5; ESI/MS+ m/z 665.2 [M]+ ; HRMS Calcd for C22H27N6O5F3
151Eu.CH3OH 
695.1456. Found 685.1438. 
 
15. Ethyl 4-amino-3-(trifluoromethyl)benzoate11 
 
4-Amino-3-(trifluoromethyl)benzonitrile (5.00 g, 26.8 mmol) was added to a stirred 
solution of H2SO4 (5 mL), EtOH (25 mL), and H2O (2 mL).  The mixture was stirred at 
95°C for 48 h with a CaCl2 drying tube fitted to the top of the condenser.  After this 
time, the reaction mixture was allowed to cool to rt before H2O (50 mL) was added and 
the pH adjusted to 7 by careful addition of K2CO3.  This was extracted into DCM 
(3 x 50 mL), dried over MgSO4, filtered, and the solvent removed under reduced 
pressure.  The resulting oil was purified by silica gel column chromatography, eluting 
with a gradient starting from 100 % toluene to 5 % DCM/toluene to yield a white solid 
(3.44 g, 55 %), m.p. 82-84°C.  1H NMR (700 MHz, CDCl3): δ = 8.12 (s, 1H, H
2), 7.92 (d, 
J = 9 Hz, 1H, H6), 6.70 (d, J = 9 Hz, 1H, H5), 4.68 (s, 2H, NH2), 4.31 (q, J = 7 Hz, 2H, 
CH2CH3), 1.34 (t, J = 7 Hz, 3H, CH3); 
13C NMR (176 MHz, CDCl3): δ = 165.8 (CO2), 148.3 
(C4), 134.2 (C6), 129.0 (q, 3JCF = 5 Hz, C
2), 124.5 (q, 1JCF = 272 Hz, CF3), 119.2 (C
1), 116.2 
(C5), 112.6 (q, 2JCF = 31 Hz, C
3), 60.7 (CH2CH3), 14.3 (CH3); 
19F NMR (658 MHz, CDCl3): 
δ = -63.1; ESI/MS+ m/z 234.2 [M+H]+; HRMS Calcd for C10H11NO2F3 234.0742. Found 
234.0749. 
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16. Ethyl 4-(2-chloroacetamido)-3-(trifluoromethyl)benzoate11 
 
Chloroacetyl chloride (2.00 g, 17.7 mmol) was added dropwise to a stirred solution of 
ethyl 4-amino-3-(trifluoromethyl)benzoate (3.44 g, 14.8 mmol) and NEt3 (1.79 g, 
17.7 mmol) in anhydrous DCM (30 mL) at 0°C under argon.  After 4 h, the crude 
mixture was washed with HCl (30 mL, 0.1 M), NaOH (30 mL, 0.1 M), and H2O (30 mL).  
The combined organic extracts were dried over MgSO4 and the solvent removed under 
reduced pressure.  The resulting residue was purified by recrystallisation from hexane 
to yield white needles (2.82 g, 61 %), m.p. 98-101°C.  1H NMR (500 MHz, CDCl3): 
δ = 8.98 (s, 1H, NH), 8.50 (d, J = 9 Hz, 1H, H5), 8.35 (d, J = 2 Hz, 1H, H2), 8.26 (dd, 
J = 2, 9 Hz, 1H, H6), 4.42 (q, J = 7 Hz, 2H, CH2CH3), 4.27 (s, 2H, CH2CO), 1.43 (t, J = 7 Hz, 
3H, CH3); 
13C NMR (126 MHz, CDCl3): δ = 165.0 (CO2), 164.5 (CONH), 138.3 (C
4), 134.5 
(C6), 128.1 (q, 3JCF = 6 Hz, C
2), 127.2 (C1), 123.7 (q, 1JCF = 274 Hz, CF3), 122.7 (C
5), 119.8 
(q, 2JCF = 31 Hz, C
3), 61.8 (CH2CH3), 43.2 (CH2CO), 14.5 (CH3); 
19F NMR (470 MHz, CDCl3): 
δ = -61.3; ESI/MS- m/z 308.2 [M-H]-; HRMS Calcd for C12H10NO3F3Cl 308.0301. Found 
308.0288. 
 
17. Ethyl-4-(2-(1,4,7,10-tetraazacyclododecan-1-yl)acetoamido)-3-
(trifluoromethyl) benzoate11 
 
A solution of ethyl 4-(2-chloroacetamido)-3-(trifluoromethyl)benzoate (0.40 g, 
1.29 mmol) in anhydrous MeCN (20 mL) was added dropwise to a stirred solution of 
1,4,7,10-tetraazacyclododecane (2.22 g, 12.9 mmol) in anhydrous MeCN (30 mL) at 
40°C under argon.  After 5 h, the solvent was removed under reduced pressure and the 
residue dissolved in DCM (20 mL).  The solution was washed repeatedly with H2O 
Chapter 6: Experimental 
 
204 
(4 x 20 mL), dried over MgSO4, and the solvent removed under reduced pressure to 
yield a light yellow oil (0.43 g, 75 %).  1H NMR (700 MHz, CDCl3): δ = 8.30 (d, J = 9 Hz, 
1H, H5), 8.26 (s, 1H, H2), 8.16 (d, J = 9 Hz, 1H, H6), 4.36 (q, J = 7 Hz, 2H, CH2CH3), 3.32 (s, 
2H, CH2CO), 2.75 (m, 8H, cyclen-CH2), 2.67 (m, 4H, cyclen-CH2), 2.61 (m, 4H, 
cyclen-CH2), 1.38 (t, J = 7 Hz, 3H, CH3); 
13C NMR (176 MHz, CDCl3): δ = 170.1 (CO2), 
164.9 (CONH), 139.1 (C4), 133.9 (C6), 127.7 (q, 3JCF = 5 Hz, C
2), 126.5 (C1), 124.4 (C5), 
123.6 (q, 1JCF = 274 Hz, CF3), 120.2 (q, 
2JCF = 32 Hz, C
3), 61.4 (CH2CH3), 61.1 (CH2CO), 
53.1 (cyclen-CH2), 47.1 (cyclen-CH2), 46.0 (cyclen-CH2), 45.4 (cyclen-CH2), 14.2 
(CH2CH3); 
19F NMR (658 MHz, CDCl3): δ = -60.4; ESI/MS
- m/z 444.4 [M-H]-; HRMS Calcd 
for C20H29N5O3F3 444.2222. Found 444.2228. 
 
18. Ethyl 3-(trifluoromethyl)-4-(2-(4,7,10-tris((ethoxy(methyl)phosphoryl)methyl) 
-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)benzoate11 
 
Ethyl-4-(2-(1,4,7,10-tetraazacyclododtetraazacyclododecan-1-yl)acetoamido)-3-
(trifluoromethyl)] benzoate (0.40 g, 0.9 mmol) was heated to 80°C in anhydrous THF 
under argon. Paraformaldehyde (0.11 g, 3.6 mmol) followed by 
diethoxymethylphosphine (0.49 g, 3.6 mmol) were added before the solution was 
heated at reflux over molecular sieves for 15 h.  After this time, the reaction mixture 
was cooled before excess paraformaldehyde was removed by filtration and the solvent 
removed under reduced pressure. The resulting orange oil was purified by mixed 
alumina/silica (4:1) gel column chromatography, eluting with a gradient starting from 
100% DCM to 6 % MeOH/DCM to yield a pale yellow oil (0.40 g, 55 %). 1H NMR 
(400 MHz, CDCl3): δ = 9.97 (br s, 1 H, NH), 8.46 (d, J = 9 Hz, 1H, H
5), 8.23 (s, 1H, H2), 
8.14 (d, J = 9 Hz, 1H, H6), 4.33 (q, J =7 Hz, 2 H, COOCH2CH3), 3.92 - 4.08 (m, 6H, POCH2), 
3.23 (br s., 2H, NCH2CO), 2.57 – 3.12 (m, 22H, cyclen-CH2, CH2P), 1.51 (d, J = 16 Hz, 3H, 
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PCH3), 1.46 (d, J = 8 Hz, 3H, PCH3), 1.43 (d, J = 8 Hz, 3H, PCH3), 1.34 (t, J = 7 Hz, 3H, 
COOCH2CH3), 1.26 (t, J = 8 Hz, 3H, POCH2CH3), 1.23 (t, J = 8 Hz, 6H, POCH2CH3); 
13C NMR (126 MHz, CDCl3): δ = 173.8, 164.9, 139.1, 134.2, 127.6 (q, 
3JCF = 5 Hz, C
2), 
126.9, 125.8, 122.5 (q, 1JCF = 274 Hz, CF3), 122.6 (q, 
2JCF = 34 Hz, C
3), 61.5, 60.4, 55.3, 
54.5, 54.2, 53.4, 52.4, 21.0, 16.6, 14.2, 13.1; 19F NMR (188 MHz, CDCl3): δ = -60.7; 
31P NMR (81 MHz, CDCl3): δ = 53.1, 52.1; ESI/MS
+ m/z 806.2 [M+H]+; HRMS Calcd for 
C32H58N5O9P3F3 806.3402. Found 806.3400.  
 
19. 3-(Trifluoromethyl)-4-(2-(4,7,10-tris((hydroxy(methyl)phosphoryl)methyl)-
1,4,7,10-tetraazacyclododecan-1-yl)acetamido)benzoic acid (L3)11 
 
 
Freshly prepared aqueous KOD solution (5 mL, 0.1 M) was added to ethyl 3-
(trifluoromethyl)-4-(2-(4,7,10-tris((ethoxy(methyl)phosphoryl)methyl)-1,4,7,10-
tetraazacyclododecan-1-yl)acetamido)benzoate (0.30 g, 0.38 mmol). The solution was 
left to stir at 40°C and the reaction monitored by 1H and 31P NMR. After 72 h, the pH of 
the solution was lowered to ca. 6 by the addition of dilute HCl(aq). The solvent was 
removed under reduced pressure and the residue washed repeatedly with DCM 
(3 x 5 mL). The resulting oil was dissolved in EtOH. The white precipitate was removed 
by filtration and the solvent removed under reduced pressure to yield a pale yellow 
gum (0.20 g, 80%). 1H NMR (400 MHz, D2O): δ = 8.31 (s, 1H, H
2), 8.18 (d, J = 8 Hz, 1H, 
H5), 7.60 (d, J = 8 Hz, 1H, H6), 3.82 (s, 2 H,  CH2CO), 3.51 (br s, 2H, cyclen-CH2), 3.32 
(br s, 4H, cyclen-CH2), 3.17 (br s, 8H, cyclen-CH2), 2.96 (br s, 2H, cyclen-CH2), 1.29 (d, 
J = 14 Hz, 6 H, PCH3), 1.22 (d, J = 14 Hz, 3H, PCH3); 
19F NMR (376 MHz, D2O): δ = -62.2; 
31P NMR (162 MHz, D2O): δ = 36.2; ESI/MS
+ m/z 694.3 [M+H]+. 
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20.  [Dy.L3] 
 
Dy(III)Cl3.6H2O (13 mg, 0.035 mmol) was added to a stirred solution of 3-
(trifluoromethyl)-4-(2-(4,7,10-tris((hydroxy(methyl)phosphoryl)methyl)-1,4,7,10-
tetraazacyclododecan-1-yl)acetamido)benzoic acid (20 mg, 0.029 mmol) in water 
(3 mL) and the pH adjusted to 5.5 using HCl(aq).  The reaction was left stirring overnight 
at 50°C.  After cooling to rt, the pH was adjusted to 10 and precipitated metal 
hydroxide was removed by centrifugation.  The solution was adjusted back to pH 5.5 
with HCl(aq). The resulting solution was dialyzed (500 MW cut-off; Spectra/Pro® biotech 
cellulose ester dialysis membrane, Spectrum Laboratories), purified by semi-
preparative RP-HPLC and lyophilized to obtain a white solid (12 mg, 50 %).  19F NMR 
(376  MHz, D2O, pH 6.5): δ = -64.5; HRMS Calcd for C24H38
160DyF3N5O9P3 851.1165. 
Found 851.1195. HPLC, tR = 4.77 min. 
 
21. [Tm.L3] 
An analogous procedure to that described for [Dy.L3] was followed, using 
Tm(III)Cl3.6H2O (13 mg, 0.035 mmol) and 3-(trifluoromethyl)-4-(2-(4,7,10-
tris((hydroxy(methyl)phosphoryl)methyl)-1,4,7,10-tetraazacyclododecan-1-yl) 
acetamido)benzoic acid (20 mg, 0.029 mmol) to obtain a white solid (18 mg, 72%). 
19F NMR (376 MHz, D2O, pH 7.5): δ = -90.3; HRMS Calcd for C24H38
169TmF3N5O9P3 
858.1099. Found 858.1113. HPLC, tR = 4.68 min. 
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22. [Dy.L4] 
N N
NN
P
O
O
P
O
O
P
O
O
H
N
O O
H
N
ODy
O
CF3
 
A solution of [Dy.L3] (10 mg, 0.012 mmol), N-(4-(hydroxymethyl)phenyl)acetamide 
(10 mg, 0.058 mmol), DIPEA (3 mg, 0.023 mmol) and HATU (10 mg, 0.026 mmol) in 
anhydrous DMF (1 mL) was stirred at rt for 48 h, with the reaction monitored by 
LC-MS.  After this time, the solvent was removed under reduced pressure.  The residue 
was dissolved in water and dialysed (500 MW cut-off, Spectra/Pro® biotech cellulose 
ester dialysis membrane, Spectrum Laboratories), purified by semi-preparative 
RP-HPLC, and lyophilised to obtain an off white solid (4 mg, 35 %). 19F NMR (376 MHz, 
H2O, pH 6.5): δ = -69.4; HRMS Calcd for C33H48
160DyF3N6O10P3 1022.1825. Found 
1022.1786. HPLC, tR = 7.56 min. 
 
23. [Tm.L4] 
To a solution of [Tm.L3] (10 mg, 0.012 mmol) in anhydrous DMSO (0.5 mL), was added 
K2CO3 (3 mg, 0.03 mmol) and the mixture stirred at rt for 30 min under argon.  After 
this time, N-(4-(chloromethyl)phenyl)acetamide (4 mg, 0.023 mmol) was added and 
the reaction stirred for 18 h.  The crude material was precipitated by dropping onto 
diethyl ether (15 mL) and isolated by centrifugation.  The residue was dissolved in 
water and dialysed (500 MW cut-off, Spectra/Pro® biotech cellulose ester dialysis 
membrane, Spectrum Laboratories), purified by semi-preparative RP-HPLC, and 
lyophilised to obtain an off white solid (4 mg, 35 %). 19F NMR (376 MHz, H2O, pH 7.8): 
δ = -102.4; ESI/MS+ m/z 1007.3 [M+H]+. HPLC, tR = 7.42 min.  
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24. [Dy.L3-chitosan] 
O
HO HO
NH2
O
OCH2CH2OH
O
HO
NH
O
OCH2CH2OH
H
x y
HN
F3C
O
O
N
N
N
N
P
O
O
P
O
O
P
O
O
Dy
 
[Dy.L3] (157 mg, 0.184 mmol) was dissolved in anhydrous DMF (2 mL) to which NMM 
(30 µL, 0.276 mmol) and TBTU (89 mg, 0.276 mmol) were added.  The mixture was 
stirred at rt for 30 min under argon, before glycol chitosan (20 mg, MW ≈ 6500 D) 
dissolved in H2O (0.2 mL) was added.  The mixture was left stirring at 40°C for a further 
18 h, before the solution was diluted with H2O (10 mL) and dialysed against Purite 
water for 48 h (1000 MW cut-off), with the bulk solvent water refreshed periodically.  
The solvent was removed under reduced pressure, before the residue dissolved in H2O 
and dialysed for a second time (5000 MW cut-off).  The solution was lyophilised to 
yield a white solid (48 mg).  19F NMR (376 MHz, D2O, pD 6.5): δ = -65.7; Mean 
Mw = 10900 D by GPC analysis. 
 
25. 4-Amino-3-(trifluoromethyl)benzoic acid11 
H2N
OH
O
CF3
 
4-Amino-3-(trifluoromethyl)benzonitrile (1.00 g, 5.4 mmol) was dissolved in freshly 
prepared aqueous KOD solution (2.5 mL, 0.1 M) and the resulting solution left to stir at 
40°C under argon, with the reaction monitored by 1H and 19F NMR spectroscopy.  The 
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reaction had proceeded to completion over 72 h, after which the pH was lowered to 
5.5 by the addition of HCl.  The resulting white precipitate was filtered and the solvent 
removed under reduced pressure to yield a white solid (0.99 g, 90 %), m.p. 81-82°C. 
1H NMR (500 MHz, CD3OD): δ = 8.05 (s, 1H, H
2), 7.89 (d, J = 8 Hz, 1H, H6), 6.84 (d, 
J = 8 Hz, 1H, H5), 4.90 (s, 2H, NH2); 
19F NMR (376 MHz, CD3OD): δ = -65.5; ESI/MS
- m/z 
204.2 [M-H]-. 
 
26. 1H‐1,2,3‐Benzotriazol‐1‐yl 4‐amino‐3‐(trifluoromethyl)benzoate11 
H2N
O
N
N
N
O
CF3
 
NMM (0.58 mL, 5.3 mmol) and TBTU (1.70 g, 5.3 mmol) were added to a solution of 
4-amino-3-(trifluoromethyl)benzoic acid (0.90 g,  4.4 mmol) dissolved in anhydrous 
DMF (5 mL) and the resulting mixture stirred at rt for 30 min.  After this time, the 
solvent was removed under reduced pressure, before the crude product was purified 
by alumina gel column chromatography, eluting with a gradient starting from 100 % 
DCM to 6 % MeOH/DCM, to yield a white solid (0.89 g, 63 %). 1H NMR (400 MHz, 
CDCl3): δ = 8.41 (s, 1H, H
2), 8.19 (d, J = 9 Hz, 1H, H6), 8.12 (d, J = 9 Hz, 1H, Ar), 7.57 (m, 
1H, Ar), 7.47 (m, 2H, Ar), 6.88 (d, J = 9 Hz, 1H, H5), 4.94 (s, 2H, NH2);
 19F NMR (376 MHz, 
CDCl3): δ = -63.3; ESI/MS
+ m/z 323.2 [M+H]+, 345.2 [M+Na]+. 
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27. PAMAM-(F8) 
PAMAM
H
N
8
O
CF3
NH2
 
PAMAM dendrimer, ethylenediamine core, generation 1.0 (37 mg, 0.0258 mmol) was 
dissolved in DMF (1 mL).  To this solution was added NMM (0.10 mL, 0.910 mmol) and 
1H‐1,2,3‐benzotriazol‐1‐yl 4‐amino‐3‐(trifluoromethyl)benzoate (100 mg, 0.310 mmol), 
before being stirred for 18 h at rt.  After this time, the solvent was removed under 
reduced pressure.  The residue was washed with DCM, followed by H2O, to yield a 
yellow-brown gum (59 mg, 78 %). 19F NMR (188 MHz, D2O, pD 6.5): δ = -64.5; MALDI
+ 
2926.5 [M+H]+, 2947.9 [M+Na]+, 2964.0 [M+K]+. 
 
28. [(Dy.L3)x-PAMAM] 
PAMAM
N
H
NN
N N
P
O
O
P
O
O
N
H
O
P
O
O
CF3
O
Dy
X
 
[Dy.L3] (42 mg, 47.4 µmol), NMM (7.2 mg, 71.1 µmol) and TBTU (23 mg, 71.1 µmol) 
were dissolved in DMF (1 mL) and the solution stirred at rt for 30 min.  After this time, 
a solution of PAMAM dendrimer, ethylenediamine core, generation 1.0 (6.8 mg, 
4.74 µmol) in DMF (0.5 mL) was added and the resulting mixture stirred at rt for 3 h.  
The solvent was removed under reduced pressure.  The residue was dissolved in H2O 
(3 mL) and dialysed against Purite water for 48 h (1000 MW cut-off), with the bulk 
solvent water refreshed periodically.  The solvent was removed under reduced 
pressure, before the residue dissolved in H2O and dialysed for a second time 
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(5000 MW cut-off).  The solution was lyophilised to yield a yellow gum (11 mg). 
19F NMR (376 MHz, D2O, pD 6.5): δ = -65.7. 
 
29. Ethyl 3-(4-amino-3-(trifluoromethyl)benzamido)propanoate 
H2N
H
N
O
CF3
O
O  
A solution of 4-amino-3-(trifluoromethyl)benzoic acid (2.00 g, 9.75 mmol), β-alanine 
ethyl ester hydrochloride (1.50 g, 9.75 mmol), EDC (2.06 g, 10.7 mmol), HOBt (1.60 g, 
10.7 mmol), and NMM (2.14 mL, 19.5 mmol) in anhydrous DMF (10 mL) was stirred at 
rt for 18 h.  After this time, the reaction mixture was concentrated under reduced 
pressure, then diluted with H2O (20 mL).  The resulting solution was extracted with 
ethyl acetate (2 x 20 mL).  The organic layers were combined and washed with H2O 
(20 mL) and brine (20 mL).  The resulting organic layer was dried over MgSO4, filtered, 
and the solvent removed under reduced pressure to give an off-white solid (2.93 g, 
99 %).  1H NMR (400 MHz, CDCl3): δ = 7.87 (d, J = 2 Hz, 1H, H
2), 7.68 (dd, J = 9, 2 Hz, 1H, 
H6), 6.79 (s, 1H, CONH), 6.72 (d, J = 9 Hz, 1H, H5), 4.54 (s, 2H, NH2), 4.15 (q, J = 7 Hz, 2H, 
OCH2CH3), 3.68 (q, J = 6 Hz, 2H,NCH2CH2CO), 2.62 (q, J = 6 Hz, 2H, NCH2CH2CO), 1.25 (t, 
J = 7 Hz, 4H, OCH2CH3); 
19F NMR (376 MHz, CDCl3): δ = -63.4; 
13C NMR (101 MHz, 
CDCl3): δ = 172.0 (CO2), 165.0 (CONH), 146.2 (C
4), 130.6 (C6), 125.2 (q, 1JCF = 5 Hz, C
2), 
123.5 (q, 1JCF = 272 Hz, CF3), 122.2 (C
1), 115.6 (C5), 111.9 (q, 1JCF = 31 Hz, C
3), 59.8 
(OCH2CH3), 34.3 (NCH2CH2CO), 33.0 (NCH2CH2CO), 13.2 (OCH2CH3); ESI/MS
+ m/z 305.2 
[M+H]+, 327.3 [M+Na]+; HRMS Calcd for C13H15N2O3F3Na 327.0932. Found 327.0934. 
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30. Ethyl 3-(4-(2-chloroacetamido)-3-(trifluoromethyl)benzamido)propanoate 
H
N
H
N
O
CF3
O
O
Cl
O
 
NEt3 (1.48 mL, 10.6 mmol) was added to a solution of ethyl 3-(4-amino-3-
(trifluoromethyl)benzamido)propanoate (2.93 g, 9.64 mmol) in anhydrous DCM 
(30 mL).  The solution was cooled to 0°C, before chloroacetyl chloride (0.84 mL, 
10.6 mmol) was added dropwise.  The reaction mixture was allowed to warm to rt and 
stirred for 18 h.  After this time, the solution was washed successively with HCl(aq) 
(0.1 M, 20 mL), NaOH(aq) (0.1 M, 20  mL), and H2O (20 mL).  The organic layer was dried 
over MgSO4, filtered, and the solvent removed under reduced pressure to give a brown 
solid.  This crude product was recrystallized from hexane to yield an off-white solid 
(0.94 g, 26 %). 1H NMR (400 MHz, CDCl3): δ = 8.91 (s, 1H, NH), 8.44 (d, J = 9 Hz, 1H, H
5), 
8.13 (s, 1H, H2), 7.92 (d, J = 9 Hz, 1H, H6), 6.91 (s, 1H, NH), 4.25 (s, 2H, CH2Cl), 4.18 (q, 
J = 7 Hz, 2H, OCH2CH3), 3.73 (m, 2H, NCH2CH2CO), 2.65 (m, 2H, NCH2CH2CO), 1.28 (t, 
J = 7 Hz, 3H, OCH2CH3); 
19F NMR (376 MHz, CDCl3): δ = -61.3; 
13C NMR (101 MHz, 
CDCl3): δ = 171.9 (CO2), 164.1 (CONH), 163.3 (CONH), 136.0 (C
4), 130.1 (C6), 129.8 (C1), 
124.8 (q, 3JCF = 5 Hz, C
2), 122.5 (q, 1JCF = 273 Hz, CF3), 121.9 (C
5), 119.0 (q, 2JCF = 31 Hz, 
C3), 60.0 (OCH2CH3), 41.9 (CH2Cl), 34.5 (NCH2CH2CO), 32.8 (NCH2CH2CO), 13.2 
(OCH2CH3); ESI/MS
+ m/z 381.2 [M+H]+, 403.2 [M+Na]+; HRMS Calcd for C15H17N2O4F3Cl 
381.0829. Found 381.0825. 
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31. Ethyl-3-(4-(2-(1,4,7,10-tetraazacyclododecan-1-yl)acetamido)-3-
(trifluoromethyl)benzamido)propanoate 
N N
NN
H
HH
H
N
O
F3C
H
N
O
O
O
 
A solution of ethyl 3-(4-(2-chloroacetamido)-3-(trifluoromethyl)benzamido)propanoate 
(0.44 g, 1.14 mmol) in anhydrous MeCN (20 mL) was added dropwise to a stirred 
solution of 1,4,7,10-tetraazacyclododecane (1.97 g, 11.4 mmol) in anhydrous MeCN 
(30 mL) at 40°C under argon.  After 5 h, the solvent was removed under reduced 
pressure and the residue dissolved in DCM (20 mL).  The solution was washed 
repeatedly with H2O (4 x 20 mL), dried over MgSO4, and the solvent removed under 
reduced pressure to yield a light yellow oil (0.42 g, 72 %). 1H NMR (400 MHz, CDCl3): 
δ = 8.25 (d, J = 9 Hz, 1H, H5), 8.09 (d, J = 2 Hz, 1H, H2), 7.86 (dd, J = 9, 2 Hz, 1H, H6), 6.90 
(s, 1H, NH), 4.17 (q, J = 7 Hz, 2H, OCH2CH3), 3.72 (m, 2H, NCH2CH2CO), 3.34 (s, 2H, 
NCH2CONH), 2.78 (br m, 8H, cyclen-CH2), 2.70 (br m, 4H, cyclen-CH2), 2.63 (br m, 6H, 
NCH2CH2CO/cyclen-CH2), 1.27 (t, J = 7 Hz, 3H, OCH2CH3); 
19F NMR (376 MHz, CDCl3): 
δ = -60.8; 13C NMR (101 MHz, CDCl3): δ = 171.8 (CO2), 169.3 (CONH), 164.4 (CONH), 
136.9 (C4), 129.8 (C6), 129.6 (C1), 124.8 (q, 3JCF = 5 Hz, C
2), 124.1 (C5), 122.6 (q, 
J = 274 Hz, CF3), 120.0 (q, J = 30 Hz, C
3), 59.9 (OCH2CH3), 59.9 (NCH2CONH), 52.1 
(cyclen-CH2), 46.1 (cyclen-CH2), 45.1 (cyclen-CH2), 44.4 (cyclen-CH2), 34.5 (NCH2CH2CO), 
32.8 (NCH2CH2CO), 13.2 (OCH2CH3); ESI/MS
+ m/z 517.4 [M+H]+; HRMS Calcd for 
C23H36N6O4F3 517.2750. Found 517.2767. 
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32. Ethyl-3-(3-(trifluoromethyl)-4-(2-(4,7,10-tris((ethoxy(methyl)phosphoryl) 
methyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)benzamido) 
propanoate 
N N
NN
H
N
O
F3C
H
N
O
O
O
P
O
OEt
P
O
EtO
P
O
EtO
 
Ethyl-3-(4-(2-(1,4,7,10-tetraazacyclododecan-1-yl)acetamido)-3-(trifluoromethyl) 
benzamido)propanoate (0.16 g, 0.31 mmol) was heated to 80°C in anhydrous THF 
under argon. Paraformaldehyde (0.11 g, 3.68 mmol) followed by 
diethoxymethylphosphine (0.50 g, 3.68 mmol) were added before the solution was 
heated at reflux over molecular sieves for 15 h.  After this time, the reaction mixture 
was cooled before excess paraformaldehyde was removed by filtration and the solvent 
removed under reduced pressure. The resulting orange oil was purified by mixed 
alumina/silica (4:1) gel column chromatography, eluting with a gradient starting from 
100% DCM to 6 % MeOH/DCM to yield a pale yellow oil (0.14 g, 50 %). 1H NMR 
(400 MHz, CDCl3): δ = 10.31 (s, 1H, NH), 8.12 (s, 1H, H
2), 7.96 (d, J = 8 Hz, 1H, H5), 7.69 
(d, J = 8 Hz, 1H, H6), 7.58 (s, 1H, NH), 4.39 (s, 2H, NCH2CONH), 4.15 (q, J = 7 Hz, 2H, 
CO2CH2CH3), 4.07 (m, 6H, NCH2P), 3.69 (m, 2H, NCH2CH2CO), 3.44 (br s, 4H, 
cyclen-CH2), 3.19 (br m, 4H, cyclen-CH2), 3.09 (br s, 8H, cyclen-CH2), 2.65 (t, J = 6 Hz, 
2H, NCH2CH2CO), 1.54 (m, 9H, PCH3), 1.30 (m, 9H, POCH2CH3), 1.25 (t, J = 7 Hz, 3H, 
CO2CH2CH3); 
19F NMR (376 MHz, CDCl3): δ = -61.8; 
31P NMR (162 MHz, CDCl3): δ = 50.7, 
49.9; ESI/MS+ m/z 877.6 [M+H]+, 899.5 [M+Na]+; HRMS Calcd for C35H62N6O10F3P3Na 
899.3590. Found 899.3610. 
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33. 3-(3-(trifluoromethyl)-4-(2-(4,7,10-tris((hydroxy(methyl)phosphoryl)methyl)-
1,4,7,10-tetraazacyclododecan-1-yl)acetamido)benzamido)propanoic acid 
(L3- βala) 
N N
NN
H
N
O
F3C
H
N
O
OH
O
P
O
OH
P
O
HO
P
O
HO
 
Freshly prepared aqueous KOD solution (5 mL, 0.1 M) was added to ethyl 3-(3-
(trifluoromethyl)-4-(2-(4,7,10-tris((ethoxy(methyl)phosphoryl)methyl)-1,4,7,10-
tetraazacyclododecan-1-yl)acetamido)benzamido)propanoate (0.10 g, 0.11 mmol). The 
solution was left to stir at 40°C and the reaction monitored by 1H and 31P NMR. After 
72 h, the pH of the solution was lowered to ca. 6 by the addition of dilute HCl(aq). The 
solvent was removed under reduced pressure and the residue washed repeatedly with 
DCM (3 x 5 mL). The resulting oil was dissolved in EtOH. The white precipitate was 
removed by filtration and the solvent removed under reduced pressure to yield a pale 
yellow gum (73 mg, 84%). 1H NMR (400 MHz, D2O): δ = 7.91 (s, 1H, H
2), 7.74 (d, 
J = 8 Hz, 1H, H5), 7.04 (d, J = 8 Hz, 1H, H6), 3.51 (m, 10H, 
NCH2CH2CO/NCH2P/NCH2CONH), 2.74 (br m, 10H, cyclen-CH2), 2.63 (br m, 6H, 
cyclen-CH2), 2.40 (t, J = 7 Hz, 3H, NCH2CH2CO), 1.14 (d, 
2JHP = 13 Hz, 9H, PCH3); 
19F NMR 
(376 MHz, D2O): δ = -62.2; 
31P NMR (162 MHz, D2O): δ = 38.9, 37.7; ESI/MS
- m/z 766.1 
[M-H]-. 
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34. [Dy.L3-βala] 
N N
NN
P
O
O
P
O
O
P
O
O
H
N
O
H
N
O
OH
O
CF3
Dy
 
Dy(III)Cl3.6H2O (24 mg, 0.063 mmol) was added to a stirred solution 3-(3-
(trifluoromethyl)-4-(2-(4,7,10-tris((hydroxy(methyl)phosphoryl)methyl)-1,4,7,10-
tetraazacyclododecan-1-yl)acetamido)benzamido)propanoic acid (40 mg, 0.052 mmol) 
in water (3 mL) and the pH adjusted to 5.5 using HCl(aq).  The reaction was left stirring 
overnight at 50°C.  After cooling to rt, the pH was adjusted to 10 and precipitated 
metal hydroxide was removed by centrifugation.  The solution was adjusted back to 
pH 5.5 with HCl(aq). The resulting solution was dialysed (500 MW cut-off; Spectra/Pro® 
biotech cellulose ester dialysis membrane, Spectrum Laboratories), and lyophilised to 
obtain a white solid (42 mg, 88 %).  19F NMR (188  MHz, D2O, pH 6.5): δ = -65.6; ESI/MS
- 
m/z 923.9 [M-H]-.  
 
35. tert-Butyl 4-amino-3-(trifluoromethyl)benzoate 
 
Perchloric acid (2-3 drops, 70 % in H2O) was added to a stirred solution of 4-amino-3-
(trifluoromethyl)benzoic acid (1.5 g, 7.32 mmol) in tert-butyl acetate (15 mL).  The 
reaction mixture was stirred for 16 h at rt.  After this time, H2O (20 mL) was added and 
the organic layer extracted.  This was then washed with H2O (2 x 20 mL) and 5 % 
Na2CO3(aq) (2 x 20 mL).  The organic layer was dried over MgSO4, filtered, and the 
solvent removed under reduced pressure.  The resulting yellow solid was purified by 
silica gel column chromatography, eluting with a gradient starting from 100 % toluene 
to 10 % DCM/toluene to yield a white solid (0.450 g, 24 %).  Rf (10 % DCM/toluene) 
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= 0.22, m.p. 122-125°C.  1H NMR (400 MHz, CDCl3): δ = 8.11 (d, J = 2 Hz, 1H, H
2), 7.92 
(dd, J = 9, 2 Hz, 1H, H6), 6.73 (d, J = 9 Hz, 1H, H5), 1.60 (s, 9H, C(CH3)3); 
19F NMR 
(376 MHz, CDCl3); δ = -64.0; 
13C NMR (101 MHz, CDCl3): δ = 163.88 (COO
tBu), 146.81 
(C4), 133.11 (C6), 127.88 (q, 3JCF = 5 Hz, C
2), 123.54 (q, 1JCF = 272 Hz, CF3), 120.14 (C
1), 
115.16 (C5), 111.70 (q, 2JCF = 30.8 Hz, C
3), 79.84 (C(CH3)3), 27.24 (C(CH3)3); ESI/MS
- m/z 
260.2 [M-H]-; HRMS Calcd for C12H13NO2F3 260.0898. Found 260.0901. 
 
36. tert-Butyl 4-(2-chloroacetamido)-3-(trifluoromethyl)benzoate 
 
Chloroacetyl chloride (0.210 g, 1.86 mmol) was added dropwise to a stirred solution of 
tert-butyl 4-amino-3-(trifluoromethyl)benzoate (0.243 g, 0.93 mmol), NEt3 (0.141 g, 
1.40 mmol), and 4-dimethylaminopyridine (ca. 10 mg) in anhydrous THF (10 mL) at 0°C 
under argon for 2 h.  After this time, the reaction was allowed to warm to rt and stirred 
for a further 18 h, before the crude mixture was concentrated under reduced pressure 
and diluted with DCM (15 mL).  This organic mixture was washed with HCl (15 mL, 
0.1 M), NaOH (15 mL, 0.1 M), and H2O (15 mL).  The combined organic extracts were 
dried over MgSO4 and the solvent removed under reduced pressure.  The resulting 
residue was purified over silica gel in toluene to yield a yellow solid (210 mg, 67 %).  
Rf (10 % DCM/toluene) = 0.32.  
1H NMR (400 MHz, CDCl3): δ = 8.92 (s, 1H, NH), 8.43 (d, 
J = 9 Hz, 1H, H5), 8.26 (d, J = 2 Hz, 1H, H2), 8.17 (dd, J = 9, 2 Hz, 1H, H6), 4.24 (s, 2H, 
CH2CO), 1.59 (s, 9H, 
tBu); 13C NMR (101 MHz, CDCl3): δ = 164.2 (CO), 163.8 (CO), 137.7 
(C4), 134.1 (C6), 128.5 (C1), 127.7 (d, J = 6 Hz, C2), 123.5 (q, 1JCF = 273 Hz, CF3), 122.4 (s, 
6C), 119.4 (q, 2JCF = 31 Hz, C
3), 82.0 (C(CH3)3), 42.9 (CH2CO), 28.1 (C(CH3)3); 
19F NMR 
(376 MHz, CDCl3): δ = -61.3; ESI/MS
- m/z 336.2 [M-H]-; HRMS Calcd for C14H14NO3F3Cl 
336.0614. Found 336.0612. 
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37. tert-Butyl-4-(2-(1,4,7,10-tetraazacyclododecan-1-yl)acetamido)-3-
(trifluoromethyl)benzoate 
 
A solution of tert-butyl 4-(2-chloroacetamido)-3-(trifluoromethyl)benzoate (300 mg, 
0.89 mmol) in anhydrous MeCN (10 mL) was added dropwise to a stirred solution of 
1,4,7,10-tetraazacyclododecane (1.53 g, 8.90 mmol) in anhydrous MeCN (20 mL) at 
40°C under argon.  After 5 h, the solvent was removed under reduced pressure and the 
residue dissolved in DCM (20 mL).  The solution was washed repeatedly with H2O 
(4 x 20 mL), dried over MgSO4, and the solvent removed under reduced pressure to 
yield a light yellow oil (360 mg, 86 %).  1H NMR (400 MHz, CDCl3): δ = 8.21 (d, J = 9 Hz, 
1H, H5), 8.16 (d, J = 2 Hz, 1H, H2), 8.06 (dd, J = 9, 2 Hz, 1H, H6), 3.27 (s, 2H, CH2CO), 2.71 
(br m, 8H, cyclen-CH2), 2.63 (br m, 4H, cyclen-CH2), 2.56 (br m, 4H, cyclen-CH2), 1.52 (s, 
9H, tBu); 13C NMR (176 MHz, CDCl3): δ = 169.1 (CO), 163.1 (CO), 137.7 (C
4), 132.8 (C6), 
127.1 (C1), 126.6 (q, J = 6 Hz, C2), 123.4 (C5), 122.7 (q, 1JCF = 274 Hz, CF3), 119.2 (q, 
J = 30 Hz, C3), 80.8 (C(CH3)3), 60.1 (NCH2CO), 52.1 (cyclen-CH2), 46.1 (cyclen-CH2), 45.1 
(cyclen-CH2), 44.4 (cyclen-CH2), 27.1 (C(CH3)3); 
19F NMR (658 MHz, CDCl3): δ = -61.3; 
ESI/MS+ m/z 474.8 [M+H]+, ESI/MS- m/z 472.7 [M-H]-; HRMS Calcd for C22H35N5O3F3 
474.2692. Found 474.2704. 
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38. tert-Butyl 3-(trifluoromethyl)-4-(2-(4,7,10-tris((ethoxy(methyl)phosphoryl) 
methyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)benzoate 
N N
NN
O
H
N
F3C
O
O
P
O
OEt
P
O
EtO
P
O
EtO
 
tert-Butyl-4-(2-(1,4,7,10-tetraazacyclododecan-1-yl)acetamido)-3-(trifluoromethyl) 
benzoate (0.31 g, 0.66 mmol) was heated to 80°C in anhydrous THF under argon. 
Paraformaldehyde (0.22 g, 7.35 mmol) followed by diethoxymethylphosphine (1.00 g, 
7.35 mmol) were added before the solution was heated at reflux over molecular sieves 
for 15 h.  After this time, the reaction mixture was cooled before excess 
paraformaldehyde was removed by filtration and the solvent removed under reduced 
pressure. The resulting orange oil was purified by mixed alumina/silica (3:1) gel column 
chromatography, eluting with a gradient starting from 100% DCM to 8 % MeOH/DCM 
to yield a pale yellow oil (0.34 g, 61 %). Rf (5 % MeOH/DCM, alumina plates) = 0.46. 
1H NMR (400 MHz, CDCl3): δ = 8.47 (d, J = 9 Hz, 1H, H
5), 8.22 (s, 1H, H2), 8.13 (d, 
J = 9 Hz, 1H, H6), 4.08 (br m, 6H, POCH2CH3), 3.84 (m, 2H, NCH2CONH), 3.29 (br s, 2H, 
cyclen-CH2), 3.15 (br s, 2H, cyclen-CH2), 2.88 (br m, 18H, cyclen-CH2/NCH2P), 1.58 (s, 
9H, CO2
tBu), 1.50 (m, 9H, PCH3), 1.31 (m, 9H, POCH2CH3); 
19F NMR (376 MHz, CDCl3): 
δ = -61.6; 31P NMR (162 MHz, CDCl3): δ = 51.9, 51.1; ESI/MS
+ m/z 835.1 [M+H]+; HRMS 
Calcd for C34H62N5O9F3P3 834.3713. Found 834.3690. 
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39. 3-(Trifluoromethyl)-4-(2-(4,7,10-tris((ethoxy(methyl)phosphoryl)methyl)-
1,4,7,10-tetraazacyclododecan-1-yl)acetamido)benzoic acid 
N N
NN
O
H
N
F3C
OH
O
P
O
OEt
P
O
EtO
P
O
EtO
 
tert-Butyl-3-(trifluoromethyl)-4-(2-(4,7,10-tris((ethoxy(methyl)phosphoryl)methyl)-
1,4,7,10-tetraazacyclododecan-1-yl)acetamido)benzoate (250 mg, 0.30 mmol) was 
dissolved in DCM (5 mL).  To this was added TFA (2 mL) and the mixture was stirred at 
rt for 3 h.  After this time, the solvent was removed under reduced pressure to give a 
crude yellow oil, which was repeatedly washed with DCM to yield a pale yellow oil 
(224 mg, 96 %). 1H NMR (400 MHz, CD3OD): δ = 8.33 (s, 1H, H
2), 8.27 (d, J = 8 Hz, 1H, 
H6), 7.88 (d, J = 8 Hz, 1H, H5), 4.14 (m, 8H, POCH2CH3/CH2CONH), 3.84 (m, 6H, NCH2P), 
3.37 (br m, 12H, cyclen-CH2), 3.22 (br m, 2H, cyclen-CH2), 3.08 (br m, 2H, cyclen-CH2), 
1.52 (d, J = 14 Hz, 9H, PCH3), 1.31 (t, J = 7 Hz, 9H); 
19F NMR (376 MHz, CD3OD): 
δ = -62.6; 31P NMR (81 MHz, CD3OD): δ = 54.9, 54.0; ESI/MS
+ m/z 779.0 [M+H]+, 800.9 
[M+Na]+; HRMS Calcd for C30H54N5O9F3P3 778.3087. Found 778.3102. 
 
40. 5-(Trifluoromethyl)pyridine-2-carboxylic acid12 
 
Butyllithium (2.5 M in hexanes, 22.1 mmol) was added dropwise to 2-bromo-5-
(trifluoromethyl)pyridine (5.00 g, 22.1 mmol) in anhydrous THF (20 mL) at -78°C.  After 
stirring for 2 h, the mixture was poured onto an excess of freshly crushed CO2(s).  The 
solvent was removed under reduced pressure and the residue dissolved in NaOH(aq) 
(2M, 50 mL).  This was washed with diethyl ether (2 x 50 mL) and acidified to pH 2 
before being extracted by diethyl ether (2 x 50 mL) and dried with MgSO4.  The solvent 
was removed under reduced pressure and the residue recyrstallised from hexane to 
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yield colourless needles (1.86 g, 44 %).  1H NMR (400 MHz, CDCl3): δ = 8.96 (s, 1H, H
6), 
8.41 (d, J = 8 Hz, 1H, H3), 8.25 (d, J = 8 Hz, 1H, H4); 19F NMR (376 MHz, CDCl3): δ = -62.6; 
ESI/MS+ m/z 192.1 [M+H]+; HRMS Calcd for C7H3NO2F3 190.0110. Found 190.0116. 
 
41. Methyl 5-(trifluoromethyl)pyridine-2-carboxylate 
 
Concentrated H2SO4 (2 mL) was added to a stirred solution of 
5-(trifluoromethyl)pyridine-2-carboxylic acid (1.50 g, 7.85 mmol) in methanol (25 mL).  
The reaction mixture was then boiled under reflux for 24 h before being cooled and 
concentrated under vacuum.  The residue was diluted in water (25 mL), neutralised 
with K2CO3 (aq), and extracted with DCM (3 x 25 mL).  The organic layers were 
combined, washed with brine (2 x 25 mL) and dried over Na2SO4.  The solvent was 
removed under reduced pressure to yield a white solid (1.28 g, 80 %).  Rf (50% 
EtOAc/hexane) = 0.49.  1H NMR (400 MHz, CDCl3): δ = 9.02 (s, 1H, H
6), 8.29 (d, J = 8 Hz, 
1H, H3), 8.13 (d, J = 8 Hz, 1H, H4), 4.07 (s, 3H, CH3); 
19F NMR (376 MHz, CDCl3): 
δ = -62.6; ESI/MS+ m/z 206.1 [M+H]+, 228.2 [M+Na]+; HRMS Calcd for C8H7F3NO2 
206.0412. Found 206.0429. 
 
42. (5-(Trifluoromethyl)pyridin-2-yl)methanol 
 
NaBH4 (0.369 g, 9.75 mmol) was added to methyl 5-(trifluoromethyl)pyridine-2-
carboxylate (1.00 g, 5.00 mmol) in EtOH (40 mL) and the resulting suspension boiled 
under reflux for 18 h.  After this time, the mixture was allowed to cool to rt then 
quenched with saturated NH4Cl solution.  The solvent was removed under reduced 
pressure and the residue dissolved in H2O (20 mL), which was then extracted with 
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EtOAc (2 x 20 mL).  The organic layers were combined, washed with H2O (30 mL) and 
brine (30 mL), and dried over Na2SO4.  The solvent was removed under reduced 
pressure to yield a colourless oil (0.643 g, 73 %). Rf (50 % EtOAc/hexane) = 0.37.  
1H NMR (400 MHz, CDCl3): δ = 8.79 (s, 1H, H
6), 7.92 (d, J = 7 Hz, 1H, H4), 7.46 (d, 
J = 7 Hz, 1H, H3), 4.83 (s, 2H, CH2), 4.29 (s, 1H, OH); 
13C NMR (101 MHz, CDCl3): 
δ = 163.4 (C2), 145.6 (q, 3JCF = 4 Hz, C
6), 133.9 (q, 3JCF = 3 Hz, C
4), 128.5 (C3), 125.5 (q, 
2JCF = 33 Hz, C
5), 123.4 (q, 1JCF = 272 Hz, CF3), 64.2 (CH2OH); 
19F NMR (376 MHz, CDCl3): 
δ = -62.8;  ESI/MS+ m/z 178.1 [M+H]+; HRMS Calcd for C7H7F3NO 178.0468. Found 
178.0480. 
 
43. 2-(Bromomethyl)-5-(trifluoromethyl)pyridine 
 
Phosphorus tribromide (0.40 mL, 4.23 mmol) was added dropwise to a solution of 
(5-(trifluoromethyl)pyridin-2-yl)methanol (500 mg, 2.82 mmol) in anhydrous DCM 
(15 mL) at 0°C under argon.  The reaction mixture was allowed to warm to rt and 
stirred for 2 h.  After this time, the reaction was quenched with NaHCO3(aq) (15 mL), 
extracted with DCM (2 x 20 mL), and dried over MgSO4 before the solvent was 
removed under reduced pressure.  The crude material was purified by silica gel column 
chromatography, eluting with a gradient starting from 100 % hexane to 20 % ethyl 
acetate/hexane to yield a pale yellow oil (210 mg, 31 %).  Rf (20 % ethyl 
acetate/hexane) = 0.49.  1H NMR (400 MHz, CDCl3): δ = 8.81 (s, 1H, H
6), 7.92 (d, 
J = 8 Hz, 1H, H4), 7.57 (d, J = 8 Hz, 1H, H3), 4.57 (s, 2H, CH2); 
13C NMR (101 MHz, CDCl3): 
δ = 160.6 (q, 4JCF = 1 Hz, C
3), 146.5 (q, 3JCF = 4 Hz, C
6), 134.3 (q, 3JCF = 4 Hz, C
4), 125.9 (q, 
2JCF = 33 Hz, C
5), 123.3 (q, 1JCF = 272 Hz, CF3), 123.2 (C
2), 32.5 (CH2Br); 
19F NMR 
(376 MHz, CDCl3): δ = -62.9;  ESI/MS
+ m/z 240.1 [M+H]+; HRMS Calcd for C7H6BrF3N 
239.9655. Found 239.9636. 
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44. (5-(Trifluoromethyl)pyridin-2-yl)methyl methanesulphonate 
N
CF3
O
S
O
O
 
(5-(Trifluoromethyl)pyridin-2-yl)methanol (0.64 g, 3.63 mmol) was dissolved in THF 
(5mL) and cooled to 5°C.  Triethylamine (1 mL, 7.26 mmol) and mesyl chloride 
(0.42 mL, 5.45 mmol) were added dropwise to this solution, upon which a white solid 
precipitated from solution.  Once addition was complete, the reaction mixture was 
allowed to warm to rt and stirred for 15 min before the solvent was removed under 
reduced pressure.  The residue was dissolved in brine (50 mL) and extracted with DCM 
(2 x 50 mL).  The organic layers were combined, dried over MgSO4, and the solvent 
removed under reduced pressure to yield a yellow oil (0.89 g, 96 %).  Rf (10 % 
MeOH/DCM) = 0.81.  1H NMR (400 MHz, CDCl3): δ = 8.87 (s, 1H, H
6), 8.01 (d, J = 8 Hz, 
1H, H4), 7.64 (d, J = 8 Hz, 1H, H3), 5.40 (s, 2H, CH2), 3.15 (s, 3H, SO2CH3); 
13C NMR 
(101 MHz, CDCl3): δ = 157.7 (q, 
4JCF = 1 Hz, C
3), 146.5 (q, 3JCF = 4 Hz, C
6), 134.4 (q, 3JCF = 4 
Hz, C4), 126.5 (q, 2JCF = 33 Hz, C
5), 123.2 (q, 1JCF = 273 Hz, CF3), 121.6 (C
2), 70.3 (SO2CH3), 
38.0 (CH2OMS); 
19F NMR (376 MHz, CDCl3): δ = -62.5;  ESI/MS
+ m/z 256.2 [M+H]+, 278.2 
[M+Na]+; HRMS Calcd for C8H9F3NO3S 256.0255. Found 256.0253. 
 
45. 1,4,7-Tris-tert-butoxycarbonyl-1,4,7,10-tetraazacyclododecane13,14 
N N
NN
H
O
O
O
O
O
O
 
A solution of di-tert-butyl dicarbonate (10.1 g, 46.7 mmol) in chloroform (65 mL) was 
added dropwise over 2 h, at 0°C, to a stirred solution of cyclen (2.86 g, 15.6 mmol) and 
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triethylamine (6.5 mL, 46.7 mmol) in chloroform (85 mL) under argon.  The reaction 
mixture was then stirred at rt for 18 h before being washed with H2O (2 x 100 mL).  The 
organic phase was dried over Na2SO4, filtered, and the solvent removed under reduced 
pressure.  The resulting white solid was purified by silica gel column chromatography, 
eluting with diethyl ether to yield a white solid (4.47 g, 61 %).  Rf (Et2O) = 0.21.  
1H NMR 
(400 MHz, CDCl3): δ = 3.61 (br s, 4H, cyclen-CH2), 3.33 (br s, 8H, cyclen-CH2), 2.83 (br s, 
4H, cyclen-CH2), 1.46 (s, 9H, 
tBu), 1.44 (s, 18H, tBu); 13C NMR (101 MHz, CDCl3): 
δ = 155.6 (CO2
tBu), 155.4 (CO2
tBu), 79.3 (C(CH3)3), 79.2 (C(CH3)3), 51.0 (cyclen-CH2), 
49.5 (cyclen-CH2), 46.0 (cyclen-CH2), 45.0 (cyclen-CH2), 28.7 (C(CH3)3), 28.5 (C(CH3)3);  
ESI/MS+ m/z 473.5 [M+H]+; HRMS Calcd for C23H45N4O6 473.3323. Found 473.3339. 
 
46. Tri-tert-butyl-10-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-tricarboxylate 
N N
NN
N CF3
O
O
O
O
O
O
 
Both 2-(bromomethyl)-5-(trifluoromethyl)pyridine and (5-(trifluoromethyl)pyridin-2-yl) 
methyl methanesulphonate were used as starting materials to form the title compound 
following identical procedures.  For example, a stirred mixture of 1,4,7-tris-tert-
butoxycarbonyl-1,4,7,10-tetraazacyclododecane (1.60 g, 3.39 mmol), (5-
(trifluoromethyl)pyridin-2-yl)methyl methanesulphonate (0.787 g, 3.08 mmol), and 
K2CO3 (0.639 g, 4.62 mmol) in anhydrous MeCN (25 mL) was boiled under reflux for 
18 h under argon.  After this, the reaction mixture was cooled and filtered before the 
solvent was removed under reduced pressure.  The resulting yellow oil was purified by 
silica gel column chromatography, eluting with a gradient starting from 100 % DCM to 
2 % MeOH/DCM to yield a yellow sticky solid (0.99 g, 51 %).  1H NMR (400 MHz, CDCl3): 
δ = 8.82 (s, 1H, H6), 7.85 (d, J = 7 Hz, 1H, H3), 7.48 (d, J = 7 Hz, 1H, H4), 3.92 (s, 2H, 
NCH2py), 3.48 (br m, 12H, cyclen-CH2), 2.74 (br m, 4H, cyclen-CH2), 1.49 (s, 18H, 
tBu), 
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1.42 (s, 9H, tBu); 13C NMR (101 MHz, CDCl3): δ = 155.2 (CO2
tBu), 154.5 (C2), 145.0 (q, 
3JCF = 6 Hz, C
6), 132.2 (q, 3JCF = 6 Hz, C
4), 124.1 (q, 2JCF = 33 Hz, C
5), 123.6 (C3), 122.6 (q, 
1JCF = 270 Hz, CF3), 78.6 (C(CH3)3), 57.1 (NCH2py), 54.0 (cyclen-CH2), 53.2 (cyclen-CH2), 
52.4 (cyclen-CH2), 49.0 (cyclen-CH2), 46.9 (cyclen-CH2), 27.7 (C(CH3)3), 27.4 (C(CH3)3); 
19F NMR (376 MHz, CDCl3) δ = -63.3; ESI/MS
+ m/z 632.5 [M+H]+, 654.5 [M+Na]+; HRMS 
Calcd for C30H49N5O6F3 632.3635. Found 632.3621. 
 
47. 1-((5-(Trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane 
 
Tri-tert-butyl-10-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclo 
dodecane-1,4,7-tricarboxylate (685 mg, 1.08 mmol) was dissolved in DCM (5 mL) with 
stirring.  To this was added TFA (3 mL) and the mixture was stirred at rt for 18 h.  After 
this time, the solvent was removed under reduced pressure before being repeatedly 
washed with DCM.  The resulting oil was dissolved in KOH(aq) (1 M, 20 mL) and 
extracted with DCM (3 x 10 mL).  The solvent was removed under reduced pressure to 
yield an orange oil (320 mg, 89 %).  1H NMR (200 MHz, CDCl3): δ = 8.69 (d, J = 2 Hz, 1H, 
H6), 7.84 (dd, J = 8, 2 Hz, 1H, H4), 7.55 (d, J = 8 Hz, 1H, H3), 3.78 (s, 2H, NCH2py), 2.76 
(m, 4H, cyclen-CH2), 2.65 (m, 8H, cyclen-CH2), 2.54 (m, 4H, cyclen-CH2); 
13C NMR 
(101 MHz, CDCl3): δ = 162.8 (C
2), 144.8 (q, 3JCF = 4 Hz, C
6), 132.8 (q, 3JCF = 3 Hz, C
4), 
124.0 (q, 2JCF = 33 Hz, C
5), 122.6 (q, 1JCF = 272 Hz, CF3), 121.5 (C
3), 59.8 (NCH2py), 50.7 
(cyclen-CH2), 46.1 (cyclen-CH2), 45.2 (cyclen-CH2), 44.1 (cyclen-CH2); 
19F NMR 
(188 MHz, CDCl3) δ = -62.8; ESI/MS
+ m/z 332.3 [M+H]+; HRMS Calcd for C15H25N5F3 
332.2062. Found 332.2061. 
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48. Triethyl-(10-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)tris(methylene)tris(methylphosphinate) 
N N
NN
N CF3
P OEt
O
P
EtO
O
PEtO
O  
1-((5-(Trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane (300 mg, 
0.91 mmol) was heated to 80°C in anhydrous THF under argon. Paraformaldehyde 
(220 mg, 7.36 mmol) followed by diethoxymethylphosphine (1.00 g, 7.36 mmol) were 
added before the solution was heated at reflux over molecular sieves for 15 h.  After 
this time, the excess paraformaldehyde was removed by filtration and the solvent 
removed under reduced pressure. The resulting orange oil was purified by mixed 
alumina/silica (4:1) gel column chromatography, eluting with a gradient starting from 
100 % DCM to 8 % MeOH/DCM, to yield a yellow oil (180 mg, 29 %), which consisted of 
a mixture of diastereoisomers.  1H NMR (400 MHz, CDCl3): δ = 8.84 (s, 1H, H
6), 7.98 (d, 
J = 8 Hz, 1H, H4), 7.78 (d, J = 8 Hz, 1H, H3), 4.70 (s, 2H, NCH2py), 4.07 (m, 6H, 
POCH2CH3), 3.84 (s, 2H, NCH2P), 3.42 (br s, 4H, NCH2P), 3.05 (br m, 16H, cyclen-CH2), 
1.53 (br m, 9H, PCH3), 1.31 (br m, 9H, POCH2CH3); 
19F NMR (376 MHz, CDCl3): δ = -62.9; 
31P NMR (162 MHz, CDCl3) δ = 52.2, 52.0; ESI/MS
+ m/z 692.2 [M+H]+; HRMS Calcd for 
C27H52N5O6F3P3 692.3077. Found 692.3064. 
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49. (10-((5-(Trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)tris(methylene)tris(methylphosphinic acid) (L5) 
 
Triethyl (10-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)tris(methylene)tris(methylphosphinate) (60 mg, 0.087 mmol) was dissolved 
in HCl (6 M, 5 mL) and stirred for 18 h at 90°C.  The solvent was removed under 
reduced pressure and the residue washed repeatedly with DCM (3 x 5 mL) and the 
resulting oil was dissolved in EtOH. The white precipitate was removed by filtration 
and the solvent removed under reduced pressure to yield the hydrochloride salt as a 
viscous yellow oil (48 mg, 91 %).  1H NMR (400 MHz, D2O): δ = 9.04 (s, 1H, H
6), 8.49 (s, 
1H, H4), 7.93 (s, 1H, H3), 4.30 (s, 2H, NCH2py), 3.33 (br s, 6H, NCH2P), 3.17 (br m, 16H, 
cyclen-CH2), 1.33 (m, 9H, PCH3);  
19F NMR (376 MHz, CDCl3): δ = -63.3; 
31P NMR 
(162 MHz, CDCl3) δ = 53.2; ESI/MS
+ m/z 608.3 [M+H]+, ESI/MS- m/z 606.3 [M-H]-. 
 
50. [Dy.L5] 
N N
NN
P
O
P O
N
PO
O
O
O
Dy CF3
 
Dy(III)Cl3.6H2O (22 mg, 0.059 mmol) was added to a solution of (10-
((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) 
tris (methylene)tris(methylphosphinic acid)  (30 mg, 0.049 mmol) dissolved in H2O 
(3 mL).  The pH was adjusted to 5.5 before stirring the solution for 18 h at 40°C.  After 
this time, the solution was allowed to cool to rt before the pH was raised to 10, causing 
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a white solid to precipitate out of solution.  This precipitate was removed by 
centrifugation and the pH of the resulting solution neutralised.  The solvent was 
removed under reduced pressure to yield a yellow solid, which was purified by 
preparative HPLC to yield a yellow solid (37 mg, 98 %).  19F NMR (376  MHz, D2O, 
pD 6.9): δ =-155.0 (major), -162.1 (minor); ESI/MS+ m/z 806.2 [M+K]+; HRMS Calcd for 
C21H36
161DyF3N5O6P3
35Cl 800.0789. Found 800.0809. 
 
51. [Tm.L5] 
An analogous procedure to that described for [Dy.L5] was followed using (10-
((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) 
tris(methylene)tris(methylphosphinic acid)   (30 mg, 0.049 mmol) and Tm(III)Cl3 
(23 mg, 0.059 mmol) to yield a yellow solid (37 mg, 97 %).  19F NMR (376  MHz, D2O, 
pD 6.9): δ = 10.9 (major), 13.5 (minor); ESI/MS+ m/z 774.3 [M+H]+, 812.2 [M+K]+; HRMS 
Calcd for C21H36
169TmF3N5O6P3
35Cl 808.0861. Found 808.0838. 
 
 
52. Tri-tert-butyl 10-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-tricarboxylate 
N N
NN
N CF3
O
O
O
O
O
O
Cl
 
A stirred mixture of 1,4,7-tris-tert-butoxycarbonyl-1,4,7,10-tetraazacyclododecane 
(2.26 g, 4.79 mmol), 3-chloro-2-(chloromethyl)-5-(trifluoromethyl)pyridine (1.00 g, 
4.35 mmol), and K2CO3 (0.90 g, 6.53 mmol) in anhydrous MeCN (25 mL) was boiled 
under reflux for 18 h under argon.  The reaction mixture was cooled and filtered 
before the solvent was removed under reduced pressure.  The resulting yellow oil was 
purified by silica gel column chromatography, eluting with a gradient starting from 
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100 % DCM to 5 % MeOH/DCM to yield a pale yellow oil (1.84 g, 64 %).  Rf (5 % 
MeOH/DCM) = 0.61.  1H NMR (400 MHz, CDCl3): δ = 8.75 (d, J = 1 Hz, 1H, H
6), 7.90 (d, 
J = 1 Hz, 1H, H4), 4.13 (s, 2H, NCH2py), 3.59 (br s, 4H, cyclen-CH2), 3.40 (br s, 8H, cyclen-
CH2), 2.84 (br s, 4H, cyclen-CH2), 1.47 (s, 9H, C(CH3)3), 1.43 (s, 18H, C(CH3)3); 
13C NMR 
(101 MHz, CDCl3): δ = 159.1 (C
2), 155.7 (CO2
tBu), 155.4 (CO2
tBu), 143.6 (q, 3JCF = 4 Hz, 
C6), 134.1 (q, 3JCF = 4 Hz, C
4), 132.0 (C3), 126.2 (q, 2JCF = 34 Hz, C
5), 122.6 (q, 
1JCF = 273 Hz, CF3), 79.5 (C(CH3)3), 79.2 (C(CH3)3), 54.8 (NCH2py), 53.7 (cyclen-CH2), 50.1 
(cyclen-CH2), 48.0 (cyclen-CH2), 47.7 (cyclen-CH2), 28.7 (C(CH3)3), 28.5 (C(CH3)3); 
19F NMR (376 MHz, CDCl3): δ = -62.3;  ESI/MS
+ m/z 666.5 [M+H]+; HRMS Calcd for 
C30H48ClF3N5O6 666.3238. Found 666.3240. 
 
53. 1-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane 
N N
NN
H
HH
N CF3
Cl
 
Tri-tert-butyl-10-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraaza- 
cyclododecane-1,4,7-tricarboxylate (150 mg, 0.225 mmol) was dissolved in DCM (2 mL) 
with stirring.  To this was added TFA (1 mL) and the mixture was stirred at rt for 18 h.  
After this time, the solvent was removed under reduced pressure before being 
repeatedly washed with DCM.  The resulting oil was dissolved in KOH(aq) (1 M, 10 mL) 
and extracted with DCM (3 x 5 mL).  The solvent was removed under reduced pressure 
to yield an orange oil (78 mg, 95 %).  1H NMR (400 MHz, CDCl3): δ = 8.68 (s, 1H, H
6), 
7.87 (s, 1H, H4), 3.92 (s, 2H, NCH2py), 2.76 (br m, 4H, cyclen-CH2), 2.67 (br s, 8H, 
cyclen-CH2), 2.53 (br s, 4H, cyclen-CH2); 
13C NMR (101 MHz, CDCl3): δ = 159.9 (C
2), 
143.6 (q, 3JCF = 4 Hz, C
6), 134.5 (q, 3JCF = 4 Hz, C
4), 132.2 (C3), 126.6 (q, 2JCF = 34 Hz, C
5), 
122.7 (q, 1JCF = 273 Hz, CF3), 58.2 (NCH2py), 51.7 (cyclen-CH2), 46.9 (cyclen-CH2), 
46.0 (cyclen-CH2), 44.8 (cyclen-CH2); 
19F NMR (376 MHz, CDCl3): δ = -62.7;  ESI/MS
+ m/z 
366.3 [M+H]+; HRMS Calcd for C15H24ClF3N5 366.1684. Found 366.1672. 
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54. Triethyl-(10-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)tris(methylene)tris(methylphosphinate) 
N N
NN
N CF3
P OEt
O
P
EtO
O
PEtO
O
Cl
 
1-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane 
(100 mg, 0.273 mmol) was heated to 80°C in anhydrous THF under argon. 
Paraformaldehyde (110 mg, 3.68 mmol) followed by diethoxymethylphosphine 
(500 mg, 3.68 mmol) were added. The solution was heated at reflux over molecular 
sieves for 15 h.  After this time, the excess paraformaldehyde was removed by 
filtration and the solvent removed under reduced pressure. The resulting orange oil 
was purified by mixed alumina/silica (4:1) gel column chromatography, eluting with a 
gradient starting from 100 % DCM to 8 % MeOH/DCM, to yield a yellow oil (130 mg, 
71 %), which was present as a mixture of diastereoisomers.  1H NMR (400 MHz, CDCl3): 
δ = 8.73 (s, 1H, H6), 7.90 (s, 1H, H4), 4.74 (s, 2H, NCH2py), 4.06 (m, 9H, POCH2CH3), 3.03 
(br m, 8H, NCH2P/cyclen-CH2), 2.79 (br m, 14H, NCH2P/cyclen-CH2), 1.53 (m, 9H, PCH3), 
1.31 (m, 9H, POCH2CH3); 
13C NMR (101 MHz, CDCl3): δ = 158.8 (C
3), 142.5 (q, J = 4 Hz, 
C6), 133.2 (q, 3JCF = 4 Hz, C
4), 131.0 (C3), 129.8 (q, 2JCF = 34 Hz, C
5), 121.6 (q, 
1JCF = 273 Hz, CF3), 59.3 (d, 
2JCP = 7 Hz, POCH2CH3), 56.2 (NCH2py), 53.9 (m, 
NCH2P/cyclen-CH2), 53.2 (m, NCH2P/cyclen-CH2), 52.8 (m, NCH2P/cyclen-CH2), 51.5 (m, 
NCH2P/cyclen-CH2), 15.7 (d, 
3JCP = 6 Hz, PCH2CH3), 12.7 (d, 
1JCP = 89 Hz, PCH3), 12.5 (d, 
J = 92 Hz, PCH3); 
19F NMR (376 MHz, CDCl3): δ = -63.2;  
31P NMR (162 MHz, CDCl3): 
δ = 54.3, 53.4; ESI/MS+ m/z 726.4 [M+H]+, 748.4 [M+Na]+; HRMS Calcd for 
C27H51N5O6F3ClP3 726.2693. Found 726.2698. 
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55. (10-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)tris(methylene)tris(methylphosphinic acid) 
(L6) 
N N
NN
N CF3
P
O
HO
P
O OH
P
O
OH
Cl
 
Triethyl-(10-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclo- 
dodecane-1,4,7-triyl)tris(methylene)tris(methylphosphinate) (125 mg, 0.17 mmol) was 
dissolved in HCl (6 M, 10 mL) and stirred for 18 h at 90°C.  The solvent was removed 
under reduced pressure and the residue washed repeatedly with DCM (3 x 5 mL) 
before the resulting oil was dissolved in EtOH. The white precipitate was removed by 
filtration and the solvent removed under reduced pressure to yield the hydrochloride 
salt as a yellow oil (107 mg, 98 %). 1H NMR (400 MHz, D2O) δ = 8.72 (s, 1H, H
6), 8.11 (s, 
1H, H4), 3.59 (m, 2H, NCH2py), 3.43 (br s, 8H, NCH2P/cyclen-CH2), 3.07 (br m, 14H, 
cyclen-CH2), 1.26 (br m, 9H, PCH3); 
19F NMR (376 MHz, CDCl3) δ = -63.0;  
31P NMR 
(162 MHz, CDCl3) δ = 53.4; ESI/MS
- m/z 640.3 [M-H]-. 
 
56. [Dy.L6] 
N N
NN
P O
P
O
PO
O
O
O
Dy N
Cl
CF3
 
Dy(III)Cl3.6H2O (8.8 mg, 0.0234 mmol) was added to a solution of (10-((3-chloro-
5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tris 
(methylene)tris(methylphosphinic acid)  (10.7 mg, 0.0167 mmol) dissolved in H2O 
(5 mL).  The pH was adjusted to 5.5 before stirring the solution for 18 h at 40°C.  After 
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this time, the solution was allowed to cool to rt before the pH was raised to 10, causing 
a white solid to precipitate out of solution.  This precipitate was removed by 
centrifugation and the pH of the resulting solution neutralised.  The solvent was 
removed under reduced pressure to yield a yellow solid, which was purified by 
preparative HPLC to yield an off-white solid (13 mg, 97 %).  19F NMR (376  MHz, D2O, 
pH 6.5): δ = -163.5 (major), -170.2 (minor); ESI/MS- m/z 837.4 [M+Cl]-; HRMS Calcd for 
C21H35
35Cl2
160DyF3N5O6P3 833.0381. Found 833.0401. 
 
57. [Er.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (5 mg, 0.00831 mmol) and Er(III)Cl3 
(4.7 mg, 0.0124 mmol) to yield an off-white solid (6.4 mg, 95 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = -16.8 (major), -13.5 (minor); ESI/MS
+ m/z 805.0 [M+H]+; HRMS Calcd 
for C21H35
35Cl166ErF3N5O6P3Na 827.0642. Found 827.0616. 
 
58. [Tb.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (10 mg, 0.0156 mmol) and Tb(III)Cl3 
(6.9 mg, 0.0187 mmol) to yield an off-white solid (12 mg, 98 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = -160.1 (major), -160.8 (minor); ESI/MS
+ m/z 820.3 [M+Na]+; HRMS 
Calcd for C21H35
35Cl159TbF3N5O6P3Na 820.0592. Found 820.0617. 
 
59. [Tm.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (10 mg, 0.0156 mmol) and Tm(III)Cl3 
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(7.2 mg, 0.0187 mmol) to yield an off-white solid (12 mg, 98 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = 17.1 (major), 20.3 (minor); ESI/MS
+ m/z 830.2 [M+Na]+; HRMS Calcd 
for C21H35
35Cl169TmF3N5O6P3Na 830.0681. Found 830.0701. 
 
60. [Ho.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (10 mg, 0.0156 mmol) and Ho(III)Cl3 
(7.1 mg, 0.0187 mmol) to yield an off-white solid (12 mg, 97 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = -108.7 (major), -112.4 (minor); ESI/MS
+ m/z 826.2 [M+Na]+; HRMS 
Calcd for C21H35
35Cl165HoF3N5O6P3Na 826.0642. Found 826.0659. 
 
61. [Gd.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (5 mg, 0.0078 mmol) and Gd(III)Cl3 
(3.5 mg, 0.0094 mmol) to yield an off-white solid (5.8 mg, 94 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = -63.8 (broad); ESI/MS
+ m/z 819.2 [M+Na]+; HRMS Calcd for 
C21H35
35Cl154GdF3N5O6P3Na 815.0547. Found 815.0559. 
 
62. [Eu.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (10 mg, 0.0156 mmol) and Eu(III)Cl3 
(6.9 mg, 0.0187 mmol) to yield an off-white solid (12 mg, 98 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = -58.9 (major), -58.2 (minor); ESI/MS
+ m/z 814.2 [M+Na]+; HRMS Calcd 
for C21H35
35Cl151EuF3N5O6P3Na 812.0537. Found 812.0553. 
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63. [Y.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (5 mg, 0.00831 mmol) and Y(III)Cl3 
(3.8 mg, 0.0124 mmol) to yield an off-white solid (5.7 mg, 95 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = -63.1 (major), -63.0 (minor); ESI/MS
+ m/z 750.2 [M+Na]+; HRMS Calcd 
for C21H35
35ClYF3N5O6P3Na 750.0397. Found 750.0415. 
 
64. [Yb.L6] 
An analogous procedure to that described for [Dy.L6] was followed using (10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)tris(methylene)tris(methylphosphinic acid) (10 mg, 0.0156 mmol) and Er(III)Cl3 
(7.2 mg, 0.0187 mmol) to yield an off-white solid (12 mg, 97 %).  19F NMR (376  MHz, 
D2O, pH 6.5): δ = -41.8 (major), -39.1 (minor); ESI/MS
- m/z 845.1 [M+Cl]-; HRMS Calcd 
for C21H35
35Cl2
170YbF3N5O6P3 843.0482. Found 843.0463. 
 
65. 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 15 
N N
NN
H
O
O
O
O
O
O
 
To a solution of 1,4,7,10-tetraazacyclododecane (2.54 g, 14.7 mmol) and NaHCO3 
(3.72 g, 44.3 mmol) in anhydrous MeCN (50 mL) was added tert-butylbromoacetate 
(6.56 mL, 44.5 mmol) under an atmosphere of argon.  The reaction mixture was stirred 
for 18 h at rt, before being filtered.  The solvent was removed under reduced pressure 
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to give a yellow oil, which was purified by recrystallization from toluene to yield a 
white solid (2.72 g, 36 %), m.p. 178-180°C. 1H NMR (400 MHz, CDCl3): δ = 10.06 (s, 1H, 
NH), 3.37 (s, 4H, CH2CO), 3.28 (s, 2H, CH2CO), 3.09 (br s, 4H, cyclen-CH2), 2.89 (br m, 
12H, cyclen-CH2), 1.45 (s, 27H, 
tBu); ESI/MS+ m/z 515.3 [M+H]+. 
 
66. tert-Butyl-2,2',2''-(10-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
 
A stirred mixture of tert-butyl 2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetate (0.90 g, 1.74 mmol), 3-chloro-2-(chloromethyl)-5-(trifluoromethyl) 
pyridine (0.48 mg, 2.09 mmol), K2CO3 (0.34 g, 2.44 mmol), and KI (ca. 5 mg) in 
anhydrous MeCN (25 mL) was boiled under reflux for 18 h under argon.  The reaction 
mixture was cooled and filtered before the solvent was removed under reduced 
pressure.  The resulting yellow oil was purified by silica gel column chromatography, 
eluting with a gradient starting from 100 % DCM to 6 % MeOH/DCM to yield a yellow 
oil (0.84 g, 68 %).  Rf (10 % MeOH/DCM) = 0.40.  
1H NMR (400 MHz, CDCl3): δ = 8.38 (d, 
J = 2 Hz, 1H, H6), 7.87 (d, J = 2 Hz, 1H, H4), 3.81 (s, 2H, NCH2py), 3.60 – 2.64 (br m, 12H, 
NCH2CO2
tBu/cyclen-CH2), 2.13 (br m, 10H, cyclen-CH2), 1.39 (s, 18H, 
tBu), 1.18 (s, 9H, 
tBu); 13C NMR (101 MHz, CDCl3): δ = 171.8 (CO2
tBu), 159.6 (C2), 141.9 (q, 3JCF = 4 Hz, C
6), 
132.9 (q, 3JCF = 7 Hz, C
4), 130.2 (C3), 125.0 (q, 2JCF = 34 Hz, C
5), 121.5 (q, 1JCF = 273 Hz, 
CF3), 81.1 (C(CH3)3), 55.8 (NCH2CO2
tBu), 54.2 (cyclen-CH2), 52.5 (cyclen-CH2), 26.8 
(C(CH3)3), 26.7 (C(CH3)3); 
19F NMR (376 MHz, CDCl3): δ = -63.4; ESI/MS
+ m/z 730.5 
[M+Na]+; HRMS Calcd for C33H53ClF3N5NaO6 730.3534. Found 730.3530. 
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67. 2,2',2''-(10-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (L7) 
 
tert-Butyl-2,2',2''-(10-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (100 mg, 0.141 mmol) was dissolved in 
HCl (6 M, 10 mL) and stirred for 18 h at 90°C.  The solvent was removed under reduced 
pressure and the residue washed repeatedly with DCM (3 x 5 mL) and the resulting oil 
was dissolved in EtOH. The white precipitate was removed by filtration and the solvent 
removed under reduced pressure to yield the hydrochloride salt as a yellow oil 
(75.5 mg, 99 %).  1H NMR (400 MHz, D2O): δ = 8.53 (s, 1H, H
6), 8.19 (s, 1H, H4), 4.07 
(br s, 2H, NCH2py), 3.75 – 3.25 (br m, 12H, NCH2CO2H/cyclen-CH2), 3.10 (br m, 10H, 
cyclen-CH2); 
19F NMR (376 MHz, D2O): δ = -63.1; ESI/MS
+ m/z 540.3 [M+H]+, ESI/MS- 
m/z 538.3 [M-H]-.  
 
68. [Dy.L7] 
 
Dy(III)Cl3.6H2O (33.5 mg, 8.9 mmol) was added to a solution of 2,2',2''-(10-((3-
chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid (40 mg, 0.074 mmol) dissolved in H2O (5 mL).  The pH was adjusted 
to 5.5 before stirring the solution for 18 h at 40°C.  After this time, the solution was 
allowed to cool to rt before the pH was raised to 10, causing a white solid to 
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precipitate out of solution.  This precipitate was removed by centrifugation and the pH 
of the resulting solution neutralised.  The solvent was removed under reduced 
pressure to give a yellow solid, which was purified by preparative HPLC to yield an 
off-white solid (49 mg, 95 %).  19F NMR (376  MHz, D2O, pH 6.5): δ = -115.9 (major), 
-126.5 (minor); ESI/MS+ m/z 722.8 [M+Na]+; HRMS Calcd for C21H26
35Cl160DyF3N5O6Na 
719.0668. Found 719.0652. 
 
69. [Tm.L7] 
An analogous procedure to that described for [Dy.L7] was followed using 2,2',2''-
(10-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid (30 mg, 0.00556 mmol) and Tm(III)Cl3 (25.6 mg, 0.0667 mmol) 
to yield an off-white solid (38 mg, 97 %).  19F NMR (376  MHz, D2O, pH 6.5): δ = -40.9 
(major), -5.6 (minor); ESI/MS+ m/z 728.7 [M+Na]+; HRMS Calcd for 
C21H26
35Cl169TmF3N5O6Na 706.0939. Found 706.0915. 
 
70. Ethyl methylphosphinate 
H
P
O
O
 
Argon was bubbled through H2O (0.066 mL, 3.67 mmol) for 30 min to deoxygenate it 
and was added dropwise to diethyl methylphosphonite (0.50 g, 3.67 mmol), cooled to 
0°C, before being stirred at rt for 18 h.  The resulting clear, equimolar solution of the 
title compound and ethanol was used without further purification (100 % conversion 
by 1H NMR spectroscopy).  1H NMR (400 MHz, CDCl3): δ = 7.22 (dq, 
1JH-P = 536, 
2JH-H = 2 Hz, 1H, PH), 4.11 (dqd, 
2JH-H = 24, 
3JH-H = 7, 
3JH-P = 4 Hz, 2H, OCH2CH3), 1.54 (dd, 
2JH-P = 15, 
3JH-H = 2 Hz, 3H, PCH3), 1.23 (t, 
3JH-H = 7 Hz, 3H, OCH2CH3); 
13C NMR (101 MHz, 
CDCl3): δ = 62.3 (d, 
2JC-P = 7 Hz, OCH2CH3), 16.1 (OCH2CH3), 14.9 (d, 
1JC-P = 95 Hz, PCH3); 
31P NMR (162 MHz, CDCl3): δ = 34.9; ESI/MS
+ m/z 109.1 [M+H]+, 131.1 [M+Na]+; HRMS 
Calcd for C3H10O2P 109.0414. Found 109.0418. 
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71. 2-Chloro-4-(trifluoromethyl)-6-methylpyridine 
N
CF3
Cl  
6-Methyl-4-trifluoromethyl-2(1H)-pyridone (0.5 g, 2.82 mmol) was dissolved in 
phosphorus oxychloride (15 mL) and the resulting mixture boiled under reflux for 3 h.  
After this time, the excess POCl3 was removed under reduced pressure.  The residue 
was poured onto ice and extracted with DCM (3 x 20 mL).  The organic phases were 
combined and washed with NaHCO3(aq) (0.1 M, 20 mL) and brine (20 mL), before being 
dried over Na2SO4.  The solvent was removed under reduced pressure to yield a 
colourless oil (0.28 g, 51 %).  Rf (2% MeOH/DCM) = 0.86.  
1H NMR (400 MHz, CDCl3): 
δ = 7.30 (s, 1H, H3), 7.23 (s, 1H, H5), 2.55 (s, 3H, CH3); 
13C NMR (101 MHz, CDCl3): 
δ = 161.1 (C6), 151.4 (C2), 141.4 (q, 2JCF = 34 Hz, C
4), 122.0 (q, 1JCF = 274 Hz, CF3), 117.8 
(q, 3JCF = 3 Hz, C
3), 117.6 (q, 3JCF = 4 Hz, C
5), 24.13 (CH3); 
19F NMR (376 MHz, CDCl3): 
δ = -64.8;  ESI/MS+ m/z 195.1 [M+H]+; HRMS Calcd for C7H6ClF3N 196.0136. Found 
196.0141. 
 
72. Ethyl methyl(4-(trifluoromethyl)-6-methylpyridin-2-yl)-2-phosphinate 
N
CF3
P
O
OEt  
2-Chloro-4-(trifluoromethyl)-6-methylpyridine (2.05 g, 10.5 mmol), ethyl 
methylphosphinate (1.59 g, 14.7 mmol, 1:1 EtOH solution), and triethylamine (3 mL) 
were added to dry, degassed toluene (10 mL).  Tetrakis(triphenylphosphine) 
palladium(0) (100 mg, 0.087 mmol) was added and the reaction mixture was degassed 
a further three times before being stirred at 100°C for 18 h under argon.  After this 
time, the solution was diluted with DCM (100 mL) and washed with HCl (1 M, 
2 x 50 mL) and H2O (3 x 50 mL).  The organic phase was dried over K2CO3 and filtered 
before the solvent was removed under reduced pressure.  The resulting yellow oil was 
purified by silica gel column chromatography, eluting with a gradient starting from 
Chapter 6: Experimental 
 
239 
100 % DCM to 2 % MeOH/DCM.  The resulting yellow oil was dissolved in hexane and 
the insoluble white solid filtered to remove excess triphenylphosphine that elutes with 
the product.   The solvent was removed under reduced pressure to yield a clear oil that 
crystallises upon standing (740 mg, 27 %).  Rf (2 % MeOH/DCM) = 0.36.  
1H NMR 
(400 MHz, CDCl3): δ = 8.03 (d, 
4JH-H = 7 Hz, 1H, H
5), 7.46 (dd, 4JH-H = 7, 
3JH-P = 2 Hz, 1H, 
H3), 4.06 (ddq, 1JH-H = 10, 
3JH-P = 8, 
3JH-H = 7 Hz, 1H, OCH2
(A)CH3), 3.81 (ddq, 
3JH-P = 14, 
1JH-H = 10, 
3JH-H = 7 Hz, 1H, OCH2
(B)CH3), 2.64 (s, 3H, py-CH3), 1.73 (d, 
2JH-P = 15 Hz, 3H, 
PCH3), 1.22 (t, 
3JH-H = 7 Hz, 3H, OCH2CH3); 
13C NMR (101 MHz, CDCl3): δ 161.1 (d, 
3JC-P = 20 Hz, C
6), 156.0 (d, 1JC-P = 158 Hz, C
2), 138.7 (qd, 2JC-F = 34, 
3JC-P = 11 Hz, C
4), 
122.6 (qd, 1JCF = 274, 
4JC-P = 3 Hz, CF3), 121.1 (dq, 
4JC-P = 7, 
3JCF = 4 Hz, C
5), 120.3 (dq, 
2JC-P = 23, 
3JCF = 4 Hz, C
3), 61.2 (d, 2JC-P = 7 Hz, OCH2CH3), 24.7 (py-CH3), 16.4 (d, 
3JC-P = 6 Hz, OCH2CH3), 13.3 (d, 
1JC-P = 105 Hz, PCH3); 
19F NMR (376 MHz, CDCl3): 
δ = -64.8; 31P NMR (162 MHz, CDCl3): δ = 38.9; ESI/MS
+ m/z 290.2 [M+Na]+; HRMS 
Calcd for C10H13F3NaNO2P 290.0537. Found 290.0534. 
 
73. 2-(Ethoxy(methyl)phosphoryl)-6-methyl-4-(trifluoromethyl)pyridine 1-oxide 
N+
CF3
P
O
OEt
O-  
m-CPBA (0.81 g, 4.69 mmol) was added to a stirred solution of ethyl methyl(4-
(trifluoromethyl)-6-methylpyridin-2-yl)-2-phosphinate (0.627 g, 2.35 mmol) in 
chloroform (20 mL).  The resulting solution was stirred at 65°C for 18 h under argon 
before being washed with NaHCO3(aq) (0.5 M, 50 mL).  The aqueous layer was extracted 
with DCM (3 x 25 mL).  The organic layers were combined, dried over MgSO4, and the 
solvent removed under reduced pressure to yield a yellow oil (0.63 g, 95 %).  1H NMR 
(400 MHz, CDCl3): δ = 8.07 (dd, 
3JH-P = 8, 
4JH-H = 2 Hz, 1H, H
3), 7.61 (d, 4JH-H = 2 Hz, 1H, 
H5), 4.12 (dq, 1JH-H = 10, 
3JH-P = 7 Hz, 1H, OCH2
(A)CH3), 3.89 (dq, 
1JH-H = 10, 
3JH-P = 7 Hz, 
1H, OCH2
(B)CH3), 2.48 (s, 3H, py-CH3), 1.90 (d, 
2JH-P = 17 Hz, 3H, PCH3), 1.24 (t, 
3JH-H = 7 Hz, 3H, OCH2CH3); 
13C NMR (101 MHz, CDCl3): δ = 150.8 (d, 
3JC-P = 3 Hz, C
6), 
143.5 (d, 1JC-P = 138 Hz, C
2), 127.1 (dq, 4JC-P = 7, 
3JC-F = 4 Hz, C
5), 127.0 (dq, 2JC-P = 7, 
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3JC-F = 4 Hz, C
3), 125.5 (qd, 2JC-F = 36, 
3JC-P = 10 Hz, C
4), 122.3 (q, 1JC-F = 272 Hz, CF3), 62.1 
(d, 2JC-P = 7 Hz, OCH2CH3), 17.5 (py-CH3), 16.3 (d, 
3JC-P = 6 Hz, OCH2CH3), 14.0 (d, 
1JC-P = 112 Hz, PCH3); 
19F NMR (376 MHz, CDCl3): δ = -63.8; 
31P NMR (162 MHz, CDCl3): 
δ = 34.1; ESI/MS+ m/z 306.2 [M+Na]+; HRMS Calcd for C10H13F3NaNO3P 306.0462. 
Found 306.0483. 
 
74. Ethyl-methyl(4-(trifluoromethyl)-6-(hydroxymethyl)pyridin-2-yl)-2-
phosphinate 
N
CF3
P
O
OEt
OH  
Trifluoroacetic anhydride (2 mL) was added to a solution of 2-(ethoxy(methyl) 
phosphoryl)-6-methyl-4-(trifluoromethyl)pyridine 1-oxide (80 mg, 0.282 mmol) in 
CHCl3 (3 mL).  The resulting mixture was heated at 60°C for 3 h under an inert 
atmosphere and the reaction was monitored by 31P NMR spectroscopy and TLC.  Upon 
completion (mixture of alcohol and trifluoroacetate), the mixture was cooled to rt and 
the solvent removed under reduced pressure.  The resulting bright yellow oil was 
stirred in EtOH (5 mL) and H2O (5mL) for 1 h.  After this time the solution was 
concentrated (ca. 2 mL) and extracted with DCM (3 x 10 mL).  The organic layers were 
combined, dried over MgSO4, and the solvent removed in vacuo to give a yellow oil.  
This crude oil was purified by silica gel column chromatography, eluting with a gradient 
starting from 100 % DCM to 5 % MeOH/DCM to yield a yellow oil (56 mg, 70 %).  Rf 
(10 % MeOH/DCM) = 0.50.  1H NMR (400 MHz, CDCl3): δ = 8.09 (d, 
3JH-P = 6 Hz, 1H, H
3), 
7.80 (s, 1H, H5), 4.89 (s, 2H, py-CH2OH), 4.73 (br s, 1H, py-CH2OH), 4.10 (ddq, 
3JH-P = 14, 
1JH-H = 10, 
3JH-H = 7 Hz, 1H, OCH2
(A)CH3), 3.86 (ddq, 
3JH-P = 14, 
1JH-H = 10, 
3JH-H = 7 Hz, 1H, 
OCH2
(B)CH3), 1.77 (d, 
2JH-P = 15 Hz, 3H, PCH3), 1.26 (t, 
3JH-H = 7 Hz, 3H, OCH2CH3); 
13C NMR (176 MHz, CDCl3): δ = 163.9 (d, 
3JC-P = 18 Hz, C
6), 155.1 (d, 1JC-P = 157 Hz, C
2), 
139.2 (qd, 2JC-F = 34, 
3JC-P = 11 Hz, C
4), 122.4 (q, 1JCF = 263 Hz, CF3), 121.3 (d, 
2JC-P = 23 Hz, C
3), 118.6 (C5), 64.5 (py-CH2OH), 61.5 (d, 
2JC-P = 6 Hz, OCH2CH3), 16.3 (d, 
3JC-P = 6 Hz, OCH2CH3), 13.3 (d, 
1JC-P = 105 Hz, PCH3); 
19F NMR (658 MHz, CDCl3): 
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δ = -64.9; 31P NMR (293 MHz, CDCl3): δ = 38.9; ESI/MS
+ m/z 306.3 [M+Na]+; HRMS 
Calcd for C10H14F3NO3P 284.0653. Found 284.0663. 
 
75.  (4-(Trifluoromethyl)-6-phosphono)pyridin-2-yl)methyl methanesulfonate 
N
CF3
P
O
OEt
OMs  
Triethylamine (55 µL, 0.40 mmol) and mesyl chloride (23 µL, 0.30 mmol) were added to 
a solution of ethyl methyl(4-(trifluoromethyl)-6-(hydroxymethyl)pyridin-2-yl)-2-
phosphinate (56 mg, 0.20 mmol) in anhydrous THF (2 mL) cooled to 5°C.  After 
addition, the solution was allowed to reach rt and monitored by TLC.  After stirring for 
15 min, the reaction was complete and the solvent was removed under reduced 
pressure.  The residue was dissolved in brine (10 mL) and extracted with DCM 
(2 x 10 mL).  The organic phases were combined, dried over MgSO4, and the solvent 
removed under reduced pressure to yield a yellow oil (72 mg, 99 %).  1H NMR 
(400 MHz, CDCl3): δ = 8.26 (d, 
3JH-P = 5 Hz, 1H, H
5), 7.81 (s, 1H, H3), 5.45 (s, 2H, 
py-CH2OMs), 4.14 (dqd, 
1JH-H = 14, 
3JH-H = 7 Hz, 
3JH-P = 3 Hz, 1H, OCH2
(A)CH3), 3.89 (dq, 
1JH-H = 14, 
3JH-H = 7, 1H, OCH2
(B)CH3), 3.17 (s, 3H, SCH3), 1.81 (d, 
2JH-P = 15 Hz, 3H, PCH3), 
1.29 (t, 3JH-H = 7 Hz, 3H, OCH2CH3); 
19F NMR (376 MHz, CDCl3): δ = -65.1; 
31P NMR 
(162 MHz, CDCl3): δ = 39.3; ESI/MS
+ m/z 362.2 [M+H]+, 385.2 [M+Na]+; HRMS Calcd for 
C11H15F3NaNO3PS 384.0261. Found 384.0258. 
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76. Ethyl-6-((1,4,7,10-tetraazacyclododecan-1-yl)methyl)-4-(trifluoromethyl) 
pyridin-2-yl(methyl)phosphinate 
N N
NN
H
HH
N
CF3
P OEt
O  
(4-(Trifluoromethyl)-6-phosphono)pyridin-2-yl)methyl methanesulfonate (72 mg, 
0.20 mmol) was added dropwise to a stirred solution of 1,4,7,10-
tetraazacyclododecane (340 mg, 1.98 mmol) in anhydrous MeCN (5 mL) at 40°C under 
argon.  After 12 h, the solvent was removed under reduced pressure and the residue 
dissolved in DCM (10 mL).  The solution was washed repeatedly with H2O (4 x 10 mL), 
dried over MgSO4, and the solvent removed under reduced pressure to yield a light 
yellow oil (79 mg, 90 %).  1H NMR (400 MHz, CDCl3): δ = 8.14 (d, 
3JH-P = 6 Hz, 1H, H
3), 
7.86 (s, 1H, H5), 4.12 (m, 1H, OCH2
(A)CH3), 3.92 (s, 2H, py-CH2), 3.86 (m, 1H, OCH2
(B)CH3), 
2.81 (br m, 4H, cyclen-CH2), 2.68 (br s, 8H, cyclen-CH2), 2.57 (br m, 4H, cyclen-CH2), 
1.79 (d, 2JH-P = 15 Hz, 3H, PCH3), 1.27 (t, 
3JH-H = 7 Hz, 3H, OCH2CH3); 
13C NMR (101 MHz, 
CDCl3): δ = 162.9 (d, 
3JC-P = 19 Hz, C
6), 156.0 (d, 1JC-P = 157 Hz, C
2), 139.2 (qd, 2JC-F = 34, 
3JC-P = 11 Hz, C
4), 122.8 (q, 1JC-F = 274 Hz, CF3), 121.8 (m, C
3), 121.1 (m, C5), 61.5 (d, 
2JC-P = 7 Hz, OCH2CH3), 60.7 (py-CH2), 52.10 (cyclen-CH2), 47.43 (cyclen-CH2), 46.49 
(cyclen-CH2), 45.57 (cyclen-CH2), 16.6 (d, 
3JC-P = 6 Hz, OCH2CH3), 13.6 (d, 
1JC-P = 105 Hz, 
PCH3); 
19F NMR (376 MHz, CDCl3): δ = -64.7; 
31P NMR (162 MHz, CDCl3): δ = 39.0; 
ESI/MS+ m/z 438.2 [M+H]+; HRMS Calcd for C18H32F3N5O2P 438.2238. Found 438.2240. 
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77. Triethyl (10-((6-(ethoxy(methyl)phosphoryl)-4-(trifluoromethyl)pyridin-2-yl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tris(methylene)tris 
(methylphosphinate) 
N N
NN
N
P OEt
O
P
EtO
O
PEtO
O
P
CF3
OEt
O
 
Ethyl 6-((1,4,7,10-tetraazacyclododecan-1-yl)methyl)-4-(trifluoromethyl)pyridin-2-
yl(methyl)phosphinate (114 mg, 0.261 mmol) was heated to 80°C in anhydrous THF 
under argon. Paraformaldehyde (110 mg, 3.67 mmol) followed by 
diethoxymethylphosphine (500 mg, 0.367 mmol) were added. The solution was boiled 
under reflux over molecular sieves for 15 h.  After this time, excess paraformaldehyde 
was removed by filtration and the solvent removed under reduced pressure. The 
resulting orange oil was purified by mixed alumina/silica (4:1) gel column 
chromatography, eluting with a gradient starting from 100 % DCM to 8 % MeOH/DCM, 
to yield a yellow oil (141 mg, 68 %) as a mixture of diastereoisomers; 1H NMR 
(400 MHz, CDCl3): δ = 8.11 (d, 
3JHP = 6 Hz, 1H, H
5), 8.03 (s, 1H, H3), 4.74 (s, 2H, NCH2py), 
4.07 (br m, 8H, POCH2CH3/NCH2P), 3.81 (m, 6H, POCH2CH3/NCH2P), 3.42 (br s, 2H, 
cyclen-CH2), 3.05 (br m, 6H, cyclen-CH2), 2.76 (br s, 8H, cyclen-CH2), 1.78 (d, 
2JH-P = 15 Hz, 3H, pyPCH3), 1.68 – 1.40 (br m, 12H, POCH2CH3), 1.39 – 1.15 (br m, 12H, 
POCH2CH3); 
19F NMR (376 MHz, CDCl3): δ = -64.8; 
31P NMR (162 MHz, CDCl3): δ = 59.0, 
53.1; ESI/MS+ m/z 798.6 [M+H]+; HRMS Calcd for C30H59F3N5O8P4 798.3266. Found 
798.3248. 
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78.  (10-((6-(Methyl) phosphinic acid-4-(trifluoromethyl)pyridin-2-yl)methyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tris(methylene)tris 
(methylphosphinic acid) (L8) 
 
N N
NN
N
P
O
HO
P
O OH
P
O
OH
P
CF3
OH
O
 
Triethyl (10-((6-(ethoxy(methyl)phosphoryl)-4-(trifluoromethyl)pyridin-2-yl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)tris(methylene)tris(methylphosphinate) (54 mg, 
0.068 mmol) was dissolved in HCl (6 M, 5 mL) and stirred for 18 h at 90°C.  The solvent 
was removed under reduced pressure and the residue washed repeatedly with DCM 
(3 x 5 mL) before the resulting oil was dissolved in EtOH. The white precipitate was 
removed by filtration and the solvent removed under reduced pressure to yield the 
trihydrochloride salt of L8 as a yellow oil (46 mg, 99 %).  1H NMR (400 MHz, D2O): 
δ = 8.02 (d, 3JHP = 5 Hz, 1H, H
5), 7.89 (s, 1H, H3), 3.64 (s, 2H, NCH2py), 3.45 (br m, 10H, 
NCH2P/cyclen-CH2), 3.10 (br m, 12H, cyclen-CH2), 1.51 (d, 
2JHP = 15 Hz, 3H, PCH3), 1.34 
(d, 2JHP = 14 Hz, 9H, PCH3); 
19F NMR (376 MHz, D2O): δ = -65.3; 
31P NMR (162 MHz, 
CDCl3): δ = 53.1; ESI/MS
+ m/z 686.3 [M+H]+, ESI/MS- m/z 684.4 [M-H]-. 
 
79. [Dy.L8]- 
N N
NN
P O
P
O
PO
N
P
O
O
CF3
O
O
O
Dy
 
Dy(III)Cl3.6H2O (38 mg, 0.101 mmol) was added to a solution of (10-((6-
(methyl)phosphinic acid-4-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclo- 
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dodecane-1,4,7-triyl)tris(methylene)tris(methylphosphinic acid) (46 mg, 0.067 mmol) 
dissolved in H2O (3 mL).  The pH was adjusted to 5.5 before stirring the solution for 
18 h at 40°C.  After this time, the solution was allowed to cool to rt before the pH was 
raised to 10, causing a white solid to precipitate out of solution.  This precipitate was 
removed by centrifugation and the pH of the resulting solution neutralised.  The 
solvent was removed under reduced pressure to give a yellow solid, which was purified 
by preparative scale RP-HPLC to yield an off-white solid (51 mg, 90 %); 19F NMR 
(376 MHz, D2O, pH 6.5): δ = -67.0; ESI/MS
- m/z 844.2 [M]-; HRMS Calcd for 
C22H38
160DyF3N5O8P4 841.0869. Found 841.0892. 
 
80. [Er.L8] 
N N
NN
P O
P
O
PO
N
P
O
O
CF3
O
O
O
Er
 
An analogous procedure to that described for [Dy.L8] was followed using (10-((6-
(methyl)phosphinic acid-4-(trifluoromethyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclo-
dodecane-1,4,7-triyl)tris(methylene)tris(methylphosphinic acid) (69 mg, 0.110 mmol) 
and Er(III)Cl3 (63 mg, 0.164 mmol) to yield an off-white solid (82 mg, 88 %); 
19F NMR 
(376  MHz, D2O, pH 6.5): δ = -61.3; ESI/MS
- m/z 847.2 [M]-; HRMS Calcd for 
C22H38
164ErF3N5O8P4 845.0909. Found 845.0932. 
 
81. 5-tert-Butyl-2-methylpyridine 
 
Copper(I) cyanide (10 mg) was added to anhydrous THF (50 mL) and the resulting 
suspension cooled to -78°C. To this was added tert-butylmagnesium chloride (14.5 mL, 
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2.0 M solution in diethyl ether, 29.1 mmol) and the mixture was maintained at -78°C 
and stirred for 20 min under an atmosphere of argon. After this time, 5-bromo-2-
methylpyridine (2.5 g, 14.5 mmol) was added.  The reaction was stirred for 3 h at -78°C 
before being allowed to warm to rt and stirred for a further 18 h.  Upon completion of 
the reaction (followed by TLC), sat. NH4OH(aq) was added dropwise to quench any 
excess Grignard reagent remaining in solution. This immediately caused the formation 
of a white precipitate in a brown solution, transforming into a clear solution containing 
a dark brown precipitate upon further addition. This mixture was then extracted with 
diethyl ether (3 x 50 mL) to obtain a colourless organic layer, separated from the deep 
blue aqueous layer. The organic layers were combined, dried over MgSO4, and the 
solvent removed under reduced pressure to yield a partially volatile yellow liquid that 
was used without any further purification (1.42 g, 66 %). Rf (50 % ethyl 
acetate/hexane) = 0.35. 1H NMR (400 MHz, CDCl3): δ = 8.31 (d, J = 2 Hz, 1H, H
6), 7.63 
(dd, J = 8, 2 Hz, 1H, H4), 7.10 (d, J = 8 Hz, 1H, H3), 2.39 (s, 3H, Me), 1.24 (s, 9H, tBu); 
13C NMR (101 MHz, CDCl3): δ = 157.6 (C
2), 148.0 (C6), 146.5 (C5), 137.4 (C4), 126.1 (C3), 
36.2 (C(CH3)3), 33.2 (C(CH3)), 23.6 (CH3); ESI/MS
+ m/z 150.2 [M+H]+; HRMS Calcd for 
C10H16N 150.1283. Found 150.1279. 
 
82. 5-tert-Butyl-2-methylpyridine 1-oxide 
 
m-CPBA (2.17 g, 12.6 mmol) was added to a stirred solution of 5-tert-butyl-2-
methylpyridine (1.25 g, 8.39 mmol) in chloroform (30 mL).  The resulting solution was 
stirred at rt for 18 h under argon before being quenched with sat. Na2SO4(aq) (10 mL) 
and stirred for 10 min.  The organic layer was extracted and washed with sat. 
NaHCO3(aq) (30 mL).  The aqueous layer was extracted with ethyl acetate (3 x 25 mL).  
All organic layers were combined, dried over Na2SO4, and the solvent removed under 
reduced pressure.  The resulting yellow liquid was purified by silica gel column 
chromatography, eluting with a gradient starting from 100 % DCM to 5 % MeOH/DCM 
Chapter 6: Experimental 
 
247 
to yield a yellow liquid (0.51 g, 37 %). Rf (10 % MeOH/DCM) = 0.39. 
1H NMR (400 MHz, 
CDCl3): δ = 8.32 (d, J = 2 Hz, 1H, H
6), 7.21 (dd, J = 8, 2 Hz, 1H, H4), 7.18 (d, J = 8 Hz, 1H, 
H3), 2.50 (s, 3H, Me), 1.31 (s, 9H, tBu); 13C NMR (101 MHz, CDCl3): δ = 147.4 (C
2), 145.7 
(C6), 137.4 (C5), 125.7 (C3), 123.7 (C4), 33.6 (C(CH)3), 30.6 (C(CH)3), 17.3 (CH3); ESI/MS
+ 
m/z 166.2 [M+H]+; HRMS Calcd for C10H16NO 166.1232. Found 166.1268. 
 
83.  (5-tert-Butylpyridin-2-yl)methanol 
 
Trifluoroacetic anhydride (10 mL) was added to a solution of 5-tert-butyl-2-
methylpyridine 1-oxide (450 mg, 2.73 mmol) in CHCl3 (15 mL).  The resulting mixture 
was heated at 60°C for 36 h under an inert atmosphere. After this time, the solvent 
was removed under reduced pressure and completion of reaction to the 
trifluoroacetate intermediate was confirmed by 1H NMR analysis. The resulting bright 
yellow oil was stirred in a mixture of EtOH (5 mL) and H2O (5mL) for 1 h to convert the 
trifluoroacetate intermediate into the desired alcohol.  The solution was concentrated 
(ca. 2 mL) and extracted with ethyl acetate (3 x 10 mL).  The organic layers were 
combined, dried over MgSO4, and the solvent removed under reduced pressure to 
yield a dark yellow oil (396 mg, 88 %). Rf (10 % MeOH/DCM) = 0.42. 
1H NMR (400 MHz, 
CDCl3): δ = 8.57 (s, 1H, H
6), 7.71 (d, J = 8 Hz, 1H, H4), 7.18 (d, J = 8 Hz, 1H, H3), 4.77 (s, 
2H, CH2OH), 1.34 (s, 9H, 
tBu); 13C NMR (101 MHz, CDCl3): δ = 153.4 (C
2), 148.5 (C6), 
141.6 (C5), 137.8 (C3), 123.7 (C4), 59.5 (CH2OH), 33.4 (C(CH)3), 29.5 (C(CH)3); ESI/MS
+ 
m/z 166.2 [M+H]+; HRMS Calcd for C10H16NO 166.1232. Found 166.1248. 
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84. (5-tert-Butylpyridin-2-yl)methyl methanesulfonate 
 
(5-tert-Butylpyridin-2-yl)methanol (396 mg, 2.40 mmol) was dissolved in THF (10 mL) 
and cooled to 5°C.  Triethylamine (0.67 mL, 4.79 mmol) and mesyl chloride (0.28 mL, 
3.60 mmol) were added dropwise to this solution, upon which a white solid 
precipitated out of solution.  Once addition was complete, the reaction mixture was 
allowed to warm to rt and stirred for 2 h, before the solvent was removed under 
reduced pressure.  During this time, the reaction was monitored by TLC to ensure that 
complete conversion to the mesylate had occurred.  The residue was treated with 
brine (10 mL) and extracted with DCM (2 x 10 mL).  The organic layers were combined, 
dried over MgSO4, and the solvent removed under reduced pressure to yield an orange 
oil, which was used immediately (530 mg, 91 %).  Rf (10 % MeOH/DCM) = 0.76. 
1H NMR 
(400 MHz, CDCl3): δ = 8.68 (d, J = 2 Hz, 1H, H
6), 7.89 (dd, J = 8, 2 Hz, 1H, H4), 7.52 (d, 
J = 8 Hz, 1H, H3), 5.39 (s, 2H, CH2OMs), 3.12 (s, 3H, SO2CH3), 1.37 (s, 9H, 
tBu);  ESI/MS+ 
m/z 244.2 [M+H]+. 
 
85. tert-Butyl-2,2',2''-(10-((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate 
 
A stirred mixture of tert-butyl 2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetate (DO3A) (19 mg, 0.038 mmol), (5-tert-butylpyridin-2-yl)methyl 
methanesulfonate (11 mg, 0.045 mmol), and K2CO3 (9 mg, 0.065 mmol) in anhydrous 
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MeCN (5 mL) was heated at 60°C for 18 h under argon.  After this time, the reaction 
mixture was cooled and filtered before the solvent was removed under reduced 
pressure.  The resulting yellow oil was purified by silica gel column chromatography, 
eluting with a gradient starting from 100 % DCM to 3 % MeOH/DCM to yield a pale 
yellow oil (18 mg, 71 %).  Rf (10 % MeOH/DCM) = 0.40. 
1H NMR (400 MHz, CDCl3): 
δ = 8.28 (d, J = 3 Hz, 1H, H6), 7.65 (dd, J = 8, 3 Hz, 1H, H4), 7.09 (d, J = 8 Hz, 1H, H3), 3.07 
(br m, 12H, NCH2COO
tBu/cyclen-CH2/NCH2py), 2.31 (br m, 12H, NCH2COO
tBu/cyclen-
CH2/NCH2py), 1.49 (s, 9H, py-C(CH3)3), 1.39 (br s, 18H, COOC(CH3)3), 1.29 (s, 9H, 
COOC(CH3)3); 
13C NMR (101 MHz, CDCl3): δ = 172.7 (COO
tBu), 155.8 (C2), 145.8 (C6), 
144.2 (C5), 133.7 (C3), 122.0 (C4), 81.8 (COOC(CH3)3), 58.3 (CH2), 55.4 (CH2), 33.3 
(pyC(CH3)3), 31.0 (pyC(CH3)3), 27.9 (COOC(CH3)3); ESI/MS
+ m/z 662.6 [M+H]+, 684.6 
[M+Na]+; HRMS Calcd for C36H64N5O6 662.4857. Found 662.4852. 
 
86. 2,2',2''-(10-((5-tert-Butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid (L9) 
 
tert-Butyl-2,2',2''-(10-((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclo-
dodecane-1,4,7-triyl)triacetate (15 mg, 0.02 mmol) was dissolved in DCM (1 mL) with 
stirring.  To this was added TFA (1 mL) and the mixture stirred at rt for 18 h.  After this 
time, the solvent was removed under reduced pressure to give a yellow oil.  This 
yellow oil was repeatedly washed with DCM to yield the triflate salt of L9 as a pale 
yellow oil (11 mg, 99 %). 1H NMR (400 MHz, D2O): δ = 8.57 (d, J = 2 Hz, 1H, H
6), 8.40 
(dd, J = 8, 2 Hz, 1H, H4), 7.85 (d, J = 8 Hz, 1H, H3), 3.97 (br s, 2H, NCH2COO
tBu/cyclen-
CH2/NCH2py), 3.72 (br m, 2H, NCH2COO
tBu/cyclen-CH2/NCH2py), 3.50 (br m, 4H, NCH2-
COOtBu/cyclen-CH2/NCH2py), 3.32 (br m, 6H, NCH2COO
tBu/cyclen-CH2/NCH2py), 3.21 
(br m, 2H, NCH2COO
tBu/cyclen-CH2/NCH2py), 2.94 (br m, 4H, NCH2COO
tBu/cyclen-
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CH2/NCH2py), 2.78 (br m, 4H, NCH2COO
tBu/cyclen-CH2/NCH2py), 1.22 (s, 9H, C(CH3)3); 
ESI/MS+ m/z 494.4 [M+H]+, 517.4 [M+Na]+; HRMS Calcd for C24H40N5O6 494.2979. 
Found 494.2970. 
 
87. [Dy.L9] 
 
Dy(III)Cl3.6H2O (4.6 mg, 0.012 mmol) was added to a stirred solution of 2,2',2''-(10-((5-
tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid 
(5.0 mg, 0.010 mmol) in water (2 mL) and the pH adjusted to 5.5 using NaOH(aq).  The 
reaction was left stirring at 50°C overnight.  After cooling to rt, the pH was increased to 
10 and precipitated metal hydroxide removed by centrifugation.  The pH was lowered 
back to 5.5, before the solvent was removed under reduced pressure and the residue 
taken up into ethanol.  Any remaining metal hydroxide precipitate and other insoluble 
material was again removed by centrifugation.  The solvent was removed under 
reduced pressure to yield a white solid (6.3 mg, 97 %).  1H NMR (400 MHz, D2O, 
pD 6.5): δ = -20.5 (tBu); ESI/MS+ m/z 654.3 [M+H]+; HRMS Calcd for C24H36
160DyN5NaO6 
673.1815. Found 673.1824. 
 
88. [Tm.L9] 
An analogous procedure to that described for the synthesis of [Dy.L9] was followed 
using 2,2',2''-(10-((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid (4.0 mg, 0.0081 mmol) and Tm(III)Cl3.6H2O (3.7 mg, 
0.0097 mmol) to give a white solid (5.2 mg, 98 %).  1H NMR (400 MHz, D2O, pD 6.5): 
δ = + 10.8 (tBu); ESI/MS+ m/z 682.3 [M+Na]+; HRMS Calcd for C24H36TmN5NaO6 
682.1906. Found 682.1880. 
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89. tert-Butyl 2,2'-(4,10-bis((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate 
N N
NN
O
O
O
O
N
N
 
(5-tert-Butylpyridin-2-yl)methyl methanesulfonate (530 mg, 2.18 mmol) and (7-tert-
butoxycarbonylmethyl-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid tert-butyl ester 
(DO2A) (874 mg, 2.18 mmol) were dissolved in anhydrous MeCN (15 mL) under an 
atmosphere of argon.  To this was added Na2CO3 (231 mg, 2.18 mmol) and the reaction 
mixture stirred at 50°C for 48 h.  During this time, the reaction was monitored by TLC 
to ensure complete consumption of the mesylate starting material had occured.  Upon 
completion, the reaction mixture was filtered before the solvent was removed under 
reduced pressure.  The resulting orange oil was purified by silica gel column 
chromatography, eluting with a gradient starting from 100 % DCM to 10 % MeOH/DCM 
to yield a yellow-orange sticky solid (284 mg, 19 %).  Rf (15 % MeOH/DCM) = 0.68.  
1H NMR (600 MHz, CDCl3): δ = 8.36 (d, J = 2 Hz, 2H, H
6), 7.63 (dd, J = 8, 2 Hz, 2H, H4), 
7.07 (d, J = 8 Hz, 2H, H3), 3.68 (br s, 4H, NCH2py), 2.76 (br m, 10H, NCH2CO2
tBu/cyclen-
CH2), 2.37 (br m, 8H, cyclen-CH2), 2.14 (br s, 2H, cyclen-CH2), 1.27 (s, 18H, 
tBu), 1.23 (s, 
18H, tBu); 13C NMR (151 MHz, CDCl3): δ = 172.0 (COO
tBu), 155.1 (C2), 146.0 (C6), 144.5 
(C5), 133.7 (C4), 122.1 (C3), 81.7 (CO2C(CH3)3), 58.1 (NCH2py), 57.2 (NCH2CO2
tBu), 53.4 
(cyclen-CH2), 50.3 (cyclen-CH2), 33.3 (pyC(CH3)3), 31.0 (pyC(CH3)3), 27.9 (CO2C(CH3)3); 
ESI/MS+ m/z 696.1 [M+H]+; HRMS Calcd for C40H67N6O4 695.5224. Found 695.5197. 
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90. 2,2'-(4,10-Bis((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetic acid (L10) 
N N
NN
O
OH
O
HO
N
N
 
tert-Butyl-2,2'-(4,10-bis((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclo-
dodecane-1,7-diyl)diacetate (18.3 mg, 0.026 mmol) was dissolved in HCl (6 M, 3 mL) 
and stirred for 18 h at 90°C.  The solvent was removed under reduced pressure and the 
residue washed repeatedly with DCM (3 x 5 mL), before being dissolved in EtOH. The 
resulting white precipitate was removed by filtration and the solvent removed under 
reduced pressure to yield the hydrochloride salt as a pale yellow gum (12.7 mg, 84 %).  
1H NMR (400 MHz, D2O): δ = 8.73 (d, J = 2 Hz, 2H, H
6), 8.51 (dd, J = 8, 2 Hz, 2H, H4), 7.89 
(d, J = 8 Hz, 2H, H3), 3.81 (br s, 4H, NCH2py), 3.46 (br s, 4H, NCH2CO2
tBu), 3.35 (br s, 4H, 
cyclen-CH2), 3.17 (br s, 4H, cyclen-CH2), 2.99 (br s, 4H, cyclen-CH2), 2.74 (br m, 4H, 
cyclen-CH2), 1.27 (s, 18H, 
tBu); ESI/MS+ m/z 583.9 [M+H]+.  
 
91. [Dy.L10]+ 
N N
NN
O
N
O
O
O
Dy
N
 
Dy(III)Cl3.6H2O (19 mg, 0.052 mmol) was added to a stirred solution of 2,2'-(4,10-bis((5-
tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetic acid 
(25 mg, 0.043 mmol) in water (2 mL) and the pH adjusted to 5.5 using NaOH(aq).  The 
reaction was left stirring at 50°C overnight.  After cooling to rt, the pH was increased to 
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10 and precipitated metal hydroxide removed by centrifugation.  The pH was lowered 
back to 5.5, before the solvent was removed under reduced pressure and the residue 
taken up into ethanol.  Any remaining metal hydroxide precipitate and other insoluble 
material was again removed by centrifugation.  The solvent was removed under 
reduced pressure to yield a white solid (30.5 mg, 96 %).  1H NMR (400 MHz, D2O, 
pD 6.5): δ = - 17.8 (tBu); ESI/MS+ m/z 744.9 [M]+; HRMS Calcd for C32H48
160DyN6O4 
740.2989. Found 740.2997. 
 
92. [Tm.L10]+ 
An analogous procedure to that described for the synthesis of [Dy.L10]+ was followed 
using 2,2'-(4,10-bis((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,7-diyl)diacetic acid (10.5 mg, 0.019 mmol) and Tm(III)Cl3.6H2O (8.7 mg, 0.023 mmol) 
to give a white solid (13.5 mg, 95 %).  1H NMR (400 MHz, D2O, pD 6.5): δ = + 6.2 (
tBu); 
ESI/MS+ m/z 750.0 [M]+; HRMS Calcd for C32H48TmN6O4 749.3079. Found 749.3100. 
 
93. [Tb.L10]+ 
An analogous procedure to that described for the synthesis of [Dy.L10]+ was followed 
using 2,2'-(4,10-bis((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,7-diyl)diacetic acid (20 mg, 0.034 mmol) and Tb(III)Cl3.6H2O (15 mg, 0.041 mmol) to 
give a white solid (24 mg, 97 %).  1H NMR (400 MHz, D2O, pD 6.5): δ = - 7.2 (
tBu); 
ESI/MS+ m/z 739.9 [M]+; HRMS Calcd for C32H48TbN6O4 739.2991. Found 739.2985. 
 
94. [Gd.L10]+ 
An analogous procedure to that described for the synthesis of [Dy.L10]+ was followed 
using 2,2'-(4,10-bis((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-
1,7-diyl)diacetic acid (12.7 mg, 0.022 mmol) and Gd(III)Cl3.6H2O (9.7 mg, 0.026 mmol) 
to give a white solid (16 mg, 98 %).  ESI/MS+ m/z 738.9 [M]+; HRMS Calcd for 
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C32H48
154GdN6O4 734.2946. Found 734.2935. r1p = 5.21 mM
-1s-1 (H2O, 0.1 M NaCl, 
60 MHz, 310 K). 
95. tert-Butyl-2,2'-(4-((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate 
 
(5-tert-Butylpyridin-2-yl)methyl methanesulfonate (530 mg, 2.18 mmol) and (7-tert-
butoxycarbonylmethyl-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid tert-butyl ester 
(DO2A) (874 mg, 2.18 mmol) were dissolved in anhydrous MeCN (15 mL) under an 
atmosphere of argon.  To this was added Na2CO3 (231 mg, 2.18 mmol) and the reaction 
mixture stirred at 50°C for 48 h.  During this time, the reaction was monitored by TLC 
to ensure complete consumption of the mesylate starting material had occured.  Upon 
completion, the reaction mixture was then filtered before the solvent was removed 
under reduced pressure.  The resulting orange oil was purified by silica gel column 
chromatography, eluting with a gradient starting from 100 % DCM to 10 % MeOH/DCM 
to yield a yellow sticky solid (470 mg, 37 %).  Rf (15 % MeOH/DCM) = 0.56.  
1H NMR 
(600 MHz, CDCl3): δ = 8.82 (d, J = 2 Hz, 1H, H
6), 7.60 (dd, J = 8, 2 Hz, 1H, H4), 7.14 (d, 
J = 8 Hz, 1H, H3), 3.65 (s, 2H, NCH2py), 3.07 (s, 12H, NCH2COO/cyclen-CH2), 2.78 (br m, 
4H, cyclen-CH2), 2.57 (br s, 4H, cyclen-CH2), 1.38 (s, 18H, COOC(CH3)3), 1.32 (s, 9H, 
pyC(CH3)3); 
13C NMR (151 MHz, CDCl3): δ = 170.5 (COO
tBu), 154.2 (C2), 147.8 (C6), 145.0 
(C5), 133.3 (C4), 123.2 (C3), 81.3 (COOC(CH3)3), 56.6 (NCH2py), 54.0 (NCH2COO), 53.4 
(cyclen-CH2), 50.6 (cyclen-CH2), 50.3 (cyclen-CH2), 46.6 (cyclen-CH2), 33.5 (pyC(CH3)3), 
31.0 (pyC(CH3)3), 28.1 (COOC(CH3)3); ESI/MS
+ m/z 549.0 [M+H]+, 576.9 [M+Na]+; HRMS 
Calcd for C30H54N5O4 548.4176. Found 548.4176. 
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96. tert-Butyl 2,2'-(4-((5-tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido) 
ethyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate 
N N
NN
O
O
O
O
N
H
S
O
O
N
 
A solution of tert-butyl-2,2'-(4-((5-tert-butylpyridin-2-yl)methyl)-1,4,7,10-tetraaza-
cyclododecane-1,7-diyl)diacetate (110 mg, 0.201 mmol), 2-methanesulphonate-N-
methanesulphonylethylamine (44 mg, 0.201 mmol), and K2CO3 (56 mg, 0.402 mmol) in 
anhydrous MeCN (10 mL) were heated at 80°C for 18 h, before the solution was cooled 
to rt and filtered.  The solvent was removed under reduced pressure to produce a 
yellow-brown oil that was purified by silica gel column chromatography, eluting with a 
gradient starting from 100 % DCM to 7 % MeOH/DCM to yield a yellow sticky solid 
(86 mg, 64 %).  1H NMR (600 MHz, CDCl3): δ = 8.66 (d, J = 2 Hz, 1H, H
6), 7.60 (dd, J = 8, 
2 Hz, 1H, H4), 7.02 (d, J = 8 Hz, 1H, H3), 3.62 (s, 2H, NCH2py), 3.32 (m, 2H, 
CH2CH2NHSO2), 3.15 (br m, 4H, NCH2COO), 2.99 (s, 3H, SO2CH3), 2.78 (br m, 6H, 
NCH2CH2NHSO2/cyclen-CH2), 2.50 (br m, 10H, cyclen-CH2), 1.35 (s, 18H, COOC(CH3)3), 
1.30 (s, 9H, pyC(CH3)3); 
13C NMR (151 MHz, CDCl3): δ = 172.1 (COO
tBu), 154.3 (C2), 147.7 
(C6), 144.9 (C5), 133.6 (C4), 122.0 (C3), 82.2 (COOC(CH3)3), 58.6 (NCH2py), 56.7 
(NCH2COO), 53.6 (cyclen-CH2), 53.4 (cyclen-CH2), 50.3 (br m, cyclen-CH2), 40.3 
(NCH2CH2NHSO2), 38.7 (SO2CH3/ NCH2CH2NHSO2), 33.5 (pyC(CH3)3), 30.9 (pyC(CH3)3), 28.1 
(COOC(CH3)3); ESI/MS
+ m/z 670.0 [M+H]+; HRMS Calcd for C33H61N6O6S 669.4373. 
Found 669.4362. 
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97. 2,2'-(4-((5-tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido)ethyl)-
1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetic acid (L13) 
N N
NN
HO
O
OH
O
N
H
S
O
O
N
 
tert-Butyl 2,2'-(4-((5-tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido)ethyl)-
1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (45 mg, 0.67 mmol) was dissolved in 
DCM (3 mL) with stirring.  To this was added TFA (1 mL) and the mixture stirred at rt 
for 18 h.  After this time, the solvent was removed under reduced pressure to give a 
yellow oil, which was repeatedly washed with DCM to yield a pale yellow oil (37 mg, 
98 %). 1H NMR (600 MHz, D2O): δ = 8.63 (d, J = 2 Hz, 1H, H
6), 8.43 (dd, J = 8, 2 Hz, 1H, 
H4), 7.87 (d, J = 8 Hz, 1H, H3), 3.94 (s, 2H, NCH2py), 3.70 (br m, 2H, NCH2COO), 3.50 
(br s, 2H, NCH2COO), 3.43 (br m, 4H, cyclen-CH2), 3.30 (br m, 6H, cyclen-CH2), 3.15 (m, 
2H, CH2CH2NHSO2), 3.03 (br m, 2H, cyclen-CH2), 2.96 (m, 2H, NCH2CH2NHSO2), 2.94 (s, 
3H, SO2CH3), 2.79 (br m, 2H, cyclen-CH2), 2.72 (br m, 2H, cyclen-CH2), 1.22 (s, 9H, 
pyC(CH3)3); ESI/MS
+ m/z 557.8 [M+H]+. 
 
98. [Dy.L11] 
N N
NN
O
O
O
O
NDyN
S
O
O
 
Dy(III)Cl3.6H2O (8.5 mg, 0.0226 mmol) was added to a stirred solution of 2,2'-(4-
((5-tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido)ethyl)-1,4,7,10-tetraaza-
cyclododecane-1,7-diyl)diacetic acid (10.5 mg, 0.0189 mmol) in water (2 mL) and the 
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pH adjusted to 5.5 using NaOH(aq).  The reaction was left stirring at 50°C overnight.  
After cooling to rt, the pH was increased to 10 and precipitated metal hydroxide 
removed by centrifugation.  The pH was lowered back to 5.5, before the solvent was 
removed under reduced pressure and the residue taken up into ethanol.  Any 
remaining metal hydroxide precipitate and other insoluble material was again 
removed by centrifugation.  The solvent was removed under reduced pressure to yield 
a white solid (13 mg, 97 %).  1H NMR (400  MHz, D2O, pD 6.5): δ = - 58.9 (
tBu); ESI/MS+ 
m/z 740.8 [M-H+Na]+; HRMS Calcd for C25H41
160DyN6O6SNa 736.1958. Found 736.1945. 
 
99. [Tb.L11] 
An analogous procedure to that described for [Dy.L11] was followed using 2,2'-(4-((5-
tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido)ethyl)-1,4,7,10-tetraaza-
cyclododecane-1,7-diyl)diacetic acid (10.5 mg, 0.019 mmol) and Tb(III)Cl3.6H2O 
(8.6 mg, 0.023 mmol) to give a white solid (12.7 mg, 94 %).  1H NMR (400  MHz, D2O, 
pD 6.5): δ = -55.8 (tBu); ESI/MS+ m/z 735.8 [M-H+Na]+; HRMS Calcd for 
C25H41
159TbN6O6SNa 735.1960. Found 735.1951. 
 
100. [Eu.L11] 
An analogous procedure to that described for [Dy.L11] was followed using 2,2'-(4-((5-
tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido)ethyl)-1,4,7,10-tetraaza-
cyclododecane-1,7-diyl)diacetic acid (3.7 mg, 6.58 µmol) and Eu(III)Cl3.6H2O (3.1 mg, 
8.56 µmol) to give a white solid (4.4 mg, 95 %). ESI/MS+ m/z 707.2 [M]+; HRMS Calcd 
for C25H42
151EuN6O6S 705.2085. Found 705.2076. 
 
101. [Gd.L11] 
An analogous procedure to that described for [Dy.L11] was followed using 2,2'-(4-((5-
tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido)ethyl)-1,4,7,10-tetraaza-
cyclododecane-1,7-diyl)diacetic acid (3.8 mg, 6.83 µmol) and Gd(III)Cl3.6H2O (3.0 mg, 
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8.19 µmol) to give a white solid (4.6 mg, 98 %). ESI/MS+ m/z 734.8 [M-H+Na]+; HRMS 
Calcd for C25H41
154TbN6O6SNa 730.1915. Found 730.1915. 
 
102. [Tm.L11] 
An analogous procedure to that described for [Dy.L11] was followed using 2,2'-(4-((5-
tert-butylpyridin-2-yl)methyl)-10-(2-(methylsulfonamido)ethyl)-1,4,7,10-tetraaza-
cyclododecane-1,7-diyl)diacetic acid (8.3 mg, 0.015 mmol) and Tm(III)Cl3.6H2O (6.9 mg, 
0.018 mmol) to give a white solid (10.5 mg, 97 %).  1H NMR (400  MHz, D2O, pD 6.5): 
δ = +44.3 (tBu); ESI/MS+ m/z 745.8 [M-H+Na]+; HRMS Calcd for C25H41
169TbN6O6SNa 
745.2048. Found 745.2066. 
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